

0001437749-25-00356810-Q AYTU BIOPHARMA, INC 202502122050212161232161235161235 0 0001437749-25-003568 10-Q 100 20241231 20250212 20250212 AYTU BIOPHARMA, INC
0001385818 2834 470883144 DE 0630 10 Q 34 001-38247 25614933 7900 E. UNION AVENUE SUITE 920 DENVER CO 80237 AYTU BIOSCIENCE, INC 20150609 AYTU BIOSCIENCE, INC. 20150609 Rosewind CORP 20070110 10-Q 1 ayutu20241231c 10q.htm FORM 10-Q ayutu20241231c 10q.htm
0001385818 false -06-30 Q2 2025 0.0001 0.0001 50,000,000 50,000,000 0 0 0 0.0001 0.0001 200,000,000 200,000,000 6,169,681 6,169,681 5,972,638 5,972,638 0.1 http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent 0 0.1 0.1 4 7 4 http://fasb.org/us-gaap/2024#DerivativeGainLossOnDerivativeNet 1.70 1.70 1 5 1 0 5 1 5 false false false false Relates to the exercise of 176,000 of the Tranche B Pre-Funded Warrants during the first quarter of fiscal 2025, which were liability classified and exercised at a price of \$0.0001 per share. Includes August 2022 Warrants, March 2022 Warrants, Avenue Capital Warrants and Tranche B Pre-Funded Warrants. See Note 16 - Warrants for definitions of these terms and further information. Warrants exercised during the first quarter of fiscal 2025 were 176,000 of the Tranche B Warrants, which were exercised at a price of \$0.0001 per share. The number of warrants outstanding as of December 31, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,630,424 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants. The number of warrants outstanding as of June 30, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,806,434 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants. As pre-funded warrants do not have an expiration date, they have been excluded from the calculation of the weighted average remaining contractual life in years. 00013858182024-07-012024-12-31 xbrli:shares 00013858182025-02-01 thunderdome:item iso4217:USD 00013858182024-12-31 00013858182024-06-30 iso4217:USDXbrli:shares 00013858182024-10-012024-12-31 00013858182023-10-012023-12-31 00013858182023-07-012023-12-31 0001385818us-gaap:CommonStockMember2024-06-30 0001385818us-gaap:AdditionalPaidInCapitalMember2024-06-30 0001385818us-gaap:RetainedEarningsMember2024-06-30 0001385818us-gaap:CommonStockMember2024-07-012024-09-30 0001385818us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-30 00013858182024-07-012024-09-30 0001385818us-gaap:RetainedEarningsMember2024-07-012024-09-30 0001385818us-gaap:CommonStockMember2024-09-30 0001385818us-gaap:AdditionalPaidInCapitalMember2024-09-30 0001385818us-gaap:RetainedEarningsMember2024-09-30 0001385818us-gaap:CommonStockMember2024-10-012024-12-31 0001385818us-gaap:AdditionalPaidInCapitalMember2024-10-012024-12-31 0001385818us-gaap:RetainedEarningsMember2024-10-012024-12-31 0001385818us-gaap:CommonStockMember2024-12-31 0001385818us-gaap:AdditionalPaidInCapitalMember2024-12-31 0001385818us-gaap:RetainedEarningsMember2024-12-31 0001385818us-gaap:CommonStockMember2023-06-30 0001385818us-gaap:AdditionalPaidInCapitalMember2023-06-30 0001385818us-gaap:RetainedEarningsMember2023-06-30 0001385818us-gaap:CommonStockMember2023-07-012023-09-30 0001385818us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-30 00013858182023-07-012023-09-30 0001385818us-gaap:RetainedEarningsMember2023-07-012023-09-30 0001385818us-gaap:AdditionalPaidInCapitalMember2023-09-30 0001385818us-gaap:RetainedEarningsMember2023-09-30 00013858182023-09-30 0001385818us-gaap:CommonStockMember2023-10-012023-12-31 0001385818us-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-31 0001385818us-gaap:RetainedEarningsMember2023-10-012023-12-31 0001385818us-gaap:CommonStockMember2023-12-31 0001385818us-gaap:AdditionalPaidInCapitalMember2023-12-31 0001385818us-gaap:RetainedEarningsMember2023-12-31 0001385818us-gaap:CommonStockMember2023-12-31 0001385818us-gaap:OtherNoncurrentLiabilitiesMember2023-09-30 0001385818us-gaap:AdhdPortfolioMemberaytu:RxSegmentMember2024-10-012024-12-31 0001385818us-gaap:AdhdPortfolioMemberaytu:RxSegmentMember2024-07-012024-12-31 0001385818us-gaap:AdhdPortfolioMemberaytu:RxSegmentMember2023-07-012023-12-31 0001385818us-gaap:ThePediatricPortfolioMemberaytu:RxSegmentMember2024-10-012024-12-31 0001385818us-gaap:ThePediatricPortfolioMemberaytu:RxSegmentMember2023-10-012023-12-31 0001385818us-gaap:ThePediatricPortfolioMemberaytu:RxSegmentMember2024-07-012024-12-31 0001385818us-gaap:ThePediatricPortfolioMemberaytu:RxSegmentMember2023-07-012023-12-31 0001385818us-gaap:ProductAndServiceOtherMemberaytu:RxSegmentMember2024-10-012024-12-31 0001385818us-gaap:ProductAndServiceOtherMemberaytu:RxSegmentMember2023-10-012023-12-31 0001385818us-gaap:ProductAndServiceOtherMemberaytu:RxSegmentMember2024-07-012024-12-31 0001385818us-gaap:ProductAndServiceOtherMemberaytu:RxSegmentMember2023-07-012023-12-31 0001385818us-gaap:ProductAndServiceOtherMemberaytu:RxSegmentMember2024-10-012024-12-31 0001385818us-gaap:RxSegmentMember2023-10-012023-12-31 0001385818us-gaap:RxSegmentMember2024-07-012024-12-31 0001385818us-gaap:RxSegmentMember2023-07-012023-12-31 0001385818us-gaap:ManufacturingEquipmentMember2024-12-31 0001385818us-gaap:ManufacturingEquipmentMember2024-06-30 0001385818us-gaap:OfficeEquipmentFurnitureAndOtherMember2024-12-31 0001385818us-gaap:OfficeEquipmentFurnitureAndOtherMember2024-06-30 0001385818us-gaap:LeaseholdImprovementsMember2024-12-31 0001385818us-gaap:LeaseholdImprovementsMember2024-06-30 0001385818us-gaap:OfficeSpaceInBerwynPennsylvaniaMember2024-06-30 0001385818us-gaap:OperatingExpenseMember2024-10-012024-12-31 0001385818us-gaap:OperatingExpenseMember2023-10-012023-12-31 0001385818us-gaap:OperatingExpenseMember2024-07-012024-12-31 0001385818us-gaap:CostOfSalesMember2024-10-012024-12-31 0001385818us-gaap:CostOfSalesMember2023-10-012023-12-31 0001385818us-gaap:CostOfSalesMember2024-07-012024-12-31 0001385818us-gaap:CostOfSalesMember2023-07-012023-12-31 0001385818us-gaap:OtherExpenseMember2024-10-012024-12-31 0001385818us-gaap:OtherExpenseMember2023-10-012023-12-31 0001385818us-gaap:OtherExpenseMember2024-07-012024-12-31 0001385818us-gaap:OtherExpenseMember2023-07-012023-12-31 utr:Y 0001385818us-gaap:TechnologyBasedIntangibleAssetsMember2024-12-31 0001385818us-gaap:DevelopedTechnologyRightsMember2024-12-31 0001385818us-gaap:TechnologyBasedIntangibleAssetsMember2024-06-30 0001385818us-gaap:DevelopedTechnologyRightsMember2024-06-30 0001385818srst:MinimumMember2024-07-012024-12-31 0001385818srst:MaximumMember2024-07-012024-12-31 0001385818us-gaap:TrisKarbinalAgreementMember2023-07-012024-12-31 0001385818us-gaap:TrisKarbinalAgreementMember2024-07-012024-12-31 0001385818us-gaap:TrisKarbinalAgreementMember2024-12-31 0001385818us-gaap:OtherNoncurrentLiabilitiesMember2024-12-31 0001385818us-gaap:EclipseBusinessCapitalLlLoanAgreementMemberus-gaap:SecuredDebtMember2024-06-12 0001385818us-gaap:Eclipse

001385818aytu:EquityBasedWarrantsMember2024-10-012024-12-31 0001385818us-gaap:SegmentContinuingOperationsMember2023-10-012023-12-31 0001385818us-gaap:SegmentContinuingOperationsMember2023-10-012023-12-31 0001385818us-gaap:SegmentContinuedOperationsMember2024-07-012024-12-31 0001385818us-gaap:SegmentContinuedOperationsMember2023-07-012023-12-31 0001385818us-gaap:SegmentDiscontinuedOperationsMember2024-10-012024-12-31 0001385818us-gaap:SegmentDiscontinuedOperationsMember2023-10-012023-12-31 0001385818us-gaap:SegmentDiscontinuedOperationsMember2024-07-012024-12-31 0001385818us-gaap:SegmentDiscontinuedOperationsMember2023-07-012023-12-31 0001385818aytu:LiabilityWarrantsMember2024-10-012024-12-31 0001385818aytu:LiabilityWarrantsMember2023-10-012023-12-31 0001385818aytu:LiabilityWarrantsMember2024-07-012024-12-31 0001385818aytu:LiabilityWarrantsMember2023-07-012023-12-31 0001385818aytu:EquityBasedWarrantsMember2024-10-012024-12-31 0001385818aytu:EquityBasedWarrantsMember2023-10-012023-12-31 0001385818aytu:EquityBasedWarrantsMember2024-07-012024-12-31 0001385818aytu:EquityBasedWarrantsMember2023-07-012023-12-31 0001385818us-gaap:RestrictedStockMember2024-10-012024-12-31 0001385818us-gaap:RestrictedStockMember2023-10-012023-12-31 0001385818us-gaap:RestrictedStockUnitsRSUMember2024-10-012024-12-31 0001385818us-gaap:RestrictedStockUnitsRSUMember2023-10-012023-12-31 0001385818us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-12-31 0001385818us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-12-31 0001385818us-gaap:EmployeeStockOptionMember2024-10-012024-12-31 0001385818us-gaap:EmployeeStockOptionMember2023-10-012023-12-31 0001385818us-gaap:EmployeeStockOptionMember2024-07-012024-12-31 0001385818us-gaap:EmployeeStockOptionMember2023-07-012023-12-31 0001385818aytu:GrandPrairieTexasManufacturingSiteMember2024-10-012024-12-31 0001385818aytu:GrandPrairieTexasManufacturingSiteMember2024-07-012024-12-31 0001385818aytu:ConsumerHealthDivestitureMember2024-10-012024-12-31 0001385818aytu:ConsumerHealthDivestitureMember2023-10-012023-12-31 0001385818aytu:ConsumerHealthDivestitureMember2024-07-012024-12-31 0001385818aytu:ConsumerHealthDivestitureMember2023-07-012023-12-31 0001385818aytu:ConsumerHealthDivestitureMember2024-06-30-4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 A For the quarterly period ended December 31, 2024 or A TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 A For the transition period from A to A Commission File Number: A 001-38247 A A AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) A Delaware A 47-0883144 (State or other jurisdiction of incorporation or organization) A (I.R.S. Employer Identification No.) A 7900 East Union Avenue, SuiteA 920, Denver, Colorado 80237 A (720) 437-6580 (Address of principal executive offices and zip code)A (Registrant's telephone number, including area code) A Securities registered pursuant to Section 12(b) of the Act: A Title of each class A Trading Symbol(s) A Name of each exchange on which registered Common Stock, par value \$0.0001 per share A YUTU A The Nasdaq Capital Market A Indicate by check mark whether the registrant (1)A has filed all reports required to be filed by Section 13 or 15(d)A of the Securities Exchange Act of 1934 during the preceding 12A months (or for such shorter period that the registrant was required to file such reports), and (2)A has been subject to such filing requirements for the past 90A days. Yes A No A Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (A\$232.405 of this chapter) during the preceding 12A months (or for such shorter period that the registrant was required to submit such files). Yes A No A Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of Acelarge accelerated filer, Acelaccelerated filer, Acelsmallest reporting company, Aceland Acelemerging growth companyA in Rule 12bA2 of the Exchange Act. A Large accelerated filer A Accelerated filer A Non-accelerated filer A Smaller reporting company A Emerging growth company A If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. A Indicate by check mark whether the registrant is a shell company (as defined in Rule 12bA2 of the Exchange Act). Yes A No A As of February 1, 2025, the registrant had 6,169,848 ofA common stock outstanding. A Table of Contents A A AYTU BIOPHARMA, INC. FORM 10-Q TABLE OF CONTENTS A Page Cautionary Information Regarding Forward-Looking Statements 3 A PART I - FINANCIAL INFORMATION 4 Item 1. Financial Statements 4 Unaudited Consolidated Balance Sheets 4 Unaudited Consolidated Statements of Operations 5 Unaudited Consolidated Statements of Stockholders' Equity 6 Unaudited Consolidated Statements of Cash Flows 7 NotesA to the Unaudited Consolidated Financial Statements 8 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 33 Item 3. Quantitative and Qualitative Disclosures About Market Risk 40 Item 4. Controls and Procedures 40 A PART II - OTHER INFORMATION 41 Item 1. Legal Proceedings 41 Item 1A. Risk Factors 42 Item 5. Other Information 43 Item 6. Exhibits 44 A SIGNATURES 45 A Table of Contents A CAUTIONARY INFORMATION REGARDING FORWARD-LOOKING STATEMENTS A This Report on Form 10-Q (AcelForm 10-QAc) (Acelreport) includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (AcelSecurities ActAc), and Section 21E of the Securities Exchange Act of 1934, as amended (AcelExchange ActAc). All statements other than statements of historical facts contained in this report, including statements regarding our anticipated future clinical and regulatory events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward looking statements are generally written in the future tense and/or are preceded by words such as Acelmay, Acelwill, Acelshould, Acelforecast, Acelcould, Acelexpect, Acelsuggest, Acelbelieve, Acelestimate, Acelcontinue, Acelanticipate, Acelintend, Acelpotential, Acelplan, Acelor similar words, or the negatives of such terms or other variations on such terms or comparable terminology. Such forward-looking statements include, without limitation: our anticipated future cash position; the planned expanded commercialization of our products and the potential future commercialization of our product candidates; our anticipated future growth rates; anticipated sales increases; anticipated net revenue increases; amounts of certain future expenses and cost of sales; our plans to acquire additional assets or dispose of assets, anticipated increases or decreases to operating expenses, and selling, general, and administrative expenses; and future events under our current and potential future collaborations. A These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including without limitation the risks described in AcelRisk FactorsAc in Part I, Item 1A of our Annual Report on Form 10-K for the year ended June 30, 2024 (Acel2024 Form 10-KAc), and in the reports we file with the United States Securities and Exchange Commission (AcelSECAc). These risks are not exhaustive. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements should not be relied upon as predictions of future events. We can provide no assurance that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. We assume no obligation to update or supplement forward-looking statements, except as may be required under applicable law. A This Form 10-Q may refer to registered trademarks that we currently own or license, such as Ayту, Ayту BioPharma, Ayту RxConnect, Neos Therapeutics, Adzenys, Adzenys ER, Adzenys XR-ODT, Cotempla, Cotempla XR-ODT, Karbinal, Poly-Vi-Flor and Tri-Vi-Flor, which are protected under applicable intellectual property laws and are our property or the property of our subsidiaries. This Form 10-Q also contains trademarks, service marks, copyrights and trade names of other companies, which are the property of their respective owners. Solely for convenience, our trademarks and tradenames referred to in this Form 10-Q may appear without the A® or A™ symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights to these trademarks and tradename. A Table of Contents A PART I - FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS AYTU BIOPHARMA, INC. UNAUDITED CONSOLIDATED BALANCE SHEETS (in thousands, except share data) A December 31, A June 30, A 2024 A 2024 A ASSETS A Current assets: A Cash and cash equivalents A \$20,398A Accounts receivable, net A 25,403A A 23,526A Inventories A 11,085A A 12,141A Prepaid expenses and other current assets A 6,167A A 5,097A Current assets of discontinued operations A A A A Total current assets A 63,053A A 61,891A Non-current assets: A Property and equipment, net A 516A A 693A Operating lease right-of-use assets A 1,178A A 829A Intangible assets, net A 49,958A A 56,253A Other non-current assets A 1,522A A 2,185A Non-current assets of discontinued operations A A A A Total non-current assets A 53,174A A 56,204A Total assets A \$116,227A A \$118,095A LIABILITIES AND STOCKHOLDERS' EQUITY A Current liabilities: A Accounts payable A 11,699A A 10,314A Accrued liabilities A 39,372A A 38,143A Revolving credit facility A 4,012A A 2,395A Current portion of debt A 1,857A A 1,857A Other current liabilities A 7,108A A 8,962A Current liabilities of discontinued operations A A A A Total current liabilities A 64,048A A 62,228A Non-current liabilities: A Debt, net of current portion A 9,983A A 10,877A Derivative warrant liabilities A 6,386A A 12,745A Other non-current liabilities A 5,045A A 4,529A Total non-current liabilities A 21,414A A 28,151A Commitments and contingencies (note 13) A A A A Stockholders' equity: A Preferred stock, par value \$.0001; 50,000,000 shares authorized; no shares issued or outstanding A A A A Common stock, par value \$.0001; 200,000,000 shares authorized; 6,169,681 and 5,972,638 shares issued and outstanding, respectively A 1A A 1A Additional paid-in capital A 348,475A A 347,688A Accumulated deficit A (317,711)A (319,973) Total stockholders' equity A 30,765A A 27,716A Total liabilities and stockholders' equity A \$116,227A A \$118,095A The accompanying notes to the unaudited consolidated financial statements are an integral part of this statement. A Table of Contents A AYTU BIOPHARMA, INC. UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) A Three Months Ended A Six Months Ended A December 31, A December 31, A 2024 A 2023 A 2024 A 2023 A Net revenue A \$16,221A A \$18,748A A \$32,795A A \$36,565A Cost of sales A 5,435A A 4,145A A 10,024A A 8,924A Gross profit A 10,786A A 14,603A A 22,771A A 27,64

portfolios. The first consists of two products for the treatment of ADHD (ADHD): ADZENYS XR-ODT (amphetamine) extended-release orally disintegrating tablets (ADZADZ) and COTEMPLA XR-ODT (methylphenidate) extended-release orally disintegrating tablets (ADZCOT) and ADZENYS together with COTEMPLA (ADZADH Portfolio). The second consists primarily of Karbinal® ER (carboxamine maleate extended-release oral suspension) (ADZKAR), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency (the ADZPEDIATRIC Portfolio). Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (ADZCODM). After the previously announced successful wind down and divestiture of the Consumer Health business that occurred during the first quarter of fiscal 2025, the Company determined that its continuing operations now operate in a single operating and reportable segment. The Company's CODM is its Chief Executive Officer who manages operations and regularly reviews the financial information of the Company's continuing operations as a single operating segment for the purposes of allocating resources and evaluating its financial performance, and for which discrete financial information is available. The results of the Consumer Health business have been reported as discontinued operations (see Note 20A "Discontinued Operations"). In July 2023, the Company entered into an exclusive collaboration, distribution and supply agreement with Medomie Pharma Ltd (ADZMEDOMIE), a privately owned pharmaceutical company, for Medomie to sell ADZENYS and COTEMPLA in Israel and the Palestinian Authority. In September 2024, the Company entered into an exclusive collaboration, distribution and supply agreement with Lupin Pharma Canada Ltd (ADZLUPIN), a subsidiary of global pharmaceutical company Lupin Limited, for Lupin to sell ADZENYS and COTEMPLA in Canada. The Company will supply ADZENYS and COTEMPLA to Medomie and Lupin based on forecasts and provide various product commercialization resources. Medomie and Lupin are responsible for seeking local regulatory approvals and marketing authorizations for both ADZENYS and COTEMPLA, which is expected to occur over the next 18 to 24 months. The agreement with Medomie and the agreement with Lupin represent the Company's first and second international commercial agreements for ADZENYS and COTEMPLA, respectively. A Table of Contents A Note 2A - Summary of Significant Accounting Policies A Principals of Consolidation A The Company's unaudited consolidated financial statements and notes thereto include the accounts of its wholly owned subsidiaries Aytu Therapeutics, LLC and Neos Therapeutics, Inc. and their respective wholly owned subsidiaries, as well as Innovus Pharmaceuticals, Inc. (ADZINNOVUS), and its wholly owned subsidiaries prior to the divestiture of Innovus on July 31, 2024. All significant inter-company balances and transactions have been eliminated in consolidation. A Basis of Presentation A The unaudited consolidated financial statements and notes thereto contained in this Form 10-Q represent the financial statements of the Company and its wholly owned subsidiaries and have been prepared pursuant to the rules and regulations of the SEC regarding interim financial reporting. Accordingly, certain information and disclosures normally included in the complete financial statements prepared in accordance with accounting principles generally accepted in the United States (ADZU.S. GAAP) have been omitted pursuant to such rules and regulations. A The unaudited consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's 2024 Form 10-K, which included all disclosures required by U.S. GAAP. In the opinion of management, these unaudited consolidated financial statements and notes thereto contain all adjustments necessary for the fair statement of the financial position of the Company and the results of operations and cash flows for the interim periods presented. The consolidated balance sheet as of June 30, 2024, was derived from the audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. The results of operations for the period ended December 31, 2024, are not necessarily indicative of expected operating results for the full year or any future period. A Use of Estimates A The preparation of financial statements and footnotes requires the use of management estimates, judgments and assumptions. Actual results may differ from estimates. In the accompanying unaudited consolidated financial statements and notes thereto, estimates are used for, but not limited to, stock-based compensation; revenue recognition; determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances; allowance for credit losses; inventory impairment; determination of right-of-use (ADZROU) assets and lease liabilities; valuation of financial instruments, warrants and derivative warrant liabilities, intangible assets, and long-lived assets; purchase price allocations and the depreciable lives of long-lived assets; accruals for contingent liabilities; and determination of the income tax provision, deferred taxes and valuation allowance. A Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. The Company periodically evaluates estimates used in the preparation of the financial statements for reasonableness. A Prior Period Reclassification A Certain prior year amounts in the Company's unaudited consolidated financial statements and the notes thereto have been reclassified to conform to the current year presentation. These reclassifications did not impact operating results for the three and six months ended December 31, 2024, and 2023, or cash flows for the six months ended December 31, 2024, and 2023, or the Company's financial position as of December 31, 2024, or June 30, 2024. A Warrants A The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance in Financial Accounting Standards Board (ADZFASB) Accounting Standards Codification (ADZASC) Topic 480, Distinguishing Liabilities from Equity (ADZASC 480E) and ASC Topic 815, Derivatives and Hedging (ADZASC 815E). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company's own common shares and whether the warrant holders could potentially require ADZ net cash settlement in a circumstance outside of the Company's control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option pricing model or Monte Carlo simulation model at issuance and for each reporting period when applicable. A 9 Table of Contents A Income Taxes A The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been no changes in tax law affecting the tax provision during the three and six months ended December 31, 2024. A The Company recorded for income (loss) from continuing operations an income tax benefit of \$0.3 million, which represented an effective tax rate of negative 74.1% and income tax expense of \$0.8 million, which represented an effective tax rate of 55.8%, for the three months ended December 31, 2024, and 2023, respectively. The Company recorded for income (loss) from continuing operations an income tax expense of \$0.1 million, which represented an effective tax rate of 6.5% and income tax expense of \$0.8 million, which represented an effective tax rate of negative 12.8% for the six months ended December 31, 2024, and 2023, respectively. These effective tax rates were primarily driven by the limitations on losses as a result of Section 382 of the Internal Revenue Code changes in ownership coupled with existing valuation allowances, the divestiture of the Company's Consumer Health business that occurred during the first quarter of fiscal 2025 and ADZ changes to the Company's first quarter of fiscal 2025 projections, which resulted in an income tax benefit for the current quarter. A An ownership change has limited the Company's ability to offset, post-change, United States federal taxable income. Section 382 of the Internal Revenue Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. Previous acquisitions, financing transactions, and equity ownership changes in the past five years have caused a significant limitation on the Company's ability to use the change in control net operating loss carryovers. The ownership changes result in increased future tax liability and are a driver of the change from a zero percent effective tax rate. A The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than not that some portion or all of its deferred tax asset will not be utilized. A The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained upon an examination. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense in the unaudited consolidated statements of operations. A Employee Retention Credit A On March 27, 2020, the United States government enacted the Coronavirus Aid, Relief, and Economic Security Act (the ADZCARES Act) to provide certain relief as a result of the COVID-19 pandemic. The CARES Act provides tax relief, along with other stimulus measures, including a provision for an Employee Retention Credit (ADZERC), which allows for employers to claim a refundable payroll tax credit against the employer share of Social Security tax equal to 70% of the qualified wages paid to employees after December 31, 2020, through September 30, 2021. The ERC was designed to encourage businesses to keep employees on the payroll during the COVID-19 pandemic. A As there is no authoritative guidance under U.S. GAAP on accounting for government assistance to for-profit business entities, the Company accounted for the ERC by analogy to International Accounting Standard (ADZIAS) 20, Accounting for Government Grants and Disclosure of Government Assistance (ADZIAS 20E). In accordance with IAS 20, the Company recorded a \$3.8 million ERC accrual in other non-current liabilities, which represents the proceeds the Company received from the ERC program during the first quarter of fiscal 2024. Further in accordance with IAS 20, when management determines it has reasonable assurance that the Company has substantially met all eligibility requirements of the ERC and following any adjustments from its regulatory audit or upon further clarifications from the Internal Revenue Code of 1986, as amended (the ADZIRC), the ERC accrual shall be recognized as a benefit in other income in the unaudited consolidated statement of operations. The associated vendor fee of \$0.4 million was expensed as incurred in the first quarter of fiscal 2024. A 10 Table of Contents A Recently Adopted Accounting Pronouncements A Debt - Debt with Conversion and Other Option A In August 2020, the FASB issued Accounting Standards Update (ADZASU) No. 2020-06, Debt "Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging" Contracts in Entity's Own Equity (Subtopic 815-40) "Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the SEC, for the fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company adopted the guidance on July 1, 2024, and the adoption of the standard did not have a material impact on the Company's consolidated financial statements. A Recent Accounting Pronouncements Not Yet Adopted A Segment Reporting - Improvements to Reportable Segment Disclosures A In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ADZASU 2023-07E). ASU 2023-07 was issued to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance should be applied retrospectively unless it is impracticable to do so. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted, including in an interim period. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company's consolidated financial statements and disclosures. A Disaggregation of Income Statement Expenses A In November 2024, the FASB issued ASU No. 2024-03, Income Statement "Reporting Comprehensive Income" Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (ADZASU 2024-03E). The amendments in ASU 2024-03 require public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; A employee compensation; and A depreciation, amortization and depletion expenses for each caption on the income statement where such expenses are included. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company's consolidated financial statements and disclosures. A For a complete set of the Company's significant accounting policies, refer to the audited consolidated financial statements and notes thereto included in the Company's 2024 Form 10-K. There have been no significant changes to the Company's significant accounting policies and ADZ there is no other accounting guidance that has been issued and not yet adopted that is applicable to the Company and that would have a material effect on the Company's unaudited consolidated financial statements and related disclosures as of December 31, 2024, and through the filing of this Form 10-Q. A 11 Table of Contents A Note 3A - Revenue A Net revenue from continuing operations consists of sales of prescription pharmaceutical products from the Company's ADHD Portfolio and Pediatric Portfolio, principally to a limited number of wholesale distributors and pharmacies in the United States. Net revenue is recognized at the point in time that control of the product transfers to the customer, which typically aligns with shipping terms (i.e., upon delivery), generally to the destination when shipped domestically within the United States, consistent with contractual terms. A Savings offers, rebates, and wholesaler chargebacks reflect the terms of underlying agreements, which may vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns may not follow historical trends. The Company's periodic adjustments of its estimates are subject to time delays between the initial product sale, and the ultimate reporting and settlement of deductions. The Company entered into negotiations with a vendor related to certain variable interest accruals that reduce revenue for the Company's ADHD Portfolio. As a result of these negotiations, the Company and the vendor agreed to a reduction to the liability purportedly owed by the Company of \$3.3 million, which resulted in a decrease in the estimated variable consideration accrual, and a related increase in net revenue of \$3.3 million in the first quarter of fiscal 2025. A Revenue by Product Portfolio A Net revenue disaggregated by significant product portfolio for the three and six months ended December 31, 2024, and 2023, were as follows: A A Three Months Ended A A Six Months Ended A A December 31, A A December 31, A A 2024 A A 2023 A A 2024 A A 2023 A A (in thousands) A ADHD Portfolio A \$13,816 A \$16,572 A \$29,080 A \$31,700 A Pediatric Portfolio A \$2,400 A \$2,145 A \$3,693 A \$4,710 A Other A \$5 A \$31 A \$22 A \$155 A Total net revenue A \$16,221 A \$18,748 A \$32,795 A \$36,565 A Other includes net revenue from various discontinued or depreciable products. The Consumer Health business was divested in the first quarter of fiscal 2025 and is reported within discontinued operations (see Note 20A "Discontinued Operations"). A Revenue by Geographic Location A The Company's net revenue is predominately within the United States, with insignificant international sales. A Note 4A - Inventories A Inventories consist of raw materials, work in process and finished goods, and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company periodically reviews the composition of its inventories to identify obsolete, slow-moving or otherwise unsaleable items. In the event that such items are identified and there are no alternate uses for the inventory, the Company will record a charge to reduce the value of the inventory to net realizable value in the period first recognized. The Company incurred inventory write-downs of less than \$0.1 million and \$0.1 million for the three months ended December 31, 2024, and 2023, respectively, and \$0.1 million for both the six months ended December 31, 2024, and 2023, respectively. A Inventories consist of the following: A A December 31, A A June 30, A A 2024 A A 2024 A A (in thousands) A Raw materials A \$494 A \$266 A Work in process A \$3,103 A \$5,725 A Finished goods A \$7,488 A \$6,150 A Inventories A \$11,085 A \$12,141 A 12 Table of Contents A Note 5A - Property and Equipment A Property and equipment are recorded at cost and depreciated on a straight-line basis over the assets' estimated economic life. Leasehold improvements are amortized over the shorter of the estimated economic life or remaining lease term. A Depreciation and amortization expense from property and equipment was less than \$0.1 million and \$0.3 million for the three months ended December 31, 2024, and 2023, respectively, and \$0.1 and \$0.6 million for the six months ended December 31, 2024, and 2023, respectively. A Property and equipment, net, consist of the following: A A December 31, A A June 30, A A 2024 A A 2024 A A (in thousands) A Manufacturing and lab equipment A \$721 A \$1,838 A Office equipment, furniture and other A \$282 A \$945 A Leasehold improvements A \$164 A \$35 A Property and equipment, gross A \$1,167 A \$2,818 A Less: accumulated depreciation and amortization A (651) A (2,125) A Property and equipment, net A \$516 A \$693 A A Note 6A - Leases A The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment, and finance lease agreements for certain equipment. These leases have original lease periods expiring between calendar year 2024 and calendar year 2030. Most leases include one or more options to renew, and the exercise of a lease renewal option typically occurs at the discretion of both parties. Certain non-real estate leases also include options to purchase the leased property. The Company's lease agreements generally do not contain any material residual value

guarantees or material restrictive covenants. The Company had no remaining finance leases recorded as of June 30, 2024. In June 2024, the Company entered into a forward-starting operating lease agreement to lease office space in Berwyn, Pennsylvania from the owner of the office space that the Company is currently renting under a sublease arrangement. The Company determined that it is an operating lease, and that lease commencement occurred in July 2024. The initial lease termination date is July 31, 2030, and under the lease agreement the Company has one five-year renewal option to extend the lease through July 2035. Undiscounted minimum monthly rent payments average approximately \$13,000 over the initial term of the lease. The Company has elected to utilize the practical expedient to not separate lease and non-lease components upon recognition and variable lease payments will be expensed as incurred. The Company recorded an operating lease ROU asset of \$0.5 million and a lease liability of \$0.5 million at lease commencement in July 2024. The ROU asset and lease liability will be recorded at present value using an incremental borrowing rate of 12.3%. The components of lease costs are as follows:

Three Months Ended	Six Months Ended	December 31
2024	2023	2023

Statement of Operations Classification (in thousands)

Lease cost	Operating lease cost
\$143A	\$143A

Operating lease cost \$143A \$265A \$741A Operating expenses Short-term lease cost \$86A \$21A \$177A \$44A Operating expenses Finance lease cost:

Amortization of leased assets	Cost of sales	Interest on lease liabilities
\$229A	\$418A	\$816A

Supplemental balance sheet information related to leases is as follows:

December 31	June 30
2024	2023

Balance Sheet Classification (in thousands)

Assets	Non-current: operating leases
\$1,178A	\$829A

Operating lease right-of-use assets

Liabilities	Current: operating leases	Non-current: operating leases
\$1,106A	\$577A	

Other non-current liabilities Total lease liabilities \$1,288A \$1,289A

The remaining weighted-average lease term and discount rate used are as follows:

December 31	June 30
2024	2023

Weighted-average remaining lease term (years)

Operating lease right-of-use assets	Weighted-average discount rate
6.6A	2.7A

Operating lease right-of-use assets \$12.1% \$10.0% Supplemental cash flow information related to leases is as follows:

Six Months Ended	December 31
2024	2023

Supplemental cash flow information related to leases is as follows:

Operating cash flows from operating leases	Operating cash flows from finance leases
\$606A	\$697A

Operating cash flows from operating leases \$606A \$697A Operating cash flows from finance leases \$6A \$2A Financing cash flows from finance leases \$6A \$46A

As of June 30, 2024, the Company did not have any remaining finance leases. As of December 31, 2024, the Company's future minimum lease payments were as follows:

Operating	2025 (remaining 6 months)	2026	2027	2028
\$123A	\$399A	\$399A	\$377A	\$208

Thereafter \$1,892A Less: imputed interest \$479A Less: tenant improvement allowance \$125A Lease liabilities \$1,288A

14 Table of Contents

Note 7A - Intangible Assets

A summary of the Company's definite-lived intangible assets as of December 31, 2024, and June 30, 2024, respectively, is as follows:

December 31	June 30
2024	2023

Gross Carrying Amount \$41,268A Accumulated Amortization \$10,300A Net Carrying Amount \$30,968A

Weighted-Average Remaining Life 13.2A

(in thousands) (in years)

Acquired product technology rights \$41,268A (\$14,791A) \$26,477A \$10.3A Acquired technology rights \$30,200A (\$6,719A) \$23,481A \$13.2A

Total intangible assets \$71,468A (\$21,510A) \$49,958A \$11.7A

Gross Carrying Amount \$41,268A Accumulated Amortization \$10,300A Net Carrying Amount \$30,968A

Weighted-Average Remaining Life 13.8A

(in thousands) (in years)

Acquired product technology rights \$41,268A (\$13,184A) \$28,084A \$10.7A Acquired technology rights \$30,200A (\$5,831A) \$24,369A \$13.8A

Total intangible assets \$71,468A (\$19,015A) \$52,453A \$12.0A

Carrying amounts are net of any impairment charges from prior periods. An intangible asset with zero net carrying amount at the end of a reporting period is not presented in the table of a future reporting period. Certain of the Company's amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1A to 20 years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was \$1.2A million for both of the three months ended December 31, 2024, and 2023, and \$2.5A million for both of the six months ended December 31, 2024, and 2023. The following table summarizes the estimated future amortization expense to be recognized over the next five fiscal years and periods thereafter:

Estimated Future Amortization Expense	2025 (remaining 6 months)	2026	2027	2028	2029	2030	Thereafter
\$2,495A	\$2,495A	\$2,495A	\$2,495A	\$2,495A	\$2,495A	\$2,495A	\$2,495A

Total future amortization expense \$49,958A

15 Table of Contents

Acquired Product Technology Rights

The acquired product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisitions of the Pediatric Portfolio in November 2019 and the Neos Acquisition in March 2021. As part of the Neos Acquisition, the Company acquired developed product technology for the production and sale of AdzenysA and Cotempla. The formulations for the ADHD products are protected by patented technology. The estimated remaining economic life of these proprietary technologies is 14A years. Karbinal A The Company acquired and assumed all rights and obligations pursuant to the supply and distribution agreement, as amended, with Tris Pharma, Inc. (the "TrisA") for the exclusive rights to commercialize KarbinalA in the United States (the "TrisA Karbinal Agreement"). The TrisA Karbinal Agreement's initial term terminates in August 2023, with an optional initial 20-year extension. A Poly-Vi-FlorA and Tri-Vi-Flor A The Company acquired and assumed all rights and obligations pursuant to a supply and license agreement and various assignment and release agreements, including a previously agreed to settlement and license agreements (the "Poly-Tri Agreements") for the exclusive rights to commercialize Poly-Vi-Flor and Tri-Vi-Flor in the United States. A Acquired Technology Rights A TRRP Technology A As part of the Neos Acquisition, the Company acquired time release resin particle (the "TRRP") proprietary technology, which is a proprietary drug delivery technology protected by the Company as a trade secret that allows the Company to modify the drug release characteristics of each of its respective products. The TRRP technology underlines each of the ADHD Portfolio core products and can potentially be used in future product development initiatives as well. A Note 8A - Accrued Liabilities A Accrued liabilities consist of the following:

December 31	June 30
2024	2023

Accrued savings offers \$14,507A \$11,054A Accrued program liabilities \$7,021A \$9,964A Accrued customer and product related fees \$5,735A \$5,395A Return reserve \$5,111A \$4,832A Accrued employee compensation \$4,397A \$4,603A Other accrued liabilities \$3,027A \$2,295A Total accrued liabilities \$39,372A \$38,143A

Accrued savings offers represent programs for the Company's patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. Accrued program liabilities include government and commercial rebates. Accrued customer and product related fees include accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions such as royalties for Pediatric Portfolio products, accrued distributor fees, and Medicaid liabilities. The return reserve represents the Company's accrual for estimated product returns. Accrued employee compensation includes sales commissions, paid time off earned, accrued payroll and accrued bonus. Other accrued liabilities consist of various other accruals, none of which individually or in the aggregate represent greater than five percent of total liabilities.

16 Table of Contents

Note 9A - Other Liabilities

Other liabilities consist of the following:

December 31	June 30
2024	2023

Fixed payment arrangements \$6,926A \$8,337A Employee retention credit \$4,375A \$3,759A Operating lease liabilities \$1,288A \$1,289A Other \$180A \$106A Total other liabilities \$12,153A \$13,491A

Less: current portion of other liabilities \$7,108A (\$8,962) Total non-current portion of other liabilities \$5,045A \$4,529A

Fixed Payment Arrangements A Fixed payment arrangements represent obligations to a licensor assumed as part of the acquisition of products from Cerecor, Inc. in 2019, including fixed and variable payments. A In May 2022, the Company entered into an agreement with Tris to terminate the license, development, manufacturing and supply agreement dated November 2, 2018, related to Tuzistra XR (the "Tuzistra License Agreement"). Pursuant to such termination, as of December 31, 2024, the Company has accrued a settlement liability of \$5.8A million in other current liabilities on the consolidated balance sheet payable to Tris, with a provision that allows the Company to pay interest on any principal amounts due but remaining unpaid past July 2024. A The Tris Karbinal Agreement grants the Company the exclusive right to distribute and sell Karbinal in the United States. The initial term of the agreement was 20 years. The Company pays Tris a royalty equal to 23.5% of net revenue from the product. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 202

on an extinguishment of debt. The Company recorded a loss on extinguishment of debt of \$6 million related to the retirement of the Avenue Capital loan in the fourth quarter of fiscal 2024.

A Eclipse Term Loan A On June 12, 2024, the Company and certain of its subsidiaries entered into Eclipse Amendment No. 5, which provided for among other things, the Eclipse Term Loan A and the Eclipse Revolving Loan A described further in Note 10 - Revolving Credit Facility. The Eclipse Term Loan A consists of a principal amount of \$13.0 million, at an interest rate of SOFR plus 7.0%, with a four-year term maturing on June 12, 2028, A and a straight-line loan amortization period of seven years, which would provide for a loan balance at the end of the four-year term of \$5.6 million to be repaid on June 12, 2028, the maturity date. The Company used the proceeds of the Eclipse Term Loan and a portion of the proceeds from warrant exercises described below to repay in full the Avenue Capital loan. The effective interest rate on the Eclipse Term Loan was 11.7% as of December 31, 2024. A 19 Table of Contents A In the event that, for any reason, all or any portion of the Eclipse Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to A (i) 3.0% of the Eclipse Term Loan if such event occurs on or before June 12, 2025, (ii) 2.0% of the Eclipse Term Loan if such event occurs after June 12, 2025, A but on or before June 12, 2026, A (iii) 1.0% of the Eclipse Term Loan if such event occurs after June 12, 2026, A but on or before June 12, 2027, and (iv) 0.5% of the Eclipse Term Loan if such event occurs after June 12, 2027, A but on or before June 12, 2028. The Company may also be required to pay an early termination fee related to the Eclipse Revolving Loan A as further described in Note 10A - Revolving Credit Facility. The Company may permanently terminate the Eclipse Agreement upon written notice to Eclipse. The Company's obligations under the Eclipse Agreement are secured by substantially all of the Company's assets, as further defined in the Eclipse Agreement. A The Eclipse Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the Company's ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make certain asset sales without the prior written consent of the Eclipse Lender. A failure to comply with these covenants could permit the Eclipse Lender to declare the Company's obligations under the agreement, together with accrued interest and fees, to be immediately due and payable, plus any additional applicable amounts relating to a prepayment or termination, as described above. As of December 31, 2024, the Company was in compliance with the covenants under the Eclipse Agreement. The Company incurred interest expense on the Eclipse Term Loan, including debt discount and issuance costs amortization, of \$0.4 million and \$0.8 million for the three and six months ended December 31, 2024, respectively. A Long-term debt consists of the following: A A December 31, A A June 30, A A 2024 A A 2024 A A (in thousands) A Term loan principal amount \$12,071 A \$13,000 A Unamortized debt discount and issuance costs A (231) A (266) Total debt A \$11,840 A \$12,734 Less: current portion of debt A (1,857) A (1,857) Total debt, net of current portion A \$9,983 A \$10,877 A Future principal payments of the Eclipse Term Loan are as follows: A A Future Principal Payments A A (in thousands) A 2025 (remaining 6 months) A \$928 A 2026 A 1,857 A 2027 A 1,857 A 2028 A 7,429 A Total future principal payments A \$12,071 A Less: unamortized debt discount and issuance costs A (231) Less: current portion of debt A (1,857) Total debt, net of current portion A \$9,983 A A 20 Table of Contents A Note 12 - Fair Value Considerations A The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to determine fair value as follows: A A Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to Ayto for identical assets or liabilities; A A Level 2: Inputs that include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and A A Level 3: Unobservable inputs that are supported by little or no market activity. A The Company's financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, derivative warrant liabilities, contingent consideration liabilities, fixed payment arrangements, and current and non-current debt. The carrying amounts of certain short-term financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Current and non-current debt are reported at their amortized costs on the Company's consolidated balance sheets. The remaining financial instruments are reported on the Company's consolidated balance sheets at amounts that approximate current fair values. The Company's carrying value of its consolidated amounts of cash and cash equivalents approximate their fair value as of December 31, 2024, and are categorized within level 1 of the U.S. GAAP fair value hierarchy. The Company's policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented. A Recurring Fair Value Measurements A The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2024, and June 30, 2024, by level within the fair value hierarchy are as follows: A A Fair Value at December 31, A A Fair Value Measurements at December 31, 2024 A A 2024 A A (Level 1) A A (Level 2) A A (Level 3) A A (in thousands) A Liabilities: A A A A A A A A A A Derivative warrant liabilities A \$6,386 A \$ac A \$ac A A \$6,386 A Total A \$6,386 A \$ac A A \$ac A A \$6,386 A A A Fair Value at June 30, A A Fair Value Measurements at June 30, 2024 A A 2024 A A (Level 1) A A (Level 2) A A (Level 3) A A (in thousands) A Liabilities: A A A A A A A A A A Derivative warrant liabilities A \$12,745 A \$ac A A \$ac A A \$12,745 A Total A \$12,745 A \$ac A A \$ac A A \$12,745 A A 21 Table of Contents A Summary of Level 3 Input Changes A A summary of changes to those fair value measures using Level 3 inputs is as follows: A A Derivative A A Warrant Liabilities A A (in thousands) A Balance as of June 30, 2024 A \$12,745 A Settlements (1) A (463) Included in earnings A (5,896) Balance as of December 31, 2024 A \$6,386 A (1) Relates to the exercise of 176,000 of the Tranche B Pre-Funded Warrants during the first quarter of fiscal 2025, which were liability classified and exercised at a price of \$0.0001 per share. A Significant Assumptions A The valuation methodologies and key assumptions used for the mark to market fair value measurements of derivative warrant liabilities as of December 31, 2024, are as follows: A A June 2023 Warrants A Warrants A A Tranche A A Other (1) A A Monte Carlo A A A A Black-Scholes A A Black-Scholes A Ayto closing stock price A \$1.70 A A \$1.70 A Equivalent term (years) A 3.4 A 2.1-2.7 Expected volatility A 80.8% A 74.7%-80.5% A Risk-free rate A 4.3% A 4.3% A Dividend yield A 0.0% A 0.0% A (1) Includes August 2022 Warrants, March 2022 Warrants, Avenue Capital Warrants and Tranche B Pre-Funded Warrants. See Note 16 - Warrants for definitions of these terms and further information. A A Note 13 - Commitments and Contingencies A Pediatric Portfolio Fixed Payments and Product Milestone A The Tris Karbinal Agreement grants the Company the exclusive right to distribute and sell Karbinal in the United States. The initial term of the agreement was 20 years. The Company pays Tris a royalty equal to 23.5% of net revenue from the product. A The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make-whole payment of \$30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Tris Karbinal Agreement make-whole payment is capped at \$2.1 million each year. The final annual make-whole payment is due in August 2025. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to \$3.0 million based on cumulative net revenue from the product, the first of which is triggered at \$40.0 million. A 22 Table of Contents A Legal Matters A Witmer Class-Action Securities Litigation A A stockholder derivative suit was filed on September 12, 2022, in the Delaware Chancery Court by Paul Witmer, derivatively and on behalf of all Ayto stockholders, against Armistice Capital, LLC, Armistice Capital Master Fund, Ltd., Steve Boyd (Armistice's Chief Investment Officer and Managing Partner, and a former director of Ayto), and certain other current and former directors of Ayto, Joshua R. Disbrow, Gary Cantrell, John Donofrio, Jr., Michael Macaluso, Carl Dockery and Ketan B. Mehta. Plaintiff amended the complaint on April 5, 2023. The Amended Complaint dropped Mr. Macaluso as a defendant and alleges that (i) Armistice facilitated the sale of assets of Cerecor in 2019 and Innovus in 2020 to Ayto in exchange for convertible securities which it subsequently converted and sold at a profit on the open market; (ii) the Armistice defendants breached their fiduciary duties, were unjustly enriched and wasted corporate assets in connection with these acquisitions; (iii) the Armistice defendants breached their fiduciary duties by engaging in insider trading; and (iv) the other directors breached their fiduciary duties, and aided and abetted the Armistice defendants' breaches of fiduciary duties, in connection with these acquisitions. The Amended Complaint sought unspecified damages, equitable relief, restitution, disgorgement of profits, enhanced governance and internal procedures, and attorneys' fees. While the Company believes that this lawsuit is without merit and have vigorously defended against it, the Company agreed to settle the matter for various corporate governance modifications and the payment of plaintiff's attorneys' fees. On January 13, 2025, the court approved the settlement. A Granules PIV A On October 31, 2024, the Company received a Paragraph IV Certification Notice Letter (the Notice Letter) from Granules Pharmaceuticals, Inc. (the Granules), stating that it intends to market a generic version of Adzenys before the expiration of all patents currently listed in the Orange Book. The Notice Letter states that Granules' New Drug Application (the NDA) for the generic version of Adzenys contains a Paragraph IV certification alleging that these patents are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the generic version of Adzenys. On December 11, 2024, the Company filed a patent infringement lawsuit against Granules which triggered a stay precluding the United States Food and Drug Administration (the FDA) from approving Granules' NDA for a generic version of Adzenys for up to 30 months or entry of judgment holding the patents invalid, unenforceable, or not infringed, whichever occurs first. On January 7, 2025, Granules submitted an answer to the complaint. This litigation is ongoing, and a trial has been scheduled for to be on December 7, 2026. The Company plans to vigorously enforce its intellectual property rights related to Adzenys. A Revive Investing A The Company had been named as a nominal plaintiff in a lawsuit by two shareholders against Armistice Capital Master Fund, Ltd, entitled Revive Investing, LLC, et al v. Armistice Master Fund, Ltd, et al, Case 1:20-cv-02849-CMA-TPO, in the United States District Court for the District of Colorado, contending that Armistice was liable for short swing trading profits in violation of Section 16(b) of the Exchange Act for certain trades it made in Company stock in 2019 and 2020 and must disgorge those profits to the Company. That matter proceeded to trial before a jury, which on January 29, 2025, returned a verdict finding no liability. A 23 Table of Contents A A Note 14 - Stockholders' Equity A The Company has 200 million shares of common stock authorized with a par value of \$0.0001 per share and 50 million shares of preferred stock authorized with a par value of \$0.0001 per share. As of December 31, 2024, included in common stock outstanding are 36,256 shares of unvested restricted stock issued to executives, directors and employees. A On September 28, 2021, the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on October 7, 2021. This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of \$100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the 2021 Shelf). The 2021 Shelf expired in October 2024. A On August 11, 2022, the Company closed on an underwritten public offering (the August 2022 Offering) utilizing the 2021 Shelf, pursuant to which it sold an aggregate of (i) 1,075,290 shares of its common stock; (ii) in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 87,500 shares of its common stock; and (iii) accompanying warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase one share of common stock for each share of common stock or each pre-funded warrant sold. The combined public offering price for each share of common stock and accompanying common warrant was \$8.60, and the combined offering price for each pre-funded warrant and accompanying common warrant was \$8.58, which equated to the public offering price per share of the common stock and accompanying common warrant, less the \$0.02 per share exercise price of each pre-funded warrant. The pre-funded warrants were exercised in full in August 2022. The common warrants have an exercise price of \$8.60 per share of common stock and are exercisable for a period of five years from issuance. The Company raised \$10.0 million in gross proceeds through the August 2022 Offering before underwriting fees and other expenses of \$0.9 million. The pre-funded and common warrants had a combined fair value of approximately \$6.0 million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholders' equity in the Company's consolidated financial statements (see Note 16 - Warrants). A On June 8, 2023, using a placement agent, the Company entered into a securities purchase agreement (the Securities Purchase Agreement) with certain institutional investors, pursuant to which the Company issued and sold an aggregate of (i) 1,743,695 shares of the Company's common stock; (ii) pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock (the June 2023 Pre-Funded Warrants); (iii) accompanying tranche A warrants to purchase 2,173,912 shares of common stock (the Tranche A Warrants); and (iv) accompanying tranche B warrants to purchase 2,173,912 shares of common stock in a best-efforts offering (the Tranche B Warrants) and the Tranche A Warrants together with the Tranche B

equity securities remained the same as they were previously under the Neos 2015 Plan. The Company allocated costs of the replacement awards attributable to pre-combination and post-combination service periods. The pre-combination service costs were included in the consideration transferred. The remaining costs attributable to the post-combination service period are being recognized as stock-based compensation expense over the remaining terms of the replacement awards. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 1 to 4 years.

A Stock Options A Stock option activity is as follows:

	Weighted Average Remaining Number of Shares	Average Contractual Life in Years	Outstanding at June 30, 2024
\$6.18A \$8.8A	Granted \$83,000A \$1.84A	At 2.3A	Forfeited/cancelled \$8,147A \$5.73A At \$6.6A
December 31, 2024			

The following table sets forth the exercise price per share of restricted stock issued outside of the equity incentive plans. As of December 31, 2024, there was \$0.2 million total unrecognized compensation cost related to non-vested RSUs granted under the equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.3 years.

A Restricted Stock Units Restricted stock activity is as follows:

	Number of Shares	Date Fair Value	Value Invested	Vested	Unvested
June 30, 2024	24,105A	\$100.34A	Granted \$20,000A \$1.79A	(7,853)A	\$15.33A
December 31, 2024					

During the six months ended December 31, 2024, the Company granted 20,000 shares of restricted stock under the equity incentive plan with a weighted average grant date fair value of \$1.79 per share. As of December 31, 2024, there was \$0.9 million total unrecognized compensation cost related to non-vested restricted stock granted under the equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.3 years.

A During the six months ended December 31, 2024, no restricted stock was granted outside of the equity incentive plan. As of December 31, 2024, there was \$0.2 million total unrecognized compensation cost related to non-vested restricted stock issued outside of the equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.5 years.

As of December 31, 2024, 4A shares of restricted stock remain unvested that were granted outside of the equity incentive plan.

A Restricted Stock Units Restricted stock units (RSUs or RSUe) activity is as follows:

	Number of Shares	Date Fair Value	Value Invested	Vested	Unvested
June 30, 2024	24,105A	\$100.34A	Granted \$20,000A \$1.79A	(7,853)A	\$15.33A
December 31, 2024					

During the six months ended December 31, 2024, no RSUs were granted. As of December 31, 2024, there was less than \$0.1 million of unrecognized compensation costs related to non-vested RSUs granted under the equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 0.2 years.

A Stock-based compensation expense related to the fair value of stock options, restricted stock, and RSUs was included in the consolidated statements of operations as set forth in the below table:

	Three Months Ended	Six Months Ended
December 31, 2024		

In thousands Cost of sales Research and development Selling and marketing General and administrative Total stock-based compensation expense

(\$20A) (\$20A) (\$20A) (\$20A)

Total stock-based compensation expense \$151A \$820A \$324A \$1,750A

Note 16 - Warrants Liability Classified Warrants

The Company accounts for liability classified warrants by recording the fair value of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of liability classified derivative financial instruments was calculated using either the Black-Scholes option pricing model or the Monte Carlo simulation model and is revalued every quarter. Changes in the fair value of liability classified derivative financial instruments in subsequent periods are recorded as unrealized derivative gain or loss in the consolidated statements of operations (see Note 12 Fair Value Considerations).

On June 8, 2023, using a placement agent, the Company entered into a securities purchase agreement (the Securities Purchase Agreement) with certain institutional investors, pursuant to which the Company issued and sold an aggregate of (i) 1,743,695 shares of the common stock; (ii) June 2023 Pre-Funded Warrants in lieu of shares to purchase 430,217 shares of common stock; (iii) accompanying Tranche A Warrants to purchase 2,173,912 shares of common stock; and (iv) accompanying Tranche B Warrants to purchase 2,173,912 shares of common stock in a best-efforts offering (the Tranche Warrants together with the Tranche B Warrants, the Common Warrants). The Common Warrants may be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of \$0.0001 per share in the same form as the June 2023 Pre-Funded Warrants (the Exchange Warrants). Each pre-funded warrant is exercisable for one share of common stock at an exercise price of \$0.0001 per share. The pre-funded warrants are immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. The Common Warrants are immediately exercisable at a price of \$1.59 per share (or \$1.5899 per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) five years after the date of issuance or (ii) 30 days following the closing price of the common stock equaling 200% of the exercise price (\$3.18 per share) for at least 40 consecutive trading days. The Tranche B Warrants were exercised in June 2024 as further described below. The Company raised \$4.0 million in gross proceeds and net proceeds were \$3.4 million after deducting offering expenses. The June 2023 Pre-Funded Warrants do not have an expiration date. The warrants had a combined fair value of approximately \$5.0 million at issuance and are classified as derivative warrant liabilities. The resulting offset is recorded in derivative warrant liabilities gain (loss) along with the issuance costs of \$0.6 million in the unaudited consolidated financial statement of operations (see Note 14A Stockholders' Equity).

On June 14, 2024, the Tranche B Warrants were exercised, generating proceeds of \$3.5 million. The Tranche B Warrants were converted into 367,478 shares of common stock and 1,806,434 Tranche B Pre-Funded Warrants to purchase shares of common stock with an exercise price of \$0.0001 per share. The Tranche B Pre-Funded Warrants, which do not have an expiration date, had a fair value of approximately \$5.1 million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholders' equity in the Company's consolidated financial statements. The Company used a portion of the proceeds from the Tranche B Warrants exercise as part of the Avenue Capital loan repayment described further in Note 11 Long-Term Debt.

A On August 11, 2022, the Company closed an offering (the August 2022 Offering), pursuant to which, the Company issued pre-funded warrants to purchase 87,500 shares of its common stock and common warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, which one common warrant to purchase one share of common stock for each share of common stock or each pre-funded warrant was sold. The pre-funded warrants had an exercise price of \$0.02 per share of common stock and were exercised in full in August 2022. The common warrants have an exercise price of \$8.60 per share of common stock and are exercisable for a period of five years from issuance. The common warrants provide that if there occurs any stock split, stock dividend stock recapitalization, or similar event (a Stock Combination Event), then the warrant exercise price will be adjusted to the greater of the quotient determined by dividing the sum of the VWAP of the common stock for each of the five lowest trading days during the 20 consecutive trading day period ending immediately preceding the 16th trading day after such Stock Combination Event, divided by a factor of five, or \$2.32, and the number of shares of common stock to be issued would be adjusted proportionately as set forth in the agreement limited to a maximum of 2,325,581 shares. The common warrants also provide that in the event the Company were to engage in an equity offering at a common stock price lower than the warrant exercise price prior to the second anniversary of a Stock Combination Event, the exercise price would be adjusted to the greater of the effective price of such equity offering or \$2.32 (see Note 14C Capital Structure).

A In November 2022 and throughout the quarter ended December 31, 2022, the Company sold shares through its ATM Sales Agreement. Per the warrant agreement in the August 2022 Offering, these sales qualified as an equity offering, and the sales price was less than the current exercise price of \$8.60. As a result, the common warrants exercise price was adjusted to \$3.30. On January 6, 2023, the Company consummated a 20 to 1 reverse stock split. Pursuant to the warrant agreement described above, the Company triggered a Stock Combination Event, and the warrant exercise price and number to be issued was adjusted based on the average of each of the lowest five trading days during the twenty-day consecutive trading day period beginning on December 30, 2022. Subsequently, as a result of the Securities Purchase Agreement in June 2023, the common warrants from the August 2022 Offering had an adjusted exercise price of \$2.32.

A Summary of warrants is as follows:

	Weighted Average Remaining Number of Shares	Average Contractual Life in Years	Outstanding at June 30, 2024
(1) \$6,075,880A \$3.71A	At 3.6A	Warrants exercised (2) \$176,000A \$0.0001A	At \$6.6A
December 31, 2024			

Pre-Funded Warrants, 1,806,434 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants. (2) Warrants exercised during the first quarter of fiscal 2025A were 176,000 of the Tranche B Warrants, which were exercised at a price of \$0.0001 per share. (3)A The number of warrants outstanding as of December 31, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,630,424A liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants. (4)A As pre-funded warrants do not have an expiration date, they have been excluded from the calculation of the weighted average remaining contractual life in years.

A Table of Contents A Note 17 - Earnings Per Share Basic net income or loss per common share is calculated by dividing net income or loss available to common stockholders by the basic weighted-average number of common shares outstanding for the respective period. Diluted net income or loss per common share is calculated by dividing adjusted net income or loss by the diluted weighted-average number of common shares outstanding, which includes the effect of potentially dilutive securities. Potentially dilutive securities for this calculation consist of warrants to purchase common stock that are either liability classified or equity classified (see Note 16A Warrants); employee stock options (see Note 15A Equity Incentive Plans); employee invested restricted stock (see Note 15A Equity Incentive Plans); and employee invested restricted stock units (see Note 15A Equity Incentive Plans).

A For the three and six months ended December 31, 2024, and 2023, if the Company incurred a net loss from continuing operations; a net loss from discontinued operations, net of tax; or a net loss then the Company did not include common equivalent shares in the computation of diluted net loss from continuing operations per share; diluted net loss from discontinued operations, net of tax; or diluted net loss per share because the effect would have been anti-dilutive. The following is a reconciliation of the numerator and denominator used in the basic per share calculations:

	Three Months Ended	Six Months Ended
December 31,		

Numerator Denominator Net income (loss) from continuing operations \$665A \$619A \$1,758A \$(6,854) Net income (loss) from discontinued operations, net of tax \$123A \$504A \$(1,486) Net income (loss) \$788A \$(220A) Adjusted numerator - net loss \$834A \$(228A) Adjustment for change in fair value of warrant liabilities \$3,016A \$(5,896A) Adjusted numerator - net (loss) income from continuing operations \$665A \$619A \$1,758A \$(6,854) Denominator: Basic weighted-average common shares outstanding \$6,132,060A \$5,517,670A \$6,100,204A \$5,499,951A Dilutive effect of warrants to purchase common stock \$2,342,087A \$2,342,087A Dilute weighted-average common shares outstanding \$8,485,112A \$7,872,794A \$5,499,951A Per share calculation: \$0.01A \$(0.15) \$0.06A \$(0.27) NET INCOME (LOSS) Numerator: \$834A \$(228A) Denominator: \$8,485,112A \$7,872,794A \$5,499,951A Diluted net income (loss) \$0.01A \$(0.15) \$0.06A \$(0.27) DILUTED: CONTINUING OPERATIONS Numerator: \$834A \$(228A) Denominator: \$8,485,112A \$7,872,794A \$5,499,951A Diluted net income (loss) \$0.01A \$(0.15) \$0.06A \$(0.27) DISCONTINUED OPERATIONS Numerator: \$123A \$(1,486) Denominator: \$123A \$(1,486) Diluted net loss (loss) \$0.01A \$(0.15) \$

business to a private, e-commerce focused company. The divested business encompasses the established e-commerce platform, certain inventory and associated consumer brands, intellectual property, external workforce and contracts, and provides for the Company to receive contingent consideration payments on certain future sales of former Consumer Health business products. The accounting requirements for reporting the Consumer Health business as discontinued operation were met when the wind down and divestiture was completed on July 31, 2024. Accordingly, the accompanying unaudited consolidated financial statements for all periods presented reflect this business as a discontinued operation and certain assets and liabilities of discontinued operations have been reclassified to the current assets of discontinued operations; non-current assets of discontinued operations; and current liabilities of discontinued operations financial statement line items on the accompanying unaudited consolidated balance sheet as of June 30, 2024. The Company elected to record the contingent consideration portion of the arrangement when the consideration is determined to be realizable and, therefore, the Company did not record a contingent consideration asset at the transaction date and any subsequent proceeds will not be recognized until the contingent consideration asset is realizable, at which point the Company recognizes it to income (loss) from discontinued operations. The key components of net income (loss) from discontinued operations, net of tax for the three and six months ended December 31, 2024, and 2023, were as follows:

Three Months Ended	Six Months Ended
December 31, 2024	December 31, 2024
Net revenue	(in thousands)
\$ 4,186	\$ 717
\$ 8,468	Cost of sales
(2,586)	(359)
(5,122)	Selling and marketing
(1,358)	(155)
(2,689)	General and administrative
(9)	(4)
(19)	Recognized contingent consideration
175	175
587	587
Loss on divestiture	
(52)	(48)
(26)	(48)
Net income (loss) from discontinued operations, net of tax	
\$ 123	(839)
\$ 504	(1,486)

The key components of assets and liabilities of discontinued operations as of June 30, 2024, were as follows:

June 30, 2024	(in thousands)																																																																																																																																																																												
ASSETS	Current assets of discontinued operations																																																																																																																																																																												
Accounts receivable, net	\$ 91																																																																																																																																																																												
Inventories	\$ 492																																																																																																																																																																												
Prepaid expenses and other current assets	\$ 538																																																																																																																																																																												
Total current assets of discontinued operations	\$ 1,121																																																																																																																																																																												
Non-current assets of discontinued operations	Other non-current assets																																																																																																																																																																												
\$ 44	Total current and non-current assets of discontinued operations																																																																																																																																																																												
\$ 1,165	LIABILITIES																																																																																																																																																																												
Current liabilities of discontinued operations	Accounts payable																																																																																																																																																																												
\$ 126	Accrued liabilities																																																																																																																																																																												
\$ 431	Total current liabilities of discontinued operations																																																																																																																																																																												
\$ 557	Table of Contents																																																																																																																																																																												
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	This discussion should be read in conjunction with the Company's 2024 Form 10-K. The following discussion and analysis contain forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those projected in the forward-looking statements. For additional information regarding these risks and uncertainties, please see the risk factors included in the Company's 2024 Form 10-K, and in Part II, Item 1A of this Form 10-Q. Objective The purpose of the Management's Discussion and Analysis (the "MD&A") is to present information that management believes is relevant to an assessment and understanding of our results of operations and cash flows for the three and six months ended December 31, 2024, and our financial condition as of December 31, 2024. The MD&A is provided as a supplement to, and should be read in conjunction with, our unaudited consolidated financial statements and notes thereto. Overview We are a pharmaceutical company focused on commercializing novel therapeutics. Our strategy is to become a leading pharmaceutical company that improves the lives of patients. We use a focused approach of in-licensing, acquiring, developing, and commercializing novel prescription therapeutics in order to continue building our portfolio of revenue-generating products and leveraging our commercial team's expertise to build leading brands within large therapeutic markets. Our primary focus is on commercializing innovative prescription products that address conditions frequently developed or diagnosed in childhood, including ADHD. We are focusing our efforts on accelerating the growth of our commercial business and achieving positive operating cash flows. To achieve these goals, we indefinitely suspended active development of our clinical development programs and have wound down and divested unprofitable operations. In July 2024 we completed the wind down and divestiture of our Consumer Health business (see Part I, Item 1, Note 20A "Discontinued Operations in this Form 10-Q for further detail) and now operate our business as a single operating and reporting segment, which is focused on our prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios, the ADHD Portfolio and the Pediatric Portfolio. The ADHD Portfolio consists of products for the treatment of ADHD, primarily Adzenys (amphetamine), an extended-release orally disintegrating tablet and Cotempla (methylphenidate), an extended-release orally disintegrating tablet. The Pediatric Portfolio consists primarily of Karbinal (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency. During the fourth quarter of fiscal 2024, we successfully completed the transition of all manufacturing of our ADHD products to a United States-based third-party contract manufacturer to improve the profitability of these products. In July 2023, we entered into an exclusive collaboration, distribution and supply agreement with Medomie, a privately owned pharmaceutical company, for Medomie to sell Adzenys and Cotempla in Israel and the Palestinian Authority. In September 2024, we entered into an exclusive collaboration, distribution and supply agreement with Lupin, a subsidiary of global pharmaceutical company Lupin Limited, for Lupin to sell Adzenys and Cotempla in Canada. We will supply Adzenys and Cotempla to Medomie and Lupin based on forecasts and provide various product commercialization resources. Medomie and Lupin are responsible for seeking local regulatory approvals and marketing authorizations for both Adzenys and Cotempla, which is expected to occur over the next 18 to 24 months. The agreement with Medomie and the agreement with Lupin represent our first and second international commercial agreements for Adzenys and Cotempla, respectively. In light of our own business activities and external developments in the biopharmaceutical industry, we regularly review our performance, prospects and risks such as the potential impact to our business resulting from our competitive landscape (i.e., entry of generic competitors, payer pressures, new branded entrants, etc.). These reviews have included consideration of potential partnerships, collaborations, and other strategic transactions such as acquisitions or divestitures of programs or technology to enhance stockholder value. We continue to evaluate potential strategic transactions and business combinations, but there can be no guarantee that we will be able to enter into such transactions, and there can be no guarantee that such transactions will achieve our desired goals. Business Environment We continue to experience inflationary pressure and have experienced supply chain disruptions related to the sourcing of raw materials, energy, logistics and labor. While we do not have sales or operations in Russia or Ukraine and we do not expect to have significant sales or operations in the Middle East, it is possible that the conflict or actions taken in response, could adversely affect some of our markets and suppliers, economic and financial markets, costs and availability of energy and materials, or cause further supply chain disruptions. We expect that inflationary pressures and supply chain disruptions could continue to be significant across the business throughout fiscal 2025. We have not experienced stock outages for our ADHD products since the launch of those products, and the pediatric product supply has remained adequate to satisfy demand for the preceding four years. In October 2024, we received a Paragraph IV Certification Notice Letter (the "Notice Letter") from Granules Pharmaceuticals, Inc. (the "Granules"), stating that it intends to market a generic version of Adzenys before the expiration of all patents currently listed in the Orange Book. The Notice Letter states that Granules' NDA for the generic version of Adzenys contains a Paragraph IV certification alleging that these patents are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the generic version of Adzenys. We timely filed a patent infringement lawsuit on December 11, 2024, against Granules to trigger a stay precluding the FDA from approving Granules' NDA for a generic version of Adzenys for up to 30 months or entry of judgment holding the patents invalid, unenforceable, or not infringed, whichever occurs first. We plan to vigorously enforce our intellectual property rights related to Adzenys. On November 11, 2024, we separated from Mark K. Oki as our Chief Financial Officer. Mr. Oki continued to work as a non-executive employee with us through December 1, 2024, and accordingly entered into a separation and release agreement (the "Separation Agreement"), pursuant to which Mr. Oki received payment for accrued but unused personal time off, a separation payment of \$0.5 million to be paid out over twelve months, COBRA coverage for up to 12 months and acceleration of any unvested options or restricted stock held by Mr. Oki. On November 11, 2024, Ryan J. Selhorn was appointed as our Chief Financial Officer, Corporate Secretary and Treasurer. Mr. Selhorn, age 43, previously served as our Executive Vice President, Finance and Business Optimization since November 2022. Prior to this, Mr. Selhorn was our Senior Vice President, Finance and Operations, Consumer Healthcare Division from February 2022 to November 2022 and as Vice President, Finance, Consumer Healthcare Division from February 2020 to February 2022. Mr. Selhorn served as Vice President and Chief Financial Officer from April 2018 at Innovus, a publicly held consumer healthcare company, until our acquisition of Innovus in February 2020. From August 2013 to April 2018, Mr. Selhorn served as Chief Financial Officer and Chief Accounting Officer of Signature Analytics, a privately held fractional Chief Financial Officer and accounting firm, where he also served as Chief Financial Officer of Medicinova, Inc., a publicly held biotechnology company. Mr. Selhorn worked at Grant Thornton LLP, a public accounting firm, from October 2003 to July 2013, most recently in the role of Senior Manager, Transaction Advisory Services. Mr. Selhorn received his B.S./B.A., Accounting and Finance from Georgetown University and is a Certified Public Accountant (inactive). <table><tr><td>Table of Contents</td><td>Results of Operations</td></tr><tr><td>The results of operations for the three and six months ended December 31, 2024, compared to the three and six months ended December 31, 2023, is as follows:</td><td>Three Months Ended</td></tr><tr><td></td><td>Six Months Ended</td></tr><tr><td>Net revenue</td><td>(in thousands)</td></tr><tr><td>\$ 16,221</td><td>\$ 18,748</td></tr><tr><td>\$ 2,527</td><td>\$ 32,795</td></tr><tr><td>\$ 36,565</td><td>\$ 3,770</td></tr><tr><td>Cost of sales</td><td>\$ 5,435</td></tr><tr><td>\$ 4,145</td><td>\$ 1,290</td></tr><tr><td>\$ 10,024</td><td>\$ 8,924</td></tr><tr><td>\$ 1,100</td><td>Gross profit</td></tr><tr><td>\$ 10,786</td><td>\$ 14,603</td></tr><tr><td>\$ 3,817</td><td>\$ 22,771</td></tr><tr><td>\$ 27,641</td><td>\$ 4,870</td></tr><tr><td>Operating expenses:</td><td>Selling and marketing</td></tr><tr><td>5,272</td><td>5,218</td></tr><tr><td>54</td><td>10,931</td></tr><tr><td>11,309</td><td>(378)</td></tr><tr><td>General and administrative</td><td>4,449</td></tr><tr><td>4,800</td><td>(351)</td></tr><tr><td>9,574</td><td>11,095</td></tr><tr><td>(1,521)</td><td>Research and development</td></tr><tr><td>522</td><td>521</td></tr><tr><td>1</td><td>948</td></tr><tr><td>1,116</td><td>(168)</td></tr><tr><td>Amortization of intangible assets</td><td>921</td></tr><tr><td>918</td><td>3</td></tr><tr><td>1,842</td><td>1,842</td></tr><tr><td>Restructuring costs</td><td>1,317</td></tr><tr><td>1,317</td><td>2,101</td></tr><tr><td>2,101</td><td>4</td></tr><tr><td>2,101</td><td>Total operating expenses</td></tr><tr><td>12,481</td><td>11,457</td></tr><tr><td>1,024</td><td>25,396</td></tr><tr><td>25,362</td><td>34</td></tr><tr><td>(Loss) income from operations</td><td>(1,695)</td></tr><tr><td>(1,695)</td><td>3,146</td></tr><tr><td>(4,841)</td><td>(2,625)</td></tr><tr><td>2,279</td><td>(4,904)</td></tr><tr><td>Other income, net</td><td>140</td></tr><tr><td>96</td><td>44</td></tr><tr><td>682</td><td>680</td></tr><tr><td>2</td><td>Interest expense</td></tr><tr><td>(1,079)</td><td>(1,166)</td></tr><tr><td>187</td><td>(2,073)</td></tr><tr><td>(2,073)</td><td>(4,765)</td></tr><tr><td>Derivative warrant liabilities gain (loss)</td><td>3,016</td></tr><tr><td>(577)</td><td>3,593</td></tr><tr><td>5,896</td><td>(6,484)</td></tr><tr><td>12,380</td><td>Income (loss) from continuing operations before income tax expense</td></tr><tr><td>382</td><td>1,399</td></tr><tr><td>(1,017)</td><td>1,880</td></tr><tr><td>(6,074)</td><td>7,954</td></tr><tr><td>Income tax benefit (expense)</td><td>283</td></tr><tr><td>1</td><td>(780)</td></tr><tr><td>1,063</td><td>(122)</td></tr><tr><td>(780)</td><td>658</td></tr><tr><td>Net income (loss) from continuing operations</td><td>665</td></tr><tr><td>619</td><td>46</td></tr><tr><td>1,758</td><td>(6,854)</td></tr><tr><td>8,612</td><td>Net income (loss) from discontinued operations, net of tax</td></tr><tr><td>123</td><td>(839)</td></tr><tr><td>962</td><td>504</td></tr><tr><td>(1,486)</td><td>1,990</td></tr><tr><td>Net income (loss)</td><td>\$ 788</td></tr><tr><td>\$ (220)</td><td>\$ 1,008</td></tr><tr><td>\$ 2,262</td><td>\$ (8,340)</td></tr><tr><td>\$ 10,602</td><td>Net Revenue</td></tr></table> Net revenue by portfolio for the three and six months ended December 31, 2024, compared to the three and six months ended December 31, 2023, is as follows: <table><tr><td>Three Months Ended</td><td>Six Months Ended</td></tr><tr><td>December 31, 2024</td><td>December 31, 2024</td></tr><tr><td>Change</td><td>Change</td></tr><tr><td>(in thousands)</td><td>(in thousands)</td></tr><tr><td>ADHD Portfolio</td><td>\$ 13,816</td></tr><tr><td>\$ 16,572</td><td>(2,756)</td></tr><tr><td>\$ 29,080</td><td>\$ 31,700</td></tr><tr><td>(2,620)</td><td>Pediatric Portfolio</td></tr><tr><td>2,400</td><td>2,145</td></tr><tr><td>255</td><td>3,693</td></tr><tr><td>4,710</td><td>(1,017)</td></tr><tr><td>Other</td><td>5</td></tr><tr><td>31</td><td>(26)</td></tr><tr><td>22</td><td>155</td></tr><tr><td>(133)</td><td>Total net revenue</td></tr><tr><td>\$ 16,221</td><td>\$ 18,748</td></tr><tr><td>\$ (2,527)</td><td>\$ 32,795</td></tr><tr><td>\$ 36,565</td><td>\$ (3,770)</td></tr></table> 35 Table of Contents During the six months ended December 31, 2024, net revenue decreased by \$3.8 million, or 10%, compared to the same period ended December 31, 2023, primarily due to a decrease in net revenue from the Pediatric Portfolio driven by payer changes last fiscal year that negatively affected prescription coverage and a decrease in ADHD Portfolio net revenue partially offset by a \$3.3 million increase in net revenue in the first quarter of fiscal 2025 related to a decrease in estimated variable consideration as a result of successful negotiations with a vendor. During the three months ended December 31, 2024, net revenue decreased by \$2.5 million, or 13%, compared to the same period ended December 31, 2023, primarily due to a decrease of \$2.8 million in the ADHD Portfolio as the macro trends continue to show a return to a more normalized status following the competitor stimulant shortages over the past 18 months, which helped to temporarily increase ADHD Portfolio net revenue in prior periods. The decrease in the ADHD Portfolio is partially offset by an increase in the Pediatric Portfolio which is driven by the success of initiatives we have implemented to increase coverage and promotion. Gross Profit During the three and six months ended December 31, 2024, gross profit decreased by \$3.8 million, or 26%, and \$4.9 million, or 18%, compared to the same periods ended December 31, 2023, respectively. Gross profit percentage was 66% and 69% for the three and six months ended December 31, 2024, compared to 78% and 76% for the same periods ended December 31, 2023, respectively. The decrease in gross profit percentage is primarily related to increased cost of sales for our ADHD Portfolio inventory as we sell through self-manufactured inventory burdened with certain fixed costs associated with its manufacture, which were capitalized into inventory costs in prior periods and is expected to normalize in the coming quarters as we finish selling through our self-manufactured inventory. Selling and Marketing During the three months ended December 31, 2024, selling and marketing expense was relatively flat compared to the same period ended December 31, 2023, and during the six months ended December 31, 2024, selling and marketing expense decreased by \$0.4 million, or 3%, compared to the same period ended December 31, 2023. Selling and marketing expense decreases are primarily driven by reduced commission expense and variable commercial marketing program fees in response to lower revenue, partially offset by increases in labor and service costs. General and Administrative During the three and six months ended December 31, 2024, general and administrative expense decreased by \$0.4 million, or 7% and \$1.5 million, or 14% compared to the same periods ended December 31, 2023. The decrease is primarily a result of continued cost reduction efforts and improved operational efficiencies. Research and Development During the three and six months ended December 31, 2024, research and development expense was relatively flat compared to the same periods ended December 31, 2023. Our research and development costs are primarily associated with support for our commercialized products and costs associated with maintaining our intellectual property on our AR-101 asset, for which we have indefinitely suspended clinical development. Amortization of Intangible Assets During the three and six months ended December 31, 2024, amortization expense of intangible assets, excluding amounts included in cost of sales, was relatively consistent compared to the same periods ended December 31, 2023. Restructuring Costs During the three and six months ended December 31, 2024, we incurred \$1.3 million and \$2.1 million of restructuring costs, respectively. Related to our previously announced operational realignment and related costs. During the three and six months ended December 31, 2023, no restructuring costs were incurred. 36 Table of Contents Other Income, Net During the three and six months ended December 31, 2024, other income, net was relatively consistent compared to the same periods ended December 31, 2023. Interest Expense During the three and six months ended December 31, 2024, interest expense decreased by \$0.2 million, or 15% and \$0.5 million, or 19%, compared to the same periods ended December 31, 2023, primarily due to the extinguishment of our \$15.0 million term loan while entering into the \$13.0 million Eclipse Term Loan on more favorable terms during the fourth quarter of fiscal 2024. Derivative Warrant Liabilities Gain (Loss) The fair value of derivative warrant liabilities is calculated using either the Black-Scholes option pricing model or the Monte Carlo simulation model and is valued at each reporting period, and changes are reflected through income or expense. For the three and six months ended December 31, 2024, we recognized an unrealized gain of \$3.0 million and \$5.9 million, respectively, from the fair value adjustment primarily driven by a decrease in our stock price during the three and six months ended December 31, 2024. For the three and six months ended December 31, 2023, we recognized an unrealized loss of \$0.6 million and \$6.5 million, respectively, from the fair value adjustment primarily driven by an increase in our stock price during the three and six months ended December 31, 2023. Income Tax Expense For income (loss) from continuing operations we recorded an income tax benefit of \$0.3 million, which represented an effective tax rate of negative 74.1% and income tax expense of \$0.8 million, which represented an effective tax rate of 55.8%, for the three months ended December 31, 2024, and 2023, respectively. For income (loss) from continuing operations we recorded an income tax expense of \$0.1 million, which represented an effective tax rate of 6.5% and income tax expense of \$0.8 million, which represented an effective tax rate of negative 12.8% for the six months ended December 31, 2024, and 2023, respectively. These effective tax rates were primarily driven by the limitations on losses as a result of Section 382 of the Internal Revenue Code changes in ownership coupled with existing valuation allowances, the divestiture of our Consumer Health business that occurred during the first quarter of fiscal 2025 and changes to our first quarter of fiscal 2025 projections, which resulted in an income tax benefit for the current quarter. A Net Income (Loss) from Discontinued Operations, Net of Tax A Net income (loss) from discontinued operations, net of tax is related to the	Table of Contents	Results of Operations	The results of operations for the three and six months ended December 31, 2024, compared to the three and six months ended December 31, 2023, is as follows:	Three Months Ended		Six Months Ended	Net revenue	(in thousands)	\$ 16,221	\$ 18,748	\$ 2,527	\$ 32,795	\$ 36,565	\$ 3,770	Cost of sales	\$ 5,435	\$ 4,145	\$ 1,290	\$ 10,024	\$ 8,924	\$ 1,100	Gross profit	\$ 10,786	\$ 14,603	\$ 3,817	\$ 22,771	\$ 27,641	\$ 4,870	Operating expenses:	Selling and marketing	5,272	5,218	54	10,931	11,309	(378)	General and administrative	4,449	4,800	(351)	9,574	11,095	(1,521)	Research and development	522	521	1	948	1,116	(168)	Amortization of intangible assets	921	918	3	1,842	1,842	Restructuring costs	1,317	1,317	2,101	2,101	4	2,101	Total operating expenses	12,481	11,457	1,024	25,396	25,362	34	(Loss) income from operations	(1,695)	(1,695)	3,146	(4,841)	(2,625)	2,279	(4,904)	Other income, net	140	96	44	682	680	2	Interest expense	(1,079)	(1,166)	187	(2,073)	(2,073)	(4,765)	Derivative warrant liabilities gain (loss)	3,016	(577)	3,593	5,896	(6,484)	12,380	Income (loss) from continuing operations before income tax expense	382	1,399	(1,017)	1,880	(6,074)	7,954	Income tax benefit (expense)	283	1	(780)	1,063	(122)	(780)	658	Net income (loss) from continuing operations	665	619	46	1,758	(6,854)	8,612	Net income (loss) from discontinued operations, net of tax	123	(839)	962	504	(1,486)	1,990	Net income (loss)	\$ 788	\$ (220)	\$ 1,008	\$ 2,262	\$ (8,340)	\$ 10,602	Net Revenue	Three Months Ended	Six Months Ended	December 31, 2024	December 31, 2024	Change	Change	(in thousands)	(in thousands)	ADHD Portfolio	\$ 13,816	\$ 16,572	(2,756)	\$ 29,080	\$ 31,700	(2,620)	Pediatric Portfolio	2,400	2,145	255	3,693	4,710	(1,017)	Other	5	31	(26)	22	155	(133)	Total net revenue	\$ 16,221	\$ 18,748	\$ (2,527)	\$ 32,795	\$ 36,565	\$ (3,770)
Table of Contents	Results of Operations																																																																																																																																																																												
The results of operations for the three and six months ended December 31, 2024, compared to the three and six months ended December 31, 2023, is as follows:	Three Months Ended																																																																																																																																																																												
	Six Months Ended																																																																																																																																																																												
Net revenue	(in thousands)																																																																																																																																																																												
\$ 16,221	\$ 18,748																																																																																																																																																																												
\$ 2,527	\$ 32,795																																																																																																																																																																												
\$ 36,565	\$ 3,770																																																																																																																																																																												
Cost of sales	\$ 5,435																																																																																																																																																																												
\$ 4,145	\$ 1,290																																																																																																																																																																												
\$ 10,024	\$ 8,924																																																																																																																																																																												
\$ 1,100	Gross profit																																																																																																																																																																												
\$ 10,786	\$ 14,603																																																																																																																																																																												
\$ 3,817	\$ 22,771																																																																																																																																																																												
\$ 27,641	\$ 4,870																																																																																																																																																																												
Operating expenses:	Selling and marketing																																																																																																																																																																												
5,272	5,218																																																																																																																																																																												
54	10,931																																																																																																																																																																												
11,309	(378)																																																																																																																																																																												
General and administrative	4,449																																																																																																																																																																												
4,800	(351)																																																																																																																																																																												
9,574	11,095																																																																																																																																																																												
(1,521)	Research and development																																																																																																																																																																												
522	521																																																																																																																																																																												
1	948																																																																																																																																																																												
1,116	(168)																																																																																																																																																																												
Amortization of intangible assets	921																																																																																																																																																																												
918	3																																																																																																																																																																												
1,842	1,842																																																																																																																																																																												
Restructuring costs	1,317																																																																																																																																																																												
1,317	2,101																																																																																																																																																																												
2,101	4																																																																																																																																																																												
2,101	Total operating expenses																																																																																																																																																																												
12,481	11,457																																																																																																																																																																												
1,024	25,396																																																																																																																																																																												
25,362	34																																																																																																																																																																												
(Loss) income from operations	(1,695)																																																																																																																																																																												
(1,695)	3,146																																																																																																																																																																												
(4,841)	(2,625)																																																																																																																																																																												
2,279	(4,904)																																																																																																																																																																												
Other income, net	140																																																																																																																																																																												
96	44																																																																																																																																																																												
682	680																																																																																																																																																																												
2	Interest expense																																																																																																																																																																												
(1,079)	(1,166)																																																																																																																																																																												
187	(2,073)																																																																																																																																																																												
(2,073)	(4,765)																																																																																																																																																																												
Derivative warrant liabilities gain (loss)	3,016																																																																																																																																																																												
(577)	3,593																																																																																																																																																																												
5,896	(6,484)																																																																																																																																																																												
12,380	Income (loss) from continuing operations before income tax expense																																																																																																																																																																												
382	1,399																																																																																																																																																																												
(1,017)	1,880																																																																																																																																																																												
(6,074)	7,954																																																																																																																																																																												
Income tax benefit (expense)	283																																																																																																																																																																												
1	(780)																																																																																																																																																																												
1,063	(122)																																																																																																																																																																												
(780)	658																																																																																																																																																																												
Net income (loss) from continuing operations	665																																																																																																																																																																												
619	46																																																																																																																																																																												
1,758	(6,854)																																																																																																																																																																												
8,612	Net income (loss) from discontinued operations, net of tax																																																																																																																																																																												
123	(839)																																																																																																																																																																												
962	504																																																																																																																																																																												
(1,486)	1,990																																																																																																																																																																												
Net income (loss)	\$ 788																																																																																																																																																																												
\$ (220)	\$ 1,008																																																																																																																																																																												
\$ 2,262	\$ (8,340)																																																																																																																																																																												
\$ 10,602	Net Revenue																																																																																																																																																																												
Three Months Ended	Six Months Ended																																																																																																																																																																												
December 31, 2024	December 31, 2024																																																																																																																																																																												
Change	Change																																																																																																																																																																												
(in thousands)	(in thousands)																																																																																																																																																																												
ADHD Portfolio	\$ 13,816																																																																																																																																																																												
\$ 16,572	(2,756)																																																																																																																																																																												
\$ 29,080	\$ 31,700																																																																																																																																																																												
(2,620)	Pediatric Portfolio																																																																																																																																																																												
2,400	2,145																																																																																																																																																																												
255	3,693																																																																																																																																																																												
4,710	(1,017)																																																																																																																																																																												
Other	5																																																																																																																																																																												
31	(26)																																																																																																																																																																												
22	155																																																																																																																																																																												
(133)	Total net revenue																																																																																																																																																																												
\$ 16,221	\$ 18,748																																																																																																																																																																												
\$ (2,527)	\$ 32,795																																																																																																																																																																												
\$ 36,565	\$ (3,770)																																																																																																																																																																												

wind down and divestiture of our Consumer Health business that was completed in the first quarter of fiscal 2025. See Part I, Item 1,Â Note 20Â  Discontinued Operations in this Form 10-Q for further detail. Â Liquidity and Capital Resources Â Sources of Liquidity Â We have obligations related to our loan agreements, milestone payments for licensed products, and manufacturing purchase commitments. Â We finance our operations through a combination of sales of our common stock and warrants, borrowings under our line of credit facilityÂ and from cash generated from operations. Â Shelf Registrations Â On September 26, 2024, we filed a shelf registration statement on Form S-3, which was declared effective by the SEC on October 15, 2024. This shelf registration statement coversÂ the offering, issuance and sale by usÂ of up to an aggregate of \$100.0 million of our common stock, preferred stock, debt securities, warrants, rights and units (the 2024Â Shelf). Through the filing date of this Form 10-QÂ \$100.0 million remainsÂ available under the 2024Â Shelf. This availability is subject to the SECs baby shelf limitation as set forth in SEC Instruction I.B.6 limitation to the Form S-3. Â 37 Table of Contents Â Eclipse Agreement Â In JuneÂ 2024, we and certain of ourÂ subsidiariesÂ entered into the Eclipse Amendment No. 5, with the Eclipse Lender. Under the Eclipse Agreement No. 5, we haveÂ two loan agreements, the Eclipse Term LoanÂ and the Eclipse Revolving Loan. Â The Eclipse Term LoanÂ consists of a principal amount of \$13.0 million, at an interest rate of SOFRÂ plus 7.0%, with a four-year term and a straight-line loan amortization period of seven years, which would provide for a loan balance at the end of the four-year term ofÂ \$5.6 million to be repaid on June 12, 2028, the maturity date. We useÂ the proceeds of the Eclipse Term Loan and a portion of the proceeds from warrant exercises described belowÂ to repayÂ in full a \$15.0 million term note. Â The Eclipse Revolving LoanÂ allows us to borrow up to \$14.5 million at an interest rate of SOFR plus 4.5%. In addition, we are required to pay an unused line fee of 0.5% of the average unused portion of the maximum Eclipse Revolving LoanÂ amount during the immediately preceding month. The ability to make borrowings and obtain advances of the Eclipse Revolving Loan remains subject to a borrowing base and reserve, and availability blockage requirements and the maturity date, as amended, is June 12, 2028. Â Cash Flows Â The following table shows cash flows for the six months ended December 31, 2024, and 2023: Â Â Â Six Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â (in thousands) Â Net cash provided by (used in) operating activities Â \$ 1,715 Â Â \$ (346) Â \$ 2,061 Â Net cash provided by (used in) investing activities Â \$ 526 Â Â \$ (250) Â \$ 776 Â Net cash used in financing activities Â \$ (1,849) Â \$ (2,860) Â \$ 1,011 Â Â Net Cash Provided By (Used In) Operating Activities Â Net cash provided by (used in) operating activities during these periods primarily reflectsÂ our net income (loss) from continuing operations, partially offset by cash provided by discontinued operations and changes in working capital and non-cash charges including stock-based compensation expense, derivative warrant liabilities gain or loss, depreciation, amortization and accretion, and other charges. Â During the six months ended December 31, 2024, net cash provided by operating activities totaled \$1.7Â million, whichÂ was primarilyÂ the result of an Â increase in accounts payable and accrued liabilities and a decrease in inventories, partially offset by increases in accounts receivable, Â prepaid expenses and other current assetsÂ andÂ cash used in operations (net income of \$2.3Â millionÂ offset primarily by non-cash depreciation, amortization and accretion, stock compensation expense and derivative warrant liabilities adjustment). Â During the six months ended December 31, 2023, net cash used in operating activities totaled \$0.4Â million. The use of cash was primarily the result of the decrease in accrued liabilities, partially offset by funds from the ERCA program recorded in other operating liabilities (see Note 2  Summary of Significant Accounting Policies and Note 9  Other Liabilities). Additionally, these were partially offset by positive cash earnings (net loss offset by non-cash depreciation, amortization and accretion, derivative warrant liabilities adjustment, and stock compensation expense). Â Net Cash Provided By (Used In) Investing Activities Â Net cash provided byÂ investing activities for the sixÂ months ended December 31, 2024, wasÂ driven by cash received from the sale of fixed assets, partially offset by cash payments for fixed asset purchases. Â Net cash used inÂ investing activities wasÂ nominal during the sixÂ months ended December 31, 2023. Â 38 Table of Contents Â Net Cash Used InÂ Financing Activities Â Net cash used in financing activities of \$1.8Â million during the six months ended December 31, 2024, was primarily from payments made to fixed payment arrangements and payments made on borrowings, partially offset by net proceeds received from the revolving credit facility.Â Â Net cash used in financing activities of \$2.9Â million during the six months ended December 31, 2023, was primarily from payments made to fixed payment arrangements and net payments made onÂ revolving credit facility. Â Contractual Obligations, Commitments and Contingencies Â As a result of our acquisitions and licensing agreements, we are contractually and contingently obliged to pay, when due, various fixed and contingent milestone payments. See Note 13 Â Commitments and Contingencies in the accompanying notes to the unaudited consolidated financial statementsÂ for further information. Â In May 2022, we entered into the Tuzistra License Agreement. Pursuant to such termination, as of December 31, 2024,Â we have accrued a settlement liability of \$5.8Â million payable to TrisÂ in other current liabilities on the consolidated balance sheet payable to Tris, with a provision that allows the CompanyÂ to pay interest on any principal amounts due but remaining unpaid past July 2024. Â Upon closing of the acquisition of a line of prescription pediatric products from Cerecor, Inc. in October 2019, we assumed payment obligations that require us to make fixed and product milestone payments.Â As of December 31, 2024, the Tris Karbinal Agreement accrued fixed payment arrangement balance was \$1.2Â millionÂ recorded in other current liabilities on the consolidated balance sheet. Â In connection with our acquisition of the assets from Rumpus VEDS, LLC, Rumpus Therapeutics, LLC, Rumpus Vascular, LLC (collectively, Rumpus), and only if we resume and ultimately complete clinical development of AR101 and gain regulatory clearances to commercialize the product in multiple markets around the world, we may be required to pay up to \$67.5 million in regulatory and commercial-based earn-out payments to Rumpus, which are primarily paid against commercial milestone achievements. Under the licensing agreement with Denovo Biopharma LLC (Denovo), we made a payment of \$0.6 million for a license fee in April 2022. In addition, upon the achievement of regulatory and commercial milestones, we may be required to pay up to \$101.7 million. Under the licensing agreement with Johns Hopkins University (JHU), upon achievement of regulatory and commercial milestone, we may be required to pay up to \$1.6 million to JHU. In fiscal 2022, two milestones payable to Rumpus were achieved totaling \$4.0 million, which were paid in 109,447 shares of common stock and \$2.6 million in cash. We also assumed the responsibility for royalties of 3.0% of net revenue from the product, with a minimum of \$20,000 per year, and upon the achievement of certain regulatory and commercial milestones, up to \$1.6 million. With clinical development currently suspended, only if and when we resume and ultimately complete clinical development of AR101, are substantially all milestone paymentsÂ payable to these parties. Â Critical Accounting Estimates Â The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the amounts of assets, liabilities, revenueÂ and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. For a detailed discussion about our critical accounting estimates, refer toÂ ourÂ 2024Â Form 10-K. Â Off-Balance Sheet Arrangements Â We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors. Â Â 39 Table of Contents Â ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Â We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide information under this item. Â ITEM 4. CONTROLS AND PROCEDURES Â Evaluation of Disclosure Controls and Procedures Â As required by Rules 13a-15(e) and 15d-15(e) under the Exchange Act, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Form 10-Q. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures wereÂ effective as of December 31, 2024, at reasonable assurance levels,Â in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the SECs rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.Â Accordingly, we believeÂ that the financial statements presented in this Form 10-Q present fairly,Â in all material respects, our financial position, results of operations and cash flows for the periods presented herein. Â Inherent Limitations on Effectiveness of Internal Controls over Financial Reporting Â Our management team, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdown can occur because of simple errors or mistakes. In particular, many of our current processes rely upon manual reviews and processes to ensure that neither human error nor system weakness has resulted in erroneous reporting of financial data. Â Changes in Internal Control over Financial Reporting Â There have been no changes in ourÂ internal control over financial reporting that occurred during the period covered by this Form 10-Q, that have a material effect, or are reasonably likely to have a material effect, on our internal control over financial reporting. Â 40 Table of Contents Â Â PART II. OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS Â From time to time, we become involved in or are threatened with legal disputes arising from our business and operations in the normal course of business. Most of these disputes are not likely to have a material effect on our business, financial condition, or operations. Â Witmer Class-Action Securities Litigation Â A stockholder derivative suit was filed on September 12, 2022, in the Delaware Chancery Court by Paul Witmer, derivatively and on behalf of all Aytu stockholders, against Armistice Capital, LLC, Armistice Capital Master Fund, Ltd., Steve Boyd (Armistices Chief Investment Officer and Managing Partner, and a former director of Aytu), and certain other current and former directors of Aytu, Joshua R. Disbrow, Gary Cantrell, John Donofrio, Jr., Michael Macaluso, Carl Dockery and Ketan B. Mehta. Plaintiff amended the complaint on April 5, 2023. The Amended Complaint dropped Mr. Macaluso as a defendant and alleges that (i) Armistice facilitated the sale of assets of Cerecor in 2019 and Innovus in 2020 to Aytu in exchange for convertible securities which it subsequently converted and sold at a profit on the open market; (ii) the Armistice defendants breached their fiduciary duties, were unjustly enriched and wasted corporate assets in connection with these acquisitions; (iii) the Armistice defendants breached their fiduciary duties by engaging in insider trading; and (iv) the other directors breached their fiduciary duties, and aided and abetted the Armistice defendants breaches of fiduciary duties, in connection with these acquisitions. The Amended Complaint sought unspecified damages, equitable relief, restitution, disgorgement of profits, enhanced governance and internal procedures, and attorneys fees. While the Company believes that this lawsuit is without merit and have vigorously defended against it, the Company agreed to settle the matter for various corporate governance modifications and the payment of plaintiffs attorneys fees. On January 13, 2025, the court approved the Settlement. Â Granules PIV Â On October 31, 2024, the CompanyÂ received a Paragraph IV Certification Notice Letter (Notice Letter) from Granules Pharmaceuticals, Inc. (Granules), stating that it intends to market a generic version of Adzenys before the expiration of all patents currently listed in the Orange Book. The Notice Letter states that Granules New Drug Application (NDA) for the generic version of Adzenys contains a Paragraph IV certification alleging that these patents are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the generic version of Adzenys. On December 11, 2024, the CompanyÂ filed a patent infringement lawsuit against Granules which triggeredÂ a stay precluding the United States Food and Drug Administration (FDA) from approving Granules NDA for a generic version of Adzenys for up to 30 months or entry of judgment holding the patents invalid, unenforceable, or not infringed, whichever occurs first. On January 7, 2025, Granules submitted an answer to the complaint. This litigation is ongoing, and a trial has been scheduled for to being on December 7, 2026. The Company plans to vigorously enforce its intellectual property rights related to Adzenys. Â Revive Investing Â The Company had been named as a nominal plaintiff in a lawsuit by two shareholders against Armistice Capital Master Fund, Ltd, entitled Revive Investing, LLC, et al v. Armistice Master Fund, Ltd, et al, Case 1:20-cv-02849-CMA-TPO, in the United States District Court for the District of Colorado, contending that Armistice was liable for short swing trading profits in violation of Section 16(b) of the Exchange Act for certain trades it made in Company stock in 2019 and 2020 and must disgorge those profits to the Company. That matter proceeded to trial before a jury, which on January 29, 2025, returned a verdict finding no liability. Â For a description of our material pending legal proceedings, see Note 13  Commitments and Contingencies of the notes to the unaudited consolidated financial statements included in Part I, Item 1 of this Form 10-Q, which is incorporated herein by reference. As of the filing of this report, no legal proceedings are pending against us that we believe individually or collectively are likely to have a materially adverse effect upon our financial condition, results of operations, or cash flows. Â 41 Table of Contents Â ITEM 1A. RISK FACTORS Â Our business faces significant risks and uncertainties. Certain important factors may have a material adverse effect on our business prospects, financial condition, and results of operations, and you should carefully consider them. The risk factors included in our 2024Â Form 10-KÂ have not materially changed, except as reflected in the following new risk factors: Â Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. Â The global credit and financial markets have experienced extreme volatility and disruptions (including as a result of actual or perceived changes in interest rates and economic inflation), which included severely diminished liquidity and credit availability, declines in consumer confidence, slower economic growth, high inflation, uncertainty about economic stability and swings in unemployment rates. The financial markets and the global economy may also be adversely affected by the impact of supply chain disruptions, labor shortages, fluctuations in currency exchange rates, changes in interest rates, military conflict, acts of terrorism or other geopolitical events. Sanctions imposed, and other actions taken, by the United States and other countries in response to geopolitical conflicts, including the one in Ukraine, may also continue to adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. There can be no assurance that a deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions, including our ability to purchase necessary supplies on acceptable terms, if at all. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to further delay or abandon clinical development plans, if we were to resume such development. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget. Â The United StatesÂ government has indicated its intent to alter its approach to international trade policy and in some cases to renegotiate, or potentially terminate, certain existing bilateral or multi-lateral trade agreements and treaties with foreign countries. In addition, the United StatesÂ government has initiated or is considering imposing tariffs on certain foreign goods. Related to this action, certain foreign governments, including China, have instituted or are considering imposing tariffs on certain United StatesÂ goods. It remains unclear what the United StatesÂ administration or foreign governments will or will not do with respect to tariffs or other international trade agreements and policies. A trade war or other governmental action related to tariffs or international trade agreements or policies has the potential to disrupt our research activities, affect our suppliers and/or the United States or global economy or certain sectors thereof and, thus, could adversely impact our businesses. Â 42 Table of Contents Â We are and may become involved in litigation or other proceedings from time to time relating to the enforcement or defense of patent and other intellectual property rights, which could cause us to divert our resources and could put our intellectual property at risk. Â To prevent infringement or unauthorized use of our intellectual property, we have in the past, and may in the future, need to file infringement claims. For example, on December 11, 2024, we filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Granules Pharmaceuticals, Inc. (see Part I, Item II,Â Managements Discussion and Analysis of Financial Condition and Results of Operations in this Form 10-QÂ for further detail of this matter). When we pursue litigation to stop another party from using the inventions claimed in any patents we own or control, that party has the right to ask the court to rule that such patents are invalid or should not be enforced against that third party. In addition to patent infringement lawsuits, we may decide to file interferences, oppositions, ex parte reexaminations, post-grant review, or inter partes review proceedings before the United StatesÂ Patent and Trademark Office (the USPTO) and corresponding foreign patent offices. Litigation and other proceedings relating to intellectual property are unpredictable and expensive and may consume time and resources and divert the attention of managerial and

[illegible]

I, Joshua R. Disbrow, certify that I have reviewed this Quarterly Report on Form 10-Q of Aytu BioPharma, Inc., dated February 12, 2025, and I am a Chief Executive Officer of Aytu BioPharma, Inc.

The following information contains forward-looking statements that are subject to risks and uncertainties. These forward-looking statements are based on our current expectations and assumptions as of the date of this report. Our actual results may differ materially from those indicated by these forward-looking statements due to various factors, including those discussed below. We caution you that these forward-looking statements are not guarantees of future performance and are subject to change without notice.

Risks and Uncertainties

Our business is subject to numerous risks and uncertainties, which could materially affect our financial condition, results of operations, and cash flows. The most significant risks include:

- Regulatory Risks:** Our business is highly regulated by the U.S. Food and Drug Administration (FDA) and other regulatory agencies. Changes in regulations or delays in obtaining necessary approvals could significantly impact our operations.
- Market Risks:** Our success depends on market acceptance of our products and services. Competition, changes in demand, and economic conditions could affect our revenue.
- Operational Risks:** Our operations involve complex processes and equipment. Operational inefficiencies, supply chain disruptions, or quality control issues could impact production and costs.
- Financial Risks:** Our financial performance is influenced by interest rates, foreign exchange fluctuations, and credit risk. We also face risks related to our debt obligations and capital structure.
- Talent Risks:** Our success relies on the expertise and retention of key personnel. Loss of senior management or difficulty attracting top talent could hinder our growth.

We will monitor these risks closely and implement strategies to mitigate their potential impact on our business.

Materiality

This report contains information that we believe is material to investors' decisions regarding our company. Materiality is determined based on the significance of the information to the overall picture of our company's financial health and operations.

Forward-Looking Statements

Statements made in this report that are not historical facts constitute forward-looking statements. These statements are based on our current beliefs and assumptions about future events and are subject to the same risks and uncertainties described above.

Legal Proceedings

There are no pending legal proceedings that we believe are likely to have a material effect on our financial condition, results of operations, or cash flows.

Other Information

In addition to the information provided in this report, we encourage investors to review our public filings, including our annual reports, quarterly reports, and press releases, for more detailed information about our company.

Contact Information

For further inquiries, please contact our Investor Relations department at [Phone Number] or [Email Address].

Signatures

/s/ Joshua R. Disbrow
Joshua R. Disbrow
Chief Executive Officer

/s/ Ryan J. Selhorn
Ryan J. Selhorn
Chief Financial Officer

Date: February 12, 2025

Location: [Address]

Witness: [Name]
[Title]
[Signature]

Notary Public: [Name]
[Title]
[Signature]

Exhibit 32.1 - Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10-Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc. for the period covered by this report.

Exhibit 32.2 - Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10-Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc. for the period covered by this report.

Exhibit 32.3 - Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10-Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc. for the period covered by this report.

Exhibit 32.4 - Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10-Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc. for the period covered by this report.

Exhibit 32.5 - Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10-Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc. for the period covered by this report.

Exhibit 32.6 - Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10-Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc. for the period covered by this report.

Exhibit 32.7 - Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10-Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc. for the period covered by this report.

Exhibit 32.8 - Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10-Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc. for the period covered by this report.

Exhibit 32.9 - Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10-Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc. for the period covered by this report.

Exhibit 32.10 - Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10-Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc. for the period covered by this report.

Exhibit 32.11 - Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10-Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc. for the period covered by this report.

Exhibit 32.12 - Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10-Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc. for the period covered by this report.

Exhibit 32.13 - Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10-Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc. for the period covered by this report.

Exhibit 32.14 - Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10-Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc. for the period covered by this report.

Exhibit 32.15 - Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10-Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc. for the period covered by this report.

Exhibit 32.16 - Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10-Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc. for the period covered by this report.

Exhibit 32.17 - Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10-Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc. for the period covered by this report.

Exhibit 32.18 - Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10-Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and

Other Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 995480 - Disclosure - Note 11 - Long-term Debt (Tables) link:calculationLink link:definitionLink link:presentationLink 995481 - Disclosure - Note 12 - Fair Value Considerations (Tables) link:calculationLink link:definitionLink link:presentationLink 995482 - Disclosure - Note 15 - Equity Incentive Plans (Tables) link:calculationLink link:definitionLink link:presentationLink 995483 - Disclosure - Note 16 - Warrants (Tables) link:calculationLink link:definitionLink link:presentationLink 995484 - Disclosure - Note 17 - Earnings Per Share (Tables) link:calculationLink link:definitionLink link:presentationLink 995485 - Disclosure - Note 20 - Discontinued Operations (Tables) link:calculationLink link:definitionLink link:presentationLink 995486 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995487 - Disclosure - Note 3 - Revenue (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995488 - Disclosure - Note 3 - Revenue - Disaggregation of Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 995489 - Disclosure - Note 4 - Inventories (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995490 - Disclosure - Note 4 - Inventories - Schedule of Inventories (Details) link:calculationLink link:definitionLink link:presentationLink 995491 - Disclosure - Note 5 - Property and Equipment (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995492 - Disclosure - Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 995493 - Disclosure - Note 6 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995494 - Disclosure - Note 6 - Leases - Lease Cost (Details) link:calculationLink link:definitionLink link:presentationLink 995495 - Disclosure - Note 6 - Leases - Lease Balance Sheet Information (Details) link:calculationLink link:definitionLink link:presentationLink 995496 - Disclosure - Note 6 - Leases - Lease Balance Sheet Information (Details) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 995497 - Disclosure - Note 6 - Leases - Schedule of Lease Liability Maturity (Details) link:calculationLink link:definitionLink link:presentationLink 995498 - Disclosure - Note 7 - Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995499 - Disclosure - Note 7 - Intangible Assets - Schedule of Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995500 - Disclosure - Note 7 - Intangible Assets - Future Amortization Expense (Details) link:calculationLink link:definitionLink link:presentationLink 995501 - Disclosure - Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995502 - Disclosure - Note 9 - Other Liabilities (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995503 - Disclosure - Note 9 - Other Liabilities - Schedule of Other Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995504 - Disclosure - Note 10 - Revolving Credit Facility (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995505 - Disclosure - Note 11 - Long-term Debt (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995506 - Disclosure - Note 11 - Long-term Debt - Schedule of Long-term Debt (Details) link:calculationLink link:definitionLink link:presentationLink 995507 - Disclosure - Note 11 - Long-term Debt - Future Principal Payments (Details) link:calculationLink link:definitionLink link:presentationLink 995508 - Disclosure - Note 12 - Fair Value Considerations (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995509 - Disclosure - Note 12 - Fair Value Considerations - Recurring Fair Value Measurements (Details) link:calculationLink link:definitionLink link:presentationLink 995510 - Disclosure - Note 12 - Fair Value Considerations - Summary of Level 3 Changes (Details) link:calculationLink link:definitionLink link:presentationLink 995511 - Disclosure - Note 12 - Fair Value Considerations - Summary of Level 3 Changes (Details) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 995512 - Disclosure - Note 12 - Fair Value Considerations - Valuation Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 995513 - Disclosure - Note 13 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995514 - Disclosure - Note 14 - Stockholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995515 - Disclosure - Note 15 - Equity Incentive Plans (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995516 - Disclosure - Note 15 - Equity Incentive Plans - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995517 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995518 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995519 - Disclosure - Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 995520 - Disclosure - Note 16 - Warrants (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995521 - Disclosure - Note 16 - Warrants - Schedule of Warrants Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink 995522 - Disclosure - Note 17 - Earnings Per Share - Schedule of Earnings Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 995523 - Disclosure - Note 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details) link:calculationLink link:definitionLink link:presentationLink 995524 - Disclosure - Note 19 - Restructuring Costs (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995525 - Disclosure - Note 20 - Discontinued Operations - Schedule of Discontinued Operations (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 aytu-20241231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 aytu-20241231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 aytu-20241231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual Derivative, Gain (Loss) on Derivative, Net Derivative warrant liabilities (gain) loss Significant Accounting Policies Note 3 - Revenue Note 4 - Inventories Note 5 - Property and Equipment Note 6 - Leases Note 7 - Intangible Assets Note 8 - Accrued Liabilities Liabilities, Noncurrent [Abstract] Note 9 - Other Liabilities Note 11 - Long-term Debt Note 12 - Fair Value Considerations Note 15 - Equity Incentive Plans Note 16 - Warrants Note 17 - Earnings Per Share Reverse Stock Split [Member] The conversion of a reverse stock split where there is a reduction in the shares outstanding. Note 20 - Discontinued Operations us-gaap LiabilitiesCurrent Total current liabilities Schedule of Maturities of Long-Term Debt [Table Text Block] Note 3 - Revenue - Disaggregation of Revenue (Details) Current liabilities of discontinued operations Total current liabilities of discontinued operations Note 4 - Inventories - Schedule of Inventories (Details) Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) Other Liabilities, Current Less: current portion of other liabilities Note 6 - Leases - Lease Cost (Details) Note 6 - Leases - Lease Balance Sheet Information (Details) Note 6 - Leases - Lease Balance Sheet Information (Details) (Parentheticals) Note 6 - Leases - Schedule of Lease Liability Maturity (Details) Note 7 - Intangible Assets - Schedule of Intangible Assets (Details) Note 7 - Intangible Assets - Future Amortization Expense (Details) Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details) Note 9 - Other Liabilities - Schedule of Other Liabilities (Details) Note 11 - Long-term Debt - Schedule of Long-term Debt (Details) Note 11 - Long-term Debt - Future Principal Payments (Details) Note 12 - Fair Value Considerations - Recurring Fair Value Measurements (Details) Share-Based Payment Arrangement, Option, Activity [Table Text Block] Note 12 - Fair Value Considerations - Summary of Level 3 Changes (Details) Note 12 - Fair Value Considerations - Summary of Level 3 Changes (Details) (Parentheticals) Granted, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) Note 12 - Fair Value Considerations - Valuation Assumptions (Details) Vested, weighted average grant date fair value (in dollars per share) Note 15 - Equity Incentive Plans - Stock Option Activity (Details) Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details) Forfeited, weighted average grant date fair value (in dollars per share) us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Unvested, weighted average grant date fair value (in dollars per share) Unvested, weighted average grant date fair value (in dollars per share) Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details) us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Forfeited, shares (in shares) Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details) Note 16 - Warrants - Schedule of Warrants Outstanding (Details) us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares) Unvested, shares (in shares) Unvested, shares (in shares) Note 17 - Earnings Per Share - Schedule of Earnings Per Share (Details) Note 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details) us-gaap LongTermDebtAndCapitalLeaseObligationsCurrent Less: current portion of debt Note 20 - Discontinued Operations - Schedule of Discontinued Operations (Details) Notes To Financial Statements Granted, shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) Notes To Financial Statements [Abstract] us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Vested, shares (in shares) Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Nonvested Restricted Stock Shares Activity [Table Text Block] Current portion of debt Less: current portion of debt Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] aytu SupplyAndDistributionAgreementExtensionTerm Supply and Distribution Agreement, Extension Term (Year) Represents the extension term of a supply and distribution agreement. Exercisable, options, weighted average exercise price (in dollars per share) Exercisable, options, weighted average remaining contractual life (Year) Exercisable, options (in shares) Outstanding, options, weighted average remaining contractual life (Year) us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, options, weighted average exercise price (in dollars per share) Outstanding, options, weighted average exercise price (in dollars per share) Forfeited/Cancelled, options, weighted average exercise price (in dollars per share) Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Goodwill and Intangible Assets Disclosure [Text Block] Granted, options, weighted average exercise price (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) Accrued liabilities Total accrued liabilities Accrued employee compensation us-gaap SettlementLiabilitiesCurrent Settlement Liabilities, Current Accounts payable Secured Debt [Member] us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) Outstanding, options (in shares) Outstanding, options (in shares) Cash received from sales of fixed assets Other accrued liabilities us-gaap PolicyTextBlockAbstract Accounting Policies us-gaap PaymentsToAcquireProductiveAssets Cash payments for fixed asset purchases us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) Dilutive effect of warrants to purchase common stock (in shares) The Pediatric Portfolio [Member] Represents the Pediatric Portfolio. Dilutive effect of unvested restricted stock and restricted stock units (in shares) us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) Non-cash investing and financing activities: us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Cash paid for income taxes Tris Karbinal Agreement [Member] Relating to Tris Karbinal Agreement. Product and Service, Other [Member] aytu FinitelivedIntangibleAssetUsefulLifeRenewablePeriod Finite-Lived Intangible Asset, Useful Life, Renewable Period (Year) Represents the renewable period for a finite-lived intangible asset. Employee retention credit Employee Retention Credit Represents the amount of employee retention credit. Liabilities, Current [Abstract] Developed Technology Rights [Member] Return reserve Represents the amount of return reserve classified as current. Accrued customer and product related fees Represents the amount of accrued customer and product related fees classified as current. Fixed payment arrangements Fixed Payment Arrangements Represents the amount of fixed payment arrangements. us-gaap Assets Total assets Supplemental disclosure of cash flow information: Equity Warrants [Member] Relating to Equity Warrants. us-gaap AssetsOfDisposalGroupIncludingDiscontinuedOperation Total current and non-current assets of discontinued operations Plan Name [Axis] Technology-Based Intangible Assets [Member] Plan Name [Domain] us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net income (loss) us-gaap NetIncomeLossAvailableToCommonStockholdersDiluted Adjusted numerator - net loss us-gaap DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet Accounts receivable, net Adjustment for change in fair value of warrant liabilities Manufacturing Equipment [Member] Represents manufacturing equipment. Share-Based Payment Arrangement [Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Office Equipment, Furniture and Other [Member] Represents office equipment, furniture and other. Finite-Lived Intangible Assets, Major Class Name [Domain] Award Type [Domain] Net income (loss) from continuing operations Net income (loss) from continuing operations us-gaap IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity Net income (loss) from discontinued operations, net of tax Award Type [Axis] Net income (loss) Net income (loss) Net income (loss) us-gaap FiniteLivedIntangibleAssetsAccumulatedAmortization Finite-lived intangible assets, amortization Finite-lived intangible assets, net Total future amortization expense Intangible assets, net Restricted Stock Units (RSUs) [Member] Finite-lived intangible assets, gross Restricted Stock [Member] Accrued program liabilities Carrying value as of the balance sheet date of obligations incurred and payable for program related liabilities. Share-Based Payment Arrangement, Option [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] aytu ClassOfWarrantOrRightIssuedDuringPeriod Class of Warrant or Right, Issued During Period (in shares) The number of warrants or rights issued during period. Warrants or Rights Disclosure [Text Block] The entire disclosure for warrants or rights. Commitments and Contingencies Disclosure [Text Block] The 2015 Plan [Member] Represents the Aytu BioScience 2015 Stock Option and Incentive Plan (the â2015 Planâ). us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less: accumulated depreciation and amortization Property and equipment, net Property and equipment, net Property and equipment, gross Long-Term Debt, Type [Axis] Long-Term Debt, Type [Domain] aytu EmployeeRetentionCreditVendorFee Employee Retention Credit, Vendor Fee Represents the amount of vendor fee from employee retention credit during the period. aytu ClassOfWarrantOrRightExercisedDuringPeriod Class of Warrant or Right, Exercised During Period (in shares) Warrants exercised (2) (in shares) The number of warrants or rights exercised during period. us-gaap DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax Income (loss) from discontinued operations before income taxes us-gaap DiscontinuedOperationTaxEffectOfDiscontinuedOperation Income tax expense Net income (loss) from discontinued operations, net of tax Net income (loss) from discontinued operations, net of tax On or Before January 26, 2023 [Member] Relating to on or before January 26, 2023. aytu LineOfCreditFacilityTerminationFeePercentageOfCommitment Line of Credit Facility, Termination, Fee, Percentage of Commitment Represents the percentage of commitment used as a termination fee of a line of credit facility. Cash flows from investing activities: us-gaap DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax Loss on divestiture Eclipse Business Capital LLC Loan Agreement [Member] Relating to Eclipse Business Capital LLC Loan Agreement. Outstanding, weighted average remaining contractual term (Year) The weighted average period of remaining contractual life of warrants or rights. Liability Warrants [Member] Represents liability warrants. us-gaap IncreaseDecreaseInOtherOperatingCapitalNet Other operating assets and liabilities, net Equity-based Warrants [Member] Represents equity-based warrants. Net income (loss) per share (note 17): Earnings Per Share [Text Block] After January 26, 2024 But Before January 26, 2025 [Member] Relating to after January 26, 2024 but before January 26, 2025. After January 26, 2023 But Before January 26, 2024 [Member] Relating to after January 26, 2023 but before January 26, 2024. Office Space in Berwyn, Pennsylvania [Member] Relating to an office space in Berwyn, Pennsylvania. Other Warrants [Member] Relating to other warrants. aytu OperatingLeaseUndiscountedMinimumMonthlyPayment Operating Lease, Undiscounted Minimum Monthly Payment Represents the undiscounted minimum monthly payment on an operating lease. aytu DebtInstrumentFinalPayment Debt Instrument, Final Payment Represents the final payment of a debt instrument. aytu DebtInstrumentPrepaymentFeePercentage Debt Instrument, Prepayment Fee, Percentage Represents the percentage of loan that is payable as a prepayment fee. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Avenue Capital Warrants [Member] Relating to the Avenue Capital Warrants. Avenue Capital Loan [Member] Relating to the Avenue Capital Loan. us-

gaap_IncomeTaxExpenseBenefitIncome Tax Expense (Benefit) Income tax benefit (expense) Accrued liabilities us-gaap_IncreaseDecreaseInAccruedLiabilities The 2020 Shelf [Member] Relating to the 2020 Shelf. aytu_SupplyAndDistributionCommitmentPeriod Supply and Distribution Commitment, Period (Year) Period covered by the supply and distribution commitment, in 'PnYnMnDnThnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Avenue Capital Issuance [Member] Relating to Avenue Capital Issuance. aytu_SaleOfStockMaximumAmountOfEquityIssuable Sale of Stock, Maximum Amount of Equity Issuable Represents the maximum monetary amount of equity issuable. Securities Purchase Agreement [Member] Relating to the Securities Purchase Agreement. us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable

aytu_SupplyAndDistributionAgreementMaximumYearlyMakeWholePayment Supply and Distribution Agreement, Maximum Yearly Make-whole Payment The maximum amount of make-whole payment per year under supply and distribution agreement. August 2022 Common and Prefunded Warrants [Member] Relating to the August 2022 Common and Prefunded Warrants.

aytu_SupplyAndDistributionAgreementMinimumSalesPerYear Supply and Distribution Agreement, Minimum Sales Per Year Th minimum amount of units to be sold per year under supply and distribution agreement. Tranche A Common Warrants [Member] Relating to Tranche A Common Warrants.

aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit Supply and Distribution Agreement, Royalty Make Whole Payment Under Annual Minimum Sales Commitment, Per Unit The amount of royalty make-whole payment per unit for sales under the minimum units for the supply and distribution agreement. Pre-Funded Warrants [Member] Relating to the Pre-Funded Warrants. Employee Retention Credit [Policy Text Block] Represents the accounting policy for employee retention credits. The August 2022 Offering [Member] Relating to the August 2022 Offering. aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales Supply and Distribution Commitment, Royalty, Percentage of Net Sales The percentage of net sales to be paid for royalties under supply and distribution agreement. August 2022 Common Warrants [Member] Relating to the August 2022 Common Warrants. August 2022 Prefunded Warrants [Member] Relating to August 2022 prefunded warrants. aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations Supply and Distribution Agreement, Maximum Milestone Obligations The maximum amount of milestone obligations of the supply and distribution agreement. Common Warrants [Member] Relating to the Common Warrants.

Tranche B Common Warrants [Member] Relating to the Tranche B Common Warrants. us-gaap_OperatingExpenses Total operating expenses Securities Purchase Agreement Warrants [Member] Relating to the Securities Purchase Agreement Warrants. aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues Supply and Distribution Agreement, First Milestone, Minimum Net Revenues The amount of net revenues to be reached to trigger the first milestone obligation of the supply and distribution agreement. us-gaap_DebtInstrumentTerm Debt Instrument, Term (Year) Common Warrants Exchanged for Pre-Funded Warrants [Member] Relating to Common Warrants exchanged for Pre-Funded Warrants. Restricted Stock and Restricted Stock Units (RSUs) [Member] Share instruments in which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met. Outside Equity Incentive Plan [Member] Relating to outside the equity incentive plan. General and administrative The 2023 Equity Incentive Plan [Member] Relating to the 2023 Equity Incentive Plan. Cash and cash equivalents us-gaap_IncreaseDecreaseInCashAndCashEquivalents Nonoperating Interest expense Total stock-based compensation expense Included in earnings Liability Pre-Funded Warrants [Member] Represents information pertaining to pre-funded warrants classified as liabilities. Amendment Flag City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Reclassification, Comparability Adjustment [Policy Text Block] us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Common stock, outstanding (in shares) Common Stock, Shares, Outstanding (in shares) Preferred stock, outstanding (in shares) Current Fiscal Year End Date us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage us-gaap_LeaseCost Total lease cost us-gaap_DebtInstrumentInterestRateEffectivePercentage Debt Instrument, Interest Rate, Effective Percentage us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Operating lease right-of-use assets Document Fiscal Period Focus Operating lease cost Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Short-term lease cost Lease, Cost [Table Text Block] Document Period End Date Operating lease right-of-use assets (Year) Entity File Number Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Document Type us-gaap_GainsLossesOnExtinguishmentOfDebt Gain (Loss) on Extinguishment of Debt Entity Small Business Entity Shell Company Document Information [Line Items] Document Information [Table] us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Balance Balance Settlements (1) Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] Restructuring costs us-gaap_BusinessExitCosts1 Business Exit Costs Variable Rate [Domain] Prime Rate [Member] Schedule of Long-Term Debt Instruments [Table Text Block] Variable Rate [Axis] us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable, net Entity Tax Identification Number Entity Central Index Key Entity Registrant Name Entity [Domain] Legal Entity [Axis] Entity Address, Address Line One Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] ecd_NonRule10b51ArrTrmtdFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] Amortization of intangible assets Entity Address, City or Town ecd_Rule10b51ArrTrmtdFlag Rule 10b5-1 Arrangement Terminated [Flag] ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] Entity Address, Postal Zip Code Entity Address, State or Province ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] Material Terms of Trading Arrangement [Text Block] Entity Common Stock, Shares Outstanding Long-Term Debt [Text Block] us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Local Phone Number us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity Line of Credit Facility, Remaining Borrowing Capacity us-gaap_TableTextBlock Notes Tables us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Line of Credit Facility, Maximum Borrowing Capacity

aytu_DisposalGroupIncludingDiscontinuedOperationRecognizedContingentConsideration Amount of recognized contingent consideration Amount of recognized contingent consideration attributable to disposal group, including, but not limited to, discontinued operation. us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Adjusted numerator - net (loss) income from continuing operations Amount after tax of income (loss) from continuing operations attributable to the parent for diluted calculation. Non-cash adjustments from discontinued operations The amount of adjustments to net income or loss from discontinued operations. Other non-cash investing and financing activities Represents the amount of other noncash investing and financing items. Stock-based compensation expense (in shares) Stock-based compensation expense Secured Overnight Financing Rate (SOFR) [Member] aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced Total lease payments Amount of lessee's undiscounted obligation for lease payment for operating lease, including lease not yet commenced. Granted, options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Forfeited/Cancelled, options (in shares) us-gaap_WarrantsAndRightsOutstandingTerm Warrants and Rights Outstanding, Term (Year) Selling and marketing Line of Credit Facility, Lender [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] us-gaap_StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues (in shares) Raw materials Lender Name [Axis] us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders'â€” equity Finished goods Work in process Derivative liability, measurement input Non-current assets of discontinued operations aytu_IncreaseDecreaseInOperatingCapitalAttributableToDiscontinuedOperations Changes in operating assets and liabilities from discontinued operations The increase (decrease) during the reporting period of all assets and liabilities used in operating activities of discontinued operations. Accumulated deficit Research and development us-gaap_AssetsNoncurrent Total non-current assets Measurement Input, Share Price [Member] Non-current assets of discontinued operations: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets Other non-current assets Short-Term Debt [Text Block] us-gaap_IncreaseDecreaseInDebt Interest Expense, Debt Measurement Input, Price Volatility [Member] Changes in operating assets and liabilities: Measurement Input, Risk Free Interest Rate [Member] us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements us-gaap_OtherNoncashIncomeExpense Other non-cash adjustments Inventory Disclosure [Text Block] Measurement Input, Expected Dividend Rate [Member] us-gaap_OperatingLeaseLiabilityNoncurrent Non-current: operating leases Schedule of Inventory, Current [Table Text Block] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Measurement Input, Expected Term [Member] Total lease liabilities us-gaap_OperatingLeaseLiability Operating Lease, Liability Less: tenant improvement allowance aytu_LesseeOperatingLeaseLiabilityTenantImprovementAllowance The amount of tenant improvement allowance for operating lease liability of lessee. Current: operating leases Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset us-gaap_FinanceLeaseLiability Finance Lease, Liability us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less: imputed interest Financing cash flows from finance leases 2028 Thereafter, future amortization expense Measurement Input Type [Axis] 2029 2025 (remaining 9 months), future amortization expense Measurement Input Type [Domain] 2030 Thereafter 2027, future amortization expense 2028, future amortization expense 2026 2029, future amortization expense 2027 2030, future amortization expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] 2026, future amortization expense Other non-current assets Stock-based compensation expense us-gaap_ShareBasedCompensation 2025 (remaining 6 months) Finite-lived intangible assets, remaining life (Year) Amortization of debt discount and issuance costs Operating expenses: Income Tax, Policy [Policy Text Block] Schedule of Finite-Lived Intangible Assets [Table Text Block] us-gaap_Depreciation Depreciation us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio Depreciation, amortization and accretion financial liabilities, fair value us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share (in dollars per share) Non-current assets: Equity [Text Block] Current assets of discontinued operations Total current assets of discontinued operations Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Common stock, par value \$.0001; 200,000,000 shares authorized; 6,169,681 and 5,972,638 shares issued and outstanding, respectively Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities: Common stock, authorized (in shares) Common Stock, Shares Authorized (in shares) us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent Inventories Common stock, issued (in shares) us-gaap_LesseeOperatingLeaseDiscountRate Lessee, Operating Lease, Discount Rate us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent Prepaid expenses and other current assets Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share (in dollars per share) Current assets of discontinued operations: Statistical Measurement [Domain] Operating cash flows from operating leases Maximum [Member] Minimum [Member] Weighted Average [Member] us-gaap_OtherAssetsCurrent Total current assets Product and Service [Axis] Product and Service [Domain] Statistical Measurement [Axis] Operating cash flows from finance leases Preferred stock, par value \$.0001; 50,000,000 shares authorized; no shares issued or outstanding Preferred stock, issued (in shares) Cash paid for interest Prepaid expenses and other current assets Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment [Table Text Block] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized (in shares) Inventories Inventories Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share (in dollars per share) Fair Value, Inputs, Level 3 [Member] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Issuance of common stock from exercise of warrants (in shares) Stock Issued During Period, Shares, Warrants Exercised (in shares) The number of shares issued for the warrants exercised. Issuance of common stock from exercise of warrants The value of stock issued for warrants exercised Proceeds from issuance of stock and warrants The cash inflow from the additional capital contribution to the entity from shares and warrants. Fair Value Hierarchy and NAV [Axis] Cash flows from operating activities: us-gaap_WarrantsAndRightsOutstanding Warrants and Rights Outstanding Statement [Line Items] Accounts receivable, net Additional paid-in capital Stockholders'â€” equity: Tranche B Pre-Funded Warrants [Member] Represents the Tranche B Pre-Funded Warrants Leasehold Improvements [Member] Other income, net Long-Lived Tangible Asset [Axis] The 2024 Shelf [Member] Represents the The 2021 Shelf registration. Long-Lived Tangible Asset [Domain] Grand Prairie, Texas Manufacturing Site [Member] Represents the Grand Prairie, Texas manufacturing site. Current assets: us-gaap_SaleOfStockPricePerShare Sale of Stock, Price Per Share (in dollars per share) Fair Value Disclosures [Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Eclipse Term loan [Member] Represents the Eclipse Term loan Net Loss From Discontinued Operations [Member] Relating to net loss from discontinued operations. us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net change in cash and cash equivalents June 2023 Warrants Tranche A [Member] Represents the June 2023 Warrants Tranche A. aytu_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense Selling and marketing amount of selling and marketing expense attributable to disposal group, including, but not limited to, discontinued operation. Consumer Health Divestiture [Member] Relating to Consumer Health Divestiture. us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price aytu_DebtInstrumentTerminationFeePercentage Debt Instrument, Termination Fee, Percentage The termination fee if the debt is terminated before or on a certain date. Commitments and contingencies (note 13) Sale of Stock [Axis] Sale of Stock [Domain] us-gaap_OperatingIncomeLoss (Loss) income from operations aytu_DebtInstrumentAmortizationPeriod Debt Instrument, Amortization Period (Year) The duration in which the debt will amortize. us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by (used in) operating activities aytu_DebtInstrumentPrepaymentFeeAmount Debt Instrument, Prepayment Fee, Amount The prepayment fee amount. us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash provided by (used in) investing activities us-gaap_OtherLiabilities Total other liabilities After June 12, 2026, but on or before June 12, 2028 [Member] Represents the termination fee if the termination is after June 12, 2026, but on or before June 12, 2028. us-gaap_GrossProfit Gross profit On or Before June 12 2025 [Member] Termination is on or before the date of June 12 2025 Cost of sales Counterparty Name [Axis] Counterparty Name [Domain] After June 12, 2026, but on or before June 12, 2027 [Member] Represents the termination fee if the termination is after June 12, 2026, but on or before June 12, 2027 Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] After June 12, 2025, but on or before June 12, 2026 [Member] Represents the termination fee if the termination is after June 12, 2025, but on or before June 12, 2026. Inventory write-down Inventory Write-down Other Liabilities [Table Text Block] us-gaap_OtherSundryLiabilities Other us-gaap_PaymentOffFinancingAndStockIssuanceCosts Payment of Financing and Stock Issuance Costs us-gaap_PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs Payment of stock issuance costs Other Liabilities Disclosure [Text Block] us-gaap_ProceedsFromIssuanceOrSaleOfEquity Proceeds from Issuance or Sale of Equity Scenario [Domain] us-gaap_ProceedsFromWarrantExercises Proceeds from Warrant Exercises us-gaap_LoanProcessingFee Loan Processing Fee Retained Earnings [Member] Revenue Net revenue Scenario [Axis] Additional Paid-in Capital [Member] Common Stock [Member] Equity Components [Axis] Equity Component [Domain] us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) Other Current Liabilities [Member] Class of Warrant or Right [Axis] Other Noncurrent Liabilities [Member] Class of Warrant or Right [Domain] us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) us-gaap_ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding (in shares) Outstanding, balance (in shares) Outstanding, balance (in shares) us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (loss) from continuing operations before income tax expense us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) us-gaap_LineOfCredit Long-Term Line of Credit us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Less: unamortized debt discount and issuance costs Disaggregation of Revenue [Table Text Block] us-gaap_RepaymentsOfLongTermDebt Payments made to borrowings Revenue from Contract with Customer [Text Block] Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Domain] Document Quarterly Report Entity Incorporation, State or Country Code Term loan principal amount General and Administrative Expense [Member] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Document Transition Report Basis of Accounting, Policy [Policy Text Block] Revolving credit facility Entity Interactive Data Current Selling and Marketing Expense [Member] Accrued savings offers Represents information related to accrued saving offers. Security Exchange Name Operating Expense [Member] Other Expense [Member] Title of 12(b) Security Total debt, net of current portion us-

gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities Total debt Cost of Sales [Member] Research and Development Expense [Member] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Nonmonetary Transaction Type [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Operating Activities [Domain] Continuing Operations [Member] Discontinued Operations [Member] Nonmonetary Transaction Type [Axis] Licensing Agreements [Text Block] The entire disclosure for licensing agreements. Warrants exercised, weighted average exercise price (in dollars per share) Class of Warrant or Right, Exercise Price, Exercised During Period (in dollars per share) Represents the exercise price of warrants or rights exercised during the period. Granted, options, weighted average remaining contractual life (Year) Weighted average remaining contractual term for option awards granted during the periof, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Operating Activities [Axis] Segments [Axis] Segments [Domain] LIABILITIES Neos 2015 Plan [Member] Represents Neos 2015 plan. Antidilutive securities (in shares) Diluted weighted-average common shares outstanding (note 17) (in shares) Diluted weighted-average common shares outstanding (in shares) us- gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent Accounts payable us- gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent Accrued liabilities Statement [Table] Diluted - discontinued operations, net of tax (in dollars per share) Statement of Financial Position [Abstract] Diluted - net loss (in dollars per share) Basic weighted-average common shares outstanding (note 17) (in shares) us- gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense Non-operating other expense, net Diluted - continuing operations (in dollars per share) us- gaap_EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent Basic - discontinued operations, net of tax (in dollars per share) Basic - net income (loss) (in dollars per share) Net income (loss) per share (in dollars per share) us- gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization Amortization of intangible assets Net proceeds received from (payments made on) revolving credit facility us- gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense General and administrative Basic - continuing operations (in dollars per share) us- gaap_DisposalGroupIncludingDiscontinuedOperationRevenue Net revenue Statement of Cash Flows [Abstract] aytu_LongTermDebtAndCapitalLeaseObligationsGross Total future principal payments Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt and capital lease obligations. us- gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold Cost of sales us- gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear 2025 (remaining 6 months) Lease Contractual Term [Domain] Statement of Stockholders' Equity [Abstract] Lease Contractual Term [Axis] Income Statement [Abstract] Disposal Groups, Including Discontinued Operations [Table Text Block] us- gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree 2028 us- gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Long-Term Debt, Maturity, Year Four Disposal Group Name [Axis] us- gaap_BusinessCombinationContingentConsiderationLiability Business Combination, Contingent Consideration, Liability Disposal Group Name [Domain] Schedule of Accrued Liabilities [Table Text Block] us- gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths 2026 Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] us- gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo 2027 aytu_PaymentsOffixedPaymentArrangements Payment made to fixed payment arrangements The cash outflow for fixed payments arrangements. Interest on lease liabilities Amortization of leased assets Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring and Related Activities Disclosure [Text Block] Liabilities, Noncurrent Total non-current liabilities Asset Acquisition, Contingent Consideration, Liability, Current us- gaap_PaymentsForProceedsFromOtherInvestingActivities Other investing activities Cash flows from financing activities: Warrants [Policy Text Block] Disclosure of the company's accounting policy regarding warrants. Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Total non-current portion of other liabilities Other Liabilities, Noncurrent Derivative warrant liabilities Rx Segment [Member] Relating to the Rx Segment. ADHD Portfolio [Member] Relating to the ADHS Portfolio. Leases Disclosure [Text Block] The entire disclosure for leases. us- gaap_StockholdersEquity Total stockholdersâ€™ equity Balance Balance Schedule of Lease by Balance Sheet Information [Table Text Block] Tabular disclosure of leases by balance sheet information. Class of Stock [Axis] Debt, net of current portion Total debt, net of current portion Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Lessee, Liability, Maturity [Table Text Block] Tabular disclosure of undiscounted cash flows of lessee's lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to lease liability recognized in statement of financial position. Accrued Liabilities [Text Block] The entire disclosure regarding accrued liabilities. aytu_AmortizationExpenseOfIntangibleAssets Amortization Expense of Intangible Assets The value of amortization expense of intangible assets. EX-101.PRE 10 aytu-20241231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 11 aytu20231231_10iqimg001.jpg begin 644 aytu20231231_10iqimg001.jpg M JC X 02D91@ ! \$ 8 !@ # # VP!# @&!@<&!0@'!P<!0@#*10-# L+ M#1D2SP4!1H?AT:!'P@!'XG('((LQ<P*7#1A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBJJ*SM+6VM[BYNL+*Q,7& MQCJRM+3U-76UJC9VN*BX*3EYN*HZ>KQO/TJ?;W^/GZ_!0 '\$P\$! 0\$! M 0\$! 0 \$' P0\$!@<('OH+ _!0 M1\$ @S\$! 0#! <7%#! 0! 0W \$' M Q\$S!12Q!A)40=A<1,B,H\$(!3*1H;1,2,S4O 58G+1!ABD-.SE!1<8+1HF MJR@!I*C4V-S@Y.D-\$149*2\$*4U155E=865!C9&5F9VA!G-T=79W~EZ@H<# MA8:B(F*DI.4E9?)F:JH.D!:-GJ*FJLK.TM:-WN+FZPL*Q<~R,*G*TM/4 MU?=-7V-G.XN/DY>;GZ,GJO/TJ?;W^/GZ_JH_#_! (1 Q\$ /P#WMV589V(" M@9)0) \$EQX@O9'E7=-/EBJ\$#U/O77?--8%G:K81M^!JG&7QV7 _O (UP M7G*NI^!TI+F9(FV,JY4H;Y.JBRQ?SKT M1=\$7Q%L'O8TBJJ)0+ZK _EJDC9 MG@PCG^!Z&O'RW&>TDZ9CA\$ _\ 9C^%>R>('AOXXWFH^)+* MRU33K6WLKJ7RO.C+94DX4G/&J;JMI*KKQOG_(-3X;6!TY,W>B1Y&4?~!MYD(U!^;ZT _^!LW?Q!^~DJK;7MMKEFGE&6*QJQD491OHPZ_C0!ZIFBO(O@W MXRO;[JWPYK&@~HVL~\$T!9=ESAU)=/3 _VKT06=6MM*T:[U2;~;VTYD?4 MX[#W#2M]@('R-GZ[037^~?B?&XXO;~VCTZZU-HBMEI VJ) (17F/AZU)= \$ M(ZGK%KX@GTZT\$K80ROLUSU)!Z#%> P_#GPGYKWE& U&O+~M;F20(IE+~R*8'S M&~!JUH _JU>~&==(U=>#XJ66G1(M=)80I/ _FE+1.CQ08 _M\A!6-5%VE+~?7JH1 M >Q%;P6YQ!3Y3MD0?W24 _GN,NYCS!\$>5MH/3H*],^6A? 8].ISIB.Z[O(MY6M?~?7J! X23J!5]C2O'5<+s/7FV.C1!M;~^/#!JY!UTP\$=O&6'JV;~ M%[DXD?~AW6';7BFTQ;~HP2%7POX!N7RT2 MS@73HCY3MDR3!2!JQZ*YUV AO0!PYX? L!)M1B.WC'DJIV;^C)3DUJ?>D M-M; M,YZ2F(I5,P3A?;Y1G7/XT?3KQD?&QT3P0X?Z5SO RYY<"S-JU&1^ZPKFO@5X1!O-XINTRXW068 M8=- XW' H/T>LZ%H-MX&+0Z3@>?>1!06Q!JYN!? B)9_JY#>O P#7&A[M]#>0 6 92?,@5X"~%5QJ@'VXMIMP4JR?<JSL=-&8/Q^E OIZ M5X#~!G6?Q7K5O(=Li@^Z>0#^ P Z(WP%!0!U6Z00%LT2VLD6R.V!7*L#X!) M>1QGOZ5ROBOX9^*(M*5)XD0\$S8DD=1&A5U1XV!P&[Y64^AH LJGVUVR[M[W MJH>QEMI5EC6~MHRRG(W+M!YUO); /Q&# H-W+@!=-N RR7 \$D#JTEORQ4- ME(-6T;X@>? 6!BETINTFADDFDEP[E>7;JXT444 5:VSAU'RFM+&E R,M&9&4^AKJQ(3?6FT76=OM+&@' /JVO@>07TKVJN9U^~6M15FB0L8,E1GJ;Y;? M-K-52,T8RBJ1JTE5JUX=(<->GC' WR^AEMH;?ZB/[MG?+4X;[G3+ MBY22'-6 \$T+PMX36VTY-5CLX5C4B!6]@9QW)?-E97B0 M A'3C~?S% &60B2YAC-P@?U![,+1,R^4[=8)19&+6210!OU_#8AOW,=XD4!9G@9RHG@MW^? Y<+!R>+9J/3FDN%#6JG; M3LLO9W=Y@<(!#Y2MM, ?XNG!L9W+L#~!#UM.DM?7' \$S6?1\$3-C:CDH[L#E M! SUT13] XML 13 R1.htm!DEA:XBWL DOCUMENT v3.25.01 Document And Entity Information - shares 6 Months Ended Dec. 31, 2024 Feb. 01, 2025 Document Information [Line Items] Â Â Â Entity Central Index Key 0001385818 Â Â Entity Registrant Name AYTU BIOPHARMA, INC. Â Â Amendment Filed false Â Â Current Fiscal Year End Date -06-30 Â Â Document Fiscal Period Focus Q2 Â Â Document Fiscal Year Focus 2025 Â Â Document Type 10-Q Â Â Document Quarterly Report true Â Â Document Period End Date Dec. 31, 2024 Â Â Document Transition Report false Â Â Entity File Number 001-38247 Â Â Entity Incorporation, State or Country Code DE Â Â Entity Tax Identification Number 47-0883144 Â Â Entity Address, Address Line One 7900 East Union Avenue, SuiteA 920 Â Â Entity Address, City or Town Denver Â Â Entity Address, State or Province CO Â Â Entity Address, Postal Zip Code 80237 Â Â City Area Code 720 Â Â Local Phone Number 437-6580 Â Â Title of 12(b) Security Common Stock, par value \$0.0001 per share Â Â Trading Symbol AYTU Â Â Security Exchange Name NASDAQ Â Â Entity Current Reporting Status Yes Â Â Entity Interactive Data Current Yes Â Â Entity Filer Category Non-accelerated Filer Â Â Entity Small Business true Â Â Entity Emerging Growth Company false Â Â Entity Shell Company false Â Â Entity Common Stock, Shares Outstanding Â 6,169,848 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_Data Type: xbrli:MonthDayItem Type Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_Data Type: dei:fiscalPeriodItem Type Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_Data Type: xbrli:YearItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_Data Type: xbrli:dateTimeItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period P type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_Data Type: dei:submissionTypeItem Type Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_Data Type: dei:stateOrProvinceItem Type Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_Data Type: dei:centralIndexKeyItem Type Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_Data Type: dei:yesNoItem Type Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_Data Type: dei:fileNumberItem Type Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_Data Type: dei:filerCategoryItem Type Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_Data Type: dei:edgarStateCountryItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_Data Type: dei:yesNoItem Type Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_Data Type: dei:employerIdItem Type Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhone Number Namespace Prefix: dei_Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_Data Type: dei:securityTitleItem Type Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_Data Type: dei:edgarExchangeCodeItem Type Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_Data Type: dei:tradingSymbolItem Type Balance Type: na Period Type: duration XML 14 R2.htm IDEA: XBRL DOCUMENT v3.25.01 Unaudited Consolidated Balance Sheets - USD (\$\$) in Thousands Dec. 31, 2024 Jun. 30, 2024 Current assets: Â Â Â Cash and cash equivalents \$ 20,398, 20,006 Accounts receivable, net 25,403 23,526 Inventories 11,085 12,141 Prepaid expenses and other current assets 6,167 5,097 Current assets of discontinued operations 0 1,121 Total current assets 63,053 61,891 Non-current assets: Â Â Â Property and equipment, net 516 693 Operating lease right-of-use assets 1,178 829 Intangible assets, net 49,958 52,453 Other non-current assets 1,522 2,185 Non-current assets of discontinued operations 0 44 Total non-current assets 53,174 56,204 Total assets 116,227 118,095 Liabilities, Current

[Abstract] $\tilde{A}$ Accounts payable 11,699 10,314 Accrued liabilities 39,372 38,143 Revolving credit facility 4,012 2,395 Current portion of debt 1,857 1,857 Other Liabilities, Current 7,108 8,962 Current liabilities of discontinued operations 0 557 Total current liabilities 64,048 62,228 Liabilities, Noncurrent [Abstract] $\tilde{A}$ Debt, net of current portion 9,983 10,877 Derivative warrant liabilities 6,386 12,745 Other Liabilities, Noncurrent 5,045 4,529 Total non-current liabilities 21,414 28,151 Commitments and contingencies (note 13) Stockholders' equity: $\tilde{A}$ Preferred stock, par value \$,0001; 50,000,000 shares authorized; no shares issued or outstanding 0 0 Common stock, par value \$,0001; 200,000,000 shares authorized; 6,169,681 and 5,972,638 shares issued and outstanding, respectively 11,095 11,095 Total paid-in capital 348,475 347,688 Accumulated deficit (317,711) (319,973) Total stockholders' equity 30,765 27,716 Total liabilities and stockholders' equity \$ 116,227 \$ 118,005 X - Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10> + Details Name: us-gaap Accounts Payable Current Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481990/310-10-45-2> + Details Name: us-gaap Accounts Receivable Net Current Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap Accrued Liabilities Current Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + References Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10> Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1> Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap Additional Paid-In Capital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of asset recognized for present right to economic benefit. + References Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48> Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-49> Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1> Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32> Reference 5: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32> Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22> Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3> Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25> Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1> Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3> Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28> Reference 12: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10> Reference 13: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12> Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1> Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 18: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 19: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 28: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7> Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30> Reference 30: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1> + Details Name: us-gaap Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - References No definition available. + Details Name: us-gaap Assets Current Abstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. + References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25> Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1> Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3> Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28> Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 7: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> Reference 17: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7> + Details Name: us-gaap Assets Noncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - References No definition available. + Details Name: us-gaap Assets Noncurrent Abstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-10> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7> Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5C> Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482130/360-10-45-9> Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B> Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-3> Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-11> + Details Name: us-gaap Assets Off Disposal Group Including Discontinued Operation Current Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI [https://asc.fasb.org/1](https://asc.fasb.org/1943274/2147483467/210-10-45-1)

<https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1> + Details Name: us-gaap CommitmentsAndContingencies Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> + Details Name: us-gaap CommonStockValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483466/210-20-50-3> + Details Name: us-gaap DerivativeLiabilitiesNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-10>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 11 -SubTopic 10 -Topic 360 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482130/360-10-45-11>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5C>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-3>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-11> + Details Name: us-gaap DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482686/350-30-45-1> + Details Name: us-gaap IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap InventoryNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-45-25>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 8: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-5>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 20: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7>Reference 21: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7> + Details Name: us-gaap LiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap LiabilitiesCurrentAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 13: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4

operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-10>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -SubParagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5C>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482130/360-10-45-9>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-3>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-11> + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479041/842-20-45-1> + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10> + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482955/340-10-05-5>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483032/340-10-45-1> + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-7A>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478451/942-360-50-1> + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionReflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> + Details Name: us-gaap_ShortTermBorrowings Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 13: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 14: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2> + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 15 R3.htm IDEA: XBRL DOCUMENT v3.25.0.1 Unaudited Consolidated Balance Sheets (Parentheticals) - \$ / shares Dec. 31, 2024 Jun. 30, 2024 Preferred stock, par value (in dollars per share) \$ 0.0001 \$ 0.0001 Preferred stock, authorized (in shares) 50,000,000 50,000,000 Preferred stock, issued (in shares) 0 0 Preferred stock, outstanding (in shares) 0 0 Common stock, par value (in dollars per share) \$ 0.0001 \$ 0.0001 Common stock, authorized (in shares) 200,000,000 200,000,000 Common stock, issued (in shares) 6,169,681 5,972,638 Common stock, outstanding (in shares) 6,169,681 5,972,638 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr-terms:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1> + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/214748112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI [https://asc.fasb.org/](https://asc.fasb.org/1943274/2147479134/946-220-S99-3)

Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap CommonStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock redeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap CommonStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock redeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares \(or preferred stock redeemable solely at the option of the issuer\) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap PreferredStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap PreferredStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 5: [http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40">http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2">http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap AmortizationOfIntangibleAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(2\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2">http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(2\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2">http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 11.L\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap CostOfGoodsAndServicesSold Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of increase \(decrease\) in the fair value of derivatives recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph \(b\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap DerivativeGainLossOnDerivativeNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap EarningsPerShareAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe amount of net income \(loss\) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6">http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52">http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1">http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2">http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3">http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15">http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1">http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1">http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11">http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7">http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2">http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B">http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4">http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1">http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1">http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2">http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1">http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1">http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap EarningsPerShareBasic Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe amount of net income \(loss\) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6">http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52">http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1">http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2">http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3">http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15">http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1">http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1">http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11">http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7">http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1">http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1">http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1">http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap EarningsPerShareDiluted Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2">http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(2\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap GeneralAndAdministrativeExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap PreferredStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant XML 16 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1 Unaudited Consolidated Statements of Operations - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2024 Dec. 31, 2023 Net revenue $ 16,221 $ 18,748 $ 32,795 $ 36,565 Cost of sales 5,435 4,145 10,024 8,924 Gross profit 10,786 14,603 22,771 27,641 Operating expenses: A A A Selling and marketing 5,272 5,218 10,931 11,309 General and administrative 4,449 4,800 9,574 11,095 Research and development 522 521 948 1,116 Amortization of intangible assets 921 918 1,842 Restructuring costs 1,317 0 2,101 0 Total operating expenses 12,481 11,457 25,396 25,362 (Loss) income from operations (1,695) 3,146 (2,625) 2,279 Other income, net 140 96 682 680 Interest expense (1,079) (1,066) (2,073) (2,549) Derivative, Gain (Loss) on Derivative, Net 3,016 (577) 5,896 (6,484) Income (loss) from continuing operations before income tax expense 382 1,399 1,880 (6,074) Income tax benefit (expense) 283 (780) (122) (780) Net income (loss) from continuing operations 665 619 1,758 (6,854) Net income (loss) from discontinued operations, net of tax 123 (839) 504 (1,486) Net income (loss) $ 788 $ (220) $ 2,262 $ (8,340) Basic weighted-average common shares outstanding (note 17) (in shares) 6,132,060 5,517,670 6,100,204 5,499,951 Diluted weighted-average common shares outstanding (note 17) (in shares) 8,485,112 5,517,670 8,782,794 5,499,951 Net income (loss) per share (note 17): A A A Basic - continuing operations (in dollars per share) $ 0.11 $ 0.29 $ (0.11) $ (0.15) Diluted - continuing operations (in dollars per share) (0.28) (0.11) (0.47) (1.25) Basic - discontinued operations, net of tax (in dollars per share) 0.02 (0.15) 0.08 (0.27) Diluted - discontinued operations, net of tax (in dollars per share) 0.01 (0.15) 0.06 (0.27) Basic - net income (loss) (in dollars per share) 0.13 (0.04) 0.37 (1.52) Diluted - net loss (in dollars per share) $ (0.26) $ (0.04) $ (0.41) $ (1.52) X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)

Topic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 22 - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI>
<https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482810/280-10-50-30>Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 7: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI)
<https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(2\)\) -Publisher FASB -URI](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 9: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(1\)\) -Publisher FASB -URI](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 14: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S9](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI)

Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.7-04(23)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2:

xbrl:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1:

asc.fasb.org/1943274/2147478524/942-20-599-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef](https://asc.fasb.org/1943274/2147480008/505-10-599-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef) -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-599-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity \(deficit\) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef](https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef) -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-599-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity \(deficit\) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef](https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef) -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-599-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity \(deficit\) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef](https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef) -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-599-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period](https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef)

[US-GAAP](#) / [FASB](#) / [asc.fasb.org/1943274/2147482740/230-10-45-28 + Details](#) Name: us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details](#) Name: us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17](#) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25](#) Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details](#) Name: us-gaap InterestPaidNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details](#) Name: us-gaap InventoryWriteDown Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details](#) Name: us-gaap NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details](#) Name: us-gaap NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](#) Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9](#) Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9](#) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](#) Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](#) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](#) Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](#) Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](#) Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6](#) Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3](#) Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](#) Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](#) Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8](#) Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](#) Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](#) Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4](#) Reference 17: [http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10](#) Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7](#) Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](#) Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](#) Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](#) Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](#) Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](#) Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](#) Reference 25: [http://www.xbrl.org/](#)

Windward Corporation on August 9, 2002, in the state of Colorado and was re-incorporated as Aytu BioScience, Inc. in the state of Delaware on June 8, 2015. Following the acquisition of Neos Therapeutics, Inc. (the "Neos Acquisition"), in March 2021 (the "Neos Acquisition"), the Company changed its name to Aytu BioPharma, Inc. The Company's strategy is to become a leading pharmaceutical company that improves the lives of patients. The Company uses a focused approach of in-licensing, acquiring, developing, and commercializing novel prescription therapeutics in order to continue building its portfolio of revenue-generating products and leveraging its commercial team's expertise to build leading brands within large therapeutic markets. The Company's primary focus is on commercializing innovative prescription products that address conditions frequently developed or diagnosed in childhood. The Company's business from continuing operations is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of attention deficit hyperactivity disorder (ADHD): Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotelma XR-ODT (methylphenidate) extended-release orally disintegrating tablets (Cotelma) and Adzenys together with Cotelma (the "ADHD Portfolio"). The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension) (Karbinal), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency (the "Pediatric Portfolio"). Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (the "CODM"). After the previously announced successful wind down and divestiture of the Consumer Health business that occurred during the first quarter of fiscal 2025, the Company determined that its continuing operations now operate in a single operating and reportable segment. The Company's CODM is its Chief Executive Officer who manages operations and regularly reviews the financial information of the Company's continuing operations as a single operating segment for the purposes of allocating resources and evaluating its financial performance, and for which discrete financial information is available. The results of the Consumer Health business have been reported as discontinued operations (see Note 20A "Discontinued Operations"). In July 2023, the Company entered into an exclusive collaboration, distribution and supply agreement with Medomie Pharma Ltd (the "Medomie"), a privately owned pharmaceutical company, for Medomie to sell Adzenys and Cotelma in Israel and the Palestinian Authority. In September 2024, the Company entered into an exclusive collaboration, distribution and supply agreement with Lupin Pharma Canada Ltd (the "Lupin"), a subsidiary of global pharmaceutical company Lupin Limited, for Lupin to sell Adzenys and Cotelma in Canada. The Company will supply Adzenys and Cotelma to Medomie and Lupin based on forecasts and provide various product commercialization resources. Medomie and Lupin are responsible for seeking local regulatory approvals and marketing authorizations for both Adzenys and Cotelma, which is expected to occur over the next 18 to 24 months. The agreement with Medomie and the agreement with Lupin represent the Company's first and second international commercial agreements for Adzenys and Cotelma, respectively. X - ReferencesNo definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap OrganizationConsolidationAndPresentationOffFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 2 - Summary of Significant Accounting Policies 6 Months Ended Dec 31, 2024 Notes to Financial Statements A Significant Accounting Policies [Text Block] A Note 2A - Summary of Significant Accounting Policies A Principals of Consolidation A The Company's unaudited consolidated financial statements and notes thereto include the accounts of its wholly owned subsidiaries Aytu Therapeutics, LLC and Neos Therapeutics, Inc. and their respective wholly owned subsidiaries, as well as Innovus Pharmaceuticals, Inc. (the "Innovus") and its wholly owned subsidiaries prior to the divestiture of Innovus on July 31, 2024. All significant inter-company balances and transactions have been eliminated in consolidation. A Basis of Presentation A The unaudited consolidated financial statements and notes thereto contained in this Form 10-Q represent the financial statements of the Company and its wholly owned subsidiaries and have been prepared pursuant to the rules and regulations of the SEC regarding interim financial reporting. Accordingly, certain information and disclosures normally included in the complete financial statements prepared in accordance with accounting principles generally accepted in the United States (the "U.S. GAAP") have been omitted pursuant to such rules and regulations. A The unaudited consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's 2024 Form 10-K, which included all disclosures required by U.S. GAAP. In the opinion of management, these unaudited consolidated financial statements and notes thereto contain all adjustments necessary for the fair statement of the financial position of the Company and the results of operations and cash flows for the interim periods presented. The consolidated balance sheet as of June 30, 2024, was derived from the audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. A The results of operations for the period ended December 31, 2024, are not necessarily indicative of expected operating results for the full year or any future period. A Use of Estimates A The preparation of financial statements and footnotes requires the use of management estimates, judgments and assumptions. Actual results may differ from estimates. In the accompanying unaudited consolidated financial statements and notes thereto, estimates are used for, but not limited to, stock-based compensation; revenue recognition; determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances; allowance for credit losses; inventory impairment; determination of right-of-use (ROU) assets and lease liabilities; valuation of financial instruments, warrants and derivative warrant liabilities, intangible assets, and long-lived assets; purchase price allocations and the depreciable lives of long-lived assets; accruals for contingent liabilities; and determination of the income tax provision, deferred taxes and valuation allowance. A Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. The Company periodically evaluates estimates used in the preparation of the financial statements for reasonableness. A Prior Period Reclassification A Certain prior year amounts in the Company's unaudited consolidated financial statements and the notes thereto have been reclassified to conform to the current year presentation. These reclassifications did not impact operating results for the three and six months ended December 31, 2024, and 2023, or cash flows for the six months ended December 31, 2024, and 2023, or the Company's financial position as of December 31, 2024, or June 30, 2024. A Warrants A The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance in Financial Accounting Standards Board (the "FASB") Accounting Standards Codification (the "ASC") Topic 480, Distinguishing Liabilities from Equity (the "ASC 480") and ASC Topic 815, Derivatives and Hedging (the "ASC 815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company's own common shares and whether the warrant holders could potentially require a net cash settlement in a circumstance outside of the Company's control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option pricing model or Monte Carlo simulation model at issuance and for each reporting period when applicable. A Income Taxes A The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been no changes in tax law affecting the tax provision during the three and six months ended December 31, 2024. A The Company recorded for income (loss) from continuing operations an income tax benefit of \$0.3 million, which represented an effective tax rate of negative 74.1% and income tax expense of \$0.8 million, which represented an effective tax rate of 55.8%, for the three months ended December 31, 2024, and 2023, respectively. The Company recorded for income (loss) from continuing operations an income tax expense of \$0.1 million, which represented an effective tax rate of 6.5% and income tax expense of \$0.8 million, which represented an effective tax rate of negative 12.8% for the six months ended December 31, 2024, and 2023, respectively. These effective tax rates were primarily driven by the limitations on losses as a result of Section 382 of the Internal Revenue Code changes in ownership coupled with existing valuation allowances, the divestiture of the Company's Consumer Health business that occurred during the first quarter of fiscal 2025 and changes to the Company's first quarter of fiscal 2025 projections, which resulted in an income tax benefit for the current quarter. A An ownership change has limited the Company's ability to offset, post-change, United States federal taxable income. Section 382 of the Internal Revenue Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. Previous acquisitions, financing transactions, and equity ownership changes in the past five years have caused a significant limitation on the Company's ability to use the change in control net operating loss carryovers. The ownership changes result in increased future tax liability and are a driver of the change from a zero percent effective tax rate. A The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than not that some portion or all of its deferred tax asset will not be utilized. A The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained upon an examination. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense in the unaudited consolidated statements of operations. A Employee Retention Credit A On March 27, 2020, the United States government enacted the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act") to provide certain relief as a result of the COVID-19 pandemic. The CARES Act provides tax relief, along with other stimulus measures, including a provision for an Employee Retention Credit (the "ERC"), which allows for employers to claim a refundable payroll tax credit against the employer share of Social Security tax equal to 70% of the qualified wages paid to employees after December 31, 2020, through September 30, 2021. The ERC was designed to encourage businesses to keep employees on the payroll during the COVID-19 pandemic. A As there is no authoritative guidance under U.S. GAAP on accounting for government assistance to for-profit business entities, the Company accounted for the ERC by analogy to International Accounting Standard (the "IAS") 20, Accounting for Government Grants and Disclosure of Government Assistance (the "IAS 20"). In accordance with IAS 20, the Company recorded a \$3.8 million ERC accrual in other non-current liabilities, which represents the proceeds the Company received from the ERC program during the first quarter of fiscal 2024. Further in accordance with IAS 20, when management determines it has reasonable assurance that the Company has substantially met all eligibility requirements of the ERC and following any adjustments from its regulatory audit or upon further clarifications from the Internal Revenue Code of 1986, as amended (the "IRC"), the ERC accrual shall be recognized as a benefit in other income in the unaudited consolidated statement of operations. The associated vendor fee of \$0.4 million was expensed as incurred in the first quarter of fiscal 2024. A Recently Adopted Accounting Pronouncements A Debt - Debt with Conversion and Other Option A In August 2020, the FASB issued Accounting Standards Update (the "ASU") No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40) ("ASU 2020-06"). Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the SEC, for the fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company adopted the guidance on July 1, 2024, and the adoption of the standard did not have a material impact on the Company's consolidated financial statements. A Recent Accounting Pronouncements Not Yet Adopted A Segment Reporting - Improvements to Reportable Segment Disclosures A In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (the "ASU 2023-07"). ASU 2023-07 was issued to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance should be applied retrospectively unless it is impracticable to do so. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted, including in an interim period. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company's consolidated financial statements and disclosures. A Disaggregation of Income Statement Expenses A In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (the "ASU 2024-03"). The amendments in ASU 2024-03 require public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation, amortization and depletion expenses for each caption on the income statement where such expenses are included. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company's consolidated financial statements and disclosures. A For a complete set of the Company's significant accounting policies, refer to the audited consolidated financial statements and notes thereto included in the Company's 2024 Form 10-K. There have been no significant changes to the Company's significant accounting policies and there is no other accounting guidance that has been issued and not yet adopted that is applicable to the Company and that would have a material effect on the Company's unaudited consolidated financial statements and related disclosures as of December 31, 2024, and through the filing of this Form 10-Q. X - ReferencesNo definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1:

[illegible]

consolidated balance sheet payable to Tris, with the provision that allows the Company to pay interest on any principal amounts due but remaining unpaid as of July 24, 2024. The Tris Karbinal Agreement grants the Company the exclusive right to distribute and sell Karbinal in the United States. The initial term of the agreement was 20 years. The Company pays Tris a royalty equal to 23.5% of net revenue from the product. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make-whole payment of \$30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Tris Karbinal Agreement make-whole payment is capped at \$2.1 million each year. The final annual make-whole payment is due in August 2025. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to \$3.0 million based on cumulative net revenue from the product, the first of which is triggered at \$40.0 million. As of December 31, 2024, the Tris Karbinal Agreement accrued fixed payment arrangement balance was \$1.2A millionA recorded in other current liabilities on the consolidated balance sheet. A Employee Retention CreditA A The \$3.8 millionA ERC accrualA in other non-current liabilities as of December 31, 2024, represents the proceeds the Company received from the ERC program during the first quarter of fiscal 2024. Please seeA Note 2 A A Significant Accounting PoliciesA for further detail. A Operating Lease LiabilitiesA A The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment. Please seeA Note 6 - Leases for further detail. A Other A Other consists of taxes payable, deferred cost related to the CompanyA A A technology transfer, andA various other accruals. A none of which individually or in the aggregate represent greater than five percent of total liabilities. A X - ReferencesNo definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for other liabilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 - SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 - SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405/tableOfContent + Details Name: us-gaap OtherLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R16.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 10 - Revolving Credit Facility 6 Months Ended Dec. 31, 2024 Notes to Financial Statements A Short-Term Debt [Text Block] Note 10 - Revolving Credit Facility A On June 12, 2024, the Company and certain of its subsidiaries entered into consent, joinder and amendment No. 5 (the A Eclispe Amendment No. 5A) to the loan and security agreement dated October 2, 2019, as amended by amendment No. 1, dated March 19, 2021, amendment No. 2, dated January 26, 2022, amendment No. 3, dated June 1, 2022, amendment No. 4 dated March 24, 2023, and the Eclipse Amendment No. 5 (together the A Eclispe AgreementA) with Eclipse Business Capital LLC (the A EclispeA), as agent, and the lenders party thereto (agent and such lenders, collectively, the A Eclispe LenderA). Under the Eclipse Amendment No. 5, which provided for among other things, two loan agreements, a term loan (the A Eclispe Term LoanA) and a revolving credit facility (the A Eclispe Revolving LoanA). The Eclipse Term Loan is described further in Note 11 - Long-Term Debt. The Eclipse Revolving Loan provides for a maximum amount available under the revolving credit facility provided under the Eclipse Agreement of \$14.5 million at an interest rate of the secured overnight financing rate as administered by the SOFR Administrator (the A SOFRA) plus 4.5%. In addition, the Company is required to pay an unused line fee of 0.5% of the average unused portion of the maximum Eclipse Revolving Loan amount during the immediately preceding month. The ability to make borrowings and obtain advances of revolving loans under the Eclipse Agreement remains subject to a borrowing base and reserve, and availability blockage requirements. The Eclipse Revolving Loan maturity date, as amended, is June 12, 2028, and the effective interest rate was 9.2% as of December 31, 2024. A In the event that, for any reason, all or any portion of the Eclipse Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to (i) 2.0% of the Eclipse Revolving Loan commitment if such event occurs on or before June 12, 2025, (ii) 1.0% of the Eclipse Revolving Loan commitment if such event occurs after June 12, 2025, but on or before June 12, 2026, and (iii) 0.5% of the Eclipse Revolving Loan commitment if such event occurs after June 12, 2026, but on or before June 12, 2028. The Company may also be required to pay an early termination fee related to the Eclipse Term Loan as further described in Note 11 - Long-Term Debt. The Company may permanently terminate the Eclipse Agreement upon written notice to Eclipse. A The Eclipse Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the CompanyA A A ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the CompanyA A A obligations under the Eclipse Agreement, together with accrued interest and fees, to be immediately due and payable, plus any additional applicable amounts relating to a prepayment or termination, as described above. AsA of December 31, 2024, the Company was in compliance with the covenants under the Eclipse Agreement. The CompanyA A A obligations under the Eclipse Agreement are secured by substantially all of the CompanyA A A assets, as defined further in the Eclipse Agreement. A Total interest expense on the Eclipse Revolving Loan, including amortization of deferred financing costs, was less than \$0.1 million for both of the three months ended December 31, 2024, and 2023, and was \$0.1 million for both of the sixA months ended December 31, 2024, and 2023. TheA amountsA drawn on the Eclipse Revolving Loan wereA \$4.0A million and \$2.4A million as ofA December 31, 2024, and June 30, 2024, respectively. The unused revolving credit facility amount as of December 31, 2024, was \$7.9A million. X - ReferencesNo definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for short-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent + Details Name: us-gaap ShortTermDebtTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R17.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 11 - Long-term Debt 6 Months Ended Dec. 31, 2024 Notes to Financial Statements A Long-Term Debt [Text Block] Note 11 - Long-Term Debt A Avenue Capital Loan A On January 26, 2022 (the A Closing DateA), the Company entered into a loan and security agreement (the A Avenue Capital AgreementA) with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund II, L.P. as lenders (the A Avenue Capital LendersA), and Avenue Capital Management II, L.P. as administrative agent (the A Avenue Capital AgentA), collectively (the A Avenue CapitalA), pursuant to which the Avenue Capital Lenders provided the Company and certain of its subsidiaries with a secured \$15.0 million loan. The interest rate on the loan was the greater of the prime rate or 3.25%, plus 7.4%, payable monthly in arrears. The maturity date of the loan was January 26, 2025. The proceeds from the Avenue Capital Agreement were used towards the repayment of the term loans. A Pursuant to the Avenue Capital Agreement, the Company was required to make interest only payments for the first 18 months following the Closing Date (the A Interest-only PeriodA). The Interest-only Period could be extended automatically without any action by any party for six months provided as of the last day of the Interest-only Period then in effect, the Company received, prior to June 15, 2023, a specified amount of net proceeds from the sale and issuance of its equity securities (the A Interest-only Milestone 1A). The Interest-only Period was able to be further extended automatically without any action by any party for an additional six months provided, the Company had achieved, prior to December 31, 2023, (i) Interest-only Milestone 1 and (ii) a specified amount of trailing 12 months revenue as of the date of determination. A On January 26, 2022 (the A Issuance DateA), as consideration for entering into the Avenue Capital Agreement, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to \$24.20 per share (the A Avenue Capital WarrantsA). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than \$24.20 prior to June 30, 2022, the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on January 31, 2027. At inception, the Company accounted for the Avenue Capital Warrants as a derivative warrant liability as the number of warrants was not fixed at the Issuance Date. The fair value of the Avenue Capital Warrants at issuance was approximately \$0.6 million. A On March 7, 2022, the Company closed on an equity offering of shares of common stock and warrantsA at an offering price of \$25.00 per share. As this offering precluded the Company from pursuing any equity financing prior to July 7, 2022, and the effective price of the March 7, 2022, offering was more than the exercise price of the Avenue Capital Warrants, the shares of common stock issuable upon exercise of the Avenue Capital Warrants were set at an exercise price of \$24.20. A On October 25, 2022, the Company entered into an agreement with Avenue Venture Opportunities Fund, L.P. (the A AvenueA) to extend the interest-only period of its existing senior secure loan facility held with Avenue. The amendment to the original loan agreement, which was executed in January 2022, extended the interest-only period to January 2024. In exchange for this extension of the interest-only period, the Company and Avenue agreed to reset the exercise price of the warrants issued in conjunction with the original loan agreement to \$8.60, corresponding to the warrant exercise price associated with the CompanyA A A August 2022 equity financing. A On June 13, 2023, in conjunction with the Securities Purchase Agreement described in Note 16 - Warrants, the interest-only period of the Avenue Capital Agreement was extended further upon the achievement of both the revenue-based milestone and equity raise-based milestone stipulated in the Avenue Capital Agreement. As a result, the interest-only period was extended to January 26, 2025. A In addition to the debt discount discussed above, the Company also incurred \$0.4 million loan origination, legal and other fees. The debt discount and issuance costs were being amortized over the term of the loan, using the effective interest method resulting in an effective rate of 16.6%. Total interest expense on the Avenue Capital loan, including debt discount amortization, wasA \$0.7A million and \$1.5 million for the three and six months ended December 31, 2023, respectively. A On June 12, 2024, the Company used proceeds from the Eclipse Term Loan and a portion of the proceeds from the exercise of warrants to repay the Avenue Capital loan in full. Upon early repayment of the Avenue Capital loan, the Company was required to pay Avenue Capital a fee equal to 1.0% of the loan or \$0.2 million. In addition, upon the payment in full of the obligations, the Company was required to pay Avenue Capital a fee in the amount of \$0.6 million (the A Final PaymentA). At inception, the Company accounted for the Final Payment as additional obligations on the debt, with the corresponding charge being recorded as debt discount. At retirement, the early termination fee, the Final Payment fee, and the write-off of all remaining related debt discount and deferred financing costs were included in the calculation of loss on extinguishment of debt. The Company recorded a loss on extinguishment of debt of \$0.6 million related to the retirement of the Avenue Capital loan in the fourth quarter of fiscal 2024. A Eclipse Term Loan A On June 12, 2024, the Company and certain of its subsidiaries entered into Eclipse Amendment No. 5, which provided for among other things,A the Eclipse Term LoanA and the Eclipse Revolving LoanA describedA further in Note 10 - Revolving Credit Facility. The Eclipse Term LoanA consists of a principal amount of \$13.0 million, at an interest rate of SOFR plus 7.0%, with a four-year term maturing on June 12, 2028,A and a straight-line loan amortization period of seven years, which would provide for a loan balance at the end of the four-year term ofA \$5.6 million to be repaid on June 12, 2028, the maturity date. The Company used the proceeds of the Eclipse Term Loan and a portion of the proceeds from warrant exercises described below to repay in full the Avenue Capital loan.A The effective interest rate on the Eclipse Term Loan was 11.7% as of December 31, 2024. A In the event that, for any reason, all or any portion of the Eclipse Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal toA (i) 3.0% of the Eclipse Term LoanA if such event occurs on or before June 12, 2025, (ii) 2.0% of the Eclipse Term LoanA if such event occurs after June 12, 2025,A but on or before June 12, 2026,A (iii) 1.0% of the Eclipse Term LoanA if such event occurs after June 12, 2026,A but on or before June 12, 2027, and (iv) 0.5% of the Eclipse Term LoanA if such event occurs after June 12, 2026,A but on or before June 12, 2028. The Company may also be required to pay an early termination fee related to the Eclipse Revolving LoanA as further described in Note 10A - Revolving Credit Facility. The Company may permanently terminate the Eclipse Agreement upon written notice to Eclipse. The CompanyA A A obligations under the Eclipse AgreementA are secured by substantially all of the CompanyA A A assets, as further defined in the Eclipse Agreement. A The Eclipse Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the CompanyA A A ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make certain asset sales without the prior written consent of the Eclipse L

December 31, 2024, are as follows: A June 2022 Warrants A A Tranche A A Other (1) A Monte Carlo & A A Black-Scholes A A Black-Scholes A Aytu closing stock price A \$ 1.70 A \$ 1.70 A Equivalent term (years) A 3.4A 2.1-2.7A Expected volatility A 80.8% A 74.7%-80.5% A Risk-free rate A 4.3% A 4.3% A Dividend yield A 0.0% A 0.0% A (1A) Includes August 2022 Warrants, March 2022 Warrants, Avenue Capital Warrants and Tranche B Pre-Funded Warrants. See Note 16 - Warrants for definitions of these terms and further information. A X - ReferencesNo definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); and (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap FairValueDisclosuresTextBlock Namespace Prefix: us-gaap Data Type: dt:types:textBlockItemType Balance Type: na Period Type: duration XML 31 R19.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 13 - Commitments and Contingencies 6 Months Ended Dec. 31, 2024 Notes to Financial Statements A Commitments and Contingencies Disclosure [Text Block] Note 13 - Commitments and Contingencies A Pediatric Portfolio Fixed Payments and Product Milestone A The Tris Karbinal Agreement grants the Company the exclusive right to distribute and sell KarbinalA in the United States. The initial term of the agreement was 20 years. The Company pays Tris a royalty equal to 23.5% of net revenue from the product. A The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercialA year that spans from AugustA 1 through JulyA 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make-whole payment of \$30 for each unit under the 70,000A unit annual minimum sales commitment through 2025. The Tris Karbinal Agreement make-whole payment is capped at \$2.1 millionA eachA year. The final annual make-whole payment is due in August 2025. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to \$3.0 million based on cumulative net revenue from theA product, the first of which is triggered at \$40.0 million. A Legal Matters A Witmer Class-Action Securities Litigation A A stockholder derivative suit was filed on September 12, 2022, in the Delaware Chancery Court by Paul Witmer, derivatively and on behalf of all Ayto stockholders, against Armistice Capital, LLC, Armistice Capital Master Fund, Ltd., Steve Boyd (ArmisticeA s Chief Investment Officer and Managing Partner, and a former director of Ayto), and certain other current and former directors of Ayto, Joshua R. Disbrow, Gary Cantrell, John Donofrio, Jr., Michael Macaluso, Carl Dockery and Ketan B. Mehta. Plaintiff amended the complaint on April 5, 2023. The Amended Complaint dropped Mr. Macaluso as a defendant and alleges that (i) Armistice facilitated the sale of assets of Cerecor in 2019 and Innovus in 2020 to Ayto in exchange for convertible securities which it subsequently converted and sold at a profit on the open market; (ii) the Armistice defendants breached their fiduciary duties, were unjustly enriched and wasted corporate assets in connection with these acquisitions; (iii) the Armistice defendants breached their fiduciary duties by engaging in insider trading; and (iv) the other directors breached their fiduciary duties, and aided and abetted the Armistice defendantsA breaches of fiduciary duties, in connection with these acquisitions. The Amended Complaint sought unspecified damages, equitable relief, restitution, disgorgement of profits, enhanced governance and internal procedures, and attorneysA fees. While the Company believesA that this lawsuit is without merit and have vigorously defended against it, the CompanyA agreed to settle the matter for various corporate governance modifications and the payment of plaintiffA s attorneysA fees. On January 13, 2025, the court approved the settlement. A Granules PIV A On October 31, 2024, the CompanyA received a Paragraph IV Certification Notice Letter (ANoticeLetterA) from Granules Pharmaceuticals, Inc. (AGranulesA), stating that it intends to market a generic version of Adzenys before the expiration of all patents currently listed in the Orange Book. The Notice Letter states that GranulesA New Drug Application (AGFDAA) for the generic version of Adzenys contains a Paragraph IV certification alleging that these patents are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the generic version of Adzenys. On December 11, 2024, the CompanyA filed a patent infringement lawsuit against Granules which triggeredA stay precluding the United States Food and Drug Administration (AFDAA) from approving GranulesA NDA for a generic version of Adzenys for up to 30 months or entry of judgment holding the patents invalid, unenforceable, or not infringed, whichever occurs first. On January 7, 2025, Granules submitted an answer to the complaint. This litigation is ongoing, and a trial has been scheduled for to be on December 7, 2026. The Company plans to vigorously enforce its intellectual property rights related to Adzenys. A Revive Investing A The Company has been named as a nominal plaintiff in a lawsuit by two shareholders against Armistice Capital Master Fund, Ltd, entitled Revive Investing, LLC, et al v. Armistice Master Fund, Ltd, et al, Case 1:20-cv-02849-CMA-TPO, in the United States District Court for the District of Colorado, contending that Armistice was liable for short swing trading profits in violation of Section 16(b) of the Exchange Act for certain trades it made in Company stock in 2019 and 2020 and must disgorge those profits to the Company. That matter proceeded to trial before a jury, which on January 29, 2025, returned a verdict finding no liability. A X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dt:types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R20.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 14 - Stockholders' Equity 6 Months Ended Dec. 31, 2024 Notes to Financial Statements A Equity [Text Block] Note 14 - StockholdersA Equity A The Company has 200 million shares of common stock authorized with a par value of \$0.0001 per share and 50 million shares of preferred stock authorized with a par value of \$0.0001 per share. AsA of December 31, 2024, included inA common stock outstanding are 36,256A shares of unvested restricted stock issued to executives, directors and employees. A On September 28, 2021, the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on October 7, 2021. This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of \$100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (theA2021 ShelfA). The 2021 Shelf expiredA in October 2024. A On August 11, 2022, the Company closed on an underwritten public offering (the AAugust 2022 OfferingA) utilizing the 2021 Shelf, pursuant to which it sold an aggregate of (i) 1,075,290 shares of its common stock; (ii) in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 87,500 shares of its common stock; and (iii) accompanying warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase one share of common stock for each share of common stock or each pre-funded warrant sold. The combined public offering price for each share of common stock and accompanying common warrant was \$8.60, and the combined offering price for each pre-funded warrant and accompanying common warrant was \$8.5

[https://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 33 R21.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 15 - Equity Incentive Plans 6 Months Ended Dec. 31, 2024 Notes to Financial Statements A Share-Based Payment Arrangement \[Text Block\] Note 15 - Equity Incentive Plans A 2023 Equity Incentive Plan A On May 18, 2023, the Company's stockholders approved the Ayto BioPharma, Inc. 2023 Equity Incentive Plan \(the "2023 Equity Incentive Plan"\). Prior to the Company's adoption of the 2023 Equity Incentive Plan, the Company awarded equity incentive grants to its directors and employees under the Ayto BioScience, Inc. 2015 Stock Option and Incentive Plan \(the "Ayto 2015 Plan"\) and the Neos Therapeutics, Inc. 2015 Stock Options and Incentive Plan \(the "Neos 2015 Plan"\), and collectively with the Ayto 2015 Plan, the "2023 Equity Incentive Plan". For the 2023 Equity Incentive Plan, the stockholders approved \(i\) 200,000 new shares; \(ii\) 87,129 shares available for grant under the 2015 Plans be allocated over the 2023 Equity Incentive Plan; and \(iii\) any shares that are returned to the Company under the 2015 Plans be added to the 2023 Equity Incentive Plan. With the approval of the 2023 Equity Incentive Plan, no additional awards will be granted under the 2015 Plans. All outstanding awards previously granted under previous stock incentive plans will remain outstanding and subject to the terms of the plans. Stock options granted under the 2023 Equity Incentive Plan have contractual terms of 10 years or less from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards and restricted stock units have a vesting period of 3A to 4 years. As of December 31, 2024, the Company had 87,636A shares that are available for grant under the 2023 Equity Incentive Plan. A Ayto 2015 Plan A On JuneA 1, 2015, the Company's stockholders approved the Ayto 2015 Plan, which, as amended in JulyA 2017, provides for the award of stock options, stock appreciation rights, restricted stock, and other equity awards. On FebruaryA 13, 2020, the Company's stockholders approved an increase to 250,000 total shares of common stock in the Ayto 2015 Plan. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Ayto prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated \(other than by exercise\) under the Ayto 2015 Plan will be added back to the shares of common stock available for issuance under the 2023 Equity Incentive Plan. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards have a vesting period ranging from 4 to 10 years, and the restricted stock units have a vesting period of 4 years. A Neos 2015 Plan A Pursuant to the Neos Acquisition, the Company assumed 3,486 stock options and 1,786 restricted stock units previously granted under the Neos 2015 Plan. Accordingly, on April 19, 2021, the Company registered 5,272 shares of its common stock under the Neos 2015 Plan with the SEC. The terms and conditions of the assumed equity securities remained the same as they were previously under the Neos 2015 Plan. The Company allocated costs of the replacement awards attributable to pre-combination and post-combination service periods. The pre-combination service costs were included in the consideration transferred. The remaining costs attributable to the post-combination service period are being recognized as stock-based compensation expense over the remaining terms of the replacement awards. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 1 to 4 years. A Stock Options A Stock option activity is as follows: A A A A A A A A Weighted A A A A A A A A Average A A A A A A A A Weighted A A A A A A A A Remaining A A A Number of A A A Average A A A Contractual A A A Options A A A Exercise Price A A A Life in Years A A Outstanding at June 30, 2024 A A 146,539A A \\$6.18A A A 8.8A A Granted A A 83,000A A \\$1.84A A A 2.3A A Forfeited/cancelled A A \(8,147\)A A \\$5.73A A A A A A Outstanding at December 31, 2024 A A 221,392A A \\$4.57A A A 8.3A A A A A A A A Exercisable at December 31, 2024 A A 81,399A A \\$9.02A A A 6.6A A During the sixA months endedA December 31, 2024, the Company granted 83,000 stock options with a weighted averageA exercise price per option of \\$1.84A. As of December 31, 2024, there was \\$0.2A millionA total unrecognized compensation costs related to non-vested stock options granted under the Company's equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.3A years. A Restricted Stock A Restricted stock activity is as follows: A A A A A A A A Weighted A A A A A A A A Average Grant A A A Number of A A Date Fair A A A Shares A A Value A Unvested at June 30, 2024 A A 24,105A A \\$100.34A A Granted A A 20,000A A \\$1.79A A Vested A A \(7,853\)A A \\$15.33A A Unvested at December 31, 2024 A A 36,252A A \\$64.38A A During the sixA months endedA December 31, 2024, the Company granted 20,000A shares of restricted stock under the Company's 2023 Equity Incentive Plan with a weighted average grant date fair value of \\$1.79 per share. As of December 31, 2024, there was \\$0.9A millionA total unrecognized compensation costsA related to non-vested restricted stock granted under the Company's equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.3A years. A During the sixA months endedA December 31, 2024, no restricted stock was granted outside of theA Company's equity incentive plans. As of December 31, 2024, there was \\$0.2A millionA total unrecognized compensation costs related to non-vested restricted stock issued outside of the Company's equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.5A years.A As of December 31, 2024, 4A shares ofA restricted stock remain unvested that were granted outside of the Company's equity incentive plan. A Restricted Stock Units A Restricted stock units \(A RSUs \) activity is as follows: A A A A A A A A Weighted A A A A A A A A Average Grant A A A Number of A A Date Fair A A A Shares A A Value A Unvested at June 30, 2024 A A 1,775A A \\$24.14A A Vested A A \(1,043\)A A \\$24.13A A Forfeited A A \(167\)A A \\$26.20A A Unvested at December 31, 2024 A A 565A A \\$23.55A A During the sixA months endedA December 31, 2024, no RSUs wereA granted. As of December 31, 2024, there was less than \\$0.1 million of unrecognized compensation costs related to non-vested RSUs granted under the Company's equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 0.2A years. A Stock-based compensation expense related to the fair value of stock options, restricted stock, and RSUs was included in the consolidated statements of operations as set forth in the below table: A A Three Months Ended A A Six Months Ended A A December 31, A A December 31, A A 2024 A A 2023 A A 2024 A A 2023 A A \(in thousands\) A Cost of sales A \\$6A A \\$1A A \\$1A A \\$1A Research and development A 1A A 2A A 3A A 3A Selling and marketing A 14A A 14A A 46A A 46A General and administrative A 136A A 136A A 704A A 274A A 1,428A Net income \(loss\) from discontinued operations, net of tax A A A A A 113A A A A A 318A Total stock-based compensation expense A 151A A \\$820A A \\$324A A \\$1,750A A X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: \[http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2:\]\(#\) \[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3:\]\(#\) \[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4:\]\(#\) \[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(h\\)\\(2\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5:\]\(#\) \[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(h\\)\\(2\\)\\(i\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6:\]\(#\) \[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(l\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X -ReferencesNo definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 34 R22.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 16 - Warrants 6 Months Ended Dec. 31, 2024 Notes to Financial Statements A Warrants or Rights Disclosure \\[Text Block\\] Note 16 - Warrants A Liability Classified Warrants A The Company accounts for liability classified warrants by recording the fair value of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of liability classified derivative financial instruments was calculated using either the Black-Scholes option pricing model or the Monte Carlo simulation model and is revalued every quarter. Changes in the fair value of liability classified derivative financial instruments in subsequent periods are recorded as unrealized derivative gain or loss in the consolidated statements of operations \\(see Note 12 A Fair Value Considerations\\). A On June 8, 2023, using a placement agent, the Company entered into a securities purchase agreement \\(the "Securities Purchase Agreement"\\) with certain institutional investors, pursuant to which the Company issued and sold an aggregate of \\(i\\) 1,743,695 shares of the Company's common stock; \\(ii\\) June 2023 Pre-Funded Warrants in lieu of shares to purchase 430,217 shares of common stock; \\(iii\\) accompanying Tranche A Warrants to purchase 2,173,912 shares of common stock; and \\(iv\\) accompanying Tranche B Warrants to purchase 2,173,912 shares of common stock in a best-efforts offering \\(the Tranche A Warrants together with the Tranche B Warrants, the "Common Warrants"\\). The Common Warrants may be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of \\\$0.0001 per share in the same form as the June 2023 Pre-Funded Warrants \\(the "Exchange Warrants"\\). Each pre-funded warrant is exercisable for one share of common stock at an exercise\]\(#\)](#)

\$0.13A \$(0.04) \$0.37A \$(1.52) The following is a reconciliation of the numerator and denominator used in the diluted per share calculations: A A Three Months Ended A A Six Months Ended A A December 31, A A December 31, A A A A 2024 A A 2023 A A 2024 A A 2023 A A (in thousands, except share and per share data) A DILUTED: CONTINUING OPERATIONS A A A A A A A A A A Numerator: A A A A A A A A Net income (loss) from continuing operations A \$665 A A \$619 A A \$1,758 A A \$(6,854) Adjustment for change in fair value of warrant liabilities A A (3,016) A A A A (5,896) A A A A Adjusted numerator - net (loss) income from continuing operations A \$(2,351) A A \$619 A A \$(4,138) A A \$(6,854) Denominator: A A A A A A A A Basic weighted-average common shares outstanding A 6,132,060 A A 5,517,670 A A 6,100,204 A A 5,499,951 A Dilutive effect of warrants to purchase common stock A 2,342,087 A A A A 2,669,216 A A A A Dilutive effect of unvested restricted stock and restricted stock units A 10,965 A A A A 13,374 A A A A Diluted weighted-average common shares outstanding A 8,485,112 A A 8,485,112 A A 8,485,112 A A 8,485,112 A A Per share calculation: A A A A A A A A Net (loss) income per share from continuing operations A \$(0.28) A A \$0.11 A A \$(0.47) A A \$(1.25) A A A A A A A A A A DILUTED: DISCONTINUED OPERATIONS A A A A A A A A Numerator: A A A A A A A A Net income (loss) from discontinued operations, net of tax A \$123 A A \$(839) A A \$504 A A \$(1,486) Denominator: A A A A A A A A Basic weighted-average common shares outstanding A 6,132,060 A A 5,517,670 A A 6,100,204 A A 5,499,951 A Dilutive effect of warrants to purchase common stock A 2,342,087 A A A A 2,669,216 A A A A Dilutive effect of unvested restricted stock and restricted stock units A 10,965 A A A A 13,374 A A A A Diluted weighted-average common shares outstanding A 8,485,112 A A 5,517,670 A A 8,782,794 A A 5,499,951 A Per share calculation: A A A A A A A A Net income (loss) per share from discontinued operations, net of tax A \$0.01 A A \$(0.15) A A \$0.06 A A \$(0.27) A A A A A A A A DILUTED: NET INCOME (LOSS) A A A A A A A A Numerator: A A A A A A A A Net income (loss) A \$788 A A \$(220) A A \$2,262 A A \$(8,340) Adjustment for change in fair value of warrant liabilities A (3,016) A A A A (5,896) A A A A Adjusted numerator - net loss A \$(228) A A \$(220) A A \$(3,634) A A \$(8,340) Denominator: A A A A A A A A Basic weighted-average common shares outstanding A 6,132,060 A A 5,517,670 A A 6,100,204 A A 5,499,951 A Dilutive effect of warrants to purchase common stock A 2,342,087 A A A A 2,669,216 A A A A Dilutive effect of unvested restricted stock and restricted stock units A 10,965 A A A A 13,374 A A A A Diluted weighted-average common shares outstanding A 8,485,112 A A 5,517,670 A A 8,782,794 A A 5,499,951 A Per share calculation: A A A A A A A A Net loss per share A \$(0.26) A A \$(0.04) A A \$(0.41) A A \$(1.52) A The following table sets forth securities that could be considered anti-dilutive, and therefore are excluded from the calculation of diluted weighted-average common shares outstanding and related per share calculations: A A Three Months Ended A A Six Months Ended A A December 31, A A December 31, A A 2024 A A 2023 A A 2024 A A 2023 A Warrants to purchase common stock - liability classified (note 16) A A 3,539,679 A A 6,498,980 A A 3,212,550 A A 6,498,980 A Warrants to purchase common stock - equity classified (note 16) A A 18,114 A A 39,072 A A 18,114 A A 39,072 A Employee unvested restricted stock (note 15) A A 25,291 A A 40,017 A A 22,882 A A 40,017 A Employee unvested restricted stock units (note 15) A A 512 A A 2,898 A A 565 A A 2,898 A Employee stock options (note 15) A A 221,392 A A 149,087 A A 221,392 A A 149,087 A Total anti-dilutive securities A A 3,804,988 A A 6,730,054 A A 3,475,503 A A 6,730,054 A X - ReferencesNo definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap EarningsPerShareTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R24.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 18 - License Agreements 6 Months Ended Dec. 31, 2024 Notes to Financial Statements A Licensing Agreements [Text Block] Note 18 - License Agreements A Activis A On October 17, 2017, the Company entered into an agreement granting Activis Laboratories FL, Inc. (aCActivisA) (acquired by Teva Pharmaceutical Industries) a non-exclusive license to certain patents owned by the Company by which Activis has the right to manufacture and market its generic version of Adzenys under its ANDA beginning on September 1, 2025, or earlier under certain circumstances. The ANDA was approved by the FDA on June 22, 2023. A Teva A On December 21, 2018, the CompanyA and Teva Pharmaceuticals USA, Inc. (aCotevaA) entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla under anA abbreviated new drug applicationA (aCANDAa) filed by Teva beginning on July 1, 2026, or earlier under certain circumstances. The ANDA was approved by the FDA on June 19, 2020. X - DefinitionThe entire disclosure for licensing agreements. + ReferencesNo definition available. + Details Name: aytu LicensingAgreementsTextBlock Namespace Prefix: aytu Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: duration XML 37 R25.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 19 - Restructuring Costs 6 Months Ended Dec. 31, 2024 Notes to Financial Statements A Restructuring and Related Activities Disclosure [Text Block] Note 19 - Restructuring Costs A As part of the Company's previously announced restructuring activities related to the wind down and divestiture of the Consumer Health businessA and the closure of the Grand Prairie, Texas manufacturing site, the Company has incurred expenses that qualify as exit and disposal costs under U.S. GAAP. These include severance and employee benefit costs as well as other direct separation benefit costs, right of use asset impairment charges, fixed asset and other asset impairment charges, accelerated depreciation of fixed assets, contract termination costs, and inventory write-downs. Severance and employee benefit costs primarily relate to cash severance. Restructuring costs associated with the Consumer Health business are recorded within the net income (loss) from discontinued operations, net of tax in the unaudited consolidated financial statement of operationsA (see Note 20A - Discontinued Operations). A The expense associated with the closure of the Grand Prairie, Texas manufacturing site such as severance and employee benefits and exit and disposal activities are included in restructuring costs in the consolidated statements of operations. There have been no inventory write-downs associated with this closure. During the three and six months ended December 31, 2024, the CompanyA incurred \$1.3A million and \$2.1A million, respectively, of costs associated with exit and disposal activities related to its previously announced operational realignment and related costs.A The Company does not expect to incurA additional significant restructuring costs. A X - ReferencesNo definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/420/tableOfContentReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap RestructuringAndRelatedActivitiesDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R26.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 20 - Discontinued Operations 6 Months Ended Dec. 31, 2024 Notes to Financial Statements A Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Note 20A - Discontinued Operations A On July 31, 2024, after the wind down of operations, the Company entered into a definitive agreement to divest its Consumer Health business to a private, e-commerce focused company. The divested business encompasses the established e-commerce platform, certain inventory and associated consumer brands, intellectual property, external workforce and contracts, and provides for the Company to receive contingent consideration payments on certain future sales of former Consumer Health business products. A The accounting requirements for reporting the Consumer Health business as discontinued operation were met when the wind down and divestiture was completed on July 31, 2024. Accordingly, the accompanying unaudited consolidated financial statements for all periods presented reflect this business as a discontinued operation and certain assets and liabilities of discontinued operations have been reclassified to the current assets of discontinued operations; non-current assets of discontinued operations; and current liabilities of discontinued operations financial statement line items on the accompanying unaudited consolidated balance sheet as of June 30, 2024. The Company elected to record the contingent consideration portion of the arrangement when the consideration is determined to be realizable and, therefore, the Company did not record a contingent consideration asset at the transaction date and any subsequent proceeds will not be recognized until the contingent consideration asset is realizable, at which point the Company recognizes it to income (loss) from discontinued operations. A The key components of net income (loss) from discontinued operations, net of tax for the three and six months ended December 31, 2024, and 2023, were as follows: A A Three Months Ended A A Six Months Ended A A December 31, A A December 31, A A 2024 A A 2023 A A 2024 A A 2023 A A Net revenue A A A A \$4,186 A A \$717 A A \$8,468 A A Cost of sales A A A A (2,586) A A A A (359) A A (5,122) Selling and marketing A A A A (1,358) A A (155) A A (2,689) General and administrative A A A A (642) A A (2) A A (1,312) Amortization of intangible assets A A A A (382) A A A A (764) Non-operating other expense, net A A A A (9) A A (4) A A (19) Recognized contingent consideration A A 175 A A A A 587 A A A A Loss on divestiture A A A A A A (254) A A A A Income (loss) from discontinued operations before income taxes A A 175 A A (791) A A 530 A A (1,438) Income tax expense A A (52) A A (48) A A (26) A A (48) Net income (loss)

(ASC 815) Topic 480, Distinguishing Liabilities from Equity (ASC 480) and ASC Topic 815, Derivatives and Hedging (ASC 815). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company's own common shares and whether the warrant holders could potentially require a net cash settlement in a circumstance outside of the Company's control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option pricing model or Monte Carlo simulation model at issuance and for each reporting period when applicable. A Income Tax, Policy [Policy Text Block] Income Taxes A The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been no changes in tax law affecting the tax provision during the three and six months ended December 31, 2024. A The Company recorded for income (loss) from continuing operations an income tax benefit of \$0.3 million, which represented an effective tax rate of negative 74.1% and income tax expense of \$0.8 million, which represented an effective tax rate of 55.8%, for the three months ended December 31, 2024, and 2023, respectively. The Company recorded for income (loss) from continuing operations an income tax expense of \$0.1 million, which represented an effective tax rate of 6.5% and income tax expense of \$0.8 million, which represented an effective tax rate of negative 12.8% for the six months ended December 31, 2024, and 2023, respectively. These effective tax rates were primarily driven by the limitations on losses as a result of Section 382 of the Internal Revenue Code changes in ownership coupled with existing valuation allowances, the divestiture of the Company's Consumer Health business that occurred during the first quarter of fiscal 2025 and changes to the Company's first quarter of fiscal 2025 projections, which resulted in an income tax benefit for the current quarter. A An ownership change has limited the Company's ability to offset, post-change, United States federal taxable income. Section 382 of the Internal Revenue Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. Previous acquisitions, financing transactions, and equity ownership changes in the past five years have caused a significant limitation on the Company's ability to use the change in control net operating loss carryovers. The ownership changes result in increased future tax liability and are a driver of the change from a zero percent effective tax rate. A The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than not that some portion or all of its deferred tax asset will not be utilized. A The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained upon an examination. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense in the unaudited consolidated statements of operations. A Employee Retention Credit [Policy Text Block] Employee Retention Credit A On March 27, 2020, the United States government enacted the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) to provide certain relief as a result of the COVID-19 pandemic. The CARES Act provides tax relief, along with other stimulus measures, including a provision for an Employee Retention Credit (ERC), which allows for employers to claim a refundable payroll tax credit against the employer share of Social Security tax equal to 70% of the qualified wages paid to employees after December 31, 2020, through September 30, 2021. The ERC was designed to encourage businesses to keep employees on the payroll during the COVID-19 pandemic. A As there is no authoritative guidance under U.S. GAAP on accounting for government assistance to for-profit business entities, the Company accounted for the ERC by analogy to International Accounting Standard (IAS) 20, Accounting for Government Grants and Disclosure of Government Assistance (IAS 20). In accordance with IAS 20, the Company recorded a \$3.8 million ERC accrual in other non-current liabilities, which represents the proceeds the Company received from the ERC program during the first quarter of fiscal 2024. Further in accordance with IAS 20, when management determines it has reasonable assurance that the Company has substantially met all eligibility requirements of the ERC and following any adjustments from its regulatory audit or upon further clarifications from the Internal Revenue Code of 1986, as amended (the IRC), the ERC accrual shall be recognized as a benefit in other income in the unaudited consolidated statement of operations. The associated vendor fee of \$0.4 million was expensed as incurred in the first quarter of fiscal 2024. A New Accounting Pronouncements, Policy [Policy Text Block] Recently Adopted Accounting Pronouncements A Debt - Debt with Conversion and Other Option A In August 2020, the FASB issued Accounting Standards Update (ASU) No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity's Own Equity (Subtopic 815-40) Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the SEC, for the fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company adopted the guidance on July 1, 2024, and the adoption of the standard did not have a material impact on the Company's consolidated financial statements. A Recent Accounting Pronouncements Not Yet Adopted A Segment Reporting - Improvements to Reportable Segment Disclosures In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07). ASU 2023-07 was issued to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance should be applied retrospectively unless it is impracticable to do so. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted, including in an interim period. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company's consolidated financial statements and disclosures. A Disaggregation of Income Statement Expenses A In November 2024, the FASB issued ASU No. 2024-03, Income Statement Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (ASU 2024-03). The amendments in ASU 2024-03 require public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation, amortization and depletion expenses for each caption on the income statement where such expenses are included. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company's consolidated financial statements and disclosures. A For a complete set of the Company's significant accounting policies, refer to the audited consolidated financial statements and notes thereto included in the Company's 2024 Form 10-K. There have been no significant changes to the Company's significant accounting policies and there is no other accounting guidance that has been issued and not yet adopted that is applicable to the Company and that would have a material effect on the Company's unaudited consolidated financial statements and related disclosures as of December 31, 2024, and through the filing of this Form 10-K. X - Definition Represents the accounting policy for employee retention credits. + References No definition available. + Details Name: aytu Employee Retention Credit Policy Text Block Namespace Prefix: aytu Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - Definition Disclosure of the company's accounting policy regarding warrants. + References No definition available. + Details Name: aytu Warrants Policy Text Block Namespace Prefix: aytu Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - References No definition available. + Details Name: us-gaap Accounting Policies Abstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + References No definition available. + Details Name: us-gaap Basis of Accounting Policy Policy Text Block Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + References Reference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-20](http://www.xbrl.org/2003/role/exampleRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-20) Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 19-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-19> Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Publisher FASB-URI https://asc.fasb.org/1943274/2147482525/740-10-45-25> Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(h\)\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(h)(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 17-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 17-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17) Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-9> Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI https://asc.fasb.org/1943274/2147482525/740-10-45-28> Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-1> + Details Name: us-gaap Income Tax Policy Text Block Namespace Prefix: us-gaap Data Type: dtr-types:text

accumulated depreciation and amortization A A (651)A A (2,125) Property and equipment, net A \$516A A \$693A X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 44 R32.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 6 - Leases (Tables) 6 Months Ended Dec. 31, 2024 Notes Tables A Lease, Cost [Table Text Block] A A Three Months Ended A A Six Months Ended A A A December 31, A A A A 2024 A A 2023 A A 2024 A A 2023 A Statement of Operations Classification A A (in thousands) A A Lease cost: A A A A A A A A A A A A A A A Operating lease cost A \$143A A \$381A A \$265A A \$741A Operating expenses Short-term lease cost A A 86A A A 21A A A 177A A A 44A Operating expenses Finance lease cost: A A A A A A A A A A A A A A A Amortization of leased assets A A A A A A A 15A A A A A 29A Cost of sales Interest on lease liabilities A A A A A A 1A A A A A A A 2A Interest expense Total lease cost A \$229A A \$418A A \$442A A \$816A A A December 31, A A June 30, A A A A 2024 A A 2024 A A Weighted-average remaining lease term (years): A A A A A A A A Operating lease right-of-use assets A A 5.6A A A 2.7A Weighted-average discount rate: A A A A A A A A Operating lease right-of-use assets A A 12.1%A A 10.0%A A Six Months Ended A A December 31, A A A A 2024 A A 2023 A A (in thousands) A Cash flow classification of lease payments: A A A A A A A A Operating cash flows from operating leases A \$606A A \$697A Operating cash flows from finance leases A \$A A A \$2A Financing cash flows from finance leases A \$A A A \$46A Schedule of Lease by Balance Sheet Information [Table Text Block] A A December 31, A A June 30, A A A A 2024A A 2024A Balance Sheet Classification A A (in thousands) A A Assets: A A A A A A A A Non-current: operating leases A \$1,178A A \$829A Operating lease right-of-use assets A A A A A A A A Liabilities: A A A A A A A A Current: operating leases A \$182A A \$712A Other current liabilities Non-current: operating leases A A 1,106A A A 577A Other non-current liabilities Total lease liabilities A \$1,288A A \$1,289A A Lessee, Liability, Maturity [Table Text Block] A A Operating A A A (in thousands) A 2025 (remaining 6 months) A \$123A 2026 A A 399A 2027 A A 377A 2028 A A 386A 2029 A A 358A 2030 A A 230A Thereafter A A 19A Total lease payments A 1,892A Less: imputed interest A A (479) Less: tenant improvement allowance A A (125) Lease liabilities A \$1,288A X - DefinitionTabular disclosure of undiscounted cash flows of lessee's lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to lease liability recognized in statement of financial position. + ReferencesNo definition available. + Details Name: aytu_LesseeLiabilityMaturityTableTextBlock Namespace Prefix: aytu_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of leases by balance sheet information. + ReferencesNo definition available. + Details Name: aytu_ScheduleOffLeaseByBalanceSheetInformationTableTextBlock Namespace Prefix: aytu_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-4> + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 45 R33.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 7 - Intangible Assets (Tables) 6 Months Ended Dec. 31, 2024 Notes Tables A Schedule of Finite-Lived Intangible Assets [Table Text Block] A A December 31, 2024 A A A Gross Carrying Amount A A Accumulated Amortization A A Net Carrying Amount A A Weighted-Average Remaining Life A A (in thousands) A A (in years) A A Acquired product technology rights A \$41,268A A \$(14,791) A \$26,477A A A 10.3A Acquired technology rights A A 30,200A A A (6,719)A A 23,481A A A 13.2A Total intangible assets A \$71,468A A \$(21,510) A \$49,958A A A 11.7A A June 30, 2024 A A A Gross Carrying Amount A A Accumulated Amortization A A Net Carrying Amount A A Weighted-Average Remaining Life A A (in thousands) A A (in years) A A Acquired product technology rights A \$41,268A A \$(13,184) A \$28,084A A A 10.7A Acquired technology rights A A 30,200A A A (5,831)A A 24,369A A A 13.8A Total intangible assets A \$71,468A A \$(19,015) A \$52,453A A A 12.0A Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] A A Estimated Future Amortization Expense A A (in thousands) A 2025 (remaining 6 months) A \$2,495A 2026 A A 4,989A 2027 A A 4,989A 2028 A A 4,989A 2029 A A 4,989A 2030 A A 2,847A Thereafter A A 24,660A Total future amortization expense A \$49,958A X - DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2> + Details Name: us-gaap_ScheduleOffFiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2> + Details Name: us-gaap_ScheduleOffFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 46 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 8 - Accrued Liabilities (Tables) 6 Months Ended Dec. 31, 2024 Notes Tables A Schedule of Accrued Liabilities [Table Text Block] A A December 31, A A June 30, A A A 2024 A A 2024 A A (in thousands) A A Accrued savings offers A \$14,507A A \$11,054A Accrued program liabilities A A 7,021A A A 9,964A Accrued customer and product related fees A A 5,735A A A 5,395A Return reserve A A 5,111A A A 4,832A Accrued employee compensation A A 3,971A A A 4,603A Other accrued liabilities A A 3,027A A A 2,295A Total accrued liabilities A \$39,372A A \$38,143A X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 47 R35.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 9 - Other Liabilities (Tables) 6 Months Ended Dec. 31, 2024 Notes Tables A Other Liabilities [Table Text Block] A A December 31, A A June 30, A A A 2024 A A 2024 A A (in thousands) A A Fixed payment arrangements A \$6,926A A \$8,337A Employee retention credit A A A 3,759A A A 3,759A Operating lease liabilities A A 1,288A A A 1,289A Other A A 180A A A 106A Total other liabilities A A 12,153A A A 13,491A Less: current portion of other liabilities A A (7,108)A A (8,962) Total non-current portion of other liabilities A \$5,045A A \$4,529A X - DefinitionTabular disclosure of other liabilities. + ReferencesNo definition available. + Details Name: us-gaap_OtherLiabilitiesTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 48 R36.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 11 - Long-term Debt (Tables) 6 Months Ended Dec. 31, 2024 Notes Tables A Schedule of Long-Term Debt Instruments [Table Text Block] A A December 31, A A June 30, A A A 2024 A A 2024 A A (in thousands) A A Term loan principal amount A \$12,071A A \$13,000A Unamortized debt discount and issuance costs A A (231)A A (266) Total debt A A 11,840A A A 12,734A Less: current portion of debt A A (1,857)A A (1,857) Total debt, net of current portion A \$9,983A A \$10,877A Schedule of Maturities of Long-Term Debt [Table Text Block] A A Future Principal Payments A A (in thousands) A 2025 (remaining 6 months) A \$928A 2026 A A 1,857A 2027 A A 1,857A 2028 A A 7,429A Total future principal payments A A 12,071A Less: unamortized debt discount and issuance costs A A (231) Less: current portion of debt A A (1,857) Total debt, net of current

[illegible]

Paragraph 231 - Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SAB Topic 6.1.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-599-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1 + Details Name: us-gaap IncomeTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap BalanceSheetLocationAxis=us-gaap OtherNoncurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R43.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 3 - Revenue (Details Textual) \$ in Millions 3 Months Ended Sep. 30, 2024 USD (\$) Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price \$ 3.3 X - DefinitionAmount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details Name: us-gaap ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 56 R44.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 3 - Revenue - Disaggregation of Revenue (Details) - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Revenue \$ 16,221 \$ 18,748 \$ 32,795 \$ 36,565 Rx Segment [Member] A A A A Revenue 16,221 18,748 32,795 36,565 Rx Segment [Member] | ADHD Portfolio [Member] A A A A Revenue 13,816 16,572 29,080 31,700 Rx Segment [Member] | The Pediatric Portfolio [Member] A A A A Revenue 2,400 2,145 3,693 4,710 Rx Segment [Member] | Product and Service, Other [Member] A A A A Revenue \$ 5 \$ 31 \$ 22 \$ 155 X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-599-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap StatementBusinessSegmentsAxis=aytu RxSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt ProductOrServiceAxis=aytu ThePediatricPortfolioMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt ProductOrServiceAxis=us-gaap ProductAndServiceOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R45.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 4 - Inventories (Details Textual) - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Inventory Write-down \$ 100 \$ 100 \$ 51 X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details Name: us-gaap InventoryWriteDown Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 58 R46.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 4 - Inventories - Schedule of Inventories (Details) - USD (\$) \$ in Thousands Dec. 31, 2024 Jun. 30, 2024 Raw materials \$ 494 \$ 266 Work in process 3,103 5,725 Finished goods 7,488 6,150 Inventories \$ 11,085 \$ 12,141 X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-599-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1 + Details Name: us-gaap InventoryFinishedGoodsNetOfReserves Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1 + Details Name: us-gaap InventoryNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-599-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1 + Details Name: us-gaap InventoryWorkInProcessNetOfReserves Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 59 R47.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 5 - Property and Equipment (Details Textual) - USD (\$) \$ in Millions 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Depreciation \$ 0.1 \$ 0.3 \$ 0.1 \$ 0.6 X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap Depreciation Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 60 R48.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD (\$) \$ in Thousands Dec. 31, 2024 Jun. 30, 2024 Property and equipment, gross \$ 1,167 \$ 2,818 Less: accumulated depreciation and amortization (651) (2,125) Property and equipment, net 516 693 Manufacturing Equipment [Member] A A Property and equipment, gross 721 1,838 Office Equipment, Furniture and Other [Member] A A Property and equipment, gross 282 945 Leasehold Improvements [Member] A A Property and equipment, gross \$ 164 \$ 35 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-599-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-599-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-599-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap PropertyPlantAndEquipmentByTypeAxis=aytu ManufacturingEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap PropertyPlantAndEquipmentByTypeAxis=aytu OfficeEquipmentFurnitureAndOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap PropertyPlantAndEquipmentByTypeAxis=us-gaap LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R49.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 6 - Leases (Details Textual) - USD (\$) Dec. 31, 2024 Jun. 30, 2024 Finance Lease, Liability A \$ 0 Operating Lease, Right-of-Use Asset \$ 1,178,000 829,000 Operating Lease, Liability \$ 1,288,000 1,289,000 Office Space in Berwyn, Pennsylvania [Member] A A Operating Lease, Undiscounted Minimum Monthly Payment A 13,000 Operating Lease, Right-of-Use Asset A 500,000 Operating Lease, Liability A \$ 500,000 Lessee, Operating Lease, Discount Rate A 12.30% X - DefinitionRepresents the undiscounted minimum monthly payment on an operating lease. + ReferencesNo definition available. + Details Name: aytu OperatingLeaseUndiscountedMinimumMonthlyPayment Namespace Prefix: aytu Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap FinanceLeaseLiability Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDiscount rate used by lessee to determine present value of operating lease payments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap LesseeOperatingLeaseDiscountRate Namespace Prefix: us-gaap Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1:

[http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_LeaseContractualTermAxis=aytu_OfficeSpaceInBerwynPennsylvaniaMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R50.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 6 - Leases - Lease Cost (Details) - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Jun. 30, 2024 Total lease cost \$ 229 \$ 418 \$ 442 \$ 816 Á Á Á Á Operating lease right-of-use assets (Year) 5 years 7 months 6 days Á 5 years 7 months 6 days Á 2 years 8 months 12 days Operating lease right-of-use assets 12.10% Á 12.10% Á 10.00% Operating cash flows from operating leases Á Á \$ 606 697 Á Operating cash flows from finance leases Á Á 0 2 Á Financing cash flows from finance leases Á Á 0 46 Á Operating Expense [Member] Á Á Á Á Operating lease cost \$ 143 381 265 741 Á Short-term lease cost 86 21 177 44 Á Cost of Sales [Member] Á Á Á Á Amortization of leased assets 0 15 0 29 Á Other Expense [Member] Á Á Á Á Interest on lease liabilities \$ 0 \$ 1 \$ 0 \$ 2 Á X - DefinitionAmount of interest expense on finance lease liability. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap_FinanceLeaseInterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest paid on finance lease liability. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(g\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of amortization expense attributable to right-of-use asset from finance lease. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(g\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4> + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(g\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4> + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of short-term lease cost, excluding expense for lease with term of one month or less. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4> + Details Name: us-gaap_ShortTermLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R51.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 6 - Leases - Lease Balance Sheet Information (Details) - USD (\$) \$ in Thousands Dec. 31, 2024 Jun. 30, 2024 Operating lease right-of-use assets \$ 1,178 \$ 829 Current: operating leases 182 712 Non-current: operating leases 1,106 577 Total lease liabilities \$ 1,288 \$ 1,289 X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 64 R52.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 6 - Leases - Lease Balance Sheet Information (Details) (Parentheticals) - USD (\$) \$ in Thousands Dec. 31, 2024 Jun. 30, 2024 Liabilities, Current [Abstract] Á Á Other Liabilities, Current \$ 7,108 \$ 8,962 Liabilities, Noncurrent [Abstract] Á Á Liabilities, Noncurrent 21,414 28,151 Other Liabilities, Noncurrent \$ 5,045 \$ 4,529 Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Other Liabilities, Current Other Liabilities, Current Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other Liabilities, Noncurrent Other Liabilities, Noncurrent X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(24\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(26\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 13: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 22: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 23:

us-gaap. Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(24\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(24))) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 65 R53.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 6 - Leases - Schedule of Lease Liability Maturity (Details) - USD (\$) \$ in Thousands Dec. 31, 2024 Jun. 30, 2024 2025 (remaining 6 months) \$ 123 A 2026 399 A 2027 377 A 2028 386 A 2029 358 A 2030 230 A Thereafter 19 A Total lease payments 1,892 A Less: imputed interest (479) A Less: tenant improvement allowance 125 A Operating Lease, Liability \$ 1,288 \$ 1,289 X - DefinitionThe amount of tenant improvement allowance for operating lease liability of lessee. + ReferencesNo definition available. + Details Name: aytu LesseeOperatingLeaseLiabilityTenantImprovementAllowance Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease, including lease not yet commenced. + ReferencesNo definition available. + Details Name: aytu LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 66 R54.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 7 - Intangible Assets (Details Textual) - USD (\$) \$ in Millions 3 Months Ended 6 Months Ended 18 Months Ended Dec. 31, 2024 Dec. 31, 2024 Dec. 31, 2024 Amortization Expense of Intangible Assets \$ 1.2 \$ 2.5 A Tris Karbinal Agreement [Member] A A Supply and Distribution Agreement, Extension Term (Year) A A 20 years Minimum [Member] A A Finite-Lived Intangible Asset, Useful Life, Renewable Period (Year) A 1 year A Maximum [Member] A A Finite-Lived Intangible Asset, Useful Life, Renewable Period (Year) A 20 years A X - DefinitionThe value of amortization expense of intangible assets. + ReferencesNo definition available. + Details Name: aytu AmortizationExpenseOfIntangibleAssets Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the renewable period for a finite-lived intangible asset. + ReferencesNo definition available. + Details Name: aytu FinitelivedIntangibleAssetUsefulLifeRenewablePeriod Namespace Prefix: aytu_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRepresents the extension term of a supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu SupplyAndDistributionAgreementExtensionTerm Namespace Prefix: aytu_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt CounterpartyNameAxis=aytu TrisKarbinalAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R55.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 7 - Intangible Assets - Schedule of Intangible Assets (Details) - USD (\$) \$ in Thousands Dec. 31, 2024 Jun. 30, 2024 Finite-lived intangible assets, gross \$ 71,468 \$ 71,468 Finite-lived intangible assets, amortization (21,510) (19,015) Finite-lived intangible assets, net \$ 49,958 \$ 52,453 Finite-lived intangible assets, remaining life (Year) 11 years 8 months 12 days 12 years Technology-Based Intangible Assets [Member] A Finite-lived intangible assets, gross \$ 41,268 \$ 41,268 Finite-lived intangible assets, amortization (14,791) (13,184) Finite-lived intangible assets, net \$ 26,477 \$ 28,084 Finite-lived intangible assets, remaining life (Year) 10 years 3 months 18 days 10 years 8 months 12 days Developed Technology Rights [Member] A A Finite-lived intangible assets, gross \$ 30,200 \$ 30,200 Finite-lived intangible assets, amortization (6,719) (5,831) Finite-lived intangible assets, net \$ 23,481 \$ 24,369 Finite-lived intangible assets, remaining life (Year) 13 years 2 months 12 days 13 years 9 months 18 days X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1:

-Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap FinitelivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap FinitelivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap FinitelivedIntangibleAssetsNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant XML 69 R57.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD (\$) \$ in Thousands Dec. 31, 2024 Jun. 30, 2024 Accrued savings offers of \$ 14,507 \$ 11,054 Accrued program liabilities 7,021 9,964 Accrued customer and product related fees 5,735 5,395 Return reserve 5,111 4,832 Accrued employee compensation 3,971 4,603 Other accrued liabilities 3,027 2,295 Total accrued liabilities \$ 39,372 \$ 38,143 X - DefinitionRepresents the amount of accrued customer and product related fees classified as current. + ReferencesNo definition available. + Details Name: aytu AccruedCustomerAndProductRelatedFeesCurrent Namespace Prefix: aytu Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for program related liabilities. + ReferencesNo definition available. + Details Name: aytu AccruedProgramRelatedLiabilities Namespace Prefix: aytu Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionRepresents information related to accrued saving offers. + ReferencesNo definition available. + Details Name: aytu AccruedSavingOffers Namespace Prefix: aytu Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionRepresents the amount of return reserve classified as current. + ReferencesNo definition available. + Details Name: aytu ReturnReserveCurrent Namespace Prefix: aytu Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap AccruedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant XML 70 R58.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 9 - Other Liabilities (Details Textual) 6 Months Ended Dec. 31, 2024 USD (\$) Jun. 30, 2024 USD (\$) Sep. 30, 2023 USD (\$) Fixed Payment Arrangements \$ 6,926,000 \$ 8,337,000 Á Employee Retention Credit 3,759,000 Á 3,759,000 Á Business Combination, Contingent Consideration, Liability 0 Á Á Other Noncurrent Liabilities [Member] Á Á Á Employee Retention Credit \$ 3,800,000 Á \$ 3,800,000 Tris Karbinal Agreement [Member] Á Á Á Supply and Distribution Commitment, Period (Year) 20 years Á Á Supply and Distribution Commitment, Royalty, Percentage of Net Sales 23.50% Á Á Supply and Distribution Agreement, Minimum Sales Per Year 70,000 Á Á Supply and Distribution Agreement, Royalty Make Whole Payment Under Annual Minimum Sales Commitment, Per Unit \$ 30 Á Á Supply and Distribution Agreement, Maximum Yearly Make-whole Payment 2,100,000 Á Á Supply and Distribution Agreement, Maximum Milestone Obligations 3,000,000 Á Á Supply and Distribution Agreement, First Milestone, Minimum Net Revenues 40,000,000 Á Á Tris Karbinal Agreement [Member] Á Other Current Liabilities [Member] Á Á Á Settlement Liabilities, Current 5,800,000 Á Á Fixed Payment Arrangements 1,200,000 Á Á X - DefinitionRepresents the amount of employee retention credit. + ReferencesNo definition available. + Details Name: aytu EmployeeRetentionCredit Namespace Prefix: aytu Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionRepresents the amount of fixed payment arrangements. + ReferencesNo definition available. + Details Name: aytu FixedPaymentArrangements Namespace Prefix: aytu Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionThe amount of net revenues to be reached to trigger the first milestone obligation of the supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues Namespace Prefix: aytu Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe maximum amount of milestone obligations of the supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu SupplyAndDistributionAgreementMaximumMilestoneObligations Namespace Prefix: aytu Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionThe maximum amount of make-whole payment per year under supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu SupplyAndDistributionAgreementMaximumYearlyMakewholePayment Namespace Prefix: aytu Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionTh minimum amount of units to be sold per year under supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu SupplyAndDistributionAgreementMinimumSalesPerYear Namespace Prefix: aytu Data Type: xbrli:decimalItem Type Balance Type: na Period Type: instant X - DefinitionThe amount of royalty make-whole payment per unit for sales under the minimum units for the supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit Namespace Prefix: aytu Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionPeriod covered by the supply and distribution commitment, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: aytu SupplyAndDistributionCommitmentPeriod Namespace Prefix: aytu Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionThe percentage of net sales to be paid for royalties under supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales Namespace Prefix: aytu Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers. + ReferencesNo definition available. + Details Name: us-gaap SettlementLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Details Name: us-gaap BalanceSheetLocationAxis=us-gaap OtherNoncurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap TypeOfArrangementAxis=aytu TrisKarbinalAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap BalanceSheetLocationAxis=us-gaap OtherCurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R59.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 9 - Other Liabilities - Schedule of Other Liabilities (Details) - USD (\$) \$ in Thousands Dec. 31, 2024 Jun. 30, 2024 Fixed payment arrangements \$ 6,926 \$ 8,337 Employee retention credit 3,759 3,759 Operating Lease, Liability 1,288 1,289 Other 180 106 Total other liabilities 12,153 13,491 Less: current portion of other liabilities (7,108) (8,962) Total non-current portion of other liabilities \$ 5,045 \$ 4,529 X - DefinitionRepresents the amount of employee retention credit. + ReferencesNo definition available. + Details Name: aytu EmployeeRetentionCredit Namespace Prefix: aytu Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionRepresents the amount of fixed payment arrangements. + ReferencesNo definition available. + Details Name: aytu FixedPaymentArrangements Namespace Prefix: aytu Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseLiability Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap OtherLiabilities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap OtherLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionThe aggregate carrying amount, as of the balance sheets date, of obligations not otherwise itemized or categorized in the footnotes to the financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap OtherSundryLiabilities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant XML 72 R60.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 10 - Revolving Credit Facility (Details Textual) - Eclipse Business Capital LLC Loan Agreement [Member] - Secured Debt [Member] - USD (\$) \$ in Millions 3 Months Ended 6 Months Ended Jun. 12, 2024 Dec. 31, 2023 Dec. 31, 2023 Dec. 31, 2023 Jun. 30, 2024 Mar. 24, 2024 Line of Credit Facility, Maximum Borrowing Capacity \$ 14.5 Á Á Á Á Debt Instrument, Basis Spread on Variable Rate 4.50% Á Á Á Á Á Line of Credit Facility, Unused Capacity, Commitment Fee Percentage 0.50% Á Á Á Á Debt Instrument, Interest Rate, Effective Percentage 9.20% Á 9.20% Á Á Á Interest Expense, Debt Á \$ 0.1 \$ 0.1 \$ 0.1 Á Long-Term Line of Credit Á 4.0 Á 4.0 Á 2.4 Á Line of Credit Facility, Remaining Borrowing Capacity Á 7.9 Á 7.9 Á Á On or Before January 26, 2023 [Member] Á Á Á Á Á Line of Credit Facility, Termination, Fee, Percentage of Commitment Á Á Á Á 2.00% After January 26, 2023 But Before January 26, 2024 [Member] Á Á Á Á Á Line of Credit Facility, Termination, Fee, Percentage of Commitment Á Á Á Á 1.00% After January 26, 2024 But Before January 26, 2025 [Member] Á Á Á Á Á Line of Credit Facility, Termination, Fee, Percentage of Commitment Á Á Á Á 0.50% X - DefinitionRepresents the percentage of commitment used as a termination fee of a line of credit facility. + ReferencesNo definition available. + Details Name: aytu LineOfCreditFacilityTerminationFeePercentageOfCommitment Namespace Prefix: aytu Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap InterestExpenseDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancellable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap LineOfCredit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap LineOfCreditFacilityRemainingBorrowingCapacity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility. + ReferencesNo definition available. + Details Name: us-gaap LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage Namespace Prefix: us-gaap Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap LineOfCreditFacilityAxis=aytu EclipseBusinessCapitalLclLoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap LongtermDebtTypeAxis=us-gaap SecuredDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt StatementScenarioAxis=aytu OnOrBeforeJanuary262023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt StatementScenarioAxis=aytu AfterJanuary262023ButBeforeJanuary262024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt StatementScenarioAxis=aytu AfterJanuary262024ButBeforeJanuary262025Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML7 R61.htm IDEA: XBRL DOCUMENT v3.25.01 Note 11 - Long-term Debt (Details Textual) - USD (\$) \$ / shares in Units, \$ in Millions 3 Months Ended 6 Months Ended Jun. 12, 2024 Jan. 26, 2022 Dec. 31, 2024 Jun. 30, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Oct. 25, 2022 Mar. 07, 2022 Avenue Capital Issuance [Member] Á Á Á Á Á Shares Issued, Price Per Share (in dollars per share) Á Á Á Á Á Á Á Á Á Á Á \$ 25 Avenue Capital Warrants [Member] Á Á Á Á Á Á Á Á Á Á Á Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Á Á Á Á Á Á Á Á Á Á Á \$ 8.65 \$ 24.2 Warrants and Rights Outstanding Á \$ 0.6 Á Á Á Á Á Avenue Capital Loan [Member] Á Á Á Á Á Á Á Á Á Á Á Debt Instrument, Face Amount Á \$ 15.0 Á Á Á Á Á Debt Instrument, Interest Rate, Stated Percentage Á 3.25% Á Á Á Á Á Á Á Á Á Á Á Loan Processing Fee Á \$ 0.4 Á Á Á Á Á Á Á Á Á Á Á Debt Instrument, Prepayment Fee, Percentage Á Á 16.60% Á Á Á Á Á Interest Expense, Debt Á Á Á Á Á \$ 0.7 Á \$ 1.5 Á Á Debt Instrument, Final Payment \$ 0.6 Á Á Á Á Á Á Á Á Á Á Á Gain (Loss) on Extinguishment of Debt Á Á Á (0.6) Á Á Á Á Á Avenue Capital Loan [Member] | After January 26, 2024 But Before January 26, 2025 [Member] Á Á Á Á Á Á Á Á Á Á Á Debt Instrument, Prepayment Fee, Percentage 1.00% Á Á Á Á Á Á Á Á Á Á Á Debt Instrument, Prepayment Fee, Amount \$ 0.2 Á Á Á Á Á Á Á Á Á Á Á Avenue Capital Loan [Member] | Prime Rate [Member] Á Á Á Á Á Á Á Á Á Á Á Debt Instrument, Basis Spread on Variable Rate Á 7.40% Á Á Á Á Á Á Á Á Á Á Á Eclipse Term loan [Member] Á Á Á Á Á Á Á Á Á Á Á Debt Instrument, Face Amount \$ 13.0 Á Á Á Á Á Á Á Á Á Á Á Interest Expense, Debt Á Á Á 0.4 Á Á Á Á Á 0.8 Á Á Á Debt Instrument, Term (Year) 4 years Á Á Á Á Á Á Á Á Á Á Á Debt Instrument, Amortization Period (Year) 7 years Á Á Á Á Á Á Á Á Á Á Á Long-Term Debt, Maturity, Year Four \$ 5.6 Á Á Á Á Á Á Á Á Á Á Á Debt Instrument, Interest Rate, Effective Percentage Á Á 11.70% Á Á Á Á Á Á Á Á Á Á Á Eclipse Term loan [Member] | On or Before June 12, 2025 [Member] Á Á Á Á Á Á Á Á Á Á Á Debt Instrument, Termination Fee, Percentage 3.00% Á Á Á Á Á Á Á Á Á Á Á Eclipse Term loan [Member] | After June 12, 2025, but on or before June 12, 2026 [Member] Á Á Á Á Á Á Á Á Á Á Á Debt Instrument, Termination Fee, Percentage 2.00% Á Á Á Á Á Á Á Á Á Á Á Eclipse Term loan [Member] | After June 12, 2026, but on or before June 12, 2027 [Member] Á Á Á Á Á Á Á Á Á Á Á Debt Instrument, Termination Fee, Percentage 1.00% Á Á Á Á Á Á Á Á Á Á Á Eclipse Term loan [Member] | After June 12, 2026, but on or before June 12, 2028 [Member] Á Á Á Á Á Á Á Á Á Á Á Debt Instrument, Termination Fee, Percentage 0.50% Á Á Á Á Á Á Á Á Á Á Á Eclipse Term loan [Member] | Secured Overnight Financing Rate (SOFR) [Member] Á Á Á Á Á Á Á Á Á Á Á Debt Instrument, Basis Spread on Variable Rate 7.00% Á Á Á Á Á Á Á Á Á Á Á X - DefinitionThe duration in which the debt will amortize. + ReferencesNo definition available. + Details Name: aytu DebtInstrumentAmortizationPeriod Namespace Prefix: aytu Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRepresents the final payment of a debt instrument. + ReferencesNo definition available. + Details Name: aytu DebtInstrumentFinalPayment Namespace Prefix: aytu Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe prepayment fee amount. + ReferencesNo definition available. + Details Name: aytu DebtInstrumentPrepaymentFeeAmount Namespace Prefix: aytu Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the percentage of loan that is payable as a prepayment fee. + ReferencesNo definition available. + Details Name: aytu DebtInstrumentPrepaymentFeePercentage Namespace Prefix: aytu Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe termination fee if the debt is terminated before or on a certain date. + ReferencesNo definition available. + Details Name: aytu DebtInstrumentTerminationFeePercentage Namespace Prefix: aytu Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap Data Type: dtr-types:percentItemBalance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925

-Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding
Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_SubsidarySaleOfStockAxis=aytu AvenueCapitalIssuanceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu AvenueCapitalWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=aytu AvenueCapitalLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=aytu AfterJanuary262024ButBeforeJanuary262025Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_PrimeRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=aytu EclipseTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=aytu OnOrBeforeJune122025Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=aytu AfterJune122025ButOnOrBeforeJune122026Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=aytu AfterJune122026ButOnOrBeforeJune122027Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=aytu AfterJune122026ButOnOrBeforeJune122028Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSoftMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R62.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 11 - Long-term Debt - Schedule of Long-term Debt (Details) - USD (\$) \$ in Thousands Dec. 31, 2024 Jun. 30, 2024 Term loan principal amount \$ 12,071 \$ 13,000 Less: unamortized debt discount and issuance costs (231) (266) Total debt 11,840 12,734 Less: current portion of debt (1,857) (1,857) Total debt, net of current portion \$ 9,983 \$ 10,877 X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of long-term debt and lease obligation, classified as current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LongTermDebtAndCapitalLeaseObligations Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt and lease obligation, classified as current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt and lease obligation, including portion classified as current. + ReferencesNo definition available. + Details Name: us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 75 R63.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 11 - Long-term Debt - Future Principal Payments (Details) - USD (\$) \$ in Thousands Dec. 31, 2024 Jun. 30, 2024 2025 (remaining 6 months) \$ 928 A 2026 1,857 A 2027 1,857 A 2028 7,429 A Total future principal payments 12,071 A Less: unamortized debt discount and issuance costs (231) \$ (266) Less: current portion of debt (1,857) (1,857) Total debt, net of current portion \$ 9,983 \$ 10,877 X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt and capital lease obligations. + ReferencesNo definition available. + Details Name: aytu_LongTermDebtAndCapitalLeaseObligationsGross Namespace Prefix: aytu Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 76 R64.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 12 - Fair Value Considerations (Details Textual) - Tranche B Pre-Funded Warrants [Member] - \$ / shares Sep. 30, 2024 Jun. 14, 2024 Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 176,000 1,806,434 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \$ 0.0001 \$ 0.0001 X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu TrancheBPreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 77 R65.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 12 - Fair Value Considerations - Recurring Fair Value Measurements (Details) - USD (\$) \$ in Thousands Dec. 31, 2024 Jun. 30, 2024 Derivative warrant liabilities \$ 6,386 \$ 12,745 Financial liabilities, fair value 6,386 12,745 Fair Value, Inputs, Level 1 [Member] A A Derivative warrant liabilities 0 0 Financial liabilities, fair value 0 0 Fair Value, Inputs, Level 2 [Member] A A Derivative warrant liabilities 0 0 Financial liabilities, fair value 0 0 Fair Value, Inputs, Level 3 [Member] A A Derivative warrant liabilities 6,386 12,745 Financial liabilities, fair value \$ 6,386 \$ 12,745 X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap_DerivativeLiabilitiesNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FinancialLiabilitiesFairValueDisclosure Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 78 R66.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 12 - Fair Value Considerations - Summary of Level 3 Changes (Details) - Fair Value, Inputs, Level 3 [Member] \$ in Thousands 6 Months Ended Dec. 31, 2024 USD (\$) Balance \$ 12,745 Settlements (1) (463) [1] Included in earnings (5,896) Balance \$ 6,386 [1] Relates to the exercise of 176,000 of the Tranche B Pre-Funded Warrants during the first quarter

of fiscal 2025, which were liability classified and exercised at a price of \$0.0001 per share. X - DefinitionAmount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3). + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2) + Details Name: us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2) + Details Name: us-gaap FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap FairValueByFairValueHierarchyLevelAxis=us-gaap FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 79 R67.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 12 - Fair Value Considerations - Summary of Level 3 Changes (Details) (Parentheticals) - USD (\$) in Thousands 3 Months Ended 6 Months Ended 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Income Statement [Abstract] A A A Derivative, Gain (Loss) on Derivative, Net \$ 3,016 (\$ 577) \$ 5,896 (\$ 6,484) Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] A A Derivative, Gain (Loss) on Derivative, Net A X - DefinitionAmount of increase (decrease) in the fair value of derivatives recognized in the income statement. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph \(b\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A) + Details Name: us-gaap DerivativeGainLossOnDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIndicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3). + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2) + Details Name: us-gaap FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItem Type: Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 80 R68.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 12 - Fair Value Considerations - Valuation Assumptions (Details) Dec. 31, 2024 Measurement Input, Share Price [Member] | June 2023 Warrants Tranche A [Member] A Derivative liability, measurement input 1.7 Measurement Input, Share Price [Member] | Other Warrants [Member] A Derivative liability, measurement input 1.7 [1] Measurement Input, Expected Term [Member] | June 2023 Warrants Tranche A [Member] A Derivative liability, measurement input 3.4 Measurement Input, Expected Term [Member] | Other Warrants [Member] | Minimum [Member] A Derivative liability, measurement input 2.1 [1] Measurement Input, Expected Term [Member] | Other Warrants [Member] | Maximum [Member] A Derivative liability, measurement input 2.7 [1] Measurement Input, Price Volatility [Member] | June 2023 Warrants Tranche A [Member] A Derivative liability, measurement input 0.808 Measurement Input, Price Volatility [Member] | Other Warrants [Member] | Minimum [Member] A Derivative liability, measurement input 0.747 [1] Measurement Input, Price Volatility [Member] | Other Warrants [Member] | Maximum [Member] A Derivative liability, measurement input 0.805 [1] Measurement Input, Risk Free Interest Rate [Member] | June 2023 Warrants Tranche A [Member] A Derivative liability, measurement input 0.043 Measurement Input, Risk Free Interest Rate [Member] | Other Warrants [Member] A Derivative liability, measurement input 0.043 [1] Measurement Input, Expected Dividend Rate [Member] | June 2023 Warrants Tranche A [Member] A Derivative liability, measurement input 0 Measurement Input, Expected Dividend Rate [Member] | Other Warrants [Member] A Derivative liability, measurement input 0 [1] [1] Includes August 2022 Warrants, March 2022 Warrants, Avenue Capital Warrants and Tranche B Pre-Funded Warrants. See Note 16 - Warrants for definitions of these terms and further information. X - DefinitionValue of input used to measure derivative liability. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2) + Details Name: us-gaap DerivativeLiabilityMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - Details Name: us-gaap MeasurementInputTypeAxis=us-gaap MeasurementInputSharePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ClassOfWarrantOrRightAxis=aytu June2023WarrantsTrancheAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ClassOfWarrantOrRightAxis=aytu OtherWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap MeasurementInputTypeAxis=us-gaap MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt RangeAxis=srt MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt RangeAxis=srt MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap MeasurementInputTypeAxis=us-gaap MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap MeasurementInputTypeAxis=us-gaap MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap MeasurementInputTypeAxis=us-gaap MeasurementInputExpectedDividendRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 81 R69.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 13 - Commitments and Contingencies (Details Textual) - Tris Karbinal Agreement [Member] 6 Months Ended Dec. 31, 2024 USD (\$) Supply and Distribution Commitment, Period (Year) 20 years Supply and Distribution Commitment, Royalty, Percentage of Net Sales 23.50% Supply and Distribution Agreement, Minimum Sales Per Year 70,000 Supply and Distribution Agreement, Royalty Make Whole Payment Under Annual Minimum Sales Commitment, Per Unit \$ 30 Supply and Distribution Agreement, Maximum Milestone Obligations 3,000,000 Supply and Distribution Agreement, First Milestone, Minimum Net Revenues 40,000,000 Maximum [Member] A Supply and Distribution Agreement, Royalty Make Whole Payment Under Annual Minimum Sales Commitment, Per Unit \$ 2,100,000 X - DefinitionThe amount of net revenues to be reached to trigger the first milestone obligation of the supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues Namespace Prefix: aytu_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe maximum amount of milestone obligations of the supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu SupplyAndDistributionAgreementMaximumMilestoneObligations Namespace Prefix: aytu_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionTh minimum amount of units to be sold per year under supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu SupplyAndDistributionAgreementMinimumSalesPerYear Namespace Prefix: aytu_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionThe amount of royalty make-whole payment per unit for sales under the minimum units for the supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit Namespace Prefix: aytu_ Data Type: xbrli:monetaryItem Type Balance Type:

Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-599-2>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-599-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-599-1>Reference 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-599-3> + Details Name: us-gaap CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionThe total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-15> + Details Name: us-gaap PaymentOfFinancingAndStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-15> + Details Name: us-gaap PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13> + Details Name: us-gaap PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-599-1> + Details Name: us-gaap PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-599-3> + Details Name: us-gaap ProceedsFromIssuanceOfSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478448/946-505-50-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-599-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-599-3>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-599-1> + Details Name: us-gaap StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2> + Details Name: us-gaap WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMndTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2> + Details Name: us-gaap WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022CommonAndPrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheACommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBCommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_CommonWarrantsExchangedForPrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_SecuritiesPurchaseAgreementWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBPrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsiarySaleOfStockAxis=aytu_The2020ShelfMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsiarySaleOfStockAxis=aytu_TheAugust2022OfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsiarySaleOfStockAxis=aytu_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsiarySaleOfStockAxis=aytu_The2024ShelfMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 83 R71.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 15 - Equity Incentive Plans (Details Textual) - USD (\$) / shares in Units, \$ in Millions 6 Months Ended May 18, 2023 Apr. 19, 2021 Jun. 01, 2015 Dec. 31, 2024 Jun. 30, 2024 Feb. 13, 2020 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) Á Á Á 221,392 146,539 Á Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) Á Á Á 83,000 Á Á Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) Á Á Á \$ 1.84 Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) Á Á Á 20,000 Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) Á Á Á \$ 1.79 Á Á Share-Based Payment Arrangement, Option [Member] Á Á Á Á Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Á Á Á \$ 0.2 Á Á Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Á Á Á 2 years 3 months 18 days Á Á Restricted Stock [Member] Á Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares) Á Á Á 565 1,775 Á Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Á Á Á 2 months 12 days Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) Á Á Á 0 Á Á Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Á Á Á \$ 0.1 Á Á The 2023 Equity Incentive Plan [Member] Á Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) 200,000 Á Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) 87,129 Á Á 87,636 Á Á The 2023 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] Á Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) 10 years Á Á Á Á The 2023 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member] Á Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) 3 years Á Á Á Á The 2023 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member] Á Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) 4 years Á Á Á Á The 2023 Equity Incentive Plan [Member] | Restricted Stock and Restricted Stock Units (RSUs) [Member] | Minimum [Member] Á Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) 3 years Á Á Á Á The 2023 Equity Incentive Plan [Member] | Restricted Stock and Restricted Stock Units (RSUs) [Member] | Maximum [Member] Á Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) 4 years Á Á Á Á The 2023 Equity Incentive Plan [Member] | Restricted Stock [Member] Á Á Á Á Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Á Á Á 2 years 3 months 18 days Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) Á Á Á 20,000 Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) Á Á Á \$ 1.79 Á Á Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Á Á Á \$ 0.9 Á Á The 2015 Plan [Member] Á Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) Á Á Á 250,000 The 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] Á Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) Á Á Á 10 years Á Á Á The 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member] Á Á Á Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Á Á Á 3 years Á Á Á The 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member] Á Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Á Á Á 4 years Á Á Á The 2015 Plan [Member] | Restricted Stock [Member] | Minimum [Member] Á Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Á Á Á 1 year Á Á Á Neos 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member] Á Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Á Á Á 4 years Á Á Á Neos 2015 Plan [Member] | Restricted Stock Units (RSUs) [Member] Á Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Á Á Á 4 years Á Á Á Neos 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member] Á Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Á Á Á 1 year Á Á Á Neos 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member] Á Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Á Á Á 4 years Á Á Á Neos 2015 Plan [Member] | Restricted Stock Units (RSUs) [Member] Á Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares) Á 1,786 Á Á Á Outside Equity Incentive Plan [Member] | Restricted Stock [Member] Á Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares) Á Á Á 4 Á Á Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Á Á Á 1 year 6 months Á Á Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) Á Á Á 0 Á Á Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Á Á Á \$ 0.2 Á Á X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMndTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -

Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=aytu_The2023EquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=aytu_RestrictedStockAndRestrictedStockUnitsRsumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=aytu_The2015PlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=aytu_OutsideEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 84 R72.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 15 - Equity Incentive Plans - Stock Option Activity (Details) - \$ / shares 6 Months Ended 12 Months Ended Dec. 31, 2024 Jun. 30, 2024 Outstanding, options (in shares) 146,539 Å Outstanding, options, weighted average exercise price (in dollars per share) \$ 6.18 Å Outstanding, options, weighted average remaining contractual life (Year) 8 years 3 months 18 days 8 years 9 months 18 days Granted, options (in shares) 83,000 Å Granted, options, weighted average exercise price (in dollars per share) \$ 1.84 Å Granted, options, weighted average remaining contractual life (Year) 2 years 3 months 18 days Å Forfeited/Cancelled, options (in shares) (8,147) Å Forfeited/Cancelled, options, weighted average exercise price (in dollars per share) \$ 5.73 Å Outstanding, options (in shares) 221,392 146,539 Outstanding, options, weighted average exercise price (in dollars per share) \$ 4.57 \$ 6.18 Exercisable, options (in shares) 81,399 Å Exercisable, options, weighted average exercise price (in dollars per share) \$ 9.02 Å Exercisable, options, weighted average remaining contractual life (Year) 6 years 7 months 6 days Å X - DefinitionWeighted average remaining contractual term for option awards granted during the perioif, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm Namespace Prefix: aytu_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration XML 85 R73.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details) 6 Months Ended Dec. 31, 2024 \$ / shares shares Granted, shares (in shares) | shares 20,000 Granted, weighted average grant date fair value (in dollars per share) | \$ / shares \$ 1.79 Restricted Stock [Member] Å Unvested, shares (in shares) | shares 24,105 Unvested, weighted average grant date fair value (in dollars per share) | \$ / shares \$ 100.34 Vested, shares (in shares) | shares (7,853) Vested, weighted average grant date fair value (in dollars per share) | \$ / shares \$ 15.33 Unvested, shares (in shares) | shares 36,252 Unvested, weighted average grant date fair value (in dollars per share) | \$ / shares \$ 64.38 X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem
Type Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit)
option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue)
Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments,
excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1:

the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities. + ReferencesReference 1:

https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(27\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(27))) - Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19:> [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(23\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(23))) - Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20:> <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI> <https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2:> <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3:> <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI> <https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7:> [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(e\)\(4\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (e)(4)-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8:> [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9:> [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10:> [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11:> [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(c\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (c)-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 12:> [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(d\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (d)-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13:> [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(d\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (d)-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14:> <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15:> <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI> <https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16:> [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(25\)\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(25))-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 17:> [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(27\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(27))) - Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18:> [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(23\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(23))) - Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19:>

[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/214748524/942-220-S99-1Reference 6](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/214748524/942-220-S99-1Reference 6): <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 7>:

gaap_SegmentContinuingOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 91 R79.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details) - shares 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Antidilutive securities (in shares) 3,804,988 6,730,054 3,475,503 6,730,054 Liability Warrants [Member] Á Á Á Antidilutive securities (in shares) 3,539,679 6,498,980 3,212,550 6,498,980 Equity-based Warrants [Member] Á Á Á Antidilutive securities (in shares) 18,114 39,072 18,114 39,072 Restricted Stock [Member] Á Á Á Antidilutive securities (in shares) 25,291 40,017 22,882 40,017 Restricted Stock Units (RSUs) [Member] Á Á Á Antidilutive securities (in shares) 512 2,898 565 2,898 Share-Based Payment Arrangement, Option [Member] Á Á Á Antidilutive securities (in shares) 221,392 149,087 221,392 149,087 X - Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1> + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aytu_LiabilityWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aytu_EquityBasedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 92 R80.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 19 - Restructuring Costs (Details Textual) - USD (\$) in Millions 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2024 Grand Prairie, Texas Manufacturing Site [Member] Á Á Business Exit Costs \$ 1.3 \$ 2.1 X - Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_BusinessExitCosts1 Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Details Name: us-gaap_RestructuringPlanAxis=aytu_GrandPrairieTexasManufacturingSiteMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 93 R81.htm IDEA: XBRL DOCUMENT v3.25.0.1 Note 20 - Discontinued Operations - Schedule of Discontinued Operations (Details) - USD (\$) in Thousands 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Jun. 30, 2024 Net income (loss) from discontinued operations, net of tax \$ 123 \$ (839) \$ 504 \$ (1,486) Á Current assets of discontinued operations: Á Á Á Á Total current assets of discontinued operations 0 Á 0 Á \$ 1,121 LIABILITIES Á Á Á Á Total current liabilities of discontinued operations 0 Á 0 Á 557 Consumer Health Divestiture [Member] Á Á Á Á Net revenue 0 4,186 717 8,468 Á Cost of sales 0 (2,586) (359) (5,122) Á Selling and marketing 0 (1,358) (155) (2,689) Á General and administrative 0 (642) (2) (1,312) Á Amortization of intangible assets 0 (382) 0 (764) Á Non-operating other expense, net 0 (9) (4) (19) Á Recognized contingent consideration 175 0 587 0 Á Loss on divestiture 0 0 (254) 0 Á Income (loss) from discontinued operations before income taxes 175 (791) 530 (1,438) Á Income tax expense (52) (48) (26) (48) Á Net income (loss) from discontinued operations, net of tax \$ 123 \$ (839) \$ 504 \$ (1,486) Á Current assets of discontinued operations: Á Á Á Á Accounts receivable, net Á Á 91 Inventories Á Á Á 492 Prepaid expenses and other current assets Á Á Á 538 Á Total current assets of discontinued operations Á Á Á 1,121 Non-current assets of discontinued operations: Á Á Á Á Other non-current assets Á Á Á 44 Á Total current and non-current assets of discontinued operations Á Á Á 1,165 LIABILITIES Á Á Á Á Accounts payable Á Á Á 126 Á Accrued liabilities Á Á Á 431 Á Total current liabilities of discontinued operations Á Á Á 557 X - Definition Amount of recognized contingent consideration attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesNo definition available. + Details Name: aytu_DisposalGroupIncludingDiscontinuedOperationRecognizedContingentConsideration Namespace Prefix: aytu_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - Definition Amount of selling and marketing expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesNo definition available. + Details Name: aytu_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense Namespace Prefix: aytu_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Definition Amount classified as assets attributable to disposal group held for sale or disposed of. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-10>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5C>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-3>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-11> + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Definition Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-10>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5C>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482130/360-10-45-9>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-11> + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-3A>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-3B>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-4>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-11>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-3>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(14)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - Definition Amount before tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-3B>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-3> + Details Name: us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Definition Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.1.7) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479360/740-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482685/740-10-50-10>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482659/740-20-45-2>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-3A>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5C>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-3B>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-4>Reference 9: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-1> + Details Name: us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Definition Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-10>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-3>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-11> + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Definition Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-10>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482130/360-10-45-9>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-3>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-11> + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B> + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B> + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B> + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-10>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482130/360-10-45-9>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-3>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-11> + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of other expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B> + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-10>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 11 -SubTopic 10 -Topic 360 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482130/360-10-45-11>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-3>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-11> + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-10>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482130/360-10-45-9>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-3>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-11> + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of revenue attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B> + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477349/740-270-45-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-3A>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5C>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-3B>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-4>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-1>Reference 9: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-3> + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-10>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5C>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482130/360-10-45-9>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-3>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-11> + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=aytu_ConsumerHealthDivestitureMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 94 Financial Report.xlsx IDEA: BAL DOCUMENT BEGIN 64V5(C(I(147BK9.7.=N)=H16V .OGDK7A.YNJO<46PZ4A!0W J=0UJRE,6#M1E7U! P04 M" "+&@Q:K-FU<^T K M+& 1O8U!R;W!S+V-O&8US9+& M.L,P#(=9?B>+?#B;-&@K:QF,+4UB @:R1!>R5?F+VJ!C1TL?> M/H%>:4.)9J3B(C(8XK;7>?S?>3D11 F!JQJ=R/27U!R&SY1!-SW2\$J> M.LP(IGD AZ2,(4&SLH+D+76MT5(G5!32!6 T@H^?J]2!P!P%!=,@I ZYL&Z> M&,<JPG(,(,)(D)O?30+L53_Q8.L&MRS'9)<#<0#ZNF2FW;@V,T>R&GK5M9G M4E(C)M;2>:(W=-&+K;ZWK!-N^47&Q%UQR(3E_GUU_^~V\$73V8/^Q M)56P:~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~<CDGZ>3UTU!SG^+ GO^-R&8C(CQN1W6^WV3T>N(=I)P+&BUIY&1&6?2R^VZ MYZ!SX&M4D-,A")JVF&F0!>*D*3&6H8;XM;L\$> 3?;>X^",C? 8'WJUE9^/5>A M6\$A@/a@1AKBG/F+<1%L P?>E1M^V5;SC MFEDJ081E!J]ASO^J]XJR^>(C7N1X^Y71X<N(=QKQ0KH?> 1VCV?>P" B^P#E M+GWI/>^Y]YVATK>WVZ22\$KVI9+2,6DSNULTSDNR+>RO JQ GH9%LE! M0AMNZ5/U2I77Y;^Y*+&@6^3IKZ%T/BS^>3Q?YI3-<S-#MW>+ZK-4OK4F\$<KT ML@>37][EUVY]E, %70@<O&KX;J=J-W#HXGIB1N0K3 M4!IOP GIQ7@>XCG9!+EJF#=>MYJCIT?OGP\$&PH^<EAWB+R(B>ZAAIC/PT,^ M>7M?F>5Q?E T%&ULK^01K=>@N-Q+!3@9& MH >X4U%#E58%?>Q@,KD*) M3(Q)Z%>GEUQJ]X]2&XJN9;5N&KREW&6TB4CQ;@>39Z0^WV60P4\$=SU5&A; M:~CVT%4!/ EFMR) M>6Q?>(Q)8Y07J]BQJ3EON>-G^LYZ(G;ZEW?! M8+>] <E^#4^YU T74.N?0=>X INDSM3(Q)OYQ1\$!=4\$ (Y4U@VJF%SU&Z.X9I&Z\$SU>?>KC"1: 5 6-8~>3+2.7#;:MX#7N83 M+&.D7L%|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~M. 44J)(L0KBJ)5? MCP@>G(GC<75!> OCX^YEUXJ+>@OVX\$SRA .88,RJ@>9YN(9#;/??.<G^58; M>YN,JOKRO5=>M K-B4.PWEE2+>=U1OJ09JFQO-H<=>_E.B1L!#J;.90">+>HOJUN)SBU6^93D3 M6HLD(UQR%G),H#>?YT+>HW8EYU+GK?PZ4\$L#!#0 (N!3%J=>CSGS08 M"> >8<=>+PO=>VJR;W-H965T&ULK5EM)JLV\$XKA&L4 M+>=>\$JG7^>0JAC685N^IMT^<@>O 2'0L5I9=DC?> ? H=9<>R1(L /@>H8JG; MTW.CX /<4>?>WOGY2XU^>KFJ;Q4Q66J]IO-5+>[D?Z9.Q9K7,M^R73<~<GO M9FHM.20:1.MJ1H@>(GJU864 FY-UJGW+>+AI=E36 ED@UJQ63(QJY)>O)XGCR M^,67FZIS1-S>?>F?W?>K^<M&KRS5BG+>%U6^&DFX^>N)A)P&>?>7-#>5+>6HN M2GZO&CXC\$J]M\$->?>B8A(81+>SBN38N&/S9!M>5<83X/BQ+2K7 H N=;3! M>~:T6.T6 XJ566_LI^>[1]PLP.((K),OJZZ@>X6T#>0+;<V(K^N^FV?QZPMH9D1.EZ>2U\$K494Q,QAV M8;9F5JSG6J,8!L1A-C=,G S^L?>U=U+2%LRO=QTI]JWN>73^T1/#64FP / M1U-N6 7!Y BUEV7QAEZ<X> <->+ M6+>G&@>VXE-4>@>R0 8#JL1!&8&9F)F\$Y]J=>Z(D3LN1,]&56 M.3TFS B?LF<V%<G(C.R(JLMB+>|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

KlII=KR%="^D"WHS MDGV7TW1?1,??^H.Q.T(YPS6#+/8,/S130)1'C(1&MNH)O9]E4>9%<0^K.K^ M356HE5%\$YNNHB=(\$=*P)A0(Q0=B)7;WN !1VG1BNN^C-K(O+UK)PBL:KFDF M6W3.A2K\$;Aq1N9U>X7FQ1AD 182C4391LQ,1^JXD)PE#8@5TS<C. K8R RH1) MZ(6ZH9S)IE&PC?7(\$*8R)Z=80BC12XQ,/>2.8F!F,9J\$|^~01JR/S^>+ M+M.BWB|B\$K;>2&|Y^|4;OXE? 1M|["JEZP MDJ]ES;\$O M%*GZT.9J;|T@M#HAQ>3>3M4Y|NF?|];#U VY MHJ15N="S" C1^?>RPPQ=1"'^N.&\$\$. =18WB;C^S5\$#>00&O C ^>|>B6&|G\$;MK ME 5%;T;O5O="WC7GU59M/D#1*ZZB_18F?; Hl\$KD|;Q3KEW1LJ\$;="PZNX"?%6|>@#185B(C X^+|171^TA;|N|_#4 C) M?@73RWM1L|C|^|^N^>2>2%SZ8Z4\$|LH1R7B15^&^"B^X%& @&@&K?3. MC|B=VWV^P\$%;XHTVR<|FZ2SU2D4^4WB04X|D>XV+L+FU I;1&4131MA MBRR|O+6+MUAR+1L 7J;\$>C#N @Z#1%BN@XQ?P-(*7Q1\$)%"%|Z1V|UB MDA;=|83X?Q".M'F1% D8ZT1X X(1D0, (VD=#&#&B%;>1>1;M?B7_?D1M^*MJT^O#|BHBEC=JN5>S9TU6W+6+/\$13M.46^?B-T>MUO >_J;+&6%&D>3J M1O>.TUT7<ZB7P|A>A\$A1\$K1UL3=087Y185V|D|_D&? 29^4L7ZSPQP M_-U/P<%&."10|Z>W4 W97-FB2^E;@P310H\$1A,OR.#@PU^*UM08K?>^QJJ MC+;P^CEB;+83M-\$20:Z54C 8*ZQI|(!@~(?!>SD)|@?K31P@&^*#\$Y^DV^1/6|>1F^R^U^6XGV9|C^V<+,%&^&^ MUPRT|?X;H:|PF^FK>04 3AV|<1^J;U^1>+&87&UE^&|02P,\$% @ BX%,6A7D MBD231P 3D |@ !X;|JW;VW^K^76%&M36L SH\$3;M&|9/L>E8J^JN?|MOQ^EN8|E&E 2M? 8EL9+&~*K(|_#J%6.6BZT014UB=>B9K|RMJ|WKZ;18;442%|@ RG4CE M?PS99G82E|P;L4N\$>C|Z;13&4V;|C|Q|HWOZ02=|0/K|4>4>IN,VNM8D M8?|MK8BSY1L|F7S_PX?H85M6?YC.KW? @|@3Y??:=2Z|D15>=92(MBRU,K>M?YF;RAKP..*L.U1% 1>*|EL54.YB+|U<+&|?^HN+^?JU=>(BU)|9J7Y19?M2>.*UHO 1>.*L! M?^VS_Y.T6P?8IC+9A+HJ75EA?>^S35Q:S? [H&H1ET9Y5G\$U>H |SAV^ M>3.CJY4YFN-05=|KM?%&ER|FXE|4B?Q23^8^ \$?~?%|(74RQ \$E<9T?P MV2^?TASC|2>_>|.U^NL1C#N.VK84>|8CB8%&^;818;4H9,3^FIM^ M7~05|5C>6^VMLD3.3458|WVU^J^JSDH^O^U^+&|L^M^V\$1S^9ANF6| DIGCO M^U+U+O<|IMNH.^P^T^U>|>#FM|(3LV^M&BGLHTZ36:~*TO|Q^GC3NS,3S,/F4>?>8C&T| MK|;L&? ZA^D6(DIKOM^U.VAIT:OTW|OO.^%KUX)QSD|WM#&KABAE+G#44. M\$K=CWI@=1SS?|J3V<#ZQ-CJ|V\$%M NQ0137B=V4|C9:A70J|7J;43~1L M>+&@421^Y2R^G2D,L2V^~L;CJM#H252TXJ^F3|^~Dp=I|J(.M M\$Q&T&3|AYOTIYW.4? 2XOM_3.UY.MQLYK^VSNFI^U/(-UZ._@15ZV?N20KJ& MZC^AN;J+4&HKI^6XSV^KDY9 G^RA?#|3 M-OOH@73FTXX:BC6|PB|>5P9| +S@>+MV<^I^CAREY|7P?M^VX%&O? IG8@|H?|;@41#W=,6C7&53|@>H^&H^S15, U,~(?!+7^H^Q|BGMK+&@>82|?J8ZHS|UG99D|E<>M^P^> "0B 8 >+&PO=VJR^W. H965&T&ULK51CLASWE|E|W8|>+ M7K%6B=1NLZ|RZKQ>%&^%(- |O|44V%R8=UNZB8);?1^2SB;M^Q^XOF&5 MJX|D^BWO1L Q5|B+UW+ZW-V4?P?R2\$;".?FUN!|!\$K6Z:Z^PK |NR| ME7Q|?#C^~IR.VGN:0?;?1^> V^ AF 55Z?4^&?7M^/9B-4L^7=E2|A/RHN\$S?962^S1\$U5K|N;|N\$C|J|WE\$|KYV|Z/?>6\$ 6LM=H16 MAJ;|;|C?|R|Y|Z?SOC3CMGZ=>1Z;5" ZP^51R/GT 42CX&|71^?3XC>?> \$M\$D (QSAQ|G5Z|F?#20_3~&K^R^X;F:6F3M11B|Z#\$5)-6|M6GER5MSGZM? MMIMC|K=V02|6G;|D?0MXX|/1L|_UO<1|;|PQ?SE9R=92I|,Y\$O\$0^_#BS\$ MJUQL4&+HIA5??>+6+C+KPG#;_@C^1J^=1N\$;C&4FBUNH,7MK^2X3|C% M^J^K+G|O^R4>69^CJXS8_YV8ZMU+L.50K6KRAFYV^ UY^>OC,IM^U|W|WR;9.T) M=XU(1A+ ?\$|T- @Z15M%;_@+N\$G\$>O=YZ^M^?JHT^I=(1P\$ M^?=>XJ|D48TM&=&@.CP|P8T5|X\$D^?|C|@>ACW^M^?>8;WB8?Q5^?I62Y|RYL MB1,6^MX L,14;_Y\$9Q|T^>T6D&CP1+GA-V58A^J">3900R M27Q5\$;^6M_-D=#>A9W?;^MJXQ\$;^?E1 M.DF|@|+7|C#_BQ=~=ZK9N%O>QX4.C>1:E |@ZS8\$HODLV9.RXB@W=2\$)V|J^M3DIF^". 6JF1>|YBCRC;ITL=|JH;N1;_R^>0%LZ9N92|) CPP2EYV6 M3 7ZHNXS&J^W+D&C^FOC?7QX4;~JC5R0LZ@7EEN M^+TAN^H^>?>^HLC-Z|).? A3FPQOYFXX8\$U4>V(M\$>HX1>|>U^6|G6>A4VP^M^%.\$Z^?5 P>391^A;OO8LE?X=HPN3.NSY;^?P>Z1|+3BEEQ6%DM:~#5 M9H\$DY^E4M-W)? W%;3|FGX(F H8VSQVH(=*>Q^*RQ~8WYJLR+UTU531<@H^N^ M%?|C^XUTL00<M;B.FN^?|7J_B?PTHNG%|7VDE>P>1:~(P<=0>+60I^*M MRQTXH|XOXL1Y9 77:ES(ZEOWI!|JRK4: M1V1^&F&W^&AQ,SP;3>Q>3A|J2Y M7-T.T;5^#>3>|H^V^VMQRL9%>S)=D M^WE^>ESL/PG323L2^|+;|TK<+>UNIQ|J|ZTJY45AHJ|?3^UL? MJN>J;GTM;^>9262:AA6Z6649,6|DR6NNDV3IWI\$> 5X.M3QDGB3 M^L^CW4<K7|J>?3^1V1>3>F.SUFUVK#940GVB M21N28AZLE^%IOCP&C^|JOBE MQ74M;^?Z&01N>C9J_L168D=MXC|C?2|?H&O6+;@&+ROGW^Y,I^?Q?4A6 MOZJNKI?;CS% RJZU_CVZ? Z@X7.3?WJQ|44 H4K5+|EN(R^3^&X9U|OJGVB M2Q=^U5(K<7^XJ9K1^D,8?#ET+HXFFV?MAR/_ 51+ P04 ^~@4Q: M4L>|< \$ "F"@& ^'AL+W=O|S|C^#7VG>A|U MB2=KYV|EXKWQCLT\$S^O.HUAO^+OC2S9\$& ^M^M%F-EXIBKOKK?6WR7XLE;I^&U^VYV6Q>Q/L|_BjX5Y7|J5F^O.^^(NJV)F0?FDSG|UEE|H|_VWVJ|;V7H|J|K| MR+^XU|>W-%?^?K M^TVB&1+EXB|VMM+NN^61B0N^M(O3B^>3.Q6V^V^N3M)Z?4JR9|OFE:UUE^U^ M M0;SAGR5=&^7_.X6XNV|PMPG10(K=>G.7=0YUW,U[U00Z? P7|H^M@&+&?J| MMA59=|&=&(G5)K6%O!< \$&|&Q5PHZY H3\$|L&WN?_L|_P|6U|H^ M.%%GNZ;*K4^+TNR3H^&^#AYUE.I.O^?81?50^KR5U_1B|S;Q9OZ|C^&5\$|L&RPHYT ^?Q/V?V1=^:ORHUJH M^D^?@&K8OCW\$L M1U07MF-1^|HDDSS12\$T\$K\$BGM1?>=3CQFL^+P|J|UW1Y3|@HUQOL>U5M=7^@ M^HXTUL|GE^Y^%C|J; DGYP|C=>R9044 M2KVCV|BVX\$3|_8.8EM&^#>5=%>@4VRA93|OZ? E;A2@|A0;6|8D|515UDP\$ M^ B0X4SM7+>3Z^1HVC^FFBWA@&K^&Q-L^?>|)(7@&^?3^1ML1|@TD>SS MKJM| KM?4-PX^K5\$<@|J+BU(C~J,9N.H|DD(KT@66NM1)=4E>_YLVD0G^ M\$;L<2^/J^>K&A:Z1K6K^8R^E=L^*^?|@|H8U|&Q^P1D7RG M3-?OK1P^P2+K?2^%WIN4YS1^ND;|AG;Y^>KCMO<=&@&^?T7_09#R=TPRVZ_Ai&Y;6# M7A^878_2=&=V^*J34@2D| @?>H8P1>0,M^/C^>Q^>AT^*#B2J.C.#EX? M9^3|J|C B^Y-D317RH^HX-W^1,JHN P-08Z,%& @ MBX%,6E+|B=^~ R14 |@>1X;|JW;W|K|EL8WMO^ID2<[*^~ M9X:2K^2JW| @|N5N=N-|YDA3|;_2PLKHJ|CNR^&T\$|JQNMK>|RR9694ZC%Q M^%E6S1\$=&GPXFK1 5E\$7FH|&XHTL|F8\$>XW|^>2^L M.VZYQ>8;83>X0Q M5:BAG+&^BDY|;_#M^"S48=~=D7M|J;V.UO9>+& M|94,J3 2HED+&CP=F|TP|)^J^V+&O^*N;B M_O9XJ|^>L+W4=U4;CLV|^W MZ;Z>Y>0,|@|_Y4N F\$!;I;_ME? 1E17A35MH^ /C#60Z|J^ZHVNHZ^YGR ME75|L5AT @R=Y6VN;^XRORI+>#5E^GQ&O4J9@D<@T>Z4YK^3NEVH)?_?1 MY\$9|-O3(=|L<C<5U^MD8A^?>52V^D%Y^Y^NK;(&X&(<8#4\$%) @DO2Q@J M\$?E #Y>6<@NZN|5AIHD E;N^*=A |H|,9N^M;|.OKN|R|PMQ65^Y\$|K^Q M.00T4C3|;OJ?RH33|WZ|YV;~2%WH8,1%-YQ@&-FXB|J|L7@&Q0^ M^CH1N? SN;~(JDB9)?96J\$8JY^0|J>3MUR F7,\$<=>0^ L5=HG9?Q1:46 MSL6DF?OM?>040GGJ6V|B6U^+Z^J^A^K /EAH,Z\$5^PHCE\$F(01L_8! M|J^B^C|OQ|TWA\$>N/E-6@%>J2W2|)_N;(<@T^H87?;T^T|_U4@>|H|_M|+<@ MR3D1|_I06^7|P>~\$VW^9+5G0|O^A^UJEX>C-C7<|>5_8DY ?DG O>Z>5\$>WSX,G M?=>V2GL>|=)90V7K_L1|38U1\$5.MV1P^+##NN,| QX4W(8NPKC)Z;LE| M8T|T=7(=4>25\$P\$T|+X=5PY M;|B^B^,"R1NAL1ASH350H 2XZA,VUSX,Z<AT\$^A/_B|J_~M^R1=ODFQEN\$ M|J^K^C^N^J^+E_#(B3_-1^4V|AORG?;?? A^D+<B51+|H+WKL>|0M+7C(6BX^2BP;Q&0^+P\$>2D|G<_A)M^Q M^?V|@>6ZQ5)<0\$M,Z2X|P>@<@%&6 MUNW^WT>F,UN?>@_U1F5:0I-3^NU+@SMB;PX,YUS=>5@ESJN69.EA9& MIK^BP+8A^?79^B^;TA+&MCB^>2M4U8=|8^FKU?7\$B@>|S8^=H^@X^?A DG1P,M^#1~10J_2.3@UXHX.^ZMX|G@&N@&?(BV.C^+72P^Q8F4I\$^V7?>^?BT^M^&A55_-DB^+? X5)4+4TBZJ05DAEW (V4(HX&6&9&E1RTDC=>D,Z|H MO6\$S R^OJF|J2)F0S^J|T|ZLVY6ZKX\$>C+E &LB1^#F(XE|W3<C^|P_ EHS|A| \$LQ^HH1; BC=&X80.<1% T0 /0%P M^H4UY2^_7K.O.KT78=5H2\$&H^&Y^T^YTF^%>WT&62-V) 57NXNG^|JF55A|>5 M^40WP^;W4|EPWB0?V93 512|?>@6<4U^M^*|_>G8N2;YP8A^R^+O5+X5J M SQ9I1\$S8 \$73183|[# /4,0ML4I|H0K)LRXZ+>09>F/C91Q?TLB07E,NYV M^L1P^G X4|O)&?>ZW7? GMC|& Z08FY^E8^?UDM2MK0|J.Y+J2E1;V3P:83-2= M+NK4^W210W|J.F -3JPSZK^H|J|C&19B^VEVS<@^_H,RDX^/_I/@H M^O|LFJY23,G/W>@<|5%W%59%>X1\$09(51EDH9|_FJ M7|5^E A^~W5,7F71HN1B>?>Y 2,V2PMLN^L,OK5MD5<= M:;&643A^_Q^>Q^>O^&#R>?>XJCE+^_6^*Q>@>L&=>?TSSBA^R/-885/>|@= 04E M8LB1^3+/_|FPB2ZL\$SNMEG>1_1D05>D;Q|?4|_O9+1J4>1>4#M3 HF<94G<=&\$P1L |W9BB6 8BYXW|ZGNY^ MQ_~B5R,DZ|<^N?7^OW^&1&E6,7^9J;|>N2D;S9A^Q/WZ01M^O?FY |MAVH^<#5^WD|ZY-T^R^J^P^?>Y:G8;?>M=M^C^XN MO? 3V=>1I9K^NND!>1=;>4-G13M^E=>D;B?<|>T5ZV%G^V^VMQ&Y^L^>#Y5H>^> M331@O.1T;|3;9E|WQJX.\$SFX|&TGQU@%1:YK<~U0<5099; M- 7<50-Z^U^_P17^/E+Y+V^+(HDEG^CJW8R;KF7^O^>JTD0Y0|1Y1784R M;O_>M>4>4EV;K,IW7\$^>8XO.B^%B=M^C(X.IJG>@>10>SDKF|N8G2E_%R1 MQK3!&_="S^7M@>5TE|>G P%02P,\$% @ BX%,6GG\$RW^M! \$0H 1<@ M^I^X;|JW;W^K: MQ\$^3K.N M0N;=>L8|D!+5Q(1B51)^H|WZW=>(R8ZSN7Z0Y&A^>>^T%>+;1Y M1^6SHZ>Z409R4^FK70!>^>_YLR+>+Q0-ZRPDP63^X=4/XQ1L8UADP.BN1DDU MD&|PN@ASMV9UH5M72<6WAQ^U|JL^K1CQ|O!>+>4^+|+TOF?|>JB\$07^ZL06 MW!|AC? 8HF:Q95;D65&83|_J^>|QZ|^QM^?=>MG9X^&VMTV5M^?>_U5-U_1=3K<^&"PC"|@D/O& M2>#=>118W@&G5A=&|;CXW4\$#S<@JL 8YJ7Q0|I\$|H2=6WW1CFE^|>@|K|J| M^6+&D^>R011FE|<4A>H^>P-FGK5Q1Z6>5TK)CMJ5\$?#FYZ;Y7R7O;00 M1R@&R^1|Z10Z7K;S^P/\$>F|>04^JH|^&5UW0-80WR^%CGA2K7H.V<^&KKG M)T=7E4X?_C|&_0)? <2 H_#X6\$1#1;E&H+E+P106B|L72.DL2|RL|5@/O M=M^VID\$^J^M06|(^76R132-D9G;O0J_1\$AA-U(13V1)ME,EZ<6 JP^F&K5 M^N;ZD|J\$RNN5,"F=D^CP? 4DB6HVH|J|V/GJ|^UM)Q1JJMUY !1#;E1B70H@P MC5RW3AL;@M^:SHRE^CR^J6=8F^+P20%L-4%TK^<@QW^A^V-ELH^8W0AS&#& M:V10HS@Z|_A|01)V9Q- R#^D^ABL101B6|>?>@>2.DB>5D&U016P^K|<= C M4UMZ(C^<AM^AM^&6&9J5V;Z^J&@&A;KV 2G^>+&9U6|J9:1F^S,C<1A8|&1? M\$%2%G^C7|Z^>9&M(LS2J+CEO:HUR^D@>2D|LOCR|B\$|^Y&4&S= MVJ7|Y1P5P\$+Y FOI@UE;13;WGHH SH1!WAM5B& Z4=11+ M8YUO |AKC 1>DNWO>S/.7082V2^*!_1^?> MPELH+G,H_76G6VI0K^7G8E MF&#�\$Z< <BBP70^Q0>ZSL.F0G=8?N+K1B1>P<|Y>|T(L=&NAH^W|W+&X MB<3;#F>^|>^FBT2J?>S^*%&|&R\$2|J5|1|9S2|Y?<3FD>+<4R M^LTH+G|F3MDMXJ-J|1|>=2|_ HYO?>+&#%=>|J.2;^\$VP.PF.J|Z^1FU2+&M7B^FGV41(G^X^H^IT 8XJ)PQ^HE^ZM3|?1?K\$&+KZ|^P+>|J|OQ85TE=6K0M MBT(1^10R;G/6? TX),"TOBP^SXA75A1-(DHM|TVE7\$ _9\$5V1|6@/WH:2L67 M\$|)LE%>=4ATF%>H\$FZ|V(&?HDL-C5^VH|XJ|&K&T5XC|@6VRK7W=C|V?U|YT-W MS31O|QY+GU^B(\$5\$YS^AXO9@\$\$W D^G&|!1_6#ITH#N1P=VX&5^G-93K M_P|_P1^>Z0E|2P,\$% @ BX%,6I^B1P^>@= 8 1D |X;|JW;W^K M^QML255M|J,P\$XKIS AD+&RVJZ,MM+^F1C2T+0! M^X^X\$;7|QHC=>NR;QQZSDE.M3UBV?^|Y|I|GQW&~>O?<5(LCKJ2;~?171 MZC2?7%&A+&RQ6: FF6Q&M2^>VF7D5A9^V1K5^DKC<|C50N1^F.YFEUW8Z<_TI MJ?>@FOJ6MBLG&2JSG@1L|!>_JY8&8QN>_M_|BZ|<^>PZW11L|Q\$?7#C<=2+>|B|;~(2%Z|>1=6G|&|8V^>Q^J|^>7^>@U&201C2-1B9^?63W^K\$-?7T 9 MPI715#GX1\$LBG|J^S&A+&W1W0F4|>@>C.(8L^2^T^P 7K8_VOQL^A^& M^M^U(4-74ABX)8\$8(9<6|8VW@OWP_E.74K4>D DX9P^|PF^+Y^E0S^CP?^YENR M^2^TZ>8IGN|32^V%I3,DZ7B8|J7^6^X\$S 14(7#G MH_68A?^8%C1&QXA20X1GCXW_)HA^SN<+KE#>+>#^M,X^M^MR|A9O=C,\$1Y.|S7M/A\$|^2UX6)G\$&@_D^?B^W\$DBG(3Y: 3#;1G\$SU<@> M09^\$1G@&-VF8Y GLJ|1H9Q4>?>MO|A^1JZH;5;D?J63>|JEW^A^*P^74 M^A0NVN0^/AD\$8+L9UQW(K-J;C^\$4ZK=50Q;0.15^>YAN+|Z@W>P_=%, P|O M2P,\$% @ BX%,6B(N+)_P^<1D |X;|JW;W^K|U755MC|LV^/XKA^&L45R^&O0|I6D2H.FUZ2^=>O2V|D1^X1;_MQL^+HQ97D2|J1?TIVOIR|RLT>1#>1|J+>|> H^T<~?>F674>5C:2P95|J\$660;LUKHQ(M^FN<6&|-E|R M^VN-O^>741(=15_XKG>+&^6-A0|I_ZHVA4|RC^%RBLEPQ;@&N^H^?>#WV M^D^A^>|>=>F91+5^M\$?>?BN6T^@^A |SYQ\$8?>P K&A>Z,B,GOUFU+OTA?|Z| M|JCGP|C9;G%#U1XX&K6M\$1^>U+@CW1>4_8|=GXO^R+6Q88=|J3LB1Y(UU M6G;8%&^>DJOVROY>|X^9Z|O|VAFD|> [648CRCCFV6AB|]^_U^ M^S^O5:NLO!1%5@|M^X|N^|!"|!CA.KT*>(?Y\$)>D_.DH^5_IRWK&6<#<+KC^V MX#1|XHJIG#;1!\$XXY|3M;X^MW|@G^&^N:U9CLN(NL^B> <|H|>1>Y>AVJNQ+L MN |V?>U=:\$^*~#^?;2ZT|J|_QX& M=|XJXQJ|Y|D^BNQK+ M@;O10DX^YMOE89Y+5MPRNO("BMCN2^<|ZP WQOQ?>?0MQ^)_H#>@&5F+ MSKYZ,4N3VW^ UC\$9+ E9|>_>FJ^ M4Y%N1B|Z#&+&^J^~?^?BZL="|,|RSH_XJ|V|(^3>+&@>U^A^|FPJP^&C&\$J|P^>_25- MT^?X^E7@FU|>+&SVS2A-1G,LAG598Q|J_HRL8H|QOE|];@&C0\$E|X.YY< MJFR^4-VZ0H,8&S9\$8XYLU>_>#OH>7&UEC3F20OXC28=M.FS-E&LLY|1KAW(O;1_SMWZ4_Q_?8M MO=&FQY6_O6B9CH:WDPA,^|ZT|Z? K_.WVMS4\$&85;PO=>VJR.W-H965T M1^M\$&^K1G;|^Y91VCYI M^?>@>12PD33T T+|J\$T^?>4ZBZMH|)_M# 9R=>@&^?>7Z|C>|IAZJ4NCKP<8 M>C^XZ:Z6R%#=- #6:~@E4^JBAD;J05(UP19|H2J20J&Y M^*^PN!| M^DOM6MCZ01=&=F#7^R^H5IG^%A?|G#ZT?#>32|0\$PE8@=>K|@YR6KYAABRL MMZ#L;D^S^6>JDR;EN+!|611^JYSDS.*)- (D7J)_>OTU<@0|P:92W K0<M^?P^P^>L1\$S^>KKR^+O^_L(F4ZC<2=1K&2A^> M^S48^~>Y^>CUD(280)>6>~HO1XN|@YGDV2N;Y|A\$R^80^ZQ^BQ;|&E^&| MH6S^&1N^?0E_X^,KKK- Z2D8A_49P^SVCG^G<~<+&KH^M^F^P^#>_&4\$>7|S|IGBLM^V^X^86G-154-V\$J^A=QU018_E;^|UD IRE9 M^9Q^?4\$>4U1&=>|J 3F9H|>M;D^V^ MWR-Q=<\$4K801^?>1.1GT4^> W_K^%K^%E QDH4.5/PB-18?H\$3C8<@>M^J0^G YO M^_1-?>=&X&X3NZH&|YV^ZKKN>HWG6^>RHNRRN19-C^1+6V1DYF|8^YZA6 MUQ^TJ&C^<+&E^UODJ9QVDQ-ZB05+_M^? H\$S1;H7^?Z=>M;C^%14TH&P|_H^_L8A0|DJF|^>HN3<@|H8X)=A>@Q|U\$910&V83B=M^ MQL^19^H^E^?^*U^CE;DDBE6^&D^80#1= 1Q2^5A= 1Q7^J;B|X^U|CG2\$ M^ MZ(J1SGD,E,07^|K>HON)(BE-M^ MU5\$;ZQXG>B^N\$=4WMRWTTD^&C^NN-<|4R_X>X4<K<=,PU^&^ V9%K1^_IY4CU<8)3(@X M^D^L= _0#N-T.&^&~ "1.T_9^Y15HGS^V^V53&_1^BZ2^ 2 CCVV1Y54X&6 M^#1U62B\$TCGY/MT M^ 64K(YQ_~^#4N;G&K^W4U6^>9^1-M^W^XJ?>X1L3RCZK>X12^>Z^>A^>X>V> M> (56)V^VITP^?/MN26TK_P1+194PAHC2A3D1U.K&=&423U^U>5^>N\$V M^H^|&L&ESS|U^21+0_4U2R>SN^1735(MAN|N2^LAMOHO^T>@>H^H^#NZVGQ M+U1+ P04 ^~+&4Q:Z61U^4&^&N\$&_0^&AL+W=O1E+3%&M^|J^Y^Y#;4>3W9Y^1,1CGA7V^6O^&M^R^OVJU|J(BG|INW1;XLM,FEPJOL>W9M2^9*>_JZ4;_ZN52^69V+;|J|V:R| M_-DR5=&M\$;_&^&U(C)61+&EPLB>49B9BT M^19ST;|^|DFMZ|^2479U^UTBTB5;6?&F2^DJE_!K_Y;|^>9714X34E73\$ M^ Q^UH_B(OD\$3I,^K&Q^P)U|JGQ8TJ9)\$HF8D/3CH^R9Z/MU(7/Z^>Z^657 DC/(Q M-100,8Y&03P>B|B#?>1:GDHC<#1<3<3^QN\$A^M\$@B^>A^?>2-QKIP^1^?M^ M&(!=17%PF,PF 8|KJW>@>1I,AQ,1AMWQ5^&K^>XR^KT X^#8^# MQCZ^>@>HRAI_.A&S^X33HAT-O<1@>1%?>@P|C;|&@>0&\$&+54 |JP&_07^OQ7 MAGN^2%>2+>Z\$ZD;G^%- |I:|G|V1Q:QX8AX|W^S\$S)|>|XK S14^+|OP-A MU>_VOJVC^A WA^>+&-%P9B=R? 3Z| M03P=H21B/19,K^<3N1B|9&5WV5E M^Y9(OC|F^?29.L&_L0E+&S^>Z7JIO|PQI^\$|>=|>VPJARDP^W^Y;3QZ|P5M^L 369^ZU 1Z18|JF5^C-S(O&SRM7|O^~9^O_1FV6Q02+>Q|_1X^OMQ^&|), M8U|U^G AO -&1ZV4A9ROR4R^&M^H|GAEW+6JD^U^W7+HEQP=50<~<^TYX|^>1| NWVY^X^J; C6P^42 MJUFN^L=&F;T|_5Z4V&Z1^&A&|F_U4M^Y^1,17X)M^U=>W10G-EDTTRAY MDON;8 0@>7^P\$0B1Y8CG7S%M|O_SO_>@>DAH\$<3&6&ZQ%)6@>_#9MAJOGWV^>+^IYZ^#8-0Y<8Q7.R1!28DA/L.E8QKIC3W8^8!SG:I^P>|>M|2+A M2P>D3CWT782WYU|PC_~F^M^0^> DWYA^>ZM+AD=|J\$N1N^&A+MOFF^?>_.. MM^*&1GHC.^A|C^XZ^F^R^V(APJM^XFOC14=XVZ,MV^B55|LEO^AK|^|?T|W^ND MM_>8!+&^6_J5LX01N1M5SLEEM.N.S2@W;J|J|CB^E|JEF.\$^HKUCJVM=Q M^7Z|5D^>P^WPOO^?62\$YAC^@>T^|CS^K^!H 45S^#5!+ P04 ^~+&4Q: MKVBPS \$^1B^0 &0 M^AL+W=OQ<ZCH\$4;FCEZ M_-O\$>@9&9QJ7F>11>I^43^AH.O!|^*.\$K\$G\$S^<G0\$6?P1 1_?>C;OGK^P 4>_5O(G79,XNW M6X02EUM.\$=IUM444^6^MTW3L3^UJH|^|^| M^J4X<@>BE|SCD04,>>1> LN0\$+EW_0=&8&|^X14W>1\$XH+|_1_16D|); M_JH=P^>P^S7GL42?A^>1P NT<13|VR61|0IT|WT|^|@3BM762AIE5>@>M^R? \$*~7I^G=Y&.;1!+SB3+H6G(900C^%!9/PX)A# M^C-W,M^;GP:SI^8^*|LPCHN(CH1%X\$S1^M^|^|^|^|H>^>|^")_/6(M^+PYN1.9/Y^B>Q>Q~&^~!>1Y\$>TKNGT60=Z ZY^V&A)AUBH|160,BOT01U^M2FX501^>G4_WPE^&+KJ|U3^7V^P^>). 2^+TEX&R_ MWA16^|&9QF?P65|>?%FUQT1XD^Q0%9%>2^>B^C|ZLB5Y|3Y+L^&H^&B(OIQZRXNT^>H^&1301+&D^M^CB^X^|U1^X^VU^RG&Y^>1D7T|P09G\$V+MZKL\$>D^G+|E2A2P OE;HD<4Z^? M^LSR;K^YOD,T0L3ZV^\$HK+MD38<C^>G^CZT@SP\$;VM2R|(^| MAXY|T^U^>7^>0R^>|TV^_HSYKQD^|Q^E|HF625^+>BIDM?Z.GSL6^QF&E^&T| MT;0Y^>2K^2|G1RF|U4>=82F8_X#>2AM^AT3H/9J/T;EXT^>NGD7L|J| MCGPY\$T<=,H)7L

QZ/L M12MB[M2D FM=5%]/YJ@< .V\$W>+!QD\$S*~\$93AC(SAR.#3AFT.Q,C2JC:T\$J3P MR8 N#:&TD;R!!JY-I0,#>9AMQ4?UQA,KPQRIH,-B471N9W7JTNBFQNJ; O2 M(\$ _L\$S@.MV24I+Z2Z>3F<+&; 8YB\$5B75YXHD(H0+9+L. UC@M70#0JITXGD M3#M#4G5M="ITG.-Q./9@G?X*YB">J.7WPQ5G1G31I%2N\$S) 192./P M07>+NIA:HN6=F+1.GM\$078G10N0!Q!IK:IRBMB+1+5-G(8J2 .00005512D MZ:21? J|C1Z[>HY>C5K7&"/J/-G/G*."B"X=X\$!..IUM7|[(C>C|/RY M3J56EDMCZB@V|VJ6+WN19Y?O;M+>[4XB.WM#&\$SO(=H1;#B>8J|OBCFE^CJ M=#E# J|VZ7WZ>N\$G5.8#J|A8-BMB BH+NMS X\$6\$|..#107| (N13%K62?/] MZ08 .1 9 >+PO=VJR:W-H965T M-1+8=CK6= 7&V_N164GAY?7;G+AMV^GPPJ|J3YLQRP>17Y7HM= M13U .J9/QDM?<47M%42ZU>+GE>+BL7 F+@<Z1E7?7E#|U0EJEP) M31~|!(EYMTI? R/<^#0<=|NYJT4N WNH!R?MO>Q=?-5.VK^><8<6?L?<GT MJY? .3JMLT.^?Y.G&VVRWSW<^<059L.F.C;_22<K1M^Mj)5^2-X;4=1/%?T@ |M@9=2MDT?""CL.E29 .WMI8!47F.JE .+8ZSK94A0\$G8035E+!V@B?OZS M4586K\$?#SY)4A=J3S1.I"/5XC&D4A [07+1+2.3GU0H?1%4R?!"M"&:?? M?7?/LO1-V\$S/R4|9R!L\$?:7947XQUF@8WY..HM6>J|.DRGE5:1?9?7TZR3 M:V|EJW|?T?&?Q./?R. I".X.YXWWE1+P8JL=@@&#T93?5&M6 M:15&3TC+33(J|H.. "PMI71"O3%B2RA?&#&=BDW#CG<(&+TD+IDB>J>HO M =K8F8#Y9E4.9C\$VH932KTV!^G'@79933\$&U)VG1THR7 M3003K6V&AX4KL4.4#QIF#0?6J8./J|"(EN"L8*OOD"C39ELDPZ1(M\$1-R\$Hz>W\$DV.;(5@/J0V>A;5+<-<\$SK89W-KJM3Z? M:(28"PEIKZWBJ.1;Y2MT6+L8[PV5OE"6"5A)P>U77+""Q;+WQSB/BC"5@ M@L|KMCJR;|JAGM@R-O.I\&0C@+&BD"80 P=*>DFC_O#K8|=VB51+ M7&70J(C0)DOB@/V/4DV9+&F"=7J/SW8(L|RGDYV?;|QC7/MO8.1IBQ|O\$>.-U.LE7@ MJ"ZA"FI9N19"R+A.&+MO0B5X0@9X\$S\$0(I=D-AUVB).JPOJ"US;45B-Z# M6*0>OX8K@<S>?189,|I+=!&Q:=-H?RMKE#ZR.#4#52T*K\$6#JCM@.YBL7.K MODM_N_RR>.NG1#0 6.;^*95.@V.2JF5R;R(\$&6F|D44F"3J VMD86ZEX5.^: M(K|&-8LF&KA1H .84(|A"V&|80E)N|P(T+D4Q\$?M7PEPLH8 B6EO\$5#11LM-|A&R|J4 9JPK5M@M|J|V&JMIAPM. I'X'RO@AKL4+O&6J6;2JYVH:ZURWN>2;.@E M*[4\$PBO F&3'479CO"1 @IX'(D=#N\$?C0E)2|I.S8KQOVP|SBS5.C7.RW M<\$4R&J8..C4?<.C.AY?+YK&P6.W.G)&E[5J|U?..9R->@C9#@< MTB .5.HC X^@ RTBIO<3/=-I? .(N#4IHf. &0P6(&.*=P\$0.WD@)LF>O MGOYR.V>YC.9S-ZUX3.WWG8W3>9?BN1N?P. + M%N#N@C|OAP%&E.F=SJSKVV"ND"FX\$=OH)9N5S0.14W2J7WW..&PO=VJR:W-H M965T)N9,V>=&0 .JJKP31*(6-DF< MFNN69&UVT>N9(|\$F?H?^69A=?)1-35RY9|-(K0"25Q\$>42V1.JK-FJS8 M@YY|>=S..L4#29?&JW.XS5 K4#4WC(961|H3|ARL<OGM+JG#YI205+ M*1..C501.%Q"7 KJ7#1AR? M% M%=>@35IXX9SU4D3.)E4Q(ZLIEE) MHA9.G+Gj3+SRWJ|716?77K\$?+RJD8&L8CAKGRJ.8H OKES#?J Z# M#@SZ?J?WASV7WZ>N#T#8YX< [JN]>12 .18GBRBPJ|EFSWH;2%N@>=;YP+ MDXQ KONT.PS?VQM?4Y3|U1|E|S;#&#NSPF9|S|WT@O2.CD9@3?<?<6A|JM @ M]=5H9<@<-SQ#F09+>4H9;U)1XS!<-<Q.CP.CK"HZ11"~*E.XT1 M8|> Q>+>9Q)4Y3:FRWU5D.1D1TT&T<ZDD\$S?R8QY+REFLJ1.KY+9R M'S? [B\$S.B.700J@>8!16%|G|ZJN+WQY+F 5RFKN8R-P4QLZ&=XX|G|)2DP17(5@+&K45J M=<@<#VC1\$#AGBYNL.W%VUD|M23)88.S@|RR)QVP7F7&LW4T:DZH>+21\$&?<IR.P<3J>=Z _>".N(F8C14HJMQ)|:H\$ MJ9V!~OCU)I9VSVPS+<X"? \$8?>=5.1N3>J28PJ9|>GWZ<KWCV.B.-N.X6B.17R8?N4.R@:TY=1!5YU.C^@&OE9.7MCZQJ M"BZLX EO+BL?&KNDT1<@DU1E939.=F2@HGJW@O&S[47K0"?_5E9IYJ4 MW"7S>25;&Y>4GS&M|P.LW.XDP+J1(|"LEWB>;|VY.|IC7 _1#B\$S HWZ MB+PE9L(N\$>2.-?2|>GN>QTV>>B?/Z4 .WCOV+&Q/198"6FH@.OZ"B"Y M L6S1O UXY/U?K|J MNCSLI .1018%Q?2F MEI#W _P42TEG?7|X@&@> 0U&RGS9.MB1P5+9>50ZSU .%L&= M|LW<*#V)3.-+2-68T>B3WK5X9GL4J2BX|4E9H:8?>0<7EV/O7P0~"YH M9U~>P7NRUOK3| [R>91XOB0N~|L2?B&K? A8=&+&F&|IX4;S@<J1T8R0OFD/#K# MNX+U.W.(I0B&W@<_I|J.A-X.PNH0)NGX|ZHIWPA4\$8C4?+&M-P0)ME|E#HTY& (&P#% 6|CQ<3A _>*YLC1G-(SX=ELR6HL7;-I-IOX\$V7%| M=GP?7\$R.7 K?;U:0!O!U_IV<@UU-G3?><@&GFN!>=B:PH^B.R&#EC2NT M%#YVS3#?O:-0=;PG)C* 0:-@;JHF.1 M|KJ&M@O|C>LYDB F@O@<J|K@|2K<@<MEX) WL#MYPZ.1.M1;M&M|J0<@L+H?7|00Q|U?>35DG9NG->?>.%U333.CBQRYB03_D9J|J1 MEME26S8;|IPSA4R/WW+<N@5?T PXY@|/G-K&ANF>2E [41\$B9A.MAKP>WCIAP@MOP7U<5V#S|G|Q 30"7*N|!P9?; 0-6HS4-KU#> >0 M@ZU>Y2\$G0JYU/N1=N5Z0>1..M=N@>;KFL^> +&42XMDK(D4#*S8.21EHW05 MDEY+SK\$31+>#&B+H1AS:6?>T\$S|8L>2|&J) N7 _P M'8'9>PO=VJR:W-H965TIAI4QK142+&ANFO|FIBHJ|5%T\$?IEI(N\$N#K1_2 M.IY#M%|JLX|+>K|(SO19XJ4W36|UG<W&E=Z8PTVDULI|ZSPL9RFO&LOT(M.L1.S.C#Z.IEZ:|H6?JA|>28&K@< M|S|S| (44M&D.9IOH.O&Q>.&.%YV\$N\$-1L+ [6C!1U(Q3YLP>9K1V+U=EV M.GMGCG3+&IP&="DTJ@<9GNODG%O"/8? @VVW\4^Z< /N|PT<+>VJ4:5D?|37X;E.22Q M_U;W+>1GIL:UT,IQ M0:9Q>+ ?@/3UPM&MF|2W4I# <J|.M|YHJ4D9%VEI(R@K/7&4Z90)!E!+ P04 M" +=@4Q:UOXT6D? .#0 &0 ^AL+W=OHYH8M?T60E|YV|L8SKI=G<@<QJ97 M"Q1T.Vj9(V.M;5.\$5XLCI"HAL0!&|;BXZ@PMW=JL&G|(R1+1\$YU?179?5 M6T|(WC2N^MPH7HREO+I.CY+CN!>0+&S(V5P.AGB=8%80F?&CD=EI55K& M? 56~HWSG7F(XW7LOC)VJ9 ^>8~N1YELM#N1.N:DD| MD\$>R:A) M#@>N?MFJBL>0|4P1 U#Y.NR.3DKW\$#A=A<KID9:|F@Y1 MQTW&+6&3.C#;CGQF<CQ:1.1#"- |"Q5-QOX4"(4E)P6\$A?>J&W%L&C;MYL M@HELDI(|.S\$&L.V.MB9>1<?>|>Y&W|H01S9R3XRM;E MV.F+GWS%U%YPP43.6<C PS2\$FC0B|BTN.B1==>6;R- /%2*B9FS%[_BFL#5X7.'Y M9ONSTH_OBT)G<7P1@BAL(Q?^N'|Z|^R* K.W;IY.(^CY9R*#XBAY" M|IU0SK\$D= MFC~7%>Z#4Q.R*0^G5.XC>Y<(<+!<+< P+|FL-- DYHRS:ZKKZ1.WT.HN& M"4+>?>Z>&Z.GJNC|>G048XV<.<#>PE05|KCZ\$|PZ.2->PB8J>G=I P=MAQ.WN9C|Y|J6TY;HJF0J84B?>5 J|KW;U0

[illegible]

[illegible]

[illegible]

11/11/2019 10:00:00 AM

H965T7!E&UL4\$!%#@-!9-%D*9A@-6<0-\$!-end XML-95-Show.js:IDEA: XBRL-DOCUMENT//Edgar(tm)Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17-U.S.C. 105. var Show=({};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=(window)?w.document.document).getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}}if(e.e.style.display='block';Show.LastAR=e);Show.hideAR=function(){Show.LastAR.style.display='none';Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p;if(e.style.display=='none'){d='block';p='1'}else{d='none';p='4'}}e.style.display=d;if(a.textContent){a.textContent+=p+a.textContent.substring(1)}else{a.innerHTMLText+=p+a.innerHTMLText.substring(1)}}}XML-96-report.css:IDEA: XBRL-DOCUMENT/*Updated 2009-11-04*/v2.2.0.24-*/DefRef-Styles*/.report-table.authRefData{background-color:#def;border:2px solid #2F4497;font-size:1em;position:absolute;}.report-table.authRefData{display:block;font-weight:bold;}.report-table.authRefData-p{margin-top:0px;}.report-table.authRefData-hide{background-color:#2F4497;padding:1px 3px 0px 0px;text-align:right;}.report-table.authRefData-hide a: hover {background-color:#2F4497;}.report-table.authRefData-body{height:150px;overflow:auto;width:400px;}.report-table.authRefData-table{font-size:1em;}.Report-Styles*/.pl-a,.pl-a:visited{color:black;text-decoration:none;}.table*/.report{background-color:white;border:2px solid #acf;clear:both;color:black;font:normal 8pt Helvetica,Arial,sans-serif;margin-bottom:2em;}.report-hr{border:1px solid #acf;}.Top-labels*/.report-th{background-color:#acf,color:black;font-weight:bold;text-align:center;}.report-th: void {background-color:transparent;color:#000000;font:bold 10pt Helvetica,Arial,sans-serif;text-align:left;}.report-pl{text-align:left;vertical-align:top;white-space:normal;width:200px;white-space:normal;}/word-wrap:break-word;*/.report-td.pl-a a{cursor:pointer;display:block;width:200px;overflow:hidden;}.report-td.pl-div a{width:200px;}.report-td.pl-a: hover {background-color:#ffc;}/Header rows...*/.report-tr.rh{background-color:#acf;color:black;font-weight:bold;}/Calendars...*/.report-re{background-color:#f0f0f0;}/Even rows...*/.report-re, .report-reu{background-color:#def;}.report-reu-td{border-bottom:1px solid black;}.report-rou-td, .report-reu-td{border-bottom:0px solid black;}/styles for footnote marker*/.report-fn{white-space:nowrap;}/styles for numeric types*/.report-num,.report-nump{text-align:right;white-space:nowrap;}.report-nump{padding-left:2em;}.report-nump{padding:0px 0.4em 0px 2em;}/styles for text types*/.report-text{text-align:left;white-space:normal;}.report-text-big{margin-bottom:1em;width:17em;}.report-text-more{display:none;}.report-text-note{font-style:italic;font-weight:bold;}.report-text-small{width:10em;}.report-sup{font-style:italic;}.report-outerFootnotes{font-size:1em;}.XML-98-FilingSummary.xml:IDEA: XBRL-DOCUMENT 3.25.0-1.html2673601true880false6>falsefalseR1.htm000-Document-DocumentAnd-Entity InformationSheethhttp://aytubio.com/20241231/role/statement-document-and-entity-informationDocumentAnd-Entity InformationCover1>falsefalseR2.htm001-Statement-Unaudited Consolidated Balance SheetsSheethhttp://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheetsUnaudited Consolidated Balance SheetsStatements2>falsefalseR3.htm002-Statement-Unaudited Consolidated Balance Sheets (Parentheticals)Sheethhttp://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets-parentheticalsUnaudited Consolidated Balance Sheets (Parentheticals)Statements3>falsefalseR4.htm003-Statement-Unaudited Consolidated Statements of OperationsSheethhttp://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operationsUnaudited Consolidated Statements of OperationsStatements4>falsefalseR5.htm004-Statement-Unaudited Consolidated Statements of Stockholders' EquitySheethhttp://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-stockholders-equityUnaudited Consolidated Statements of Stockholders' EquityStatements5>falsefalseR6.htm005-Statement-Unaudited Consolidated Statements of Cash FlowsSheethhttp://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flowsUnaudited Consolidated Statements of Cash FlowsStatements6>falsefalseR7.htm006-Disclosure-Note 1-Nature of BusinessSheethhttp://aytubio.com/20241231/role/statement-note-1-nature-of-businessNote 1-Nature of BusinessNotes7>falsefalseR8.htm007-Disclosure-Note 2-Summary of Significant Accounting PoliciesSheethhttp://aytubio.com/20241231/role/statement-note-2-summary-of-significant-accounting-policiesNote 2-Summary of Significant Accounting PoliciesNotes8>falsefalseR9.htm008-Disclosure-Note 3-RevenueSheethhttp://aytubio.com/20241231/role/statement-note-3-revenueNote 3-RevenueNotes9>falsefalseR10.htm009-Disclosure-Note 4-InventoriesSheethhttp://aytubio.com/20241231/role/statement-note-4-inventoriesNote 4-InventoriesNotes10>falsefalseR11.htm010-Disclosure-Note 5-Property and EquipmentSheethhttp://aytubio.com/20241231/role/statement-note-5-property-and-equipmentNote 5-Property and EquipmentNotes11>falsefalseR12.htm011-Disclosure-Note 6-LeasesSheethhttp://aytubio.com/20241231/role/statement-note-6-leasesNote 6-LeasesNotes12>falsefalseR13.htm012-Disclosure-Note 7-Intangible AssetsSheethhttp://aytubio.com/20241231/role/statement-note-7-intangible-assetsNote 7-Intangible AssetsNotes13>falsefalseR14.htm013-Disclosure-Note 8-Accrued LiabilitiesSheethhttp://aytubio.com/20241231/role/statement-note-8-accrued-liabilitiesNote 8-Accrued LiabilitiesNotes14>falsefalseR15.htm014-Disclosure-Note 9-Other LiabilitiesSheethhttp://aytubio.com/20241231/role/statement-note-9-other-liabilitiesNote 9-Other LiabilitiesNotes15>falsefalseR16.htm015-Disclosure-Note 10-Revolving Credit FacilitySheethhttp://aytubio.com/20241231/role/statement-note-10-revolving-credit-facilityNote 10-Revolving Credit FacilityNotes16>falsefalseR17.htm016-Disclosure-Note 11-Long-term DebtSheethhttp://aytubio.com/20241231/role/statement-note-11-longterm-debtNote 11-Long-term DebtNotes17>falsefalseR18.htm017-Disclosure-Note 12-Fair Value ConsiderationsSheethhttp://aytubio.com/20241231/role/statement-note-12-fair-value-considerationsNote 12-Fair Value ConsiderationsNotes18>falsefalseR19.htm018-Disclosure-Note 13-Commitments and ContingenciesSheethhttp://aytubio.com/20241231/role/statement-note-13-commitments-and-contingenciesNote 13-Commitments and ContingenciesNotes19>falsefalseR20.htm019-Disclosure-Note 14-Stockholders' EquitySheethhttp://aytubio.com/20241231/role/statement-note-14-stockholders-equityNote 14-Stockholders' EquityNotes20>falsefalseR21.htm020-Disclosure-Note 15-Equity Incentive PlansSheethhttp://aytubio.com/20241231/role/statement-note-15-equity-incentive-plansNote 15-Equity Incentive PlansNotes21>falsefalseR22.htm021-Disclosure-Note 16-WarrantsSheethhttp://aytubio.com/20241231/role/statement-note-16-warrantsNote 16-WarrantsNotes22>falsefalseR23.htm022-Disclosure-Note 17-Earnings Per ShareSheethhttp://aytubio.com/20241231/role/statement-note-17-earnings-per-shareNote 17-Earnings Per ShareNotes23>falsefalseR24.htm023-Disclosure-Note 18-License AgreementsSheethhttp://aytubio.com/20241231/role/statement-note-18-license-agreementsNote 18-License AgreementsNotes24>falsefalseR25.htm024-Disclosure-Note 19-Restructuring CostsSheethhttp://aytubio.com/20241231/role/statement-note-19-restructuring-costsNote 19-Restructuring CostsNotes25>falsefalseR26.htm025-Disclosure-Note 20-Discontinued OperationsSheethhttp://aytubio.com/20241231/role/statement-note-20-discontinued-operationsNote 20-Discontinued OperationsNotes26>falsefalseR27.htm995445-Disclosure-Insider Trading ArrangementsSheethhttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes27>falsefalseR28.htm995472-Disclosure-Significant Accounting Policies (Policies)Sheethhttp://aytubio.com/20241231/role/statement-significant-accounting-policies-policiesSignificant Accounting Policies (Policies)Policieshthttp://aytubio.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies28>falsefalseR29.htm995473-Disclosure-Note 3-Revenue (Tables)Sheethhttp://aytubio.com/20241231/role/statement-note-3-revenue-tablesNote 3-Revenue (Tables)Tableshthttp://aytubio.com/20241231/role/statement-note-3-revenue29>falsefalseR30.htm995474-Disclosure-Note 4-Inventories (Tables)Sheethhttp://aytubio.com/20241231/role/statement-note-4-inventories-tablesNote 4-Inventories (Tables)Tableshthttp://aytubio.com/20241231/role/statement-note-4-inventories30>falsefalseR31.htm995475-Disclosure-Note 5-Property and Equipment (Tables)Sheethhttp://aytubio.com/20241231/role/statement-note-5-property-and-equipment-tablesNote 5-Property and Equipment (Tables)Tableshthttp://aytubio.com/20241231/role/statement-note-5-property-and-equipment31>falsefalseR32.htm995476-Disclosure-Note 6-Leases (Tables)Sheethhttp://aytubio.com/20241231/role/statement-note-6-leases-tablesNote 6-Leases (Tables)Tableshthttp://aytubio.com/20241231/role/statement-note-6-leases32>falsefalseR33.htm995477-Disclosure-Note 7-Intangible Assets (Tables)Sheethhttp://aytubio.com/20241231/role/statement-note-7-intangible-assets-tablesNote 7-Intangible Assets (Tables)Tableshthttp://aytubio.com/20241231/role/statement-note-7-intangible-assets33>falsefalseR34.htm995478-Disclosure-Note 8-Accrued Liabilities (Tables)Sheethhttp://aytubio.com/20241231/role/statement-note-8-accrued-liabilities-tablesNote 8-Accrued Liabilities (Tables)Tableshthttp://aytubio.com/20241231/role/statement-note-8-accrued-liabilities34>falsefalseR35.htm995479-Disclosure-Note 9-Other Liabilities (Tables)Sheethhttp://aytubio.com/20241231/role/statement-note-9-other-liabilities-tablesNote 9-Other Liabilities (Tables)Tableshthttp://aytubio.com/20241231/role/statement-note-9-other-liabilities35>falsefalseR36.htm995480-Disclosure-Note 11-Long-term Debt (Tables)Sheethhttp://aytubio.com/20241231/role/statement-note-11-longterm-debt-tablesNote 11-Long-term Debt (Tables)Tableshthttp://aytubio.com/20241231/role/statement-note-11-longterm-debt36>falsefalseR37.htm995481-Disclosure-Note 12-Fair Value Considerations (Tables)Sheethhttp://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-tablesNote 12-Fair Value Considerations (Tables)Tableshthttp://aytubio.com/20241231/role/statement-note-12-fair-value-considerations37>falsefalseR38.htm995482-Disclosure-Note 15-Equity Incentive Plans (Tables)Sheethhttp://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-tablesNote 15-Equity Incentive Plans (Tables)Tableshthttp://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans38>falsefalseR39.htm995483-Disclosure-Note 16-Warrants (Tables)Sheethhttp://aytubio.com/20241231/role/statement-note-16-warrants-tablesNote 16-Warrants (Tables)Tableshthttp://aytubio.com/20241231/role/statement-note-16-warrants39>falsefalseR40.htm995484-Disclosure-Note 17-Earnings Per Share (Tables)Sheethhttp://aytubio.com/20241231/role/statement-note-17-earnings-per-share-tablesNote 17-Earnings Per Share (Tables)Tableshthttp://aytubio.com/20241231/role/statement-note-17-earnings-per-share40>falsefalseR41.htm995485-Disclosure-Note 20-Discontinued Operations (Tables)Sheethhttp://aytubio.com/20241231/role/statement-note-20-discontinued-operations-tablesNote 20-Discontinued Operations (Tables)Tableshthttp://aytubio.com/20241231/role/statement-note-20-discontinued-operations41>falsefalseR42.htm995486-Disclosure-Note 2-Summary of Significant Accounting Policies (Details Textual)Sheethhttp://aytubio.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textualNote 2-Summary of Significant Accounting Policies (Details Textual)Details42>falsefalseR43.htm995487-Disclosure-Note 3-Revenue (Details Textual)Detailshthttp://aytubio.com/20241231/role/statement-note-3-revenue-tables43>falsefalseR44.htm995488-Disclosure-Note 3-Revenue-Disaggregation of Revenue (Details)Sheethhttp://aytubio.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-detailsNote 3-Revenue-Disaggregation of Revenue (Details)Details44>falsefalseR45.htm995489-Disclosure-Note 4-Inventories (Details Textual)Sheethhttp://aytubio.com/20241231/role/statement-note-4-inventories-details-textualNote 4-Inventories (Details Textual)Detailshthttp://aytubio.com/20241231/role/statement-note-4-inventories-tables45>falsefalseR46.htm995490-Disclosure-Note 4-Inventories-Schedule of Inventories (Details)Sheethhttp://aytubio.com/20241231/role/statement-note-4-inventories-schedule-of-inventories-detailsNote 4-Inventories-Schedule of Inventories (Details)Details46>falsefalseR47.htm995491-Disclosure-Note 5-Property and Equipment (Details Textual)Sheethhttp://aytubio.com/20241231/role/statement-note-5-property-and-equipment-details-textualNote 5-Property and Equipment (Details Textual)Detailshthttp://aytubio.com/20241231/role/statement-note-5-property-and-equipment-tables47>falsefalseR48.htm995492-Disclosure-Note 5-Property and Equipment-Schedule of Property and Equipment (Details)Sheethhttp://aytubio.com/20241231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-detailsNote 5-Property and Equipment-Schedule of Property and Equipment (Details)Details48>falsefalseR49.htm995493-Disclosure-Note 6-Leases (Details Textual)Sheethhttp://aytubio.com/20241231/role/statement-note-6-leases-tables49>falsefalseR50.htm995494-Disclosure-Note 6-Leases-Lease Cost (Details)Sheethhttp://aytubio.com/20241231/role/statement-note-6-leases-lease-cost-detailsNote 6-Leases-Lease Cost (Details)Details50>falsefalseR51.htm995495-Disclosure-Note 6-Leases-Lease Balance Sheet Information (Details)Sheethhttp://aytubio.com/20241231/role/statement-note-6-leases-lease-balance-sheet-information-detailsNote 6-Leases-Lease Balance Sheet Information (Details)Details51>falsefalseR52.htm995496-Disclosure-Note 6-Leases-Lease Balance Sheet Information (Details) (Parentheticals)Sheethhttp://aytubio.com/20241231/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticalsNote 6-Leases-Lease Balance Sheet Information (Details) (Parentheticals)Details52>falsefalseR53.htm995497-Disclosure-Note 6-Leases-Schedule of Lease Liability Maturity (Details)Sheethhttp://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-detailsNote 6-Leases-Schedule of Lease Liability Maturity (Details)Details53>falsefalseR54.htm995498-Disclosure-Note 7-Intangible Assets (Details Textual)Sheethhttp://aytubio.com/20241231/role/statement-note-7-intangible-assets-details-textualNote 7-Intangible Assets (Details Textual)Detailshthttp://aytubio.com/20241231/role/statement-note-7-intangible-assets-tables54>falsefalseR55.htm995499-Disclosure-Note 7-Intangible Assets-Schedule of Intangible Assets (Details)Sheethhttp://aytubio.com/20241231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-detailsNote 7-Intangible Assets-Schedule of Intangible Assets (Details)Details55>falsefalseR56.htm995500-Disclosure-Note 7-Intangible Assets-Future Amortization Expense (Details)Sheethhttp://aytubio.com/20241231/role/statement-note-7-intangible-assets-future-amortization-expense-detailsNote 7-Intangible Assets-Future Amortization Expense (Details)Details56>falsefalseR57.htm995501-Disclosure-Note 8-Accrued Liabilities-Schedule of Accrued Liabilities (Details)Sheethhttp://aytubio.com/20241231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-detailsNote 8-Accrued Liabilities-Schedule of Accrued Liabilities (Details)Details57>falsefalseR58.htm995502-Disclosure-Note 9-Other Liabilities (Details Textual)Sheethhttp://aytubio.com/20241231/role/statement-note-9-other-liabilities-details-textualNote 9-Other Liabilities (Details Textual)Detailshthttp://aytubio.com/20241231/role/statement-note-9-other-liabilities-tables58>falsefalseR59.htm995503-Disclosure-Note 9-Other Liabilities-Schedule of Other Liabilities (Details)Sheethhttp://aytubio.com/20241231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-detailsNote 9-Other Liabilities-Schedule of Other Liabilities (Details)Details59>falsefalseR60.htm995504-Disclosure-Note 10-Revolving Credit Facility (Details Textual)Sheethhttp://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textualNote 10-Revolving Credit Facility (Details Textual)Detailshthttp://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility60>falsefalseR61.htm995505-Disclosure-Note 11-Long-term Debt (Details Textual)Sheethhttp://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textualNote 11-Long-term Debt (Details Textual)Detailshthttp://aytubio.com/20241231/role/statement-note-11-longterm-debt-tables61>falsefalseR62.htm995506-Disclosure-Note 11-Long-term Debt-Schedule of

Long-term Debt (Details)Sheethttp://aytubio.com/20241231/role/statement-note-11-longterm-debt-schedule-of-longterm-debtdetailsNote 11 – Long-term Debt – Schedule of Long-term Debt (Details)Details62 falsefalseR63.htm995507 – Disclosure – Note 11 – Long-term Debt – Future Principal Payments (Details)Sheethttp://aytubio.com/20241231/role/statement-note-11-longterm-debt-future-principal-payments-detailsNote 11 – Long-term Debt – Future Principal Payments (Details)Details63 falsefalseR64.htm995508 – Disclosure – Note 12 – Fair Value Considerations (Details Textual)Sheethttp://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-details-textualNote 12 – Fair Value Considerations (Details Textual)Detailshttp://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-tables64 falsefalseR65.htm995509 – Disclosure – Note 12 – Fair Value Considerations – Recurring Fair Value Measurements (Details)Sheethttp://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-detailsNote 12 – Fair Value Considerations – Recurring Fair Value Measurements (Details)Details65 falsefalseR66.htm995510 – Disclosure – Note 12 – Fair Value Considerations – Summary of Level 3 Changes (Details)Sheethttp://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-detailsNote 12 – Fair Value Considerations – Summary of Level 3 Changes (Details)Details66 falsefalseR67.htm995511 – Disclosure – Note 12 – Fair Value Considerations – Summary of Level 3 Changes (Details) (Parentheticals)Sheethttp://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details-parentheticalsNote 12 – Fair Value Considerations – Summary of Level 3 Changes (Details) (Parentheticals)Details67 falsefalseR68.htm995512 – Disclosure – Note 12 – Fair Value Considerations – Valuation Assumptions (Details)Sheethttp://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-detailsNote 12 – Fair Value Considerations – Valuation Assumptions (Details)Details68 falsefalseR69.htm995513 – Disclosure – Note 13 – Commitments and Contingencies (Details Textual)Sheethttp://aytubio.com/20241231/role/statement-note-13-commitments-and-contingencies-details-textualNote 13 – Commitments and Contingencies (Details Textual)Detailshttp://aytubio.com/20241231/role/statement-note-13-commitments-and-contingencies69 falsefalseR70.htm995514 – Disclosure – Note 14 – Stockholders' Equity (Details Textual)Sheethttp://aytubio.com/20241231/role/statement-note-14-stockholders-equity-details-textualNote 14 – Stockholders' Equity (Details Textual)Detailshttp://aytubio.com/20241231/role/statement-note-14-stockholders-equity70 falsefalseR71.htm995515 – Disclosure – Note 15 – Equity Incentive Plans (Details Textual)Sheethttp://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textualNote 15 – Equity Incentive Plans (Details Textual)Detailshttp://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-tables71 falsefalseR72.htm995516 – Disclosure – Note 15 – Equity Incentive Plans – Stock Option Activity (Details)Sheethttp://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-option-activity-detailsNote 15 – Equity Incentive Plans – Stock Option Activity (Details)Details72 falsefalseR73.htm995517 – Disclosure – Note 15 – Equity Incentive Plans – Restricted Stock Activity (Details)Sheethttp://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-detailsNote 15 – Equity Incentive Plans – Restricted Stock Activity (Details)Details73 falsefalseR74.htm995518 – Disclosure – Note 15 – Equity Incentive Plans – Restricted Stock Unit Activity (Details)Sheethttp://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-detailsNote 15 – Equity Incentive Plans – Restricted Stock Unit Activity (Details)Details74 falsefalseR75.htm995519 – Disclosure – Note 15 – Equity Incentive Plans – Stock Compensation Expense (Details)Sheethttp://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-detailsNote 15 – Equity Incentive Plans – Stock Compensation Expense (Details)Details75 falsefalseR76.htm995520 – Disclosure – Note 16 – Warrants (Details Textual)Sheethttp://aytubio.com/20241231/role/statement-note-16-warrants-details-textualNote 16 – Warrants (Details Textual)Detailshttp://aytubio.com/20241231/role/statement-note-16-warrants-tables76 falsefalseR77.htm995521 – Disclosure – Note 16 – Warrants – Schedule of Warrants Outstanding (Details)Sheethttp://aytubio.com/20241231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-detailsNote 16 – Warrants – Schedule of Warrants Outstanding (Details)Details77 falsefalseR78.htm995522 – Disclosure – Note 17 – Earnings Per Share – Schedule of Earnings Per Share (Details)Sheethttp://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-detailsNote 17 – Earnings Per Share – Schedule of Earnings Per Share (Details)Details78 falsefalseR79.htm995523 – Disclosure – Note 17 – Earnings Per Share – Schedule of Anti-Dilutive Securities (Details)Sheethttp://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-detailsNote 17 – Earnings Per Share – Schedule of Anti-Dilutive Securities (Details)Details79 falsefalseR80.htm995524 – Disclosure – Note 19 – Restructuring Costs (Details Textual)Sheethttp://aytubio.com/20241231/role/statement-note-19-restructuring-costs-details-textualNote 19 – Restructuring Costs (Details Textual)Detailshttp://aytubio.com/20241231/role/statement-note-19-restructuring-costs-80 falsefalseR81.htm995525 – Disclosure – Note 20 – Discontinued Operations – Schedule of Discontinued Operations (Details)Sheethttp://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-detailsNote 20 – Discontinued Operations – Schedule of Discontinued Operations (Details)Details81 falsefalseAll ReportsBookAll Reports aytu-20241231.xsdaytu-20241231_cal.xmlaytu-20241231_def.xmlaytu-20241231_lab.xmlaytu-20241231_pre.xmlaytu20241231c_10q.htm aytu20231231_10qimg001.jpg http://fasb.org/us-gaap/2024http://xbrli.sec.gov/dei/2024http://xbrli.sec.gov/ecd/2024truetrueJSON 401-MetaLinks:json hDEA:XBRL DOCUMENT {"version":"2.2","instance":{"aytu20241231c_10q.htm":{"asnpref":"aytu","nsuri":"http://aytubio.com/20241231","dts":{"schema":{"local":{"aytu-20241231.xsd"},"remote":{"http://www.xbrli.org/2003/xbrli-instance-2003-12-31.xsd"},"http://www.xbrli.org/2003/xbrli-linkbase-2003-12-31.xsd"},"http://www.xbrli.org/2003/xt-2003-12-31.xsd"},"http://www.xbrli.org/2003/xlink-2003-12-31.xsd"},"http://www.xbrli.org/2005/xbrldt-2005.xsd"},"http://www.xbrli.org/2006/ref-2006-02-27.xsd"},"http://www.xbrli.org/lrr/role/negated-2009-12-16.xsd"},"http://www.xbrli.org/lrr/role/net-2009-12-16.xsd"},"http://www.xbrli.org/lrr/role/reference-2009-12-16.xsd"},"https://www.xbrli.org/2020/extensible-enumerations-2.0.xsd"},"https://www.xbrli.org/dtr/type/2020-01-21/types.xsd"},"https://www.xbrli.org/dtr/type/2022-03-31/types.xsd"},"https://xbrli.fasb.org/srt/2024/elts/srt-2024.xsd"},"https://xbrli.fasb.org/srt/2024/elts/srt-roles-2024.xsd"},"https://xbrli.fasb.org/srt/2024/elts/srt-types-2024.xsd"},"https://xbrli.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"},"https://xbrli.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd"},"https://xbrli.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"},"https://xbrli.sec.gov/country/2024/country-2024.xsd"},"https://xbrli.sec.gov/currency/2024/currency-2024.xsd"},"https://xbrli.sec.gov/dei/2024/dei-2024.xsd"},"https://xbrli.sec.gov/ecd/2024/ecd-2024.xsd"},"https://xbrli.sec.gov/exch/2024/exch-2024.xsd"},"https://xbrli.sec.gov/naics/2024/naics-2024.xsd"},"https://xbrli.sec.gov/sic/2024/sic-2024.xsd"},"https://xbrli.sec.gov/stpr/2024/stpr-2024.xsd"},"calculationLink":{"local":{"aytu-20241231_cal.xml"},"definitionLink":{"local":{"aytu-20241231_def.xml"},"labelLink":{"local":{"aytu-20241231_lab.xml"},"presentationLink":{"local":{"aytu-20241231_pre.xml"},"inline":{"local":{"aytu20241231c_10q.htm"},"keyStandard":309,"keyCustom":51,"axisStandard":27,"axisCustom":0,"memberStandard":34,"memberCustom":48,"hidden":{"total":50,"http://fasb.org/us-gaap/2024":40,"http://xbrli.sec.gov/ecd/2024":4,"http://aytubio.com/20241231":1,"http://xbrli.sec.gov/dei/2024":5},"contextCount":267,"entityCount":1,"segmentCount":88,"elementCount":572,"unitCount":6,"baseTaxonomies":{"http://fasb.org/us-gaap/2024":927,"http://xbrli.sec.gov/dei/2024":29,"http://xbrli.sec.gov/ecd/2024":4},"report":{"R1":{"role":"http://aytubio.com/20241231/role/statement-document-and-entity-information","longName":"000 – Document – Document And Entity Information","shortName":"Document And Entity Information","isDefault":true,"groupType":"document","subGroupType":"","menuCat":"Cover","order":1,"firstAnchor":{"contextRef":"d-2024-07-01-2024-12-31","name":"dei:EntityRegistrantName","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"b","span","p","div","body","html"},"reportCount":1,"baseRef":"aytu20241231c_10q.htm","first":true,"unique":true},"R2":{"role":"http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets","longName":"001 – Statement – Unaudited Consolidated Balance Sheets","shortName":"Unaudited Consolidated Balance Sheets","isDefault":false,"groupType":"statement","subGroupType":"","menuCat":"Statements","order":2,"firstAnchor":{"contextRef":"i-2024-12-31","name":"us-gaap:CashAndCashEquivalentsAtCarryingValue","unitRef":"USD","xsiNil":"false","lang":null,"decimals":3,"ancestors":{"td","tr","tbody","table","div","body","html"},"reportCount":1,"baseRef":"aytu20241231c_10q.htm","first":true,"unique":true},"R3":{"role":"http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets-parenteticals","longName":"002 – Statement – Unaudited Consolidated Balance Sheets (Parenteticals)","shortName":"Unaudited Consolidated Balance Sheets (Parenteticals)","isDefault":false,"groupType":"statement","subGroupType":"parentetical","menuCat":"Statements","order":3,"firstAnchor":null,"uniqueAnchor":null},"R4":{"role":"http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations","longName":"003 – Statement – Unaudited Consolidated Statements of Operations","shortName":"Unaudited Consolidated Statements of Operations","isDefault":false,"groupType":"statement","subGroupType":"","menuCat":"Statements","order":4,"firstAnchor":{"contextRef":"d-2024-10-01-2024-12-31","name":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax","unitRef":"USD","xsiNil":"false","lang":null,"decimals":3,"ancestors":{"td","tr","tbody","table","div","body","html"},"reportCount":1,"baseRef":"aytu20241231c_10q.htm","first":true,"unique":true},"R5":{"role":"http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-stockholders-equity","longName":"004 – Statement – Unaudited Consolidated Statements of Stockholders' Equity","shortName":"Unaudited Consolidated Statements of Stockholders' Equity","isDefault":false,"groupType":"statement","subGroupType":"","menuCat":"Statements","order":5,"firstAnchor":{"contextRef":"i-2023-06-30-StatementEquityComponentsAxis-CommonStockMember","name":"us-gaap:SharesOutstanding","unitRef":"Share","xsiNil":"false","lang":null,"decimals":"INF","ancestors":{"td","tr","tbody","table","div","body","html"},"reportCount":1,"baseRef":"aytu20241231c_10q.htm","first":true},"R6":{"role":"http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows","longName":"005 – Statement – Unaudited Consolidated Statements of Cash Flows","shortName":"Unaudited Consolidated Statements of Cash Flows","isDefault":false,"groupType":"statement","subGroupType":"","menuCat":"Statements","order":6,"firstAnchor":{"contextRef":"d-2024-07-01-2024-12-31","name":"us-gaap:NetIncomeLoss","unitRef":"USD","xsiNil":"false","lang":null,"decimals":3,"ancestors":{"b","td","tr","tbody","table","div","body","html"},"reportCount":1,"baseRef":"aytu20241231c_10q.htm","first":true},"R7":{"role":"http://aytubio.com/20241231/role/statement-note-1-nature-of-business","longName":"006 – Disclosure – Note 1 – Nature of Business","shortName":"Note 1 – Nature of Business","isDefault":false,"groupType":"disclosure","subGroupType":"","menuCat":"Notes","order":7,"firstAnchor":{"contextRef":"d-2024-07-01-2024-12-31","name":"us-gaap:OrganizationConsolidationAndPresentationOffFinancialStatementsDisclosureTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"body","html"},"reportCount":1,"baseRef":"aytu20241231c_10q.htm","first":true,"unique":true},"R8":{"role":"http://aytubio.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies","longName":"007 – Disclosure – Note 2 – Summary of Significant Accounting Policies","shortName":"Note 2 – Summary of Significant Accounting Policies","isDefault":false,"groupType":"disclosure","subGroupType":"","menuCat":"Notes","order":8,"firstAnchor":{"contextRef":"d-2024-07-01-2024-12-31","name":"us-gaap:SignificantAccountingPoliciesTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"body","html"},"reportCount":1,"baseRef":"aytu20241231c_10q.htm","first":true,"unique":true},"R9":{"role":"http://aytubio.com/20241231/role/statement-note-3-revenue","longName":"008 – Disclosure – Note 3 – Revenue","shortName":"Note 3 – Revenue","isDefault":false,"groupType":"disclosure","subGroupType":"","menuCat":"Notes","order":9,"firstAnchor":{"contextRef":"d-2024-07-01-2024-12-31","name":"us-gaap:RevenueFromContractWithCustomerTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"body","html"},"reportCount":1,"baseRef":"aytu20241231c_10q.htm","first":true,"unique":true},"R10":{"role":"http://aytubio.com/20241231/role/statement-note-4-inventories","longName":"009 – Disclosure – Note 4 – Inventories","shortName":"Note 4 – Inventories","isDefault":false,"groupType":"disclosure","subGroupType":"","menuCat":"Notes","order":10,"firstAnchor":{"contextRef":"d-2024-07-01-2024-12-31","name":"us-gaap:InventoryDisclosureTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"body","html"},"reportCount":1,"baseRef":"aytu20241231c_10q.htm","first":true,"unique":true},"R11":{"role":"http://aytubio.com/20241231/role/statement-note-5-property-and-equipment","longName":"010 – Disclosure – Note 5 – Property and Equipment","shortName":"Note 5 – Property and Equipment","isDefault":false,"groupType":"disclosure","subGroupType":"","menuCat":"Notes","order":11,"firstAnchor":{"contextRef":"d-2024-07-01-2024-12-31","name":"us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock","unitRef":null,"xsiNil":"false","lang":"en-US","decimals":null,"ancestors":{"body","html"},"reportCount":1,

```

Ref: "aytu20241231c-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "body": "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true }, "R12": { "role": "http://aytubio.com/20241231/role/statement-note-6-leases", "longName": "011-Disclosure - Note 6 - Leases", "shortName": "Note 6 - Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d-2024-07-01-2024-12-31", "name": "aytu:LeasesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "body": "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true }, "R13": { "role": "http://aytubio.com/20241231/role/statement-note-7-intangible-assets", "longName": "012-Disclosure - Note 7 - Intangible Assets", "shortName": "Note 7 - Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "body": "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true }, "R14": { "role": "http://aytubio.com/20241231/role/statement-note-8-accrued-liabilities", "longName": "013 - Disclosure - Note 8 - Accrued Liabilities", "shortName": "Note 8 - Accrued Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d-2024-07-01-2024-12-31", "name": "aytu:AccruedLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "body": "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true }, "R15": { "role": "http://aytubio.com/20241231/role/statement-note-9-other-liabilities", "longName": "014 - Disclosure - Note 9 - Other Liabilities", "shortName": "Note 9 - Other Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "body": "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true }, "R16": { "role": "http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility", "longName": "015-Disclosure - Note 10 - Revolving Credit Facility", "shortName": "Note 10 - Revolving Credit Facility", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "body": "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true }, "R17": { "role": "http://aytubio.com/20241231/role/statement-note-11-longterm-debt", "longName": "016 - Disclosure - Note 11 - Long-term Debt", "shortName": "Note 11 - Long-term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "body": "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true }, "R18": { "role": "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations", "longName": "017 - Disclosure - Note 12 - Fair Value Considerations", "shortName": "Note 12 - Fair Value Considerations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "body": "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true }, "R19": { "role": "http://aytubio.com/20241231/role/statement-note-13-commitments-and-contingencies", "longName": "018 - Disclosure - Note 13 - Commitments and Contingencies", "shortName": "Note 13 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "body": "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true }, "R20": { "role": "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity", "longName": "019 - Disclosure - Note 14 - Stockholders' Equity", "shortName": "Note 14 - Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "body": "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true }, "R21": { "role": "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans", "longName": "020 - Disclosure - Note 15 - Equity Incentive Plans", "shortName": "Note 15 - Equity Incentive Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "body": "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true }, "R22": { "role": "http://aytubio.com/20241231/role/statement-note-16-warrants", "longName": "021 - Disclosure - Note 16 - Warrants", "shortName": "Note 16 - Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "d-2024-07-01-2024-12-31", "name": "aytu:WarrantsOrRightsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "body": "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true }, "R23": { "role": "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share", "longName": "022 - Disclosure - Note 17 - Earnings Per Share", "shortName": "Note 17 - Earnings Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "body": "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true }, "R24": { "role": "http://aytubio.com/20241231/role/statement-note-18-license-agreements", "longName": "023 - Disclosure - Note 18 - License Agreements", "shortName": "Note 18 - License Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "d-2024-07-01-2024-12-31", "name": "aytu:LicensingAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "body": "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true }, "R25": { "role": "http://aytubio.com/20241231/role/statement-note-19-restructuring-costs", "longName": "024-Disclosure - Note 19 - Restructuring Costs", "shortName": "Note 19 - Restructuring Costs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "body": "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true }, "R26": { "role": "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations", "longName": "025 - Disclosure - Note 20 - Discontinued Operations", "shortName": "Note 20 - Discontinued Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "body": "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true }, "R27": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": null, "uniqueAnchor": null }, "R28": { "role": "http://aytubio.com/20241231/role/statement-significant-accounting-policies-policies", "longName": "995472 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ { "us-gaap:SignificantAccountingPoliciesTextBlock", "body": "html", "reportCount": 1, "baseRef": "aytu20241231
```

```

{"unitAnchor": {"contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"aytu": "LeasesDisclosureTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true}], "R33": {"role": "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-tables", "longName": "995477 - Disclosure - Note 7 - Intangible Assets (Tables)", "shortName": "Note 7 - Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": {"contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:ScheduleOffiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true}, {"uniqueAnchor": {"contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:ScheduleOffiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"aytu": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true}], "R34": {"role": "http://aytubio.com/20241231/role/statement-note-8-accrued-liabilities-tables", "longName": "995478 - Disclosure - Note 8 - Accrued Liabilities (Tables)", "shortName": "Note 8 - Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": {"contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"aytu": "AccruedLiabilitiesTableTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true}, {"uniqueAnchor": {"contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"aytu": "AccruedLiabilitiesTableTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true}], "R35": {"role": "http://aytubio.com/20241231/role/statement-note-9-other-liabilities-tables", "longName": "995479 - Disclosure - Note 9 - Other Liabilities (Tables)", "shortName": "Note 9 - Other Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": {"contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:OtherLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"aytu": "OtherLiabilitiesTableTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true}, {"uniqueAnchor": {"contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:OtherLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"aytu": "OtherLiabilitiesTableTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true}], "R36": {"role": "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-tables", "longName": "995480 - Disclosure - Note 11 - Long-term Debt (Tables)", "shortName": "Note 11 - Long-term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": {"contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"aytu": "LongTermDebtTableTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true}, {"uniqueAnchor": {"contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"aytu": "LongTermDebtTableTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true}], "R37": {"role": "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-tables", "longName": "995481 - Disclosure - Note 12 - Fair Value Considerations (Tables)", "shortName": "Note 12 - Fair Value Considerations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": {"contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:ScheduleOffairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"us-gaap:FairValueDisclosuresTableTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true}, {"uniqueAnchor": {"contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:ScheduleOffairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"aytu": "FairValueDisclosuresTableTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true}], "R38": {"role": "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-tables", "longName": "995482 - Disclosure - Note 15 - Equity Incentive Plans (Tables)", "shortName": "Note 15 - Equity Incentive Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": {"contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTableTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true}, {"uniqueAnchor": {"contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"aytu": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true}, {"uniqueAnchor": {"contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"aytu": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true}], "R39": {"role": "http://aytubio.com/20241231/role/statement-note-16-warrants-tables", "longName": "995483 - Disclosure - Note 16 - Warrants (Tables)", "shortName": "Note 16 - Warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": {"contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"aytu": "WarrantsOrRightsDisclosureTableTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true}, {"uniqueAnchor": {"contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"aytu": "WarrantsOrRightsDisclosureTableTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true}], "R40": {"role": "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-tables", "longName": "995484 - Disclosure - Note 17 - Earnings Per Share (Tables)", "shortName": "Note 17 - Earnings Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": {"contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"us-gaap:EarningsPerShareTableTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true}, {"uniqueAnchor": {"contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"aytu": "EarningsPerShareTableTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true}], "R41": {"role": "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-tables", "longName": "995485 - Disclosure - Note 20 - Discontinued Operations (Tables)", "shortName": "Note 20 - Discontinued Operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": {"contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTableTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true}, {"uniqueAnchor": {"contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"aytu": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTableTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true}, {"uniqueAnchor": {"contextRef": "d-2024-07-01-2024-12-31", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ance
```

"aytu:LeasesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true } }, "R50": { "role": "http://aytubio.com/20241231/role/statement-note-6-leases-lease-cost-details", "longName": "995494 - Disclosure - Note 6 - Leases - Lease Cost (Details)", "shortName": "Note 6 - Leases - Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "d_2024-10-01_2024-12-31", "name": "us-gaap:LeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "us-gaap:LeaseCostTableTextBlock", "aytu:LeasesDisclosureTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true } }, "R51": { "role": "http://aytubio.com/20241231/role/statement-note-6-leases-lease-balance-sheet-information-details", "longName": "995495 - Disclosure - Note 6 - Leases - Lease Balance Sheet Information (Details)", "shortName": "Note 6 - Leases - Lease Balance Sheet Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true } }, "R52": { "role": "http://aytubio.com/20241231/role/statement-note-6-leases-lease-balance-sheet-information-details-parenteticals", "longName": "995496 - Disclosure - Note 6 - Leases - Lease Balance Sheet Information (Details) (Parenteticals)", "shortName": "Note 6 - Leases - Lease Balance Sheet Information (Details) (Parenteticals)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parentetical", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true } }, "R53": { "role": "http://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "longName": "995497 - Disclosure - Note 6 - Leases - Schedule of Lease Liability Maturity (Details)", "shortName": "Note 6 - Leases - Schedule of Lease Liability Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "aytu:LesseeLiabilityMaturityTableTextBlock", "aytu:LeasesDisclosureTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true } }, "R54": { "role": "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-details-textual", "longName": "995498 - Disclosure - Note 7 - Intangible Assets (Details Textual)", "shortName": "Note 7 - Intangible Assets (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "d_2024-10-01_2024-12-31", "name": "aytu:AmortizationExpenseOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": { "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true } }, "R55": { "role": "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "longName": "995499 - Disclosure - Note 7 - Intangible Assets - Schedule of Intangible Assets (Details)", "shortName": "Note 7 - Intangible Assets - Schedule of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "us-gaap:ScheduleOffiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true } }, "R56": { "role": "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "longName": "995500 - Disclosure - Note 7 - Intangible Assets - Future Amortization Expense (Details)", "shortName": "Note 7 - Intangible Assets - Future Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOffFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "us-gaap:ScheduleoffiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true } }, "R57": { "role": "http://aytubio.com/20241231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details", "longName": "995501 - Disclosure - Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details)", "shortName": "Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "aytu:AccruedSavingsOffers", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "aytu:AccruedLiabilitiesTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true } }, "R58": { "role": "http://aytubio.com/20241231/role/statement-note-9-other-liabilities-details-textual", "longName": "995502 - Disclosure - Note 9 - Other Liabilities (Details Textual)", "shortName": "Note 9 - Other Liabilities (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "aytu:FixedPaymentArrangements", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "us-gaap:OtherLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true } }, "R59": { "role": "http://aytubio.com/20241231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details", "longName": "995503 - Disclosure - Note 9 - Other Liabilities - Schedule of Other Liabilities (Details)", "shortName": "Note 9 - Other Liabilities - Schedule of Other Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "aytu:FixedPaymentArrangements", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "us-gaap:OtherLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true } }, "R60": { "role": "http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual", "longName": "995504 - Disclosure - Note 10 - Revolving Credit Facility (Details Textual)", "shortName": "Note 10 - Revolving Credit Facility (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "i_2024-06-12_LineOfCreditFacilityAxis-EclipseBusinessCapitalLeLoanAgreementMember-LongtermDebtTypeAxis-SecuredDebtMember", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": { "p", "us-gaap:ShortTermDebtTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true } }, "R61": { "role": "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details", "longName": "995505 - Disclosure - Note 11 - Long-term Debt (Details Textual)", "shortName": "Note 11 - Long-term Debt (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "i_2022-03-07-SubsidiarySaleOfStockAxis-AvenueCapitalIssuanceMember", "name": "us-gaap:SharesIssuedPricePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "p", "us-gaap:LongTermDebtTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true } }, "R62": { "role": "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details", "longName": "995506 - Disclosure - Note 11 - Long-term Debt - Schedule of Long-term Debt (Details)", "shortName": "Note 11 - Long-term Debt - Schedule of Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true } }, "R63": { "role": "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-future-principal-payments-details", "longName": "995507 - Disclosure - Note 11 - Long-term Debt - Future Principal Payments (Details)", "shortName": "Note 11 - Long-term Debt - Future Principal Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOffPrincipalRemainderOffFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "us-gaap:ScheduleOfMaturitiesOffLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true } }, "R64": { "role": "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-details-textual", "longName": "995508 - Disclosure - Note 12 - Fair Value Considerations (Details Textual)", "shortName": "Note 12 - Fair Value Considerations (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "i_2024-09-30-ClassOfWarrantOrRightAxis-FrancheBPreferredWarrantsMember", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "p", "td", "tr", "tbody": "table", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true } }, "R65": { "role": "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details", "longName": "995509 - Disclosure - Note 12 - Fair Value Considerations - Recurring Fair Value Measurements (Details)", "shortName": "Note 12 - Fair Value Considerations - Recurring Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:DerivativeLiabilitiesNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true } }, "R66": { "role": "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details", "longName": "995510 - Disclosure - Note 12 - Fair Value Considerations - Summary of Level 3 Changes (Details)", "shortName": "Note 12

-Fair Value Considerations - Summary of Level 3 Changes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "d_2024-06-30-FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-06-30-FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "first": true, "unique": true }, "R67": { "role": "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details-parentheticals", "longName": "995511 - Disclosure - Note 12 - Fair Value Considerations - Summary of Level 3 Changes (Details) (Parentheticals)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "d_2024-10-01-2024-12-31", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "first": true, "unique": true }, "R68": { "role": "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "longName": "995512 - Disclosure - Note 12 - Fair Value Considerations - Valuation Assumptions (Details)", "shortName": "Note 12 - Fair Value Considerations - Valuation Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "d_2024-12-31-ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember-MeasurementInputTypeAxis-MeasurementInputExpectedTermMember", "name": "us-gaap:DerivativeLiabilityMeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "td": "tr", "tbody": "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "first": true, "unique": true }, "R69": { "role": "http://aytubio.com/20241231/role/statement-note-13-commitments-and-contingencies-details-textual", "longName": "995513 - Disclosure - Note 13 - Commitments and Contingencies (Details Textual)", "shortName": "Note 13 - Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "d_2024-07-01-2024-12-31-TypeOfArrangementAxis-TrisKarbinalAgreementMember", "name": "aytu:SupplyAndDistributionCommitmentPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-12-31-RangeAxis-MaximumMember_TypeOfArrangementAxis-TrisKarbinalAgreementMember", "name": "aytu:SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": { "p": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "unique": true }, "R70": { "role": "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual", "longName": "995514 - Disclosure - Note 14 - Stockholders' Equity (Details Textual)", "shortName": "Note 14 - Stockholders' Equity (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "d_2024-07-01-2024-12-31", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2022-08-11-ClassOfWarrantOrRightAxis-August2022CommonAndPrefundedWarrantsMember", "name": "us-gaap:SaleOfStockPricePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "p": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "unique": true }, "R71": { "role": "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual", "longName": "995515 - Disclosure - Note 15 - Equity Incentive Plans (Details Textual)", "shortName": "Note 15 - Equity Incentive Plans (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "td": "tr", "tbody": "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31-AwardTypeAxis-EmployeeStockOptionMember", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": { "p": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "unique": true }, "R72": { "role": "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details", "longName": "995516 - Disclosure - Note 15 - Equity Incentive Plans - Stock Option Activity (Details)", "shortName": "Note 15 - Equity Incentive Plans - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "td": "tr", "tbody": "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01-2024-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "td": "tr", "tbody": "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "unique": true }, "R73": { "role": "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "longName": "995517 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details)", "shortName": "Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "d_2024-07-01-2024-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "td": "tr", "tbody": "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30-AwardTypeAxis-RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "td": "tr", "tbody": "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "unique": true }, "R74": { "role": "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details", "longName": "995518 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details)", "shortName": "Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "i_2024-06-30-AwardTypeAxis-RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "td": "tr", "tbody": "table", "us-gaap:NonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30-AwardTypeAxis-RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "td": "tr", "tbody": "table", "us-gaap:NonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "first": true }, "R75": { "role": "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "longName": "995519 - Disclosure - Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details)", "shortName": "Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "d_2024-10-01-2024-12-31", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-10-01-2024-12-31", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "first": true }, "R76": { "role": "http://aytubio.com/20241231/role/statement-note-16-warrants-details-textual", "longName": "995520 - Disclosure - Note 16 - Warrants (Details Textual)", "shortName": "Note 16 - Warrants (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "d_2024-07-01-2024-12-31", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-06-2023-01-06-NonmonetaryTransactionTypeAxis-ReverseStockSplitMember", "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "p": "aytu:WarrantsOrRightsDisclosureTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "unique": true }, "R77": { "role": "http://aytubio.com/20241231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details", "longName": "995521 - Disclosure - Note 16 - Warrants - Schedule of Warrants Outstanding (Details)", "shortName": "Note 16 - Warrants - Schedule of Warrants Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "td": "tr", "tbody": "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "aytu:WarrantsOrRightsDisclosureTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "aytu20241231c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01-2024-12-31", "name": "aytu:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "td": "tr", "tbody": "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "aytu:WarrantsOrRightsDisclosureTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "unique": true }, "R78": { "role": "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "longName": "995522 - Disclosure - Note 17 - Earnings Per Share - Schedule of Earnings Per Share (Details)", "shortName": "Note 17 - Earnings Per Share - Schedule of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "d_2024-10-01-2024-12-31", "name": "us-gaap:IncomeLossFromContinuingOperations", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "b": "td", "tr": "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-10-01-2024-12-31", "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "tbody": "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "aytu20241231c_10q.htm", "unique": true }, "R79": { "role": "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details", "longName": "995523 - Disclosure - Note 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details)", "shortName": "Note 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details)", "isDefault": "false",

"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "d-2024-10-01-2024-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html", "div", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true], "uniqueAnchor": { "contextRef": "d-2024-10-01-2024-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html", "div", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true] }, "R80": { "role": "http://aytubio.com/20241231/role/statement-note-19-restructuring-costs-details-textual", "longName": "995524 - Disclosure - Note 19 - Restructuring Costs (Details Textual)", "shortName": "Note 19 - Restructuring Costs (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "d-2024-10-01-2024-12-31_RestructuringPlanAxis-GrandPrairieTexasManufacturingSiteMember", "name": "us-gaap:BusinessExitCosts1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": ["p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true, "unique": true] }, "R81": { "role": "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details", "longName": "995525 - Disclosure - Note 20 - Discontinued Operations - Schedule of Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "d-2024-10-01-2024-12-31", "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "first": true], "uniqueAnchor": { "contextRef": "d-2024-10-01-2024-12-31_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-ConsumerHealthDivestitureMember", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html", "reportCount": 1, "baseRef": "aytu20241231c-10q.htm", "unique": true] }, "tag": { "us-gaap:AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "presentation": ["http://aytubio.com/20241231/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap:AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": ["http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets"], "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 5.0 }, "presentation": ["http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r68", "r65"] }, "us-gaap:AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": ["http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets"], "parentTag": "us-gaap:OtherAssetsCurrent", "weight": 1.0, "order": 3.0 }, "presentation": ["http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r73"] }, "aytu:AccruedCustomerAndProductRelatedFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231", "localname": "AccruedCustomerAndProductRelatedFeesCurrent", "crdr": "credit", "calculation": ["http://aytubio.com/20241231/role/statement-note-8-acrued-liabilities-schedule-of-acrued-liabilities-details"], "parentTag": "us-gaap:AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "presentation": ["http://aytubio.com/20241231/role/statement-note-8-acrued-liabilities-schedule-of-acrued-liabilities-details"], "lang": { "en-us": { "role": { "label": "Accrued customer and product related fees", "documentation": "Represents the amount of accrued customer and product related fees classified as current." } } }, "auth_ref": [] }, "us-gaap:AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": ["http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets"], "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://aytubio.com/20241231/role/statement-note-8-acrued-liabilities-schedule-of-acrued-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": ["http://aytubio.com/20241231/role/statement-note-8-acrued-liabilities-schedule-of-acrued-liabilities-details", "http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "Accrued liabilities", "totalLabel": "Total accrued liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r71"] }, "aytu:AccruedLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aytubio.com/20241231", "localname": "AccruedLiabilitiesTextBlock", "presentation": ["http://aytubio.com/20241231/role/statement-note-8-acrued-liabilities"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities [Text Block]", "documentation": "The entire disclosure regarding accrued liabilities." } } }, "auth_ref": [] }, "aytu:AccruedProgramRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231", "localname": "AccruedProgramRelatedLiabilities", "crdr": "credit", "calculation": ["http://aytubio.com/20241231/role/statement-note-8-acrued-liabilities-schedule-of-acrued-liabilities-details"], "parentTag": "us-gaap:AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "presentation": ["http://aytubio.com/20241231/role/statement-note-8-acrued-liabilities-schedule-of-acrued-liabilities-details"], "lang": { "en-us": { "role": { "label": "Accrued program liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for program related liabilities." } } }, "auth_ref": [] }, "aytu:AccruedSavingsOffers": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231", "localname": "AccruedSavingsOffers", "crdr": "credit", "calculation": ["http://aytubio.com/20241231/role/statement-note-8-acrued-liabilities-schedule-of-acrued-liabilities-details"], "parentTag": "us-gaap:AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "presentation": ["http://aytubio.com/20241231/role/statement-note-8-acrued-liabilities-schedule-of-acrued-liabilities-details"], "lang": { "en-us": { "role": { "label": "Accrued savings offers", "documentation": "Represents information related to accrued saving offers." } } }, "auth_ref": [] }, "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": ["http://aytubio.com/20241231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details"], "parentTag": "us-gaap:PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 0.0 }, "presentation": ["http://aytubio.com/20241231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Less: accumulated depreciation and amortization", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r29", "r159", "r523"] }, "us-gaap:AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": ["http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets"], "parentTag": "us-gaap:StockholdersEquity", "weight": 1.0, "order": 3.0 }, "presentation": ["http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r81", "r685", "r860"] }, "us-gaap:AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r566", "r722", "r723", "r724", "r726", "r798", "r861"] }, "aytu:AdhdPortfolioMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "AdhdPortfolioMember", "presentation": ["http://aytubio.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "ADHD Portfolio [Member]", "documentation": "Relating to the ADHD Portfolio." } } }, "auth_ref": [] }, "aytu:AdjustedIncomeLossFromContinuingOperationsDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231", "localname": "AdjustedIncomeLossFromContinuingOperationsDiluted", "crdr": "credit", "presentation": ["http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details"], "lang": { "en-us": { "role": { "label": "Adjusted numerator - net (loss) income from continuing operations", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent for diluted calculation." } } }, "auth_ref": [] }, "aytu:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInDiscontinuedOperations", "crdr": "debit", "calculation": ["http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows"], "parentTag": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 }, "presentation": ["http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Non-cash adjustments from discontinued operations", "documentation": "The amount of adjustments to net income or loss from discontinued operations." } } }, "auth_ref": [] }, "us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities:" } } }, "auth_ref": [] }, "aytu:AfterJanuary262023ButBeforeJanuary262024Member": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "AfterJanuary262023ButBeforeJanuary262024Member", "presentation": ["http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual"], "lang": { "en-us": { "role": { "label": "After January 26, 2023 But Before January 26, 2024 [Member]", "documentation": "Relating to after January 26, 2023 but before January 26, 2024." } } }, "auth_ref": [] }, "aytu:AfterJanuary262024ButBeforeJanuary262025Member": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "AfterJanuary262024ButBeforeJanuary262025Member", "presentation": ["http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "After January 26, 2024 But Before January 26, 2025 [Member]", "documentation": "Relating to after January 26, 2024 but before January 26, 2025." } } }, "auth_ref": [] }, "aytu:AfterJune122025ButOnOrBeforeJune122026Member": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "AfterJune122025ButOnOrBeforeJune122026Member", "presentation": ["http://aytubio.com/20241231/role/statement-note-11-longterm-debt", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "After June 12, 2025, but on or before June 12, 2026 [Member]", "documentation": "Represents the termination fee if the termination is after June 12, 2026, but on or before June 12, 2026." } } }, "auth_ref": [] }, "aytu:AfterJune122026ButOnOrBeforeJune122027Member": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "AfterJune122026ButOnOrBeforeJune122027Member", "presentation": ["http://aytubio.com/20241231/role/statement-note-11-longterm-debt", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "After June 12, 2026, but on or before June 12, 2027 [Member]", "documentation": "Represents the termination fee if the termination is after June 12, 2026, but on or before June 12, 2027." } } }, "auth_ref": [] }, "aytu:AfterJune122026ButOnOrBeforeJune122028Member": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "AfterJune122026ButOnOrBeforeJune122028Member", "presentation": ["http://aytubio.com/20241231/role/statement-note-11-longterm-debt", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "After June 12, 2026, but on or before June 12, 2028 [Member]", "documentation": "Represents the termination fee if the termination is after June 12, 2026, but on or before June 12, 2028." } } }, "auth_ref": [] }, "us-gaap:AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details"], "lang": { "en-us": { "role": { "label": "Total stock-based compensation expense", "documentation": "Amount of expense for award under

share-based payment arrangement. Excludes amount capitalized. } } }, "auth_ref": { "r401", "r406" }, "dei-AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024/", "localname": "AmendmentFlag", "presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information"}, "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } }, "auth_ref": { "r401", "r406" }, "dei-AmendmentFlag": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231/", "localname": "AmortizationExpenseOfIntangibleAssets", "crdr": "debit", "presentation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-details-textual"}, "lang": { "en-us": { "role": { "label": "aytu_AmortizationExpenseOfIntangibleAssets", "terseLabel": "Amortization Expense of Intangible Assets", "documentation": "The value of amortization expense of intangible assets." } } }, "auth_ref": { "r6", "r275", "r281", "r649" }, "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": { "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details"}, "lang": { "en-us": { "role": { "label": "Antidilutive securities (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": { "r223" }, "us-gaap-ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": { "http://aytubio.com/20241231/role/statement-note-13-committments-and-contingencies"}, "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": { "r432" }, "us-gaap-AssetAcquisitionContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals"}, "lang": { "en-us": { "role": { "label": "Asset Acquisition, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as current." } } }, "auth_ref": { "r792" }, "us-gaap-Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets", "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets"}, "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": { "r128", "r140", "r162", "r185", "r227", "r230", "r247", "r250", "r257", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r433", "r435", "r467", "r515", "r589", "r645", "r646", "r685", "r701", "r760", "r761", "r811" }, "us-gaap-AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets"}, "lang": { "en-us": { "role": { "label": "Current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": { "r185", "r257", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r433", "r435", "r467", "r760", "r761", "r811" }, "us-gaap-AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets"}, "lang": { "en-us": { "role": { "label": "Non-current assets", "documentation": "Total non-current assets." } } }, "auth_ref": { "r185", "r257", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r433", "r435", "r467", "r760", "r761", "r811" }, "us-gaap-AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details"}, "lang": { "en-us": { "role": { "label": "Current assets of discontinued operations", "totalLabel": "Total current assets of discontinued operations", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r185", "r257", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r433", "r435", "r467", "r760", "r761", "r811" }, "us-gaap-AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details"}, "lang": { "en-us": { "role": { "label": "Current assets of discontinued operations", "totalLabel": "Total current assets of discontinued operations", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r185", "r257", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r433", "r435", "r467", "r760", "r761", "r811" }, "us-gaap-AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details"}, "lang": { "en-us": { "role": { "label": "Non-current assets of discontinued operations", "totalLabel": "Total non-current assets of discontinued operations", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r185", "r257", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r433", "r435", "r467", "r760", "r761", "r811" }, "us-gaap-August2022CommonAndPrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity", "presentation": { "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual"}, "lang": { "en-us": { "role": { "label": "August 2022 Common Warrants [Member]", "documentation": "Relating to the August 2022 Common and Prefunded Warrants." } } }, "auth_ref": { "r185", "r257", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r433", "r435", "r467", "r760", "r761", "r811" }, "us-gaap-August2022CommonAndPrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity", "presentation": { "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual"}, "lang": { "en-us": { "role": { "label": "August 2022 Common Warrants [Member]", "documentation": "Relating to the August 2022 Common Warrants." } } }, "auth_ref": { "r185", "r257", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r433", "r435", "r467", "r760", "r761", "r811" }, "us-gaap-August2022PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity", "presentation": { "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual"}, "lang": { "en-us": { "role": { "label": "August 2022 Prefunded Warrants [Member]", "documentation": "Relating to August 2022 prefunded warrants." } } }, "auth_ref": { "r185", "r257", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r433", "r435", "r467", "r760", "r761", "r811" }, "us-gaap-AvenueCapitalIssuanceMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231/role/statement-note-11-longterm-debt", "presentation": { "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textual"}, "lang": { "en-us": { "role": { "label": "Avenue Capital Issuance [Member]", "documentation": "Relating to Avenue Capital Issuance." } } }, "auth_ref": { "r185", "r257", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r433", "r435", "r467", "r760", "r761", "r811" }, "us-gaap-AvenueCapitalLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231/role/statement-note-11-longterm-debt", "presentation": { "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textual"}, "lang": { "en-us": { "role": { "label": "Avenue Capital Loan [Member]", "documentation": "Relating to the Avenue Capital Loan." } } }, "auth_ref": { "r185", "r257", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r433", "r435", "r467", "r760", "r761", "r811" }, "us-gaap-AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans", "presentation": { "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details"}, "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": { "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400" }, "us-gaap-BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aytubio.com/20241231/role/statement-significant-accounting-policies", "presentation

presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."} }}, {"auth_ref": "r1", "us-gaap_BusinessCombinationContingentConsiderationLiability": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": {"http://ayttubio.com/20241231/role/statement-note-9-other-liabilities-details-textual": {"lang": {"en-us": {"role": {"label": "us-gaap_BusinessCombinationContingentConsiderationLiability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } }}, "auth_ref": {"r39", "r124", "r429", "r449", "r450", "r451"} }}, "us-gaap_BusinessExitCosts1": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessExitCosts1", "crdr": "debit", "presentation": {"http://ayttubio.com/20241231/role/statement-note-19-restructuring-costs-details-textual": {"lang": {"en-us": {"role": {"label": "us-gaap_BusinessExitCosts1", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation." } }}, "auth_ref": {"r6"} }}, "us-gaap_CashAndCashEquivalentsAtCarryingValue": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": {"http://ayttubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets": {"parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 4.0}, "presentation": {"http://ayttubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets": {"lang": {"en-us": {"role": {"label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } }}, "auth_ref": {"r21", "r157", "r632"} }}, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": {"http://ayttubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"lang": {"en-us": {"role": {"label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } }}, "auth_ref": {"r21", "r102", "r182"} }}, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": {"http://ayttubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"parentTag": null, "weight": null, "order": null, "root": true}, "presentation": {"http://ayttubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"lang": {"en-us": {"role": {"label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net change in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } }}, "auth_ref": {"r0", "r102"} }}, "dei_CityAreaCode": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": {"http://ayttubio.com/20241231/role/statement-document-and-entity-information": {"lang": {"en-us": {"role": {"label": "City Area Code", "documentation": "Area code of city"} } }}, "auth_ref": {} }}, "us-gaap_ClassOfWarrantOrRightAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": {"http://ayttubio.com/20241231/role/statement-note-11-longterm-debt", "http://ayttubio.com/20241231/role/statement-note-11-longterm-debt-details-textual", "http://ayttubio.com/20241231/role/statement-note-12-fair-value-considerations", "http://ayttubio.com/20241231/role/statement-note-12-fair-value-considerations-details-textual", "http://ayttubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "http://ayttubio.com/20241231/role/statement-note-14-stockholders-equity", "http://ayttubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual", "http://ayttubio.com/20241231/role/statement-note-16-warrants", "http://ayttubio.com/20241231/role/statement-note-16-warrants-details-textual": {"lang": {"en-us": {"role": {"label": "Class of Warrant or Right {Axis}", "documentation": "Information by type of warrant or right issued." } }}, "auth_ref": {"r35"} }}, "us-gaap_ClassOfWarrantOrRightDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": {"http://ayttubio.com/20241231/role/statement-note-11-longterm-debt", "http://ayttubio.com/20241231/role/statement-note-11-longterm-debt-details-textual", "http://ayttubio.com/20241231/role/statement-note-12-fair-value-considerations", "http://ayttubio.com/20241231/role/statement-note-12-fair-value-considerations-details-textual", "http://ayttubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "http://ayttubio.com/20241231/role/statement-note-14-stockholders-equity", "http://ayttubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual", "http://ayttubio.com/20241231/role/statement-note-16-warrants", "http://ayttubio.com/20241231/role/statement-note-16-warrants-details-textual": {"lang": {"en-us": {"role": {"label": "Class of Warrant or Right {Domain}", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } }}, "auth_ref": {} }}, "aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod": {"xbrltype": "perShareItemType", "nsuri": "http://ayttubio.com/20241231", "localname": "ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod", "presentation": {"http://ayttubio.com/20241231/role/statement-note-16-warrants-details-textual", "http://ayttubio.com/20241231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details": {"lang": {"en-us": {"role": {"label": "Warrants exercised, weighted average exercise price (in dollars per share)", "documentation": "Represents the exercise price of warrants or rights exercised during the period." } }}, "auth_ref": {} }}, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": {"http://ayttubio.com/20241231/role/statement-note-11-longterm-debt-details-textual", "http://ayttubio.com/20241231/role/statement-note-12-fair-value-considerations-details-textual", "http://ayttubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual", "http://ayttubio.com/20241231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details": {"lang": {"en-us": {"role": {"label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "documentation": "Class of Warrant or Right, Exercise Price, Exercised During Period (in dollars per share)", "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)", "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } }}, "auth_ref": {"r350"} }}, "aytu_ClassOfWarrantOrRightExercisedDuringPeriod": {"xbrltype": "sharesItemType", "nsuri": "http://ayttubio.com/20241231", "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "presentation": {"http://ayttubio.com/20241231/role/statement-note-16-warrants-details-textual", "http://ayttubio.com/20241231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details": {"lang": {"en-us": {"role": {"label": "Class of Warrant or Right, Exercised During Period (in shares)", "documentation": "The number of warrants or rights exercised during period." } }}, "auth_ref": {} }}, "aytu_ClassOfWarrantOrRightIssuedDuringPeriod": {"xbrltype": "sharesItemType", "nsuri": "http://ayttubio.com/20241231", "localname": "ClassOfWarrantOrRightIssuedDuringPeriod", "presentation": {"http://ayttubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual": {"lang": {"en-us": {"role": {"label": "Class of Warrant or Right, Issued During Period (in shares)", "documentation": "The number of warrants or rights issued during period." } }}, "auth_ref": {} }}, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": {"http://ayttubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual", "http://ayttubio.com/20241231/role/statement-note-16-warrants-details-textual": {"lang": {"en-us": {"role": {"label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } }}, "auth_ref": {} }}, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": {"http://ayttubio.com/20241231/role/statement-note-12-fair-value-considerations-details-textual", "http://ayttubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual", "http://ayttubio.com/20241231/role/statement-note-16-warrants-details-textual": {"lang": {"en-us": {"role": {"label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } }}, "auth_ref": {"r350"} }}, "us-gaap_ClassOfWarrantOrRightOutstanding": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": {"http://ayttubio.com/20241231/role/statement-note-16-warrants-details-textual", "http://ayttubio.com/20241231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details": {"lang": {"en-us": {"role": {"label": "us-gaap_ClassOfWarrantOrRightOutstanding", "documentation": "Class of Warrant or Right, Outstanding (in shares)", "periodStartLabel": "Outstanding, balance (in shares)", "periodEndLabel": "Outstanding, balance (in shares)", "documentation": "Number of warrants or rights outstanding." } }}, "auth_ref": {} }}, "aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife": {"xbrltype": "durationItemType", "nsuri": "http://ayttubio.com/20241231", "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualLife", "presentation": {"http://ayttubio.com/20241231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details": {"lang": {"en-us": {"role": {"label": "Outstanding, weighted average remaining contractual term (Year)", "documentation": "The weighted average period of remaining contractual life of warrants or rights." } }}, "auth_ref": {} }}, "us-gaap_CommitmentsAndContingencies": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": {"http://ayttubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets": {"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0}, "presentation": {"http://ayttubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets": {"lang": {"en-us": {"role": {"label": "Commitments and contingencies (note 13)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains; arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } }}, "auth_ref": {"r77", "r132", "r518", "r576"} }}, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": {"http://ayttubio.com/20241231/role/statement-note-13-commitments-and-contingencies": {"lang": {"en-us": {"role": {"label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } }}, "auth_ref": {"r113", "r300", "r301", "r627", "r749", "r755"} }}, "us-gaap_CommonStockMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": {"http://ayttubio.com/20241231/role/statement-unaudited-consolidated-statements-of-stockholders-equity": {"lang": {"en-us": {"role": {"label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } }}, "auth_ref": {"r692", "r693", "r694", "r696", "r697", "r698", "r699", "r722", "r723", "r726", "r798", "r858", "r861"} }}, "us-gaap_CommonStockParOrStatedValuePerShare": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": {"http://ayttubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual", "http://ayttubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets-parentheticals": {"lang": {"en-us": {"role": {"label": "Common stock, par value (in dollars per share)", "documentation": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } }}, "auth_ref": {"r00"} }}, "us-gaap_CommonStockSharesAuthorized": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": {"http://ayttubio.com/20241231/role/statement-note-14-stockholders-equity

details-textual": "http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets-parenteticals"}], "lang": {"en-us": {"role": {"label": "Common stock, authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." }}, "auth_ref": {"r80", "r577"}}, "us-gaap-CommonStockSharesIssued": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets-parenteticals"}}, "lang": {"en-us": {"role": {"label": "Common stock, issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." }}, "auth_ref": {"r90"}}, "us-gaap-CommonStockSharesOutstanding": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": {"http://aytubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual"}}, "parentTag": {"us-gaap-StockholdersEquity", "weight": 1.0, "order": 1.0}}, "presentation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets"}}, "lang": {"en-us": {"role": {"label": "Common stock, par value \$0.001; 200,000,000 shares authorized; 6,169,681 and 5,972,638 shares issued and outstanding, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for value of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." }}, "auth_ref": {"r80", "r520", "r685"}}, "aytu-CommonWarrantsExchangedForPrefundedWarrantsMember": {"xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "CommonWarrantsExchangedForPrefundedWarrantsMember", "presentation": {"http://aytubio.com/20241231/role/statement-note-14-stockholders-equity"}, "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20241231/role/statement-note-16-warrants"}, "http://aytubio.com/20241231/role/statement-note-16-warrants-details-textual", "lang": {"en-us": {"role": {"label": "Common Warrants Exchanged for Prefunded Warrants [Member]", "documentation": "Relating to Common Warrants exchanged for Pre-Funded Warrants." }}, "auth_ref": {"aytu-CommonWarrantsMember"}, "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "CommonWarrantsMember", "presentation": {"http://aytubio.com/20241231/role/statement-note-14-stockholders-equity"}, "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20241231/role/statement-note-16-warrants"}, "http://aytubio.com/20241231/role/statement-note-16-warrants-details-textual", "lang": {"en-us": {"role": {"label": "Common Warrants [Member]", "documentation": "Relating to the Common Warrants." }}, "auth_ref": {"us-gaap-ConsolidationPolicyTextBlock"}, "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": {"http://aytubio.com/20241231/role/statement-significant-accounting-policies"}, "lang": {"en-us": {"role": {"label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." }}, "auth_ref": {"r41", "r641"}}, "aytu-ConsumerHealthDivestitureMember": {"xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "ConsumerHealthDivestitureMember", "presentation": {"http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details"}, "lang": {"en-us": {"role": {"label": "Consumer Health Divestiture [Member]", "documentation": "Relating to Consumer Health Divestiture." }}, "auth_ref": {"us-gaap-ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"}, "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "presentation": {"http://aytubio.com/20241231/role/statement-note-3-revenue-details-textual", "lang": {"en-us": {"role": {"label": "us-gaap-ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "terseLabel": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price", "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained." }}, "auth_ref": {"r656"}}, "us-gaap-CostOfGoodsAndServicesSold": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "presentation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations"}, "parentTag": {"us-gaap-GrossProfit", "weight": 1.0, "order": 0.0}}, "presentation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations"}, "lang": {"en-us": {"role": {"label": "Cost of sales", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." }}, "auth_ref": {"r93", "r94", "r507"}}, "us-gaap-CostOfSalesMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": {"http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details"}, "http://aytubio.com/20241231/role/statement-note-6-leases-lease-cost-details"}, "lang": {"en-us": {"role": {"label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." }}, "auth_ref": {"srt-CounterpartyNameAxis"}, "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": {"http://aytubio.com/20241231/role/statement-note-7-intangible-assets"}, "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-details-textual", "lang": {"en-us": {"role": {"label": "Counterparty Name [Axis]", "documentation": "The duration in which the debt will amortize." }}, "auth_ref": {"r186", "r187", "r319", "r339", "r499", "r505", "r514", "r638", "r640"}}, "dei-CurrentFiscalYearEndDate": {"xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": {"http://aytubio.com/20241231/role/statement-document-and-entity-information"}, "lang": {"en-us": {"role": {"label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format -MM-DD." }}, "auth_ref": {"aytu-DebtInstrumentAmortizationPeriod"}, "xbrltype": "durationItemType", "nsuri": "http://aytubio.com/20241231", "localname": "DebtInstrumentAmortizationPeriod", "presentation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textual", "lang": {"en-us": {"role": {"label": "aytu-DebtInstrumentAmortizationPeriod", "terseLabel": "Debt Instrument, Amortization Period (Year)", "documentation": "The duration in which the debt will amortize." }}, "auth_ref": {"us-gaap-DebtInstrumentAxis"}, "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textual"}, "lang": {"en-us": {"role": {"label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." }}, "auth_ref": {"r17", "r70", "r71", "r129", "r131", "r188", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r650", "r651", "r652", "r653", "r654", "r674", "r719", "r750", "r751", "r752", "r806", "r808"}}, "us-gaap-DebtInstrumentBasisSpreadOnVariableRate1": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": {"http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textual"}, "lang": {"en-us": {"role": {"label": "us-gaap-DebtInstrumentBasisSpreadOnVariableRate1", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." }}, "auth_ref": {"us-gaap-DebtInstrumentCarryingAmount"}, "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "presentation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details"}, "parentTag": {"us-gaap-LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0, "order": 1.0}}, "presentation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details"}, "lang": {"en-us": {"role": {"label": "Term loan principal amount", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." }}, "auth_ref": {"r17", "r131", "r332"}}, "us-gaap-DebtInstrumentFaceAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "presentation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textual", "lang": {"en-us": {"role": {"label": "us-gaap-DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." }}, "auth_ref": {"r316", "r475", "r476", "r651", "r652", "r674"}}, "aytu-DebtInstrumentFinalPayment": {"xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231", "localname": "DebtInstrumentFinalPayment", "presentation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textual"}, "lang": {"en-us": {"role": {"label": "aytu-DebtInstrumentFinalPayment", "terseLabel": "Debt Instrument, Final Payment", "documentation": "Represents the final payment of a debt instrument." }}, "auth_ref": {"us-gaap-DebtInstrumentInterestRateEffectivePercentage"}, "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": {"http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textual"}, "lang": {"en-us": {"role": {"label": "us-gaap-DebtInstrumentInterestRateEffectivePercentage", "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." }}, "auth_ref": {"r73", "r334", "r475", "r476", "

```

{"id": "r652", "r652": "r674", "us-gaap": "us-gaap:Depreciation", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [{"http://aytubio.com/20241231/role/statement-note-5-property-and-equipment-details-textual", "lang": {"en-us": {"role": {"label": "us-gaap:Depreciation", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."}}}], "auth_ref": {"r6", "r28"}, "us-gaap": "us-gaap:DepreciationDepletionAndAmortization", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": [{"http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows", "parentTag": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0}], "presentation": [{"http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows", "lang": {"en-us": {"role": {"label": "Depreciation, amortization and accretion", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."}}}], "auth_ref": {"r6", "r227", "r235", "r250", "r645", "r646"}, "us-gaap": "us-gaap:DerivativeGainLossOnDerivativeNet", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "calculation": [{"http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations", "parentTag": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0}], "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows", "parentTag": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0}], "presentation": [{"http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details-parenttheicals", "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows", "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations", "lang": {"en-us": {"role": {"label": "Derivative, Gain (Loss) on Derivative, Net", "negatedLabel": "Derivative warrant liabilities (gain) loss", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."}}}], "auth_ref": {"r796"}], "us-gaap": "us-gaap:DerivativeLiabilitiesNoncurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "calculation": [{"http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets", "parentTag": "us-gaap:LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0}], "presentation": [{"http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details", "http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets", "lang": {"en-us": {"role": {"label": "Derivative warrant liabilities", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both; and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."}}}], "auth_ref": {"r168"}], "us-gaap": "us-gaap:DerivativeLiabilityMeasurementInput", "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityMeasurementInput", "presentation": [{"http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "lang": {"en-us": {"role": {"label": "Derivative liability, measurement input", "documentation": "Value of input used to measure derivative liability."}}}], "auth_ref": {"r449", "r450", "r451"}], "us-gaap": "us-gaap:DevelopedTechnologyRightsMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopedTechnologyRightsMember", "presentation": [{"http://aytubio.com/20241231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "lang": {"en-us": {"role": {"label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."}}}], "auth_ref": {"r123", "r737", "r738", "r739", "r740", "r741", "r743", "r746", "r747"}], "us-gaap": "us-gaap:DilutiveSecurities", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DilutiveSecurities", "crdr": "credit", "calculation": [{"http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "parentTag": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 0.0}], "presentation": [{"http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "lang": {"en-us": {"role": {"label": "Adjustment for change in fair value of warrant liabilities", "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options; restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities."}}}], "auth_ref": {"r23"}], "us-gaap": "us-gaap:DisaggregationOfRevenueTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [{"http://aytubio.com/20241231/role/statement-note-3-revenue-tables", "lang": {"en-us": {"role": {"label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."}}}], "auth_ref": {"r763"}], "us-gaap": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [{"http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans", "lang": {"en-us": {"role": {"label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement."}}}], "auth_ref": {"r372", "r374", "r402", "r403", "r405", "r664"}], "us-gaap": "us-gaap:DisclosureTextBlockAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract", "presentation": [{"http://aytubio.com/20241231/role/statement-note-1-nature-of-business", "http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt", "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations", "http://aytubio.com/20241231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20241231/role/statement-note-16-warrants", "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share", "http://aytubio.com/20241231/role/statement-note-18-license-agreements", "http://aytubio.com/20241231/role/statement-note-19-restructuring-costs", "http://aytubio.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies", "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations", "http://aytubio.com/20241231/role/statement-note-3-revenue", "http://aytubio.com/20241231/role/statement-note-4-inventories", "http://aytubio.com/20241231/role/statement-note-5-property-and-equipment", "http://aytubio.com/20241231/role/statement-note-6-leases", "http://aytubio.com/20241231/role/statement-note-7-intangible-assets", "http://aytubio.com/20241231/role/statement-note-8-accrued-liabilities", "http://aytubio.com/20241231/role/statement-note-9-other-liabilities", "lang": {"en-us": {"role": {"label": "us-gaap:DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements"}}, "auth_ref": {}], "us-gaap": "us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "crdr": "credit", "presentation": [{"http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details", "lang": {"en-us": {"role": {"label": "us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "terseLabel": "Income (loss) from discontinued operations before income taxes", "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."}}}], "auth_ref": {"r51", "r52", "r53", "r54", "r55", "r61", "r92", "r824"}], "us-gaap": "us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax", "crdr": "debit", "presentation": [{"http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details", "lang": {"en-us": {"role": {"label": "us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax", "negatedTerseLabel": "Loss on divestiture", "documentation": "Amount before tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation."}}}], "auth_ref": {"r51", "r53", "r55"}], "us-gaap": "us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "crdr": "debit", "presentation": [{"http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details", "lang": {"en-us": {"role": {"label": "us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "terseLabel": "Income tax expense", "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal."}}}], "auth_ref": {"r52", "r53", "r54", "r55", "r61", "r65", "r411", "r421"}], "us-gaap": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "crdr": "debit", "calculation": [{"http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details", "parentTag": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 2.0}], "presentation": [{"http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details", "lang": {"en-us": {"role": {"label": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "terseLabel": "Accounts receivable, net", "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal
```

"DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "terseLabel": "Inventories", "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r1", "r47", "r63", "r109", "r111" } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense", "crdr": "debit", "presentation": { "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense", "negatedTerseLabel": "Non-operating other expense, net", "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": { "r62" } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "terseLabel": "Other non-current assets", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r1", "r2", "r47", "r63", "r111" } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r1", "r47", "r63", "r109", "r111" } }, "aytu_DisposalGroupIncludingDiscontinuedOperationRecognizedContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231", "localname": "DisposalGroupIncludingDiscontinuedOperationRecognizedContingentConsideration", "crdr": "credit", "presentation": { "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "lang": { "en-us": { "role": { "label": "aytu_DisposalGroupIncludingDiscontinuedOperationRecognizedContingentConsideration", "terseLabel": "Recognized contingent consideration", "documentation": "Amount of recognized contingent consideration attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": { } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "presentation": { "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue", "terseLabel": "Net revenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": { "r62", "r155" } }, "aytu_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231", "localname": "DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense", "crdr": "debit", "presentation": { "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "lang": { "en-us": { "role": { "label": "aytu_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense", "negatedTerseLabel": "Selling and marketing", "documentation": "Amount of selling and marketing expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": { } }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations": { "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": { "r46", "r108" } }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": { "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": { "r661", "r662" } }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": { } }, "dei_DocumentFiscalYearFocus": { "xbrltype": "yearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": { } }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": { } }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": { } }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": { "r705" } }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": { "r706" } }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEG submission type, or the word 'Other'." } } }, "auth_ref": { } }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": { "lang": { "en-us": { "role": { "label": "Net income (loss) per share (note 17)", "auth_ref": { } }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "calculation": { "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": { "lang": { "en-us": { "role": { "label": "Basic - net income (loss) (in dollars per share)", "totalLabel": "Net income (loss) per share (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r175", "r194", "r195", "r196", "r197", "r198", "r199", "r205", "r208", "r220", "r221", "r222", "r226", "r427", "r431", "r445", "r446", "r511", "r529", "r642" } }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": { "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": { "lang": { "en-us": { "role": { "label": "Diluted - net loss (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": { "r175", "r194", "r195", "r196", "r197", "r198", "r199", "r208", "r220", "r221", "r222", "r226", "r427", "r431", "r445", "r446", "r511", "r529", "r642" } }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share": { "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": { "r204", "r223", "r224", "r225" } }, "aytu_EclipseBusinessCapitalLlcLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "EclipseBusinessCapitalLlcLoanAgreementMember", "presentation": { "http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility": { "http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual": { "lang": { "en-us": { "role": { "label": "Eclipse Business Capital LLC Loan Agreement [Member]", "documentation": "Relating to Eclipse Business Capital LLC Loan Agreement." } } }, "auth_ref": { } }, "aytu_EclipseTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "EclipseTermLoanMember", "presentation": { "http://aytubio.com/20241231/role/statement-note-11-longterm-debt": { "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textual": { "lang": { "en-us": { "role": { "label": "Eclipse Term loan [Member]", "documentation": "Represents the Eclipse Term loan." } } }, "auth_ref": { } }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": { "http://aytubio.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": { "r412", "r667" } }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20241231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": { "lang": { "en-us": { "role": { "label": "Accrued employee compensation", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r71" } }, "aytu_EmployeeRetentionCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231", "localname": "EmployeeRetentionCredit", "crdr": "credit", "calculation": { "http://aytubio.com/20241231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": { "parentTag": "us-gaap_OtherLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual": { "http://aytubio.com/20241231/role/statement-note-9-other-liabilities-details-textual": { "http://aytubio.com/20241231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": { "lang": { "en-us": { "role": { "label": "Employee retention credit", "terseLabel": "Employee Retention Credit", "documentation": "Represents the amount of employee retention credit." } } }, "auth_ref": { } }, "aytu_EmployeeRetentionCreditPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aytubio.com/20241231", "localname": "EmployeeRetentionCreditPolicyTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-significant-accounting-policies-policies": { "lang": { "en-us": { "role": { "label": "Employee Retention Credit [Policy Text Block]", "documentation": "Represents the accounting policy for employee retention credits." } } }, "auth_ref": { } }, "aytu_EmployeeRetentionCreditVendorFee": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231", "localname": "EmployeeRetentionCreditVendorFee", "crdr": "debit", "presentation": { "http://aytubio.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual": { "lang": { "en-us": { "role": { "label": "aytu_EmployeeRetentionCreditVendorFee", "terseLabel": "Employee Retention Credit, Vendor Fee", "documentation": "Represents the amount of vendor fee from

```

employee retention credit during the period." } } }, "auth_ref": {} } }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": { "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual", "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r404" } } }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": { "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual", "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": { "r791" } } }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": { "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual", "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": { "r791" } } }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": { "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": {} } }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information", "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": {} } }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information", "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": {} } }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information", "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": {} } }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information", "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": {} } }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information", "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": { "r703" } } }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information", "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": {} } }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information", "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": {} } }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information", "http://aytubio.com/20241231/role/statement-note-1-nature-of-business", "http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-future-principal-payments-details", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-tables", "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations", "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-details-textual", "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details", "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details", "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details-parentheticals", "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-tables", "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "http://aytubio.com/20241231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20241231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity", "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-tables", "http://aytubio.com/20241231/role/statement-note-16-warrants", "http://aytubio.com/20241231/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20241231/role/statement-note-16-warrants-outstanding-details", "http://aytubio.com/20241231/role/statement-note-16-warrants-tables", "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share", "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details", "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-tables", "http://aytubio.com/20241231/role/statement-note-18-license-agreements", "http://aytubio.com/20241231/role/statement-note-19-restructuring-costs", "http://aytubio.com/20241231/role/statement-note-19-restructuring-costs-details-textual", "http://aytubio.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies", "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations", "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details", "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-tables", "http://aytubio.com/20241231/role/statement-note-3-revenue", "http://aytubio.com/20241231/role/statement-note-3-revenue-details-textual", "http://aytubio.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://aytubio.com/20241231/role/statement-note-3-revenue-tables", "http://aytubio.com/20241231/role/statement-note-4-inventories", "http://aytubio.com/20241231/role/statement-note-4-inventories-details-textual", "http://aytubio.com/20241231/role/statement-note-4-inventories-schedule-of-inventories-details", "http://aytubio.com/20241231/role/statement-note-4-inventories-tables", "http://aytubio.com/20241231/role/statement-note-5-property-and-equipment", "http://aytubio.com/20241231/role/statement-note-5-property-and-equipment-details-textual", "http://aytubio.com/20241231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details", "http://aytubio.com/20241231/role/statement-note-5-property-and-equipment-tables", "http://aytubio.com/20241231/role/statement-note-6-leases", "http://aytubio.com/20241231/role/statement-note-6-leases-details-textual", "http://aytubio.com/20241231/role/statement-note-6-leases-lease-balance-sheet-information-details", "http://aytubio.com/20241231/role/statement-note-6-leases
```

"presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": { "r703" } } }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": { "r703" } } }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } } }, "auth_ref": { "r703" } } }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } } }, "auth_ref": { "r703" } } }, "aytu_EquityBasedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Equity-based Warrants [Member]", "documentation": "Represents equity-based warrants." } } } }, "auth_ref": { "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-stockholders-equity": { "lang": { "en-us": { "role": { "label": "Equity Component {Domain}", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } } }, "auth_ref": { "r10", "r152", "r172", "r173", "r174", "r189", "r190", "r191", "r193", "r198", "r200", "r202", "r228", "r258", "r259", "r286", "r351", "r419", "r420", "r424", "r425", "r426", "r428", "r430", "r431", "r437", "r438", "r439", "r440", "r441", "r442", "r444", "r468", "r469", "r470", "r471", "r472", "r473", "r477", "r478", "r498", "r528", "r553", "r554", "r555", "r566", "r615" } } }, "aytu_EquityWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-stockholders-equity": { "lang": { "en-us": { "role": { "label": "Equity Warrants [Member]", "documentation": "Relating to Equity Warrants." } } } }, "auth_ref": { "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-tables": { "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } } }, "auth_ref": { "r449", "r450", "r670" } } }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": { "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details": { "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details": { "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } } }, "auth_ref": { "r324", "r364", "r365", "r366", "r367", "r368", "r369", "r447", "r448", "r449", "r450", "r451", "r459", "r460", "r462", "r500", "r501", "r502", "r651", "r652", "r658", "r659", "r660", "r670" } } }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations": { "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings; (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } } }, "auth_ref": { "r455", "r457", "r458", "r459", "r462", "r463", "r464", "r465", "r466", "r510", "r668", "r671" } } }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": { "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details": { "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } } }, "auth_ref": { "r324", "r364", "r369", "r448", "r460", "r500", "r658", "r659", "r660", "r668" } } }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": { "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details": { "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } } }, "auth_ref": { "r324", "r364", "r369", "r448", "r460", "r501", "r651", "r652", "r658", "r659", "r660", "r668" } } }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": { "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details": { "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details": { "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } } }, "auth_ref": { "r324", "r364", "r365", "r366", "r367", "r368", "r369", "r448", "r449", "r450", "r451", "r460", "r502", "r651", "r652", "r658", "r659", "r660", "r668", "r670" } } }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-tables": { "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } } }, "auth_ref": { "r452", "r456", "r461" } } }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": { "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details": { "lang": { "en-us": { "role": { "label": "Included in earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } } }, "auth_ref": { "r453", "r461" } } }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "crdr": "debit", "presentation": { "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details": { "lang": { "en-us": { "role": { "label": "Settlements (1)", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } } }, "auth_ref": { "r454", "r461" } } }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": { "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details": { "lang": { "en-us": { "role": { "label": "Balance", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } } }, "auth_ref": { "r452", "r461" } } }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": { "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details": { "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details": { "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } } }, "auth_ref": { "r324", "r364", "r365", "r366", "r367", "r368", "r369", "r447", "r448", "r449", "r450", "r451", "r459", "r460", "r462", "r500", "r501", "r502", "r651", "r652", "r658", "r659", "r660", "r668", "r670" } } }, "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList", "presentation": { "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details-parentheticals": { "lang": { "en-us": { "role": { "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)." } } } }, "auth_ref": { "r453", "r461" } } }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-note-6-leases-lease-cost-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-6-leases-lease-cost-details": { "lang": { "en-us": { "role": { "label": "Interest on lease liabilities", "documentation": "Amount of interest expense on finance lease liability." } } } }, "auth_ref": { "r482", "r487", "r676" } } }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": { "http://aytubio.com/20241231/role/statement-note-6-leases-lease-cost-details": { "lang": { "en-us": { "role": { "label": "Operating cash flows from finance leases", "documentation": "Amount of interest paid on finance lease liability." } } } }, "auth_ref": { "r484", "r490" } } }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": { "http://aytubio.com/20241231/role/statement-note-6-leases-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiability", "terseLabel": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } } }, "auth_ref": { "r480", "r493" } } }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": { "http://aytubio.com/20241231/role/statement-note-6-leases-lease-cost-details": { "lang": { "en-us": { "role": { "label": "Financing cash flows from finance leases", "documentation": "Amount of cash outflow for principal payment on finance lease." } } } }, "auth_ref": { "r483", "r490" } } }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-note-6-leases-lease-cost-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 0.0 } } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-6-leases-lease-cost-details": { "lang": { "en-us": { "role": { "label": "Amortization of leased assets", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } } }, "auth_ref": { "r482", "r487", "r676" } } }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": { "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details": { "lang": { "en-us": { "role": { "label": "Financial liabilities, fair value", "documentation": "Fair value of financial obligations, including, but not

limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities." } } }, "auth_ref": { "r799", "r800", "r804" } }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "negatedLabel": "Finite-lived intangible assets, amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": { "r160", "r264", "r280", "r649" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 0.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "lang": { "en-us": { "role": { "label": "Thereafter, future amortization expense", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r744", "r863" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 5.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "lang": { "en-us": { "role": { "label": "2026, future amortization expense", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r282", "r630", "r649" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOffiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOffiscalYear", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 6.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "lang": { "en-us": { "role": { "label": "2025 (remaining 9 months), future amortization expense", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": { "r863" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "lang": { "en-us": { "role": { "label": "2030, future amortization expense", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r282", "r630", "r649" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "lang": { "en-us": { "role": { "label": "2029, future amortization expense", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r282", "r630", "r649" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "lang": { "en-us": { "role": { "label": "2028, future amortization expense", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r282", "r630", "r649" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 4.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "lang": { "en-us": { "role": { "label": "2027, future amortization expense", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r282", "r630", "r649" } }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": { "r274", "r276", "r277", "r278", "r279", "r280", "r283", "r284", "r509", "r630" } }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "lang": { "en-us": { "role": { "label": "Finite-lived intangible assets, gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": { "r264", "r280", "r509", "r649" } }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": { "r274", "r276", "r277", "r278", "r279", "r280", "r283", "r284", "r509", "r630" } }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "lang": { "en-us": { "role": { "label": "Finite-lived intangible assets, net", "totalLabel": "Total future amortization expense", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": { "r508", "r743" } }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "lang": { "en-us": { "role": { "label": "Finite-lived intangible assets, remaining life (Year)", "documentation": "Remaining amortization period of finite-lived intangible assets, in PnYnMnDnFnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r508" } }, "aytu_FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod": { "xbrltype": "durationItemType", "nsuri": "http://aytubio.com/20241231", "localname": "FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod", "presentation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-details-textual", "lang": { "en-us": { "role": { "label": "aytu_FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod", "terseLabel": "Finite-Lived Intangible Asset, Useful Life, Renewable Period (Year)", "documentation": "Represents the renewable period for a finite-lived intangible asset." } } }, "auth_ref": { } }, "aytu_FixedPaymentArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231", "localname": "FixedPaymentArrangements", "crdr": "credit", "calculation": { "http://aytubio.com/20241231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details", "parentTag": "us-gaap_OtherLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-9-other-liabilities-details-textual", "http://aytubio.com/20241231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details", "lang": { "en-us": { "role": { "label": "Fixed payment arrangements", "terseLabel": "Fixed Payment Arrangements", "documentation": "Represents the amount of fixed payment arrangements." } } }, "auth_ref": { } }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": { "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textual", "lang": { "en-us": { "role": { "label": "us-gaap_GainsLossesOnExtinguishmentOfDebt", "terseLabel": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": { "r6", "r31", "r32" } }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations", "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations", "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": { "r97", "r599" } }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": { "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": { "r97" } }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": { "r735", "r736" } }, "aytu_GrandPrairieTexasManufacturingSiteMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "GrandPrairieTexasManufacturingSiteMember", "presentation": { "http://aytubio.com/20241231/role/statement-note-19-restructuring-costs", "http://aytubio.com/20241231/role/statement-note-19-restructuring-costs-details-textual", "lang": { "en-us": { "role": { "label": "Grand Prairie, Texas Manufacturing Site [Member]", "documentation": "Represents the Grand Prairie, Texas manufacturing site." } } }, "auth_ref": { } }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations", "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations", "lang": { "en-us": { "role": { "label": "us-gaap_GrossProfit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": { "r89", "r95", "r139", "r185", "r257", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r467", "r643", "r645", "r728", "r729", "r730", "r731", "r732", "r760" } }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "calculation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations", "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations", "lang": { "en-us": { "role": { "label": "Net income (loss) from continuing operations", "totalLabel": "Net income (loss) from continuing operations", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": { "r40", "r91", "r104", "r194", "r195", "r196", "r197", "r198", "r218", "r222", "r431" } }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": {
"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight":
1.0, "order": 1.0 } }, "presentation": { "http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": { "lang": { "en-us": { "role": { "label":
"us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Income (loss) from continuing operations
before income tax expense", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before
deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": { "r90", "r134", "r139", "r512", "r525", "r643", "r645",
"r728", "r729", "r730", "r731", "r732" } }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
"crdr": "credit", "presentation": { "http://aytbubio.com/20241231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details-parentheticals": { "lang":
{ "en-us": { "role": { "label": "Income (loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount
after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": { "r126", "r139", "r185", "r192", "r198",
"r257", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r427", "r431", "r446", "r467", "r525", "r643", "r728", "r729", "r730", "r731", "r732", "r760" } },
"us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "PerShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromContinuingOperationsPerBasicShare", "calculation": { "http://aytbubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-
share-details": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://aytbubio.com/20241231/role/statement-note-17-
earnings-per-share-schedule-of-earnings-per-share-details", "http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": { "lang": { "en-us": { "role": { "label": "Basic - continuing operations (in dollars per share)", "documentation": "The amount of net income (loss) from continuing operations per each share of
common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r91", "r135", "r175", "r192", "r194", "r195", "r196", "r197", "r198", "r208", "r220", "r221",
"r427", "r431", "r446", "r511", "r825" } }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "PerShareItem", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": { "http://aytbubio.com/20241231/role/statement-note-17-earnings-per-
share-schedule-of-earnings-per-share-details", "http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": { "lang": { "en-us": { "role": { "label": "Diluted - continuing operations (in dollars per share)", "documentation": "The amount of net income (loss) derived from continuing operations during the period
available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the
issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": { "r91", "r175", "r192",
"r194", "r195", "r196", "r197", "r198", "r208", "r220", "r221", "r222", "r431", "r446", "r511", "r825" } }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": {
"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } },
"presentation": { "http://aytbubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details",
"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": { "lang": { "en-us": { "role": { "label": "Net income (loss) from discontinued
operations, net of tax", "terseLabel": "Net income (loss) from discontinued operations, net of tax", "documentation": "Amount after tax of income (loss) from a discontinued
operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain
(loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref":
{ "r51", "r52", "r53", "r54", "r55", "r65", "r155", "r423", "r526" } }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "crdr": "credit",
"calculation": { "http://aytbubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0, "order": 0.0 } }, "presentation": { "http://aytbubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "lang": {
"en-us": { "role": { "label": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "terseLabel": "Net income (loss) from discontinued
operations, net of tax", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the
income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and
adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": { "r51", "r52", "r53", "r54", "r55", "r61", "r65", "r126" } }, "us-
gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "xbrltype": "PerShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "calculation": { "http://aytbubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-
earnings-per-share-details": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://aytbubio.com/20241231/role/statement-
note-17-earnings-per-share-schedule-of-earnings-per-share-details", "http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": { "lang":
{ "en-us": { "role": { "label": "Basic - discontinued operations, net of tax (in dollars per share)", "documentation": "Per basic share amount, after tax, of income (loss) from the
day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": { "r92", "r175", "r213", "r220",
"r221", "r820", "r825" } }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "xbrltype": "PerShareItem", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "presentation": { "http://aytbubio.com/20241231/role/statement-note-17-
earnings-per-share-schedule-of-earnings-per-share-details", "http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": { "lang": { "en-
us": { "role": { "label": "Diluted - discontinued operations, net of tax (in dollars per share)", "documentation": "Per diluted share amount, after tax, of income (loss) from the
day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": { "r127", "r213", "r220", "r221" }
} }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "presentation": {
"http://aytbubio.com/20241231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details-parentheticals": { "lang": { "en-us": { "role": { "label":
"Income Statement Abstract" } } }, "auth_ref": {} }, "us-
gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
"presentation": { "http://aytbubio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "lang": { "en-us": { "role": { "label":
"Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": { "r661", "r662" } }, "us-
gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": {
"http://aytbubio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "http://aytbubio.com/20241231/role/statement-note-6-leases-
lease-cost-details": { "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in income
where disaggregated amount has been reported." } } }, "auth_ref": { "r287", "r289", "r293", "r453", "r456", "r461", "r550", "r552", "r600", "r630", "r669", "r829" } }, "us-
gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain",
"presentation": { "http://aytbubio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details",
"http://aytbubio.com/20241231/role/statement-note-6-leases-lease-cost-details": { "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance {Domain}",
"documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": { "r289", "r293", "r453", "r456", "r461", "r550", "r552",
"r600", "r630", "r669", "r829" } }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag":
"us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://aytbubio.com/20241231/role/statement-note-2-summary-
of-significant-accounting-policies-details-textual", "http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": { "lang": { "en-us": { "role": { "label":
"us-gaap_IncomeTaxExpenseBenefit", "terseLabel": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax benefit (expense)", "documentation": "Amount of
current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": { "r142", "r150", "r201", "r202", "r227",
"r238", "r250", "r411", "r412", "r421", "r530", "r667" } }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeTaxPolicyTextBlock", "presentation": { "http://aytbubio.com/20241231/role/statement-significant-accounting-policies-policies": { "lang": { "en-us": { "role":
{ "label": "Income Tax, Policy {Policy Text Block}", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for
recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit
carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial
statements." } } }, "auth_ref": { "r171", "r409", "r410", "r413", "r414", "r415", "r418", "r562" } }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": { "http://aytbubio.com/20241231/role/statement-unaudited-consolidated-
statements-of-cash-flows": { "lang": { "en-us": { "role": { "label": "Cash paid for income taxes", "documentation": "Amount, after refund, of cash paid to foreign, federal, state,
and local jurisdictions as income tax." } } }, "auth_ref": { "r22", "r181", "r416", "r417" } }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://aytbubio.com/20241231/role/statement-
unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": { "lang": { "en-us": { "role": { "label": "us-
gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount
of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } },
"auth_ref": { "r51" } }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag":
"us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://aytbubio.com/20241231/role/statement-
unaudited-consolidated-statements-of-cash-flows": { "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts
receivable, net", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit
sale of goods and services." } } }, "auth_ref": { "r51" } }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://aytbubio.com/20241231/role/statement-unaudited-consolidated-
statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": {
"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": { "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
"documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying
transactions that are classified as operating activities." } } }, "auth_ref": { "r51" } }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": { "http://aytbubio.com/20241231/role/statement-
unaudited-consolidated-statements-of-cash-flows": { "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities." } } }, "auth_ref": {} },
"aytu_IncreaseDecreaseInOperatingCapitalAttributableToDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://aytbubio.com/20241231", "localname":
"IncreaseDecreaseInOperatingCapitalAttributableToDiscontinuedOperations", "crdr": "credit", "calculation": { "http://aytbubio.com/20241231/role/statement-unaudited-
consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": {
"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": { "lang": { "en-us": { "role": { "label":
"aytu_IncreaseDecreaseInOperatingCapitalAttributableToDiscontinuedOperations", "negatedLabel": "Changes in operating assets and liabilities from discontinued
operations", "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities of discontinued operations." } } },
"auth_ref": {} }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-
flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": {
"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": { "lang": { "en-us": { "role": { "label": "us-

gaap_IncreaseDecreaseInOtherOperatingCapitalNet", "negatedLabel": "Other operating assets and liabilities, net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": { "r5" } }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://aytbio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://aytbio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": { "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": { "r5" } } }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "calculation": { "http://aytbio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://aytbio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "lang": { "en-us": { "role": { "label": "Dilutive effect of warrants to purchase common stock (in shares)", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method." } } }, "auth_ref": { "r209", "r210", "r211", "r222" } } }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://aytbio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": -1.0, "order": 0.0 } }, "presentation": { "http://aytbio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "lang": { "en-us": { "role": { "label": "Dilutive effect of unvested restricted stock and restricted stock units (in shares)", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": { "r209", "r210", "r212", "r222", "r373" } } }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "auth_ref": { "r707" } }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://aytbio.com/20241231/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://aytbio.com/20241231/role/statement-unaudited-consolidated-balance-sheets": { "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpenseDebt", "terseLabel": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": { "r98", "r329", "r335", "r653", "r654" } } }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://aytbio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://aytbio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": { "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpenseNonoperating", "negatedLabel": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": { "r234", "r715" } } }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": { "http://aytbio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": { "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": { "r177", "r179", "r180" } } }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": { "http://aytbio.com/20241231/role/statement-note-4-inventories": { "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": { "r260" } } }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://aytbio.com/20241231/role/statement-note-4-inventories-schedule-of-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": -1.0, "order": 0.0 } }, "presentation": { "http://aytbio.com/20241231/role/statement-note-4-inventories-schedule-of-inventories-details": { "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": { "r107", "r635" } } }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://aytbio.com/20241231/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": -1.0, "order": 2.0 } }, "http://aytbio.com/20241231/role/statement-note-4-inventories-schedule-of-inventories-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://aytbio.com/20241231/role/statement-note-4-inventories-schedule-of-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://aytbio.com/20241231/role/statement-note-4-inventories-schedule-of-inventories-details": { "lang": { "en-us": { "role": { "label": "Inventories", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": { "r165", "r633", "r685" } } }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://aytbio.com/20241231/role/statement-note-4-inventories-schedule-of-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://aytbio.com/20241231/role/statement-note-4-inventories-schedule-of-inventories-details": { "lang": { "en-us": { "role": { "label": "Raw materials", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": { "r107", "r637" } } }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://aytbio.com/20241231/role/statement-note-4-inventories-schedule-of-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://aytbio.com/20241231/role/statement-note-4-inventories-schedule-of-inventories-details": { "lang": { "en-us": { "role": { "label": "Work in process", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": { "r107", "r636" } } }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://aytbio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": { "http://aytbio.com/20241231/role/statement-note-4-inventories-details-textual": { "http://aytbio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": { "lang": { "en-us": { "role": { "label": "Inventory write-down", "terseLabel": "Inventory Write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": { "r261" } } }, "aytu_June2023WarrantsTrancheAMember": { "xbrltype": "domainItemType", "nsuri": "http://aytbio.com/20241231", "localname": "June2023WarrantsTrancheAMember", "presentation": { "http://aytbio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details": { "lang": { "en-us": { "role": { "label": "June 2023 Warrants Tranche A [Member]", "documentation": "Represents the June 2023 Warrants Tranche A." } } }, "auth_ref": { } } }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": { "http://aytbio.com/20241231/role/statement-note-6-leases": { "http://aytbio.com/20241231/role/statement-note-6-leases-details-textual": { "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": { "r495", "r713" } } }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": { "http://aytbio.com/20241231/role/statement-note-6-leases": { "http://aytbio.com/20241231/role/statement-note-6-leases-details-textual": { "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": { "r495", "r713" } } }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://aytbio.com/20241231/role/statement-note-6-leases-lease-cost-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://aytbio.com/20241231/role/statement-note-6-leases-lease-cost-details": { "lang": { "en-us": { "role": { "label": "us-gaap_LeaseCost", "totalLabel": "Total lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": { "r486", "r676" } } }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": { "http://aytbio.com/20241231/role/statement-note-6-leases-tables": { "lang": { "en-us": { "role": { "label": "Lease Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": { "r809" } } }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": { "http://aytbio.com/20241231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": { "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": { "r110", "r494" } } }, "aytu_LeasesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aytbio.com/20241231", "localname": "LeasesDisclosureTextBlock", "presentation": { "http://aytbio.com/20241231/role/statement-note-6-leases": { "lang": { "en-us": { "role": { "label": "Leases Disclosure [Text Block]", "documentation": "The entire disclosure for leases." } } }, "auth_ref": { } }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": { "http://aytbio.com/20241231/role/statement-note-4-and-entity-information", "http://aytbio.com/20241231/role/statement-note-1-nature-of-business", "http://aytbio.com/20241231/role/statement-note-10-revolving-credit-facility", "http://aytbio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual", "http://aytbio.com/20241231/role/statement-note-11-longterm-debt", "http://aytbio.com/20241231/role/statement-note-11-longterm-debt-details-textual", "http://aytbio.com/20241231/role/statement-note-11-longterm-debt-future-principal-payments-details", "http://aytbio.com/20241231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details", "http://aytbio.com/20241231/role/statement-note-11-longterm-debt-tables", "http://aytbio.com/20241231/role/statement-note-12-fair-value-considerations", "http://aytbio.com/20241231/role/statement-note-12-fair-value-considerations-details-textual", "http://aytbio.com/20241231/role/statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details", "http://aytbio.com/20241231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details", "http://aytbio.com/20241231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details-parentheticals", "http://aytbio.com/20241231/role/statement-note-12-fair-value-considerations-tables", "http://aytbio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "http://aytbio.com/20241231/role/statement-note-13-commitments-and-contingencies", "http://aytbio.com/20241231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytbio.com/20241231/role/statement-note-14-stockholders-equity", "http://aytbio.com/20241231/role/statement-note-14-stockholders-equity-details-textual", "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans", "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details", "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-tables", "http://aytbio.com/20241231/role/statement-note-16-warrants", "http://aytbio.com/20241231/role/statement-note-16-warrants-details-textual", "http://aytbio.com/20241231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details", "http://aytbio.com/20241231/role/statement-note-16-warrants-tables", "http://aytbio.com/20241231/role/statement-note-17-earnings-per-share", "http://aytbio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details", "http://aytbio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "http://aytbio.com/20241231/role/statement-note-17-earnings-per-share-tables", "http://aytbio.com/20241231/role/statement-note-18-license-agreements", "http://aytbio.com/20241231/role/statement-note-19-restructuring-costs", "http://aytbio.com/20241231/role/statement-note-19-restructuring-costs-details-textual", "http://aytbio.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies", "http://aytbio.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://aytbio.com/20241231/role/statement-note-20-discontinued-operations", "http://aytbio.com/20241231/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details", "http://aytbio.com/20241231/role/statement-note-20-discontinued-operations-tables",

```
"http://aytubio.com/20241231/role/statement-note-3-revenue", "http://aytubio.com/20241231/role/statement-note-3-revenue-details-textual",  
"http://aytubio.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://aytubio.com/20241231/role/statement-note-3-revenue-tables",  
"http://aytubio.com/20241231/role/statement-note-4-inventories", "http://aytubio.com/20241231/role/statement-note-4-inventories-details-textual",  
"http://aytubio.com/20241231/role/statement-note-4-inventories-schedule-of-inventories-details", "http://aytubio.com/20241231/role/statement-note-4-inventories-tables",  
"http://aytubio.com/20241231/role/statement-note-5-property-and-equipment", "http://aytubio.com/20241231/role/statement-note-5-property-and-equipment-details-textual",  
"http://aytubio.com/20241231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details", "http://aytubio.com/20241231/role/statement-note-5-property-and-equipment-tables",  
"http://aytubio.com/20241231/role/statement-note-6-leases", "http://aytubio.com/20241231/role/statement-note-6-leases-details-textual",  
"http://aytubio.com/20241231/role/statement-note-6-leases-lease-balance-sheet-information-details", "http://aytubio.com/20241231/role/statement-note-6-leases-lease-balance-sheet-information-details-parenteticals", "http://aytubio.com/20241231/role/statement-note-6-leases-lease-cost-details",  
"http://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "http://aytubio.com/20241231/role/statement-note-6-leases-tables",  
"http://aytubio.com/20241231/role/statement-note-7-intangible-assets", "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-details-textual",  
"http://aytubio.com/20241231/role/statement-note-7-intangible-assets-future-amortization-expense-details", "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-tables", "http://aytubio.com/20241231/role/statement-note-8-accrued-liabilities", "http://aytubio.com/20241231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details",  
"http://aytubio.com/20241231/role/statement-note-8-accrued-liabilities-tables", "http://aytubio.com/20241231/role/statement-note-9-other-liabilities",  
"http://aytubio.com/20241231/role/statement-note-9-other-liabilities-details-textual", "http://aytubio.com/20241231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details", "http://aytubio.com/20241231/role/statement-note-9-other-liabilities-tables", "http://aytubio.com/20241231/role/statement-significant-accounting-policies",  
"http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets", "http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets-parenteticals", "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statement-of-cash-flows", "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations",  
{"xbrlType": "label", "textBlockItem": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." }, {"authRef": "r1"}, {"xbrlType": "TextBlockItem", "textBlockItem": "nsuri", "http://aytubio.com/20241231/", "localName": "LesseeLiabilityMaturityTableTextBlock", "presentation": "http://aytubio.com/20241231/role/statement-note-6-leases-tables", "lang": "en-us", "role": "label", "LesseeLiabilityMaturityTableTextBlock", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to lease liability recognized in statement of financial position.", "authRef": "r1"}, {"us-gaap-LesseeOperatingLeaseDiscountRate": {"xbrlType": "percentage", "nsuri": "http://fasb.org/us-gaap/2024/", "localName": "LesseeOperatingLeaseDiscountRate", "presentation": "http://aytubio.com/20241231/role/statement-note-6-leases-details-textual", "lang": "en-us", "role": "label", "us-gaap-LesseeOperatingLeaseDiscountRate", "terseLabel": "Lessee Operating Lease Discount Rate", "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "authRef": "r675"}, {"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {"xbrlType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024/", "localName": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": "http://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "parentTag": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced", "weight": 1.0, "order": 0.0 }, "presentation": "http://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "lang": "en-us", "role": "label", "Thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "authRef": "r493"}, {"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {"xbrlType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024/", "localName": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": "http://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "parentTag": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced", "weight": 1.0, "order": 5.0 }, "presentation": "http://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "lang": "en-us", "role": "label", "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "authRef": "r493"}, {"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {"xbrlType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024/", "localName": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": "http://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "parentTag": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced", "weight": 1.0, "order": 1.0 }, "presentation": "http://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "lang": "en-us", "role": "label", "2030", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "authRef": "r493"}, {"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {"xbrlType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024/", "localName": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": "http://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "parentTag": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced", "weight": 1.0, "order": 2.0 }, "presentation": "http://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "lang": "en-us", "role": "label", "2029", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "authRef": "r493"}, {"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {"xbrlType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024/", "localName": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": "http://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "parentTag": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced", "weight": 1.0, "order": 3.0 }, "presentation": "http://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "lang": "en-us", "role": "label", "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "authRef": "r493"}, {"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {"xbrlType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024/", "localName": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": "http://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "parentTag": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced", "weight": 1.0, "order": 4.0 }, "presentation": "http://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "lang": "en-us", "role": "label", "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "authRef": "r493"}, {"us-gaap-LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {"xbrlType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024/", "localName": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": "http://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "parentTag": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced", "weight": 1.0, "order": 6.0 }, "presentation": "http://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "lang": "en-us", "role": "label", "2025 (remaining 6 months)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "authRef": "r810"}, {"aytu_LesseeOperatingLeaseLiabilityTenantImprovementAllowance": {"xbrlType": "monetaryItem", "nsuri": "http://aytubio.com/20241231/", "localName": "LesseeOperatingLeaseLiabilityTenantImprovementAllowance", "crdr": "credit", "presentation": "http://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "lang": "en-us", "role": "label", "verboselabel": "Less: tenant improvement allowance", "label": "aytu_LesseeOperatingLeaseLiabilityTenantImprovementAllowance", "documentation": "The amount of tenant improvement allowance for operating lease liability of lessee." }, {"authRef": "r1"}, {"aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced": {"xbrlType": "monetaryItem", "nsuri": "http://aytubio.com/20241231/", "localName": "LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced", "crdr": "debit", "calculation": "http://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": "http://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "lang": "en-us", "role": "label", "Total Lease Payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease, including lease not yet commenced." }, {"authRef": "r1"}, {"us-gaap-LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {"xbrlType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024/", "localName": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": "http://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "lang": "en-us", "role": "label", "us-gaap-LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negated
```

"auth_ref": {"r1", "r47", "r63", "r109", "r111", "r154", "r155"}}, "aytu_LiabilityPrefundedWarrantsMember": {"xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231/", "localname": "LiabilityPrefundedWarrantsMember", "presentation": {"http://aytubio.com/20241231/role/statement-note-16-warrants", "http://aytubio.com/20241231/role/statement-note-16-warrants-details-textual"}, "lang": {"en-us": {"role": {"label": "Liability Prefunded Warrants [Member]", "documentation": "Represents information pertaining to pre-funded warrants classified as liabilities."}}}, "auth_ref": {}, "aytu_LiabilityWarrantsMember": {"xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231/", "localname": "LiabilityWarrantsMember", "presentation": {"http://aytubio.com/20241231/role/statement-note-16-warrants", "http://aytubio.com/20241231/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details"}, "lang": {"en-us": {"role": {"label": "Liability Warrants [Member]", "documentation": "Represents liability warrants."}}}, "auth_ref": {}, "aytu_LicensingAgreementsTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://aytubio.com/20241231/", "localname": "LicensingAgreementsTextBlock", "presentation": {"http://aytubio.com/20241231/role/statement-note-18-license-agreements"}, "lang": {"en-us": {"role": {"label": "Licensing Agreements [Text Block]", "documentation": "The entire disclosure for licensing agreements."}}}, "auth_ref": {}, "us-gaap_LineOfCredit": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "LineOfCredit", "crdr": "credit", "presentation": {"http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual"}, "lang": {"en-us": {"role": {"label": "us-gaap_LineOfCredit", "terseLabel": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long-term obligation to refinance the short-term obligation on a long-term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long-term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."}}}, "auth_ref": {"r17", "r131", "r822"}}, "us-gaap_LineOfCreditFacilityAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "LineOfCreditFacilityAxis", "presentation": {"http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual"}, "lang": {"en-us": {"role": {"label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."}}}, "auth_ref": {"r69", "r74", "r719", "r758", "r759"}}, "us-gaap_LineOfCreditFacilityLenderDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "LineOfCreditFacilityLenderDomain", "presentation": {"http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual"}, "lang": {"en-us": {"role": {"label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."}}}, "auth_ref": {"r69", "r74", "r719", "r758"}}, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": {"http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual"}, "lang": {"en-us": {"role": {"label": "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."}}}, "auth_ref": {"r69", "r74"}}, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": {"http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual"}, "lang": {"en-us": {"role": {"label": "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity", "terseLabel": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."}}, "auth_ref": {"r69", "r74", "r306"}}, "aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment": {"xbrltype": "percentItemType", "nsuri": "http://aytubio.com/20241231/", "localname": "LineOfCreditFacilityTerminationFeePercentageOfCommitment", "presentation": {"http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual"}, "lang": {"en-us": {"role": {"label": "aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment", "terseLabel": "Line of Credit Facility, Termination, Fee, Percentage of Commitment", "documentation": "Represents the percentage of commitment used as a termination fee of a line of credit facility."}}}, "auth_ref": {}, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": {"http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual"}, "lang": {"en-us": {"role": {"label": "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "terseLabel": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility."}}}, "auth_ref": {}, "us-gaap_LoanProcessingFee": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "LoanProcessingFee", "crdr": "debit", "presentation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textual"}, "lang": {"en-us": {"role": {"label": "us-gaap_LoanProcessingFee", "terseLabel": "Loan Processing Fee", "documentation": "Expenses paid for obtaining loans which includes expenses such as application and origination fees."}}}, "auth_ref": {"dei_LocalPhoneNumber": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024/", "localname": "LocalPhoneNumber", "presentation": {"http://aytubio.com/20241231/role/statement-document-and-entity-information"}, "lang": {"en-us": {"role": {"label": "Local Phone Number", "documentation": "Local phone number for entity."}}}, "auth_ref": {}, "us-gaap_LongTermDebtAndCapitalLeaseObligations": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "presentation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details"}, "lang": {"en-us": {"role": {"label": "Total debt, net of current portion", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent."}}}, "auth_ref": {"r17", "r517"}}, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "crdr": "credit", "presentation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details"}, "lang": {"en-us": {"role": {"label": "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent", "negatedLabel": "Less: current portion of debt", "documentation": "Amount of long-term debt and lease obligation, classified as current."}}}, "auth_ref": {"r73"}}, "aytu_LongTermDebtAndCapitalLeaseObligationsGross": {"xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231/", "localname": "LongTermDebtAndCapitalLeaseObligationsGross", "crdr": "credit", "calculation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-future-principal-payments-details": {"parentTag": null, "weight": null, "order": null, "root": true}}, "presentation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-future-principal-payments-details"}, "lang": {"en-us": {"role": {"label": "Total future principal payments", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt and capital lease obligations."}}}, "auth_ref": {}, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "crdr": "credit", "calculation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details": {"parentTag": null, "weight": null, "order": null, "root": true}}, "presentation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details"}, "lang": {"en-us": {"role": {"label": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "totalLabel": "Total debt", "documentation": "Amount of long-term debt and lease obligation, including portion classified as current."}}}, "auth_ref": {}, "us-gaap_LongTermDebtCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets": {"parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0}}, "presentation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-future-principal-payments-details": {"parentTag": "aytu_LongTermDebtAndCapitalLeaseObligationsGross", "weight": 1.0, "order": 3.0}}, "presentation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-future-principal-payments-details"}, "lang": {"en-us": {"role": {"label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-future-principal-payments-details": {"parentTag": "aytu_LongTermDebtAndCapitalLeaseObligationsGross", "weight": 1.0, "order": 1.0}}, "presentation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-future-principal-payments-details"}, "lang": {"en-us": {"role": {"label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "terseLabel": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."}}, "auth_ref": {"r8", "r188", "r327"}}, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "presentation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textual"}, "lang": {"en-us": {"role": {"label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "terseLabel": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."}}, "auth_ref": {"r8", "r188", "r327"}}, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-future-principal-payments-details": {"parentTag": "aytu_LongTermDebtAndCapitalLeaseObligationsGross", "weight": 1.0, "order": 2.0}}, "presentation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-future-principal-payments-details"}, "lang": {"en-us": {"role": {"label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-future-principal-payments-details": {"parentTag": "aytu_LongTermDebtAndCapitalLeaseObligationsGross", "weight": 1.0, "order": 0.0}}, "presentation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-future-principal-payments-details"}, "lang": {"en-us": {"role": {"label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOffiscalYear": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOffiscalYear", "crdr": "credit", "calculation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets": {"parentTag": "aytu_LongTermDebtAndCapitalLeaseObligationsGross", "weight": 1.0, "order": 0.0}}, "presentation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-future-principal-payments-details"}, "lang": {"en-us": {"role": {"label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOffiscalYear", "terseLabel": "2025 (remaining 6 months)", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year."}}}, "auth_ref": {"r721"}}, "us-gaap_LongTermDebtNoncurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets": {"parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0}}, "presentation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-future-principal-payments-details"}, "lang": {"en-us": {"role": {"label": "Debt, net of current portion", "terseLabel": "Total debt, net of current portion", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."}}}, "auth_ref": {"r164}}}, "us-gaap_LongTermDebtTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "LongTermDebtTextBlock", "presentation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt"}, "lang": {"en-us": {"role": {"label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt."}}}, "auth_ref": {"r114"}}, "us-gaap_LongTermDebtTypeAxis": {"xbrltype": "stringItemType",

```

"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [{"http://aytbubio.com/20241231/role/statement-note-10-revolving-credit-facility", "http://aytbubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual"}, {"http://aytbubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual", "lang": {"en-us": {"role": {"label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt."}}}], "auth_ref": [{"r17", "r30", "r750", "r751", "r752"}], "us-gaap-LongtermDebtTypeDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [{"http://aytbubio.com/20241231/role/statement-note-10-revolving-credit-facility", "http://aytbubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual"}, {"http://aytbubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual", "lang": {"en-us": {"role": {"label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."}}}], "auth_ref": [{"r17", "r30", "r750", "r751", "r752"}], "aytu-ManufacturingEquipmentMember": {"xbrltype": "domainItemType", "nsuri": "http://aytbubio.com/20241231", "localname": "ManufacturingEquipmentMember", "presentation": [{"http://aytbubio.com/20241231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details"}, {"http://aytbubio.com/20241231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details", "lang": {"en-us": {"role": {"label": "Manufacturing Equipment [Member]", "documentation": "Represents manufacturing equipment."}}}], "auth_ref": [], "srt_MaximumMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [{"http://aytbubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details"}, {"http://aytbubio.com/20241231/role/statement-note-13-commitments-and-contingencies"}, {"http://aytbubio.com/20241231/role/statement-note-13-commitments-and-contingencies-details-textual"}, {"http://aytbubio.com/20241231/role/statement-note-15-equity-incentive-plans"}, {"http://aytbubio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual"}, {"http://aytbubio.com/20241231/role/statement-note-16-warrants"}, {"http://aytbubio.com/20241231/role/statement-note-16-warrants-details-textual"}, {"http://aytbubio.com/20241231/role/statement-note-7-intangible-assets"}, {"http://aytbubio.com/20241231/role/statement-note-7-intangible-assets-details-textual"}, {"http://aytbubio.com/20241231/role/statement-note-7-intangible-assets-details-textual", "lang": {"en-us": {"role": {"label": "Maximum [Member]", "documentation": "Maximum value of asset and liability."}}}], "auth_ref": [{"r302", "r303", "r304", "r305", "r370", "r407", "r451", "r506", "r549", "r551", "r558", "r568", "r569", "r620", "r621", "r622", "r623", "r624", "r628", "r629", "r647", "r655", "r663", "r670", "r671", "r672", "r687", "r762", "r813", "r814", "r815", "r816", "r817", "r818"}], "us-gaap-MeasurementInputExpectedDividendRateMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [{"http://aytbubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details"}, {"http://aytbubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "lang": {"en-us": {"role": {"label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."}}}], "auth_ref": [{"r801", "r802", "r803"}], "us-gaap-MeasurementInputExpectedTermMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": [{"http://aytbubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details"}, {"http://aytbubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "lang": {"en-us": {"role": {"label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."}}}], "auth_ref": [{"r801", "r802", "r803"}], "us-gaap-MeasurementInputPriceVolatilityMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [{"http://aytbubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details"}, {"http://aytbubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "lang": {"en-us": {"role": {"label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."}}}], "auth_ref": [{"r670", "r801", "r802", "r803"}], "us-gaap-MeasurementInputRiskFreeInterestRateMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [{"http://aytbubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details"}, {"http://aytbubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "lang": {"en-us": {"role": {"label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."}}}], "auth_ref": [{"r801", "r802", "r803"}], "us-gaap-MeasurementInputSharePriceMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputSharePriceMember", "presentation": [{"http://aytbubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details"}, {"http://aytbubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "lang": {"en-us": {"role": {"label": "Measurement Input, Share Price [Member]", "documentation": "Measurement input using share price of saleable stock."}}}], "auth_ref": [{"r801", "r802", "r803"}], "us-gaap-MeasurementInputTypeAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": [{"http://aytbubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details"}, {"http://aytbubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "lang": {"en-us": {"role": {"label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability."}}}], "auth_ref": [{"r449", "r450", "r451", "r670"}], "us-gaap-MeasurementInputTypeDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": [{"http://aytbubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details"}, {"http://aytbubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "lang": {"en-us": {"role": {"label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability."}}}], "auth_ref": [{"r449", "r450", "r451", "r670"}], "srt_MinimumMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [{"http://aytbubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details"}, {"http://aytbubio.com/20241231/role/statement-note-15-equity-incentive-plans"}, {"http://aytbubio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual"}, {"http://aytbubio.com/20241231/role/statement-note-16-warrants"}, {"http://aytbubio.com/20241231/role/statement-note-16-warrants-details-textual"}, {"http://aytbubio.com/20241231/role/statement-note-7-intangible-assets"}, {"http://aytbubio.com/20241231/role/statement-note-7-intangible-assets-details-textual"}, {"http://aytbubio.com/20241231/role/statement-note-7-intangible-assets-details-textual", "lang": {"en-us": {"role": {"label": "Minimum [Member]", "documentation": "Minimum value of asset and liability."}}}], "auth_ref": [{"r302", "r303", "r304", "r305", "r370", "r407", "r451", "r506", "r549", "r551", "r558", "r568", "r569", "r620", "r621", "r622", "r623", "r624", "r628", "r629", "r647", "r655", "r663", "r670", "r671", "r672", "r687", "r762", "r813", "r814", "r815", "r816", "r817", "r818"}], "ecd-MtrlTermsOfFrddArrTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfFrddArrTextBlock", "presentation": [{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}, {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": {"en-us": {"role": {"label": "Material Terms of Trading Arrangement [Text Block]", "documentation": "Material terms of trading arrangement."}}}], "auth_ref": [{"r708"}], "aytu-Neos2015PlanMember": {"xbrltype": "domainItemType", "nsuri": "http://aytbubio.com/20241231", "localname": "Neos2015PlanMember", "presentation": [{"http://aytbubio.com/20241231/role/statement-note-15-equity-incentive-plans"}, {"http://aytbubio.com/20241231/role/statement-note-15-equity-incentive-plans", "lang": {"en-us": {"role": {"label": "Neos 2015 Plan [Member]", "documentation": "Represents Neos 2015 plan."}}}], "auth_ref": [], "us-gaap-NetCashProvidedByUsedInFinancingActivities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": [{"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows"}, {"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows", "lang": {"en-us": {"role": {"label": "Cash flows from financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."}}}], "auth_ref": [{"r178}], "us-gaap-NetCashProvidedByUsedInFinancingActivitiesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [{"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows"}, {"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows", "lang": {"en-us": {"role": {"label": "Cash flows from financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."}}}], "auth_ref": [{"r178}], "us-gaap-NetCashProvidedByUsedInInvestingActivities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
```

"localname": "NonRule10b51ArrTrmtdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "ecd-NonRule10b51ArrTrmtdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "auth_ref": { "r708" } } } }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows", "lang": { "en-us": { "role": { "label": "Non-cash investing and financing activities", "auth_ref": {} }, "us-gaap_NonmonetaryTransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonmonetaryTransactionTypeAxis", "presentation": { "http://aytubio.com/20241231/role/statement-note-16-warrants", "documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange.", "auth_ref": { "r496", "r497", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684" } }, "us-gaap_NonmonetaryTransactionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonmonetaryTransactionTypeDomain", "presentation": { "http://aytubio.com/20241231/role/statement-note-16-warrants", "documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange.", "auth_ref": { "r496", "r497", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684" } }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-tables", "lang": { "en-us": { "role": { "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "auth_ref": { "r15" } }, "aytu_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual", "auth_ref": {} }, "aytu_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]", "auth_ref": {} }, "aytu_OfficeEquipmentFurnitureAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "OfficeEquipmentFurnitureAndOtherMember", "presentation": { "http://aytubio.com/20241231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details", "lang": { "en-us": { "role": { "label": "Office Equipment, Furniture and Other [Member]", "documentation": "Represents office equipment, furniture and other.", "auth_ref": {} }, "aytu_OfficeSpaceInBerwynPennsylvaniaMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "OfficeSpaceInBerwynPennsylvaniaMember", "presentation": { "http://aytubio.com/20241231/role/statement-note-6-leases", "documentation": "Relating to an office space in Berwyn, Pennsylvania.", "auth_ref": {} }, "aytu_OnOrBeforeJanuary262023Member": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "OnOrBeforeJanuary262023Member", "presentation": { "http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility", "documentation": "Relating to on or before January 26, 2023.", "auth_ref": {} }, "aytu_OnOrBeforeJune122025Member": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "OnOrBeforeJune122025Member", "presentation": { "http://aytubio.com/20241231/role/statement-note-11-longterm-debt", "documentation": "Termination is on or before the date of June 12 2025.", "auth_ref": {} }, "us-gaap_OperatingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenseMember", "presentation": { "http://aytubio.com/20241231/role/statement-note-6-leases-lease-cost-details", "lang": { "en-us": { "role": { "label": "Operating Expense [Member]", "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.", "auth_ref": { "r14" } }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations", "lang": { "en-us": { "role": { "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "auth_ref": {} }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations", "lang": { "en-us": { "role": { "label": "Operating expenses", "auth_ref": {} }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations", "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "(Loss) income from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "auth_ref": { "r139", "r643", "r728", "r729", "r730", "r731", "r732" } }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-note-6-leases-lease-cost-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-6-leases-lease-cost-details", "lang": { "en-us": { "role": { "label": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "auth_ref": { "r488", "r676" } }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://aytubio.com/20241231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": { "parentTag": "us-gaap_OtherLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-6-leases-lease-balance-sheet-information-details", "http://aytubio.com/20241231/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "http://aytubio.com/20241231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details", "lang": { "en-us": { "role": { "verboseLabel": "Total lease liabilities", "label": "us-gaap_OperatingLeaseLiability", "terseLabel": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "auth_ref": { "r480" } }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": { "http://aytubio.com/20241231/role/statement-note-6-leases-lease-balance-sheet-information-details", "lang": { "en-us": { "role": { "label": "Operating lease liability current, classified as current.", "auth_ref": { "r480" } }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOffFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrentStatementOffFinancialPositionExtensibleList", "presentation": { "http://aytubio.com/20241231/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals", "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "auth_ref": { "r481" } }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": { "http://aytubio.com/20241231/role/statement-note-6-leases-lease-balance-sheet-information-details", "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseLiabilityNoncurrent", "terseLabel": "Non-current: operating leases", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "auth_ref": { "r480" } }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOffFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrentStatementOffFinancialPositionExtensibleList", "presentation": { "http://aytubio.com/20241231/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals", "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "auth_ref": { "r481" } }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": { "http://aytubio.com/20241231/role/statement-note-6-leases-lease-cost-details", "lang": { "en-us": { "role": { "label": "Operating cash flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "auth_ref": { "r485", "r490" } }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-6-leases-details-textual", "http://aytubio.com/20241231/role/statement-note-6-leases-lease-balance-sheet-information-details", "http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets", "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets", "terseLabel": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "auth_ref": { "r479" } }, "aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231", "localname": "OperatingLeaseUndiscountedMinimumMonthlyPayment", "crdr": "credit", "presentation": { "http://aytubio.com/20241231/role/statement-note-6-leases-details-textual", "lang": { "en-us": { "role": { "label": "aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment", "terseLabel": "Operating Lease, Undiscounted Minimum Monthly Payment", "documentation": "Represents the undiscounted minimum monthly payment on an operating lease.", "auth_ref": {} }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": { "http://aytubio.com/20241231/role/statement-note-6-leases-lease-cost-details", "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent", "terseLabel": "Operating Lease right-of-use assets", "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "auth_ref": { "r492", "r676" } }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm", "presentation": { "http://aytubio.com/20241231/role/statement-note-6-leases-lease-cost-details", "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets (Year)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "auth_ref": { "r491", "r676" } }, "us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffFinancialStatementsDisclosureTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-1-nature-of-business", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "auth_ref": { "r45", "r125", "r559", "r560" } }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20241231/role/statement-note-8-acrued-liabilities-schedule-of-acrued-liabilities-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-note-8-acrued-liabilities-schedule-of-acrued-liabilities-details", "lang": { "en-us": { "role": { "label": "Other accrued liabilities", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "auth_ref": { "r71" } }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets", "lang": { "en-us": { "role": { "label": "us-gaap_OtherAssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of current assets classified as other.", "auth_ref": { "r167", "r685" } }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets", "lang": { "en-us": { "role": { "label": "Other non-current assets", "documentation": "Amount of noncurrent assets classified as other.", "auth_ref": { "r161" } }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesMember", "presentation": { "http://aytubio.com/20241231/role/statement-note-9-other-liabilities", "http://aytubio.com/20241231/role/statement-note-9-other-liabilities-details-textual", "lang": { "en-us": { "role": { "label": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities.", "auth_ref": {} }, "us-gaap_OtherExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherExpenseMember",

```
presentation": {"http://aytubio.com/20241231/role/statement-note-6-leases-lease-cost-details": {"lang": {"en-us": {"role": {"label": "Other Expense [Member]", "documentation": "Primary financial statement caption encompassing other expense." } } }, "auth_ref": {"r14": {"us-gaap-OtherLiabilities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilities", "crdr": "credit", "calculation": {"http://aytubio.com/20241231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": {"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {"http://aytubio.com/20241231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": {"lang": {"en-us": {"role": {"label": "us-gaap-OtherLiabilities", "totalLabel": "Total other liabilities", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": {"r130": {"r516": {"r572": {"r573": {"r701": {"r823": {"r859": { "us-gaap-OtherLiabilitiesCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets": {"parentTag": "us-gaap-LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": {"http://aytubio.com/20241231/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals": {"http://aytubio.com/20241231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets": {"lang": {"en-us": {"role": {"label": "Other Liabilities, Current", "negatedLabel": "Less: current portion of other liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": {"r71": {"r685": { "us-gaap-OtherLiabilitiesDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": {"http://aytubio.com/20241231/role/statement-note-9-other-liabilities": {"lang": {"en-us": {"role": {"label": "Other Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for other liabilities." } } }, "auth_ref": {"r71": {"r76": {"r748": { "us-gaap-OtherLiabilitiesNoncurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets": {"parentTag": "us-gaap-LiabilitiesNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": {"http://aytubio.com/20241231/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals": {"http://aytubio.com/20241231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets": {"lang": {"en-us": {"role": {"label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": {"r76": { "us-gaap-OtherLiabilitiesTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesTableTextBlock", "presentation": {"http://aytubio.com/20241231/role/statement-note-9-other-liabilities-tables": {"lang": {"en-us": {"role": {"label": "Other Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other liabilities." } } }, "auth_ref": { "us-gaap-OtherNoncashIncomeExpense": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"lang": {"en-us": {"role": {"label": "us-gaap-OtherNoncashIncomeExpense", "negatedLabel": "Other non-cash adjustments", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": {"r104": { "aytu-OtherNoncashInvestingAndFinancingItems": {"xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"lang": {"en-us": {"role": {"label": "Other non-cash investing and financing activities", "documentation": "Represents the amount of other noncash investing and financing items." } } }, "auth_ref": { "us-gaap-OtherNoncurrentLiabilitiesMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": {"http://aytubio.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies": {"http://aytubio.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual": {"http://aytubio.com/20241231/role/statement-note-9-other-liabilities": {"http://aytubio.com/20241231/role/statement-note-9-other-liabilities-details-textual": {"lang": {"en-us": {"role": {"label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": { "us-gaap-OtherNonoperatingIncomeExpense": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": {"parentTag": "us-gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": {"lang": {"en-us": {"role": {"label": "Other income, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": {"r99": { "us-gaap-OtherSundryLiabilities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherSundryLiabilities", "crdr": "credit", "calculation": {"http://aytubio.com/20241231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": {"parentTag": "us-gaap-OtherLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": {"http://aytubio.com/20241231/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": {"lang": {"en-us": {"role": {"label": "us-gaap-OtherSundryLiabilities", "terseLabel": "Other", "documentation": "The aggregate carrying amount, as of the balance sheets date, of obligations not otherwise itemized or categorized in the footnotes to the financial statements." } } }, "auth_ref": {"r71": {"r76": {"r130": { "aytu-OtherWarrantsMember": {"xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details": {"lang": {"en-us": {"role": {"label": "Other Warrants [Member]", "documentation": "Relating to other warrants." } } }, "auth_ref": { "aytu-OutsideEquityIncentivePlanMember": {"xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans": {"http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual": {"lang": {"en-us": {"role": {"label": "Outside Equity Incentive Plan [Member]", "documentation": "Relating to outside the equity incentive plan." } } }, "auth_ref": { "us-gaap-PaymentOffFinancingAndStockIssuanceCosts": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentOffFinancingAndStockIssuanceCosts", "crdr": "credit", "presentation": {"http://aytubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual": {"http://aytubio.com/20241231/role/statement-note-16-warrants-details-textual": {"lang": {"en-us": {"role": {"label": "us-gaap-PaymentOffFinancingAndStockissuanceCosts", "terseLabel": "Payment of Financing and Stock Issuance Costs", "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities." } } }, "auth_ref": {"r20": { "us-gaap-PaymentsForProceedsFromOtherInvestingActivities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"parentTag": "us-gaap-NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"lang": {"en-us": {"role": {"label": "us-gaap-PaymentsForProceedsFromOtherInvestingActivities", "negatedLabel": "Other investing activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": {"r712": {"r716": { "aytu-PaymentsOffixedPaymentArrangements": {"xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"lang": {"en-us": {"role": {"label": "aytu-PaymentsOffixedPaymentArrangements", "negatedLabel": "Payment made to fixed payment arrangements", "documentation": "The cash outflow for fixed payments arrangements." } } }, "auth_ref": { "us-gaap-PaymentsOfStockIssuanceCosts": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": {"http://aytubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual": {"http://aytubio.com/20241231/role/statement-note-16-warrants-details-textual": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"lang": {"en-us": {"role": {"label": "us-gaap-PaymentsOfStockissuanceCosts", "terseLabel": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of stock issuance costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": {"r20": { "us-gaap-PaymentsToAcquireProductiveAssets": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "calculation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"parentTag": "us-gaap-NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"lang": {"en-us": {"role": {"label": "us-gaap-PaymentsToAcquireProductiveAssets", "negatedLabel": "Cash payments for fixed asset purchases", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": {"r141": {"r793": {"r794": {"r795": { "us-gaap-PlanNameAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": {"http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans": {"http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual": {"lang": {"en-us": {"role": {"label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": {"r765": {"r766": {"r767": {"r768": {"r769": {"r770": {"r771": {"r772": {"r773": {"r774
```

"label": "Pre-Funded Warrants [Member]", "documentation": "Relating to the Pre-Funded Warrants.", "auth_ref": {}, "us-gaap_PrepaidExpenseCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": {}}, "http://aytbubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets": {"parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 1.0}}, "presentation": {"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets": {"en-us": {"role": {"label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."}}, "auth_ref": {"r166", "r262", "r263", "r634"}}, "us-gaap_PrimeRateMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrimeRateMember", "presentation": {"http://aytbubio.com/20241231/role/statement-note-11-longterm-debt": {"http://aytbubio.com/20241231/role/statement-note-11-longterm-debt-details-textual": {"en-us": {"role": {"label": "Prime Rate [Member]", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers."}}, "auth_ref": {}, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": {"http://aytbubio.com/20241231/role/statement-significant-accounting-policies": {"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0}}, "presentation": {"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"en-us": {"role": {"label": "Proceeds from issuance of stock and warrants", "documentation": "The cash inflow from the additional capital contribution to the entity from shares and warrants."}}, "auth_ref": {}, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": {"http://aytbubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual": {"http://aytbubio.com/20241231/role/statement-note-16-warrants-details-textual": {"en-us": {"role": {"label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity", "terseLabel": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."}}, "auth_ref": {"r33", "r563"}}, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "crdr": "debit", "calculation": {"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0}}, "presentation": {"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"en-us": {"role": {"label": "Net proceeds received from (payments made on) revolving credit facility", "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets)."}, "auth_ref": {}, "us-gaap_ProceedsFromSaleOfProductiveAssets": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "calculation": {"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0}}, "presentation": {"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"en-us": {"role": {"label": "Cash received from sales of fixed assets", "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets."}}, "auth_ref": {"r100"}}, "us-gaap_ProceedsFromWarrantExercises": {"xbrltype": "monetaryItemType", "nsuri": "http://aytbubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual": {"http://aytbubio.com/20241231/role/statement-note-16-warrants-details-textual": {"en-us": {"role": {"label": "us-gaap_ProceedsFromWarrantExercises", "terseLabel": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."}}, "auth_ref": {"r717"}}, "us-gaap_ProductAndServiceOtherMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductAndServiceOtherMember", "presentation": {"http://aytbubio.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details": {"en-us": {"role": {"label": "Product and Service, Other [Member]", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other."}}, "auth_ref": {"r764"}}, "srt_ProductOrServiceAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": {"http://aytbubio.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details": {"en-us": {"role": {"label": "Product and Service [Axis]", "auth_ref": {"r253", "r507", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r631", "r657", "r686", "r687", "r688", "r690", "r691", "r756", "r757", "r763", "r826", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857"}}, "srt_ProductsAndServicesDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": {"http://aytbubio.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details": {"en-us": {"role": {"label": "Product and Service [Domain]", "auth_ref": {"r253", "r507", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r631", "r657", "r686", "r687", "r688", "r690", "r691", "r756", "r757", "r763", "r826", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857"}}, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": {"http://aytbubio.com/20241231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": {"en-us": {"role": {"label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."}}, "auth_ref": {"r77", "r494"}}, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": {"http://aytbubio.com/20241231/role/statement-note-5-property-and-equipment": {"en-us": {"role": {"label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."}}, "auth_ref": {"r108", "r145", "r148", "r149"}}, "us-gaap_PropertyPlantAndEquipmentGross": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": {"http://aytbubio.com/20241231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": {"parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0}}, "presentation": {"http://aytbubio.com/20241231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": {"en-us": {"role": {"label": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."}}, "auth_ref": {"r110", "r158", "r524"}}, "us-gaap_PropertyPlantAndEquipmentNet": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": {"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets": {"parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 4.0}}, "http://aytbubio.com/20241231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-schedule-of-property-and-equipment-details": {"parentTag": null, "weight": null, "order": null, "root": true}}, "presentation": {"http://aytbubio.com/20241231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-net": {"totalLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."}}, "auth_ref": {"r77", "r494", "r513", "r524", "r685"}}, "us-gaap_PropertyPlantAndEquipmentTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": {"http://aytbubio.com/20241231/role/statement-note-5-property-and-equipment-tables": {"en-us": {"role": {"label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation."}}, "auth_ref": {"r77"}}, "us-gaap_PropertyPlantAndEquipmentTypeDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": {"http://aytbubio.com/20241231/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": {"en-us": {"role": {"label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."}}, "auth_ref": {"r110", "r494"}}, "srt_RangeAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": {"http://aytbubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details": {"http://aytbubio.com/20241231/role/statement-note-13-commitments-and-contingencies": {"http://aytbubio.com/20241231/role/statement-note-15-equity-incentive-plans": {"http://aytbubio.com/20241231/role/statement-note-16-warrants": {"http://aytbubio.com/20241231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details": {"http://aytbubio.com/20241231/role/statement-note-7-intangible-assets": {"http://aytbubio.com/20241231/role/statement-note-7-intangible-assets-details-textual": {"en-us": {"role": {"label": "Statistical Measurement [Axis]", "auth_ref": {"r302", "r303", "r304", "r305", "r363", "r370", "r397", "r398", "r399", "r407", "r451", "r503", "r504", "r506", "r549", "r551", "r558", "r568", "r569", "r620", "r621", "r622", "r623", "r624", "r628", "r629", "r647", "r655", "r663", "r670", "r671", "r672", "r673", "r687", "r694", "r753", "r762", "r802", "r814", "r815", "r816", "r817", "r818"}}, "srt_RangeMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": {"http://aytbubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details": {"http://aytbubio.com/20241231/role/statement-note-13-commitments-and-contingencies": {"http://aytbubio.com/20241231/role/statement-note-15-equity-incentive-plans": {"http://aytbubio.com/20241231/role/statement-note-16-warrants": {"http://aytbubio.com/20241231/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details": {"http://aytbubio.com/20241231/role/statement-note-7-intangible-assets": {"http://aytbubio.com/20241231/role/statement-note-7-intangible-assets-details-textual": {"en-us": {"role": {"label": "Statistical Measurement [Domain]", "auth_ref": {"r302", "r303", "r304", "r305", "r363", "r370", "r397", "r398", "r399", "r407", "r451", "r503", "r504", "r506", "r549", "r551", "r558", "r568", "r569", "r620", "r621", "r622", "r623", "r624", "r628", "r629", "r647", "r655", "r663", "r670", "r671", "r672", "r673", "r687", "r694", "r753", "r762", "r802", "r814", "r815", "r816", "r817", "r818"}}, "us-gaap_RepaymentsOfLongTermDebt": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": {"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0}}, "presentation": {"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": {"en-us": {"role": {"label": "us-gaap_RepaymentsOfLongTermDebt", "negatedLabel": "Payments made to borrowings", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."}}, "auth_ref": {"r101", "r564"}}, "srt_RepurchaseAgreementCounterpartyNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": {"http://aytbubio.com/20241231/role/statement-note-7-intangible-assets": {"http://aytbubio.com/20241231/role/statement-note-7-intangible-assets-details-textual": {"en-us": {"role": {"label": "Counterparty Name [Domain]", "auth_ref": {"r186", "r187", "r319", "r339", "r499", "r505", "r514", "r639", "r640"}}, "us-gaap_ResearchAndDevelopmentExpense": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": {"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of operations": {"parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0}}, "presentation": {"http://aytbubio.com/20241231/role/statement-unaudited-consolidated-statements-of operations": {"en-us": {"role": {"label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."}}, "auth_ref": {"r408", "r630", "r645", "r819"}}, "us-gaap_ResearchAndDevelopmentExpenseMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": {"http://aytbubio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details": {"en-us": {"role": {"label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported

facts about research and development expense have been included." } } } , "auth_ref": {} } , "aytu_RestrictedStockAndRestrictedStockUnitsRsusMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231/", "localname": "RestrictedStockAndRestrictedStockUnitsRsusMember", "presentation": {} } , "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual" } , "lang": { "en-us": { "role": { "label": "Restricted Stock and Restricted Stock Units (RSUs) [Member]", "documentation": "Share instruments in which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } } , "auth_ref": {} } , "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "RestrictedStockMember", "presentation": { "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity", "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details" } } , "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } } , "auth_ref": { "r24" } } , "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "RestrictedStockUnitsRSUMember", "presentation": {} } , "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details" } , "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } } , "auth_ref": {} } , "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-19-restructuring-costs", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } } , "auth_ref": { "r290", "r291", "r292", "r295", "r299" } } , "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } } , "presentation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations" } , "lang": { "en-us": { "role": { "label": "Restructuring costs", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } } , "auth_ref": { "r6", "r296", "r297", "r754" } } , "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "RestructuringPlanAxis", "presentation": { "http://aytubio.com/20241231/role/statement-note-19-restructuring-costs", "http://aytubio.com/20241231/role/statement-note-19-restructuring-costs-details-textual" } , "lang": { "en-us": { "role": { "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } } , "auth_ref": {} } , "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "RestructuringPlanDomain", "presentation": { "http://aytubio.com/20241231/role/statement-note-19-restructuring-costs", "http://aytubio.com/20241231/role/statement-note-19-restructuring-costs-details-textual" } , "lang": { "en-us": { "role": { "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } } , "auth_ref": {} } , "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets" } , "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } } , "auth_ref": { "r82", "r118", "r521", "r556", "r557", "r565", "r578", "r685" } } , "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "RetainedEarningsMember", "presentation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-stockholders-equity", "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } } , "auth_ref": { "r152", "r189", "r190", "r191", "r193", "r198", "r200", "r202", "r258", "r259", "r286", "r419", "r420", "r424", "r425", "r426", "r428", "r430", "r431", "r437", "r439", "r440", "r442", "r444", "r477", "r478", "r553", "r555", "r566", "r861" } } } , "aytu_ReturnReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231/", "localname": "ReturnReserveCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20241231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } } , "presentation": { "http://aytubio.com/20241231/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" } , "lang": { "en-us": { "role": { "label": "Return reserve", "documentation": "Represents the amount of return reserve classified as current." } } } , "auth_ref": {} } , "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://aytubio.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations" } , "lang": { "en-us": { "role": { "verboseLabel": "Revenue", "label": "Net revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } } , "auth_ref": { "r137", "r138", "r227", "r231", "r232", "r245", "r250", "r253", "r254", "r255", "r360", "r361", "r507" } } , "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-3-revenue", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } } , "auth_ref": { "r151", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r362" } } } , "aytu_ReverseStockSplitMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231/", "localname": "ReverseStockSplitMember", "presentation": { "http://aytubio.com/20241231/role/statement-note-16-warrants", "http://aytubio.com/20241231/role/statement-note-16-warrants-details-textual" } , "lang": { "en-us": { "role": { "label": "Reverse Stock Split [Member]", "documentation": "The conversion of a reverse stock split where there is a reduction in the shares outstanding." } } } , "auth_ref": {} } , "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024/", "localname": "Rule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" } , "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]", "auth_ref": { "r708" } } } , "ecd_Rule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024/", "localname": "Rule10b51ArrTrmtdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" } , "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmtdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } } , "auth_ref": { "r708" } } } , "aytu_RxSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231/", "localname": "RxSegmentMember", "presentation": { "http://aytubio.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details" } , "lang": { "en-us": { "role": { "label": "Rx Segment [Member]", "documentation": "Relating to the Rx Segment." } } } , "auth_ref": {} } } , "aytu_SaleOfStockMaximumAmountOfEquityIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231/", "localname": "SaleOfStockMaximumAmountOfEquityIssuable", "crdr": "credit", "presentation": { "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual" } , "lang": { "en-us": { "role": { "label": "aytu_SaleOfStockMaximumAmountOfEquityIssuable", "terseLabel": "Sale of Stock, Maximum Amount of Equity Issuable", "documentation": "Represents the maximum monetary amount of equity issuable." } } } , "auth_ref": {} } , "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": { "http://aytubio.com/20241231/role/statement-note-11-longterm-debt", "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20241231/role/statement-note-16-warrants", "http://aytubio.com/20241231/role/statement-note-16-warrants-details-textual" } , "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } } , "auth_ref": {} } , "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "SaleOfStockPricePerShare", "presentation": { "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual" } , "lang": { "en-us": { "role": { "label": "us-gaap_SaleOfStockPricePerShare", "terseLabel": "Sale of Stock, Price Per Share (in dollars per share)", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } } , "auth_ref": {} } , "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024/", "localname": "ScenarioUnspecifiedDomain", "presentation": { "http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textual" } , "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } } , "auth_ref": { "r203", "r371", "r710", "r725" } } } , "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-8-accrued-liabilities-tables" } , "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } } , "auth_ref": {} } , "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-tables" } , "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } } , "auth_ref": { "r24" } } , "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-tables" } , "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } } , "auth_ref": { "r38" } } , "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-tables" } , "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } } , "auth_ref": { "r17", "r33", "r34", "r44", "r116", "r117", "r651", "r653", "r721", "r806" } } , "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-tables" } , "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } } , "auth_ref": { "r9", "r13", "r18", "r47", "r56", "r57", "r58", "r59", "r60", "r64", "r66", "r67", "r112" } } , "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-tables" } , "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } } , "auth_ref": { "r727" } } } , "us-

gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-tables": { "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fail, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."} } }, "auth_ref": { "r799", "r800" } }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-tables": { "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": { "r649", "r742" } }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-4-inventories-tables": { "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": { "r19", "r86", "r87", "r88" } }, "aytu_ScheduleOfLeaseByBalanceSheetInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aytubio.com/20241231", "localname": "ScheduleOfLeaseByBalanceSheetInformationTableTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-6-leases-tables": { "lang": { "en-us": { "role": { "label": "Schedule of Lease by Balance Sheet Information [Table Text Block]", "documentation": "Tabular disclosure of leases by balance sheet information." } } }, "auth_ref": { "11", "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-tables": { "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": { "r8" } }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-tables": { "lang": { "en-us": { "role": { "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": { "r121" } }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-tables": { "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": { "r11", "r12", "r120" } }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-16-warrants-tables": { "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": { "r35" } }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": { "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-tables": { "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": { "r649", "r744" } }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtMember", "presentation": { "http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual": { "lang": { "en-us": { "role": { "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": { "11", "us-gaap_SecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": { "http://aytubio.com/20241231/role/statement-note-11-longterm-debt": { "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textual": { "lang": { "en-us": { "role": { "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral." } } }, "auth_ref": { "r797" } }, "aytu_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "SecuritiesPurchaseAgreementMember", "presentation": { "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity": { "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual": { "http://aytubio.com/20241231/role/statement-note-16-warrants": { "http://aytubio.com/20241231/role/statement-note-16-warrants-details-textual": { "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement [Member]", "documentation": "Relating to the Securities Purchase Agreement." } } }, "auth_ref": { "11", "aytu_SecuritiesPurchaseAgreementWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "SecuritiesPurchaseAgreementWarrantsMember", "presentation": { "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity": { "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual": { "http://aytubio.com/20241231/role/statement-note-16-warrants": { "http://aytubio.com/20241231/role/statement-note-16-warrants-details-textual": { "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement Warrants [Member]", "documentation": "Relating to the Securities Purchase Agreement Warrants." } } }, "auth_ref": { "11", "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": { "r702" } }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://aytubio.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": { "r704" } }, "us-gaap_SegmentContinuingOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentContinuingOperationsMember", "presentation": { "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "lang": { "en-us": { "role": { "label": "Continuing Operations [Member]", "documentation": "Component of an entity expected to operate in the foreseeable future." } } }, "auth_ref": { "11", "us-gaap_SegmentDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDiscontinuedOperationsMember", "presentation": { "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "lang": { "en-us": { "role": { "label": "Discontinued Operations [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, classified as held-for-sale or disposed of by sale or by means other than sale, and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale." } } }, "auth_ref": { "r4", "r48", "r49", "r50" } }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": { "http://aytubio.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details": { "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": { "r137", "r138", "r139", "r140", "r227", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r255", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r285", "r294", "r298", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r644", "r645", "r646", "r648", "r689", "r826", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857" } }, "us-gaap_SegmentOperatingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentOperatingActivitiesDomain", "presentation": { "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "lang": { "en-us": { "role": { "label": "Operating Activities [Domain]", "documentation": "Operations of an entity including continuing and discontinued operations." } } }, "auth_ref": { "11", "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations": { "lang": { "en-us": { "role": { "label": "Selling and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": { "11", "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": { "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details": { "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": { "r97" } }, "us-gaap_SettlementLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SettlementLiabilitiesCurrent", "crdr": "credit", "presentation": { "http://aytubio.com/20241231/role/statement-note-9-other-liabilities-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap_SettlementLiabilitiesCurrent", "terseLabel": "Settlement Liabilities, Current", "documentation": "Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers." } } }, "auth_ref": { "11", "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": { "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-cash-flows": { "lang": { "en-us": { "role": { "verboselabel": "Stock-based compensation expense", "label": "us-gaap_ShareBasedCompensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": { "r5" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": { "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDnInHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": { "r664" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": { "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details": { "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedLabel": "Forfeited, shares (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": { "r391" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": { "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details": { "lang": { "en-us": { "role": { "label": "Forfeited, weighted average grant date fair value (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit)

option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } } , "auth_ref": { "r391" } } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": { "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details" }, "lang": { "en-us": { "role": { "label": "Granted, shares (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } } , "auth_ref": { "r389" } } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details" }, "lang": { "en-us": { "role": { "label": "Granted, weighted average grant date fair value (in dollars per share)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } } , "auth_ref": { "r389" } } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": { "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" }, "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)", "periodStartLabel": "Unvested, shares (in shares)", "periodEndLabel": "Unvested, shares (in shares)", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } } , "auth_ref": { "r386", "r387" } } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": { "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" }, "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value (in dollars per share)", "periodStartLabel": "Unvested, weighted average grant date fair value (in dollars per share)", "periodEndLabel": "Unvested, weighted average grant date fair value (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } } , "auth_ref": { "r386", "r387" } } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": { "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" }, "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Vested, shares (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } } , "auth_ref": { "r390" } } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" }, "lang": { "en-us": { "role": { "label": "Vested, weighted average grant date fair value (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } } , "auth_ref": { "r390" } } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": { "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual" }, "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } } , "auth_ref": { } } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": { "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual" }, "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } } , "auth_ref": { "r666" } } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": { "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual" }, "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } } , "auth_ref": { "r36" } } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": { "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details" }, "lang": { "en-us": { "role": { "label": "Exercisable, options (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } } , "auth_ref": { "r380" } } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": { "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details" }, "lang": { "en-us": { "role": { "label": "Exercisable, options, weighted average exercise price (in dollars per share)", "documentation": "The weighted average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } } , "auth_ref": { "r380" } } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": { "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details" }, "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Forfeited/Cancelled, options (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } } , "auth_ref": { "r384" } } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": { "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details", "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details" }, "lang": { "en-us": { "role": { "label": "Granted, options (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } } , "auth_ref": { "r382" } } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": { "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details", "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details" }, "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)", "periodStartLabel": "Outstanding, options (in shares)", "periodEndLabel": "Outstanding, options (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } } , "auth_ref": { "r378", "r379" } } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": { "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details", "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details" }, "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Outstanding, options, weighted average exercise price (in dollars per share)", "periodEndLabel": "Outstanding, options, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } } , "auth_ref": { "r378", "r379" } } } , "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain", "presentation": { "http://aytbio.com/20241231/role/statement-note-14-stockholders-equity", "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details" }, "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } } , "auth_ref": { "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400" } } } , "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": { "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details" }, "lang": { "en-us": { "role": { "label": "Forfeited/Cancelled, options, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } } , "auth_ref": { "r384" } } } , "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": { "http://aytbio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytbio.com/20241231/role/statement-note-15-equity-

```

incentive-plans-stock-option-activity-details"]}, {"lang": {"en-us": {"role": {"label": "Granted, options, weighted average exercise price (in dollars per share)", "terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)"}, "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } }}, {"auth_ref": {"r382"}}, {"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": {"http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual"}, {"lang": {"en-us": {"role": {"label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDnFnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } }}, {"auth_ref": {"r665"}}, {"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": {"http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"}, {"lang": {"en-us": {"role": {"label": "Exercisable, options, weighted average remaining contractual life (Year)", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDnFnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } }}, {"auth_ref": {"r36"}}, {"aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": {"xbrltype": "durationItemType", "nsuri": "http://aytubio.com/20241231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm", "presentation": {"http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"}, {"lang": {"en-us": {"role": {"label": "Granted, options, weighted average remaining contractual life (Year)", "documentation": "Weighted average remaining contractual term for option awards granted during the period, in 'PnYnMnDnFnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } }}, {"auth_ref": {}}, {"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": {"http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"}, {"lang": {"en-us": {"role": {"label": "Outstanding, options, weighted average remaining contractual life (Year)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDnFnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } }}, {"auth_ref": {"r122"}}, {"us-gaap_SharesIssuedPricePerShare": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": {"http://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textual"}, {"lang": {"en-us": {"role": {"label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share (in dollars per share)", "documentation": "Per share or per unit amount of equity securities issued." } }}, {"auth_ref": {}}, {"us-gaap_SharesOutstanding": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-stockholders-equity"}, {"lang": {"en-us": {"role": {"label": "us-gaap_SharesOutstanding", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } }}, {"auth_ref": {}}, {"us-gaap_ShortTermBorrowings": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets"}, {"parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, {"presentation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-balance-sheets"}, {"lang": {"en-us": {"role": {"label": "Revolving credit facility", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } }}, {"auth_ref": {"r68", "r129", "r685", "r821"}}, {"us-gaap_ShortTermDebtTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTextBlock", "presentation": {"http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility"}, {"lang": {"en-us": {"role": {"label": "Short-Term Debt [Text Block]", "documentation": "The entire disclosure for short-term debt." } }}, {"auth_ref": {"r114"}}, {"us-gaap_ShortTermLeaseCost": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": {"http://aytubio.com/20241231/role/statement-note-6-leases-lease-cost-details"}, {"parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 }, {"presentation": {"http://aytubio.com/20241231/role/statement-note-6-leases-lease-cost-details"}, {"lang": {"en-us": {"role": {"label": "Short-term lease cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } }}, {"auth_ref": {"r489", "r676"}}, {"us-gaap_SignificantAccountingPoliciesTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": {"http://aytubio.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies"}, {"lang": {"en-us": {"role": {"label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } }}, {"auth_ref": {"r105", "r183"}}, {"us-gaap_StatementBusinessSegmentsAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": {"http://aytubio.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details"}, {"lang": {"en-us": {"role": {"label": "Segments [Axis]", "documentation": "Information by business segments." } }}, {"auth_ref": {"r137", "r138", "r139", "r140", "r153", "r227", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r255", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r285", "r288", "r294", "r298", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r644", "r645", "r646", "r648", "r689", "r826", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857"}}, {"us-gaap_StatementEquityComponentsAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": {"http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-stockholders-equity"}, {"lang": {"en-us": {"role": {"label": "Equity Components [Axis]", "documentation": "Information by component of equity." } }}, {"auth_ref": {"r10", "r80", "r83", "r84", "r152", "r172", "r173", "r174", "r189", "r190", "r191", "r193", "r198", "r200", "r202", "r228", "r258", "r259", "r286", "r351", "r419", "r420", "r424", "r425", "r426", "r428", "r430", "r431", "r437", "r438", "r439", "r440", "r441", "r442", "r444", "r468", "r469", "r470", "r474", "r472", "r473", "r477", "r478", "r498", "r528", "r553", "r554", "r555", "r566", "r615"}}, {"us-gaap_StatementLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": {"http://aytubio.com/20241231/role/statement-note-1-nature-of-business", "http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20241231/role/statement-note-10-revolving-credit-facility-details-textual", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-future-principal-payments-details", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt-tables", "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations", "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-details-textual", "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details", "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-summary-of-level-3-changes-details-parentheticals", "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-tables", "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-valuation-assumptions-details", "http://aytubio.com/20241231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20241231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity", "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-stock-option-activity-details", "http://aytubio.com/202
```

[illegible]

Investment Agreement, Maximum Yearly Make-whole Payment, "documentation": "The maximum amount of make-whole payment per year under supply and distribution agreement." } } }, "auth_ref": [] }, "aytu_SupplyAndDistributionAgreementMinimumSalesPerYear": { "xbrltype": "decimalItemType", "nsuri": "http://aytubio.com/20241231", "localname": "SupplyAndDistributionAgreementMinimumSalesPerYear", "presentation": ["http://aytubio.com/20241231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20241231/role/statement-note-9-other-liabilities-details-textual"], "lang": { "en-us": { "role": { "label": "aytu_SupplyAndDistributionAgreementMinimumSalesPerYear", "terseLabel": "Supply and Distribution Agreement, Minimum Sales Per Year", "documentation": "The minimum amount of units to be sold per year under supply and distribution agreement." } } }, "auth_ref": [] }, "aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20241231", "localname": "SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit", "crdr": "credit", "presentation": ["http://aytubio.com/20241231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20241231/role/statement-note-9-other-liabilities-details-textual"], "lang": { "en-us": { "role": { "label": "aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit", "terseLabel": "Supply and Distribution Agreement, Royalty Make Whole Payment Under Annual Minimum Sales Commitment, Per Unit", "documentation": "The amount of royalty make-whole payment per unit for sales under the minimum units for the supply and distribution agreement." } } }, "auth_ref": [] }, "aytu_SupplyAndDistributionCommitmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://aytubio.com/20241231", "localname": "SupplyAndDistributionCommitmentPeriod", "presentation": ["http://aytubio.com/20241231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20241231/role/statement-note-9-other-liabilities-details-textual"], "lang": { "en-us": { "role": { "label": "aytu_SupplyAndDistributionCommitmentPeriod", "terseLabel": "Supply and Distribution Commitment, Period (Year)", "documentation": "Period covered by the supply and distribution commitment, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales": { "xbrltype": "percentItemType", "nsuri": "http://aytubio.com/20241231", "localname": "SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales", "presentation": ["http://aytubio.com/20241231/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20241231/role/statement-note-9-other-liabilities-details-textual"], "lang": { "en-us": { "role": { "label": "aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales", "terseLabel": "Supply and Distribution Commitment, Royalty, Percentage of Net Sales", "documentation": "The percentage of net sales to be paid for royalties under supply and distribution agreement." } } }, "auth_ref": [] }, "us-gaap-TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock", "presentation": ["http://aytubio.com/20241231/role/statement-note-11-longterm-debt-tables", "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations-tables", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans-tables", "http://aytubio.com/20241231/role/statement-note-16-warrants-tables", "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share-tables", "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations-tables", "http://aytubio.com/20241231/role/statement-note-3-revenue-tables", "http://aytubio.com/20241231/role/statement-note-4-inventories-tables", "http://aytubio.com/20241231/role/statement-note-5-property-and-equipment-tables", "http://aytubio.com/20241231/role/statement-note-6-leases-tables", "http://aytubio.com/20241231/role/statement-note-7-intangible-assets-tables", "http://aytubio.com/20241231/role/statement-note-8-accrued-liabilities-tables", "http://aytubio.com/20241231/role/statement-note-9-other-liabilities-tables"], "lang": { "en-us": { "role": { "label": "us-gaap-TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "us-gaap-TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": ["http://aytubio.com/20241231/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20241231/role/statement-note-16-warrants", "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share", "http://aytubio.com/20241231/role/statement-note-18-revenue", "http://aytubio.com/20241231/role/statement-note-19-other-assets", "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations"], "lang": { "en-us": { "role": { "label": "TechnologyBasedIntangibleAssetsMember", "terseLabel": "Technology-Based Intangible Assets [Member]", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": ["r16", "r737", "r738", "r739", "r740", "r741", "r743", "r746", "r747"] }, "aytu-The2015PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "The2015PlanMember", "presentation": ["http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20241231/role/statement-note-16-warrants", "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share", "http://aytubio.com/20241231/role/statement-note-18-revenue", "http://aytubio.com/20241231/role/statement-note-19-other-assets", "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations"], "lang": { "en-us": { "role": { "label": "The2015PlanMember", "terseLabel": "The 2015 Plan [Member]", "documentation": "Represents the Aytu BioScience 2015 Stock Option and Incentive Plan (the '2015 Plan')." } } }, "auth_ref": [] }, "aytu-The2020ShelfMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "The2020ShelfMember", "presentation": ["http://aytubio.com/20241231/role/statement-note-14-stockholders-equity", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20241231/role/statement-note-16-warrants", "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share", "http://aytubio.com/20241231/role/statement-note-18-revenue", "http://aytubio.com/20241231/role/statement-note-19-other-assets", "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations"], "lang": { "en-us": { "role": { "label": "The2020ShelfMember", "terseLabel": "The 2020 Shelf [Member]", "documentation": "Relating to the 2020 Shelf." } } }, "auth_ref": [] }, "aytu-The2023EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "The2023EquityIncentivePlanMember", "presentation": ["http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20241231/role/statement-note-16-warrants", "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share", "http://aytubio.com/20241231/role/statement-note-18-revenue", "http://aytubio.com/20241231/role/statement-note-19-other-assets", "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations"], "lang": { "en-us": { "role": { "label": "The2023EquityIncentivePlanMember", "terseLabel": "The 2023 Equity Incentive Plan [Member]", "documentation": "Relating to the 2023 Equity Incentive Plan." } } }, "auth_ref": [] }, "aytu-The2024ShelfMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "The2024ShelfMember", "presentation": ["http://aytubio.com/20241231/role/statement-note-14-stockholders-equity", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20241231/role/statement-note-16-warrants", "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share", "http://aytubio.com/20241231/role/statement-note-18-revenue", "http://aytubio.com/20241231/role/statement-note-19-other-assets", "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations"], "lang": { "en-us": { "role": { "label": "The2024ShelfMember", "terseLabel": "The 2024 Shelf [Member]", "documentation": "Represents the The 2021 Shelf registration." } } }, "auth_ref": [] }, "aytu-TheAugust2022OfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "TheAugust2022OfferingMember", "presentation": ["http://aytubio.com/20241231/role/statement-note-14-stockholders-equity", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20241231/role/statement-note-16-warrants", "http://aytubio.com/20241231/role/statement-note-17-earnings-per-share", "http://aytubio.com/20241231/role/statement-note-18-revenue", "http://aytubio.com/20241231/role/statement-note-19-other-assets", "http://aytubio.com/20241231/role/statement-note-20-discontinued-operations"], "lang": { "en-us": { "role": { "label": "TheAugust2022OfferingMember", "terseLabel": "The August 2022 Offering [Member]", "documentation": "Relating to the August 2022 Offering." } } }, "auth_ref": [] }, "aytu-ThePediatricPortfolioMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20241231", "localname": "ThePediatricPortfolioMember", "presentation": ["http://aytubio.com/20241231/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://aytubio.com/20241231/role/statement-note-4-inventories", "http://aytubio.com/20241231/role/statement-note-5-property-and-equipment", "http://aytubio.com/20241231/role/statement-note-6-leases", "http://aytubio.com/20241231/role/statement-note-7-intangible-assets", "http://aytubio.com/20241231/role/statement-note-8-accrued-liabilities", "http://aytubio.com/20241231/role/statement-note-9-other-liabilities", "http://aytubio.com/20241231/role/statement-note-10-debt", "http://aytubio.com/20241231/role/statement-note-11-longterm-debt", "http://aytubio.com/20241231/role/statement-note-12-fair-value-considerations", "http://aytubio.com/20241231/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20241231/role/statement-note-14-stockholders-equity", "http://aytubio.com/20241231/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20241231/role/statement-note-16-warrants", "http://aytubio

```

per-share-schedule-of-earnings-per-share-details", "http://aytubio.com/20241231/role/statement-unaudited-consolidated-statements-of-operations", "lang": {"en-us": {"role": {"label": "Basic weighted-average common shares outstanding (note 17) (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } }}, "auth_ref": {"r205": "r222" } }, "aytu_statement-statement-note-11-longterm-debt-future-principal-payments-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-11-longterm-debt-future-principal-payments-details", "lang": {"en-us": {"role": {"label": "Note 11 - Long-term Debt - Future Principal Payments (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-11-longterm-debt-schedule-of-longterm-debt-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-11-longterm-debt-schedule-of-longterm-debt-details", "lang": {"en-us": {"role": {"label": "Note 11 - Long-term Debt - Schedule of Long-term Debt (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-11-longterm-debt-tables": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-11-longterm-debt-tables", "lang": {"en-us": {"role": {"label": "Note 11 - Long-term Debt" } }}, "auth_ref": {"aytu_statement-statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-12-fair-value-considerations-recurring-fair-value-measurements-details", "lang": {"en-us": {"role": {"label": "Note 12 - Fair Value Considerations - Recurring Fair Value Measurements (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-12-fair-value-considerations-summary-of-level-3-changes-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-12-fair-value-considerations-summary-of-level-3-changes-details", "lang": {"en-us": {"role": {"label": "Note 12 - Fair Value Considerations - Summary of Level 3 Changes (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-12-fair-value-considerations-summary-of-level-3-changes-details-parentheticals": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-12-fair-value-considerations-summary-of-level-3-changes-details-parentheticals", "lang": {"en-us": {"role": {"label": "Note 12 - Fair Value Considerations - Summary of Level 3 Changes (Details) (Parentheticals)" } }}, "auth_ref": {"aytu_statement-statement-note-12-fair-value-considerations-tables": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-12-fair-value-considerations-tables", "lang": {"en-us": {"role": {"label": "Note 12 - Fair Value Considerations" } }}, "auth_ref": {"aytu_statement-statement-note-12-fair-value-considerations-valuation-assumptions-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-12-fair-value-considerations-valuation-assumptions-details", "lang": {"en-us": {"role": {"label": "Note 12 - Fair Value Considerations - Valuation Assumptions (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-activity-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "lang": {"en-us": {"role": {"label": "Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details", "lang": {"en-us": {"role": {"label": "Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-15-equity-incentive-plans-stock-compensation-expense-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "lang": {"en-us": {"role": {"label": "Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-15-equity-incentive-plans-stock-option-activity-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-15-equity-incentive-plans-stock-option-activity-details", "lang": {"en-us": {"role": {"label": "Note 15 - Equity Incentive Plans - Stock Option Activity (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-15-equity-incentive-plans-tables": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-15-equity-incentive-plans-tables", "lang": {"en-us": {"role": {"label": "Note 15 - Equity Incentive Plans" } }}, "auth_ref": {"aytu_statement-statement-note-16-warrants-schedule-of-warrants-outstanding-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-16-warrants-schedule-of-warrants-outstanding-details", "lang": {"en-us": {"role": {"label": "Note 16 - Warrants - Schedule of Warrants Outstanding (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-16-warrants-tables": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-16-warrants-tables", "lang": {"en-us": {"role": {"label": "Note 16 - Warrants" } }}, "auth_ref": {"aytu_statement-statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details", "lang": {"en-us": {"role": {"label": "Note 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "lang": {"en-us": {"role": {"label": "Note 17 - Earnings Per Share - Schedule of Earnings Per Share (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-17-earnings-per-share-tables": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-17-earnings-per-share-tables", "lang": {"en-us": {"role": {"label": "Note 17 - Earnings Per Share" } }}, "auth_ref": {"aytu_statement-statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details", "lang": {"en-us": {"role": {"label": "Note 20 - Discontinued Operations - Schedule of Discontinued Operations (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-20-discontinued-operations-tables": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-20-discontinued-operations-tables", "lang": {"en-us": {"role": {"label": "Note 20 - Discontinued Operations" } }}, "auth_ref": {"aytu_statement-statement-note-3-revenue-disaggregation-of-revenue-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-3-revenue-disaggregation-of-revenue-details", "lang": {"en-us": {"role": {"label": "Note 3 - Revenue - Disaggregation of Revenue (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-3-revenue-tables": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-3-revenue-tables", "lang": {"en-us": {"role": {"label": "Note 3 - Revenue" } }}, "auth_ref": {"aytu_statement-statement-note-4-inventories-schedule-of-inventories-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-4-inventories-schedule-of-inventories-details", "lang": {"en-us": {"role": {"label": "Note 4 - Inventories - Schedule of Inventories (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-4-inventories-tables": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-4-inventories-tables", "lang": {"en-us": {"role": {"label": "Note 4 - Inventories" } }}, "auth_ref": {"aytu_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details", "lang": {"en-us": {"role": {"label": "Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-5-property-and-equipment-tables": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-5-property-and-equipment-tables", "lang": {"en-us": {"role": {"label": "Note 5 - Property and Equipment" } }}, "auth_ref": {"aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-6-leases-lease-balance-sheet-information-details", "lang": {"en-us": {"role": {"label": "Note 6 - Leases - Lease Balance Sheet Information (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details-parentheticals": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-6-leases-lease-balance-sheet-information-details-parentheticals", "lang": {"en-us": {"role": {"label": "Note 6 - Leases - Lease Balance Sheet Information (Details) (Parentheticals)" } }}, "auth_ref": {"aytu_statement-statement-note-6-leases-lease-cost-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-6-leases-lease-cost-details", "lang": {"en-us": {"role": {"label": "Note 6 - Leases - Lease Cost (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-6-leases-schedule-of-lease-liability-maturity-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-6-leases-schedule-of-lease-liability-maturity-details", "lang": {"en-us": {"role": {"label": "Note 6 - Leases - Schedule of Lease Liability Maturity (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-6-leases-tables": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-6-leases-tables", "lang": {"en-us": {"role": {"label": "Note 6 - Leases" } }}, "auth_ref": {"aytu_statement-statement-note-7-intangible-assets-future-amortization-expense-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-7-intangible-assets-future-amortization-expense-details", "lang": {"en-us": {"role": {"label": "Note 7 - Intangible Assets - Future Amortization Expense (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-7-intangible-assets-schedule-of-intangible-assets-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "lang": {"en-us": {"role": {"label": "Note 7 - Intangible Assets - Schedule of Intangible Assets (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-7-intangible-assets-tables": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-7-intangible-assets-tables", "lang": {"en-us": {"role": {"label": "Note 7 - Intangible Assets" } }}, "auth_ref": {"aytu_statement-statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231", "localname": "statement-statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details", "lang": {"en-us": {"role": {"label": "Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details)" } }}, "auth_ref": {"aytu_statement-statement-note-8-accrued-liabilities-tables": {"xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20241231
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

http://www.xbrl.org/2009/role/commonPracticeRef="Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6", "r847": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef="Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A", "r848": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef="Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A", "r849": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef="Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A", "r850": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef="Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A", "r851": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef="Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A", "r852": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef="Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A", "r853": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef="Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B", "r854": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef="Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B", "r855": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef="Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B", "r856": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef="Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-80-50-2", "r857": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef="Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-80-50-2", "r858": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef="Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748009/946-205-45-4", "r859": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef="Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1", "r860": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef="Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1", "r861": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef="Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3", "r862": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef="Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3", "r863": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef="Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2", "r864": {"role": "http://www.xbrl.org/2009/role/commonPracticeRef="Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "ZIP 102437749-25-003568-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-25-003568-xbrl.zip M4\$!#10 ((N13%Kt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

68U!*A46GvJr3>+@*O^G&FvjPFFH7s27)>/6\5 M3PKQ4QZ562R,*6234D6)43;--,4W40U+064U!,X>N:&&N&U35%0U&OQAO#6VT/MM/16MQB7,M)>0^WY{BCD}!
@*X2R4P/K8Y&@W@#1#?<=<^&R!ON1GNVRB|+BWYOP2YR-N:MT93/NFZ0Y?Y[M]>#?2*090804M*OY7D+@O_<Q4:1H/L@O_-K9:A,50=STF5*L,Y
M#1>+&K4*~1V7+7YBY<5EX<#4#13HDLO0#KJ#B MA2Y7Y><_JH^U/9P(SIU^AK(R2=|2@ LH3|NT7GLN2|)#YQ(3+)>Z M38FZ/7,P3LH|1N>K^&@.+.%8\$=,
{63G*25,C638GU#*M ,OUP^TPXV|+ #25VP|W<_746+NH@J5N|56/>5A_!YMQ>BS5VSVR/EGKQ@Z*ETFKGQ<@WD\$21,Q7Y-G\$BS24+|D>_X3M)78\$2TRF^Y M)31__
[C^F^XJ|E>R\$&4+@M!^VUH^XW2-4\$0?M8(-&+UX>P00+V6= G|2(G1X0,6YP3|17VLA^<K^<K+16,CZ)KWKQ P|1A|D;4|6K|QRF&D;M2K#PU<=
MZN0!<@G3@BQAA.XFA|<@T^RB|/E#<=<^&E#-VFFIE6#<^?=>#H@70)HR,0(OVP)^/!3^W>-|FK|9Q{QLH+>?QSV=1^O^ M7FNU0KDO|PTGT)?|MD/&ZMAN)D/5S@(-9-
TGXE^3#1|GQ?GD5.5+V^NWV MYPPF&42C%APW^1-V53|3X|H<@WIN<.<.%+E\$>+E7,Z A:0,6^D>Y<^=<CL=M+/U/&\$_NK\$>?<=
=1W_U^>NPTK^>1^>|C|Q^R_G3KL0+<+FHHW^<|V^O_U^<K-U^>F3ZFMX^<0_J_>Z M'66+38^|KKBK\$|MO:MSK3UN^AK+|LH J MZHL=NJUKB|L M>#Z P7^!^G-
<+Z\$5#0UH>T^>D>SW<(E,X3{26G^&8A^E)+-<0P|T4P|B|,P<@)K9+ M/O/<^<Q,&&^!^A_B7,RDFX?M]#4M0^51KUQ1^ZC8N:MQ\$(_J8^<^_W=VQ5_MQ^*NQUQ?<
jY|<@V|Uc8&^H_S^+)?Q@&G\$+|7^<+F&UL.CW?|H1-NUW=8 MA<80Q P|^<_AU5RFAC58^0_<_L6JZ8005A(U^A_K=6^P?#O|3?>?G.^ MJAM|VH4,FTZ>3+<
BDD0A-W<81;3D2S^!N@:NA&G

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

FF3%U=U%L\$HEUUO%L%1NH@B88F%#2%IMIS\$%M&Y%Q'D'A"(4U=CYK1)HUSF\$F7%K'RA@KZ<"/%C\$IS1<1<GQS
U=U%BM4SD284LWLN%N:LXIA=6"YVE>OHHO/VJ91=8DNIN>=IFIO+<COTMRU%7OEY===100?7Z?+SH5=WJL E10+S8%<AD>=Q2W<=%M&17\$P)1MXT
0195URLP1@H<NRL1=HW=<E0=<@GNFSYQK081AZ<3R0L0B+1 C/<=J+M+U1@K8t.U17.8Y-8<?10CVC:8Z7NRVPH\$E*MLT7Z6CFYV=3J7<G'U M%>>C#?T#X-
7-0%2#D#VXG%1=T/3#1=H1YCU<...D%9Q3W-H+HKV13L1MH1>=...1L%C/M1#MZ11+6.C&1S/0B%GLZ32_QRT6PDMW60X17Z MCZ1 M*PQ/DUN<@PRV68L03-
%<0v>K-L13X11HPV05F-K/<11KM=H M9?E=H+W&BNGB12=<2%P(1\$=9:5.5E1U?Q98SB7"WP6<=X%J:A M:E4:E40%5F1Y74GW?%<1
"FE+RR#3P#W49"LTZ.SHLWNXR<2CLOWKA M"FU+>8N54U0T1C.NGB:TVNW150I2BH5UIM;QRID4Q'Q"H*W\$;7^MH4U74TT1.FDY1\$C3A1E><6XVPKHFNINFKF28\$
MPU+IT.Y1<4V3_Y1<M%OXO<DIEG9# "M&WGVIS1.\$C M1+>4U/42FVR MG<E84M1=L:9Z99G<_HU3\$H1<H% M7Q3<7\$3.HH(NW0E+70-B4 M+X6.DE_X)F?
&6NS7129M1<Y13+AO2FB?>V1<XKROF*Q6W62IB544+> M?741(B&6A)HLB17?0BHK<?>T16BRZ<?QO1FLPB8R12>8#6GGH0HP:M>1>C@ S#>VQ\$S% C.TST?
(18MH2=<MX0W92>+<16(G0H0+V6 1X9NZUWV AUG MCCET.F7P1R\$<1^ MTE<HUU.86?>P@>...ZUON?0B\$Q'P<Q'N.C6X4E6: MW.53"HM TW1F7Y&<#K&=YC6>_ER7T
24ECX=<M5VCV10?>M1H4UWS M1H63H1B?>T@ASZVD<8V41V4/>U A90026(P.ZZY)>Z_U9<@<X'DMBV; M\$<M+U X5B16G?>--RERQ\$1=GI?>90X+I\$*>O>NUP.(561EH%
IF11M6A+<H>?>U15ZBZK1B9Z'A3JN1 M.C1B<=>92G99EW EHBTFX%<Y1HP3P1T+<@ H%Y1L9%#H\$RMSL9#.J1 L M.M5Z1%1FIEZ==<Q\$PN+EEVR
>F80S/M5ZLOC_4E+Y1+W=Z6QW=PF7(2=<MJ@137-2J>YGM\$LYK:73N1PQ-TX.358PE1<1\$H\$G6YSY9R7L1AC1 M3&MH=>N(KEF)7\$R:TF
(G53J5J31+1+TEJ05WLHKWJK1586X3: L.B# MD9/HZD302GIV08ES0WK<@B71-Q_<QMY" P">+FFBDOOAW1.47U14Y2ST
M-0<=<S1=OQ3M6B 9W<=SW\$W&P<6+<WAS?7%Q1400VMI1SPNPGY(EA) @<MR3JXH?>Z<_<WWC#>Z)RUU1<@ULRA:1DZ?1HCN7<@ACX#>1WYXHH<@HB' M'5YIM/A8Z<_
(00O6:HZNUB(K%<P%7F.T5%2H+<1+80\$1Y1RM55\$<O45 M821F5NUP C JZDCK2=<36%1F<V71 A\$S<9S*V4 Z1=F7X<CPD)2%1 M=>Z. QP23E255E4.4N-
TJ6-<1+HONV1P1+1#1&11NR.KSL1U1D47T M1Q:ET\$<Q10(H1C MZ^<1^BO@)>1H%GA>?>Y1=LD6@>O1?U"U1U4V1.65F8 M\$Q<8%<H03+?>P16W3<_<Q2O1SOQ_0ZHF41F%BBZ2?
%2Y31H15FNP>KG6+<91 TS\$ 1BYH1 M\$V1GZT AHLF6?7%9GP1L ES_R1+<A Q\$5Q:65BNXC1W?>O910HG&XGF H'M M1C8ZESU0Z<O1H<H&W3W<_<1
%>5FX<C1<R1JWZ?>G<=<FJ.F 1EW<"Q MW+A?>64& MHM;AHUS\$G6E241-J191DS;ZLYR)-B=JEU9K42SV);B2P 4ACK?K/VB&O M4ESIB<6<4<WO<=<SN\$794H<1Q1-
515<=<E<P_1JOF14JBL<UJHK H% M5&81OE5Y7D?7M?<H/H1C1<_<W3TSK15L 3D&4Y7P1D7? C2RK<RU7O_ M1L+<6:52E89=<5&41Q1Z?>VF3<KBZ=1W1A1Z 9K6V8K3731E47?<?
MM41:QZDY M6.9E01?<=<A-9+Z 271ZQ23K3Y VV 729C@3;1<_<9+2W&6Z 3E<=<A8Q11PT454\$N(S%143 M5QC&3XM75?>HSHA>WK1: M1+YVQOMP<8.16K19R1VPIQJ31#<?
(31 L1=<8X%<Z2<=<6ZS1CP?>M0DZKX1P<P<6<U1OPH1 M'0N%N1?77?>H0Z41+<WSN1QWD_X(4VMG01D/OZZ<4 W6BQM17Z2751G0 M3<((=>D>O21SOQ_0ZHF41F%BBZ2?
5EY4\$B?>D<=F.WE.U7XKX1M6DZ2Z1? M1<IS2GHW1Q=WYS6<_CWI?T7<5YBROQ2G6G9 K.GSHOAG147 @<M MZ86GB1W/U<C1<6%<7<E1FTG2=>E1NHH<_
O1OVGH1<F66E M1TPO;FEP169M77.K'E0>_<XTA1<U K<_3M:F+K/07WOF_B<KDI@5\$1BM MB4C'H85H?>14<1G_N131>8<=<GL#4\$4U?CJZH?>((CA0CZUC#1_Y8U/)<_<?
MPP8W9GKELUC1<1>1(S)>ZVY1H<KBK\$2.SYN'O10<1<_<751 CVZ<CQ8H M11:OO1<=>L/2.5Q1W?>Z/IN\$F<UNROMIO=51>=>T<@EKG76725QJ>W51N MOXSPXCO<1?>Z<?
9Y>C1K'M75P_2\$W61NPA<=<CX 40+D7?K<=<6<_<2G<?>M.WEN.BN1<1 ENYPA01 @<SYQ13(4V7P3<P<+>3%K1(77U0&S1T1?>XJD<@H1W1YU9A1@1<?
IKS3<@<BHWK8:7W?>OKT1 8GTBWB\$Y<=<151B26?>76?>3P M+1T F<=<=<A9ZAH<3\$Q<@SHOG<1<X1N9DH?>M11X&SB1H7USQ<606 M1LD?>=<1
>4<=<J5B91J3H<=<1MR<ED+BGFY<=<Z1Y1RVVHY6CN (K3<UPY1HD?> MQ NXG3G<=<NQ4NE9Y<AHD15PM4H<2.B MDK+1Y?>=H8?>HT1L0<=<J1 N1.P7VX1LP1T7Q<@<?
N7OX<E=OPC&=<A91 M1<HAK2A.N"Z19FZ428V1V<1QH1XVKJ.N1=>(<ZB<82K9F.L19>=<UC19.MXN.4>=<M 5:Q@9A%Z=<140PPR101Z<@<089P_3+8+6<_<?
<71+1FOT\$WM2Q0?>=<S.48 M+18R?>S:6H"A89+<H1O1RBJOEGARQ_1J2&4'LS<=<S=>3\$W\$7Q=1(OLMT71XROX/>1V<VZX:4%<_<35<+<1 8WF<O<_<1.PRWYSY 8N40<_<Q
M=XR.OYB1+>3>1A<C'GO=<=<GARS 0-M1H1QBPF<1T851<=<6PMW M.5\$1TQOOM M_9<=<6_XXB1=<1R1&KY1A&XQ SP7-BJA<@<=<MP@XMI*%B<9UDH1Q+<_<?
<+1H\$5\$<1+<1C1<N&8.B602<=<M>=<+<33?>P61MB<_TR18R0 Q_U1H M1A) B621W@<D@2<=<X?>V0.2 JED<V%46P+1I7Q 3#8BSB11+119S10 (RSWL<1Y"MC8<XIP
PB=<A&8EEFAO<D\$WH9)H4H G/K0?>OZ<3+Z13BGVY# M1.YX<@<NO<-(7&D\$9Y 3_PU EL1)KD21<#ED 0LGN<_YTP1U1D101RX7A?Y MA24.LH;H3;8S1X<=<6 M71&NK7<_<4
XPTX3<40@06<0HVB5>_T(1\$STC M2)T L.W%<1N35H<@2A<14 6#9<=<1J.N\$N%#(10.HN 21QJZX39<_<PH>11VD M.U7WTFDXFCD\$ 3P 61GCI<_W0TFUWJO.BW"
M+8X4+<@<X.ER518F.RWC<@<FGLFN>?>1E1)H#<@<884K19XB<B?>2N>017-T M6P#S1YR89<@<=>+1T TS<_<NT<=<P\$>

1. 2G 1. NJ 25% 0.00MMIR. =%1Y21H0XMMJR.D4418=+ M=0. &2HGA4MPE57SKHYOIP<>E#0H4U;E-X;D#S;5%+YG&=ZYX.*E#I
M13M98H8K7199\$SWO#MOJQUO:GVZ.1#W\$JR.AH0T6#A&LH/GVTO.M7IPQ=SMU7+1J1:FOVHL13J3HDVA15GMA4M+DYG1M5PA-U8<+&MOQP6IRA6
M1P*09BPA592D/F+6;DPU@CK31D.=>M*P107FU87U0.79;=>C=C.MVEXH.HLH191M9C2=>Q5H=U(DS1_OKH7OKH1POKU1B5_OUG;M(GHBD_W5
MW.G@W<5%&Z);&S=>C9N71S=&G:AHFEO.1LSRR37J=>JN15M.(HJKJRN=B7G.MC.92S62=>IU0+YJK:Q4RW+1S1+5E@OZJ2P1IG5+JSAVHD51B=UJZP(9.
MHUSUA=2>0.6WODUH.M56V905EV18S;W6;14H9P1H1WYMYV1=>2UKR.H1YK<C#H69>=>M71/O3ZV.YF2TC(F-DW.V3TEK3-JT1Q/IOF9#2DCA4V33V15)-234E9+0
MIG1PD=1Y@837QFQ0494*=>BZ27W&K=XYOQH.M1C#E%+FAI=18%M%#H6.Y.MH9A@5PL.GNULG.57%OAPQ#HU-31B#;(%7W+&+&WV1L;2JQ2X8BCR1-MXQT3H<JFGE-
&C4.0C#W2A66.8LB5<3%.(69Y1M37BUD>BAF/VYDHLB.#343V>2+3.K6FABGQ9.5XW.G31H26G-6SV.HJ.N=&H.N.C;M1.27B1B.S>7D.M5J8+J7T.VC.XJX.
LY3=>M1W+2N671HAF100Z.M5T9AIK?M.X@JR.<+<1TZ#P.NR7R7?&CJW<=>4T/S#11FTTU<H%#<79UJ.1T.MU2J+ZF9J@?C@WFW78S72T.RA777B7B1P@HNOU-F.MH1:
H1H1H#V<1/X21.SOPW.G#CCN#0#O#K<3FE6H1RG525.XZ>3A#826-K<MTFG56.O17.NJLOQ>=>AL.O4)KGTENAGVR/VJ61+7<=>HGLF1OHC#&Z+1.M\$#7WC.;
(QY9B9EJH69HMX1@P.32Z.H1@<NJZOH&137+14H9E=006Y71P@R#>BYU#25V&G<ENL@<NKM2X7F#3R2V+V@J+WD1?P1CM?T.XO6HGT3@<Y#X4N1V2(OT54K=24:C5
M.W9>T2A1592C24B4%G:AO=7M.O1H#P#<=>1D>NWL-#617:805.M2VU-#<C#&H>SEI#&9G+10HKS1FTBW1>.<=>#410&A9/LG<5%&E#57.MCKU#KX.V17EY=N/VX
8YCRJ@<QDWSN3DEH89ORG6G4U.P-M#&JOH>=>X&C.MG78PC=>50ISB9#F4T*1<=>Q6TK#&BBJ7JTKJBVEQP3(ZAARW2P@C#VX)>=>M3L.V1VYB73416G.V167C#YPN%2AHL#<#
I>8M.9KC#X+6@<G4L.YH2S1#M.M5:Z.OJK=US1Y2B74JK\$+1.OCAW7+RO6.UNYIAD&518LG>=&NPP?IO77OD2+M+@UB;+ID#X%ANXR/KT=AFICI-UI77C9Y9-
5SV1P#1YENYFCWAKI@9C1U.D2@YR@>2.N=>00#>1@V;+X#N1.MH7+1#EV#BD1GVH5>4F3.XN1=LWK2.M.HY.VF.FITMGW#P9=>0<NG>7GW1&J7T/F(R.&2.&K%&W-
>Q=>K.NMN+MMJID1@XU3T#Z)U.MHTZPPZ.2+IZXOW4+1#1.S.CU.M#H+@K97=>#61.4OY+1+M1.LDY1YQQWDB+25>=>1E0XMYUKIOQIG&07XS.A45.Z1V1+PM@IS
MOQ#PRFYA767&R91OU.WYK.VZ>=>YH80A72D.2+3J2M2P=N=>1L+9+1.LIA.MPD-OWD7KR60=>1M.C.W6W.15+57T.U3E5A(=>?7-P#MYC+WN#PKB_0.M=REOTFMU7
+PCNREY.CDGQYGI1(NY31J1.H2AIU.VH1U.OE83C.U1.8.X=0=>GL1KEE04V7H#R9?>XIZ1BD9GMEF@XN6ZM4YH
M@O14.FX553/(SXU2:UAWX#67)WSDC/G9>2A1S.C.#)FEH-V5)H#T#%N7A.M8&7.2#1.TPC:R7V(IY15I44FX0.2JX9#G2UNH&HK55#RLH25W10QM.M.DD6.1+M.FL:
FL7M=H3.WP#ABV&@<CGGL2EB7>3<@K&C&S.C1WL.MS1#F1#&#YE4+4EH@X77M*#3*#NDJ3SG1G#C739>ZQ.MAL01R1>1J>
08#76WVWQ?QC@<Q)XIZ1X#Q#S.CA)J17Q0S.C3Q1M<SRU(Y2<4#4K76S25XZ=OU#LS1N1T7.C149T/749TK9P<1ID1>3K1MAN5V#AR3L
WK55933+>=&8EJL<CQ@<11PET>XBEY#05.MIEG#63PUW5S&E#B.LML#<15&6P1@<1Z3JHDP#<@<YD<5>M.H1+L.LD#6&5H03=>IVJQ14MM@>#2OW#?>#_GH
2.2FDISA22&D>1.1%#6#R#B.91LW=>E#N5#B/32K3&4.MC1V2&2)WQF.UH.N@C10Z4.OBOHNSFN#J3.82CUC.GMLT1(NRR<#%)M1#<1C
+5<64MILW8Y9M3DXCE.3/B<F5H10<=>GR@/6>RE.19G%4.F#T&?HID.M4%#OP#&TNP9S5TFRYT.U&62EQ.O.BIR2P(B)0TR7HIVNFDZ.K/FODMIA-MY91V-
75<KRPYF#>J.D4K195+M2FY7H8JQ1A7HSD3H.B.YXJ.G1C#GK>M1+TY.VC.J1Y#12)WMA21H99F8SV51TJ.B.XHL0&1#>P.NR6)M(KVZIS\$5+120<-(F
Y+>F.LOMFVG>J>5-BEEFOZ1Q1OU4TH&S1+L#J.S#M1LMZB(V.SWONH9P#TD1L.SAF&B5.#00B22RH#H1#>7H86GF&+U#M>1&6&D&Z.A#>2D1DTS1
(+L#<C37<#>C.3D0E=QW@R+6MDY>V>YMK1ID1Q1.Y1Y.Y7B1Z(TLH;#E#2+>1D#W.MR.U#M+P<2LDLKG>H5>GS>ZP=H1<@<1Y17%7PP.G&G7\$2<=>SR?7PQ/SVY
M571GXJ32W9132=>=>GT.COG;HJ.HJG7+ZBB>64X@YZU.R#J#ZGFGIC-MKKBIA/RV.NA#K174H.HUJP@<S855/H50AAYQMZ1#G1Z>6+1E16.Y1
M0#>+U>IY+H705V>+1S<U743SO377>15D1<+<SI4EC7V51M1H1N-Q.M.OX#E6R2U%#HAJ1@>3A4.F#SGOIW#N.FCHLYAOJ:DZTHVE;<20C.M=>6#(JZ>#
1A/4A.HV0>=>M=HBT.YYA.FL.PY:CJS=HFF14.G.MOY.B1N>#4B;1CX+624+&1(4P.6)Y1PWOHND90<=>@1AX<#TAJ#&ZQWS.MYXR63Q?ZAL-
1YH.HL.KS.OFSCM.OHT<1M1M&U.PHJ9P+4791#2MU.CM1L1WU81C1EX-RPT4P.3M1ZB832@Z1>O>@<B#&#VY<C#AY0UBB.M1#&24.B9?>
1VBD1C1U+>+F3.CY@<WAIR.LD6.WWNWMA1=UD1Z-N2\$Y.M.M2C6LDEVS#>S147HU<#1.P.HPS7@GYV8P351+K091K<2E+>#1+5M.MI(0+L+Y&V896-
UCSHOR<9Z17&U.XM21GKLR90<ARP.T5.M&JYLW.MEQV#&0:01VUNDAQA88W.5+>M#1.HWRK.VUW<6*G.DU7O1&RFEW1#>#2OR210V0K.5R15(5VD>#>MD#
M5>PY\$)T31=>#RQ6(D16#RR<H8+>#Y3+1NEBQTB145WS4Q8HU1E0)>=>1BQ1H1.MZF+>#G7J8L6Z6+>#N5JR+>2%Q>IBQ>31#>+2M2#->OIT<16OUFUMU6A8IBZ
M61+>#Y#41ZG9Z16+>1.GD81M5NSWLU<2+>QJM.ISZ05BQ.EBH15(M1-SZ).M510D+9J.T4*03VY#N%#14#>+>#MBQ5=3010H1U.2R.MXV+>?
CN6+>#Y#Z#NP71<=&K5H55R9M6G6OR>2>16+>#ZE+>1#>#5K=M5JFM.M1+>V65H#M1<#>P3V7DHHWU2N.TARV67%9E1T09JHK7=K8K8K8K8Y.O6>+>M
P16D1=91M&A+U<G#K1+CM<G#KMG60P1W+>C1V3Y1A@<B.O9.3Q#Y#M1#<O>NO?Z.DIV.X#1.0G.CH9%8M=HY<3#92E1M1D1DW6+15.6922#TLC)MDE:(A=3)B?>
KE5N#<1+JOY)M3M0>.#90K1GN<#KVC6P.51X5SDR.O=M.4YHX1U1(WO#W+>1R1HFS>GABID.VY.ZXW&51#TG#&#MN<6EM<NFRZD1P0.M1A.N0U-2
7H9.IXT2V2=E3IAVOHHA#G1M5TA+

[illegible]

656;@Q#>?XP"U4\$S=V+;+F+>12"20V(5%1L:M&QH@WOC:KXT#9D:ZG9S9Y3.)#Q:~+U+U+@8#%". M#BP<93RD@#1L:Q4O)3T V+:D>F4R)Z&8U"CX'Z'1L/Q?MXYT(K-V>C>R)D9
MMJN:U;OK/R:UQW:L8(KMW'W'=HGKPT2IRI>+7G3<K/25'Z'NP'>?7#1 M-@0HC-1F7?BNGWVY>4>V+T:V:BT>ZWQ'=>DA7&6PX FIUT/15.B5PJX'<Q<
M217X1>=<6;.0FX1K4W'D=DHF V+1A2T4S=<D>.8%(NE\$S4'01&BK<KF+M<1L4#-1J09T#V1+Q0 B2V:HC K#XIHGENLO'FXKCV4AU654'G6T'>7L M<D-184ZA1P21#WL9
C-1L0?7-TJ=5'Q1?TZW=AO:5JG4:ESUHL 3'TJ MDQ>O>>E1SVE68G3:FYRVF'<Q>213UCU4A E80QP6'>2+(<9F0D2+Y Z\$1 M'941Z8MFL&RC41LH=H#):T(F:USHL=4FXH
(A0&GF-Z=O1119C<41V'3N)M0/96'N-EXEIK1HSU1T'P'KRB MRJ)HWV#VFY'<3M'17A:M-BU6FTQSH5*3M<H>.<1\$Z29'Z>8151YIE
M65(57D3)FVMD M+4C6#08.2CKT&F9.FXIP2%NJJ@L95=5ZJH<=>13 L1VNR<M1SY Q&L1Y2W@%<*>MS;F=XZIG<C(<B-DB/CP24P(BXTPS5D4#RLSROH8#Q&M
8#G(3ED>13ED(=6L'FV>V-TZ8'>=4L'W>WR\$H<?D2W'5%<L\$>J8Y/1H-7+MXOQO'E24S'>W>+1C-1H/CH20XNVYOR>G-LT(IN5B1R'IDIC'HLK KQ;S'G'Q'GN 3X/
M'W%305W5="N<2+1JN11 9C'JZ1' MXID/P'HM)WQY'GVOY'BSY@H/H R6-(79WIE941ST>G3'G+NTN45B'<3Q.S1 M89D'>55+1.LDP-721D3\$S51C8XXJG1+14WU
UMOV4)WA<Q.A0>#T1HB' M#<=>35;NAXC.V0M'M ACIP/12N.NYS:PT'X&XWIXI(MCSU)E2L'YCGF/L P M%<1'<HD7O(ZC<+L90.RU1'X12K&@F1VBWTF8'PS BU(A 6&3B&3C<C
MC-78&2DHB7.7BS 8 QO ODLU1+1'W7AWX/L MD P3)1L'<?00V'K9TL=F15GKGH<A MT.KJB'FK8'N(K7ZDDIH61FJ7YS8T'E'W'WR>4R2+141X-25K+12(61A
M<XBIXJ9Z9K.9R%V>64<1J<DINI&FE9G'4'XUZXSN59B>B72.Q<%<G2-ZIR0R6 MXJ=173.<=>15;U:2>#8E>1J.F1Z5=<@0.6@J4=VHIEU60ABF<=>OBLU8T.E7
M'X<=>CSUOIM96N'9;6H&MMWCZF UXCX 05IXN'E M1CIV/EDBSOJAA>26\$SD'X0.303:2A;N:Z>6ET F3#>=>1>S0P\$=<@704HO(MD)P.NGKU@<W'Q>491C?<
K5+OMH1RA'7H9N;1459H'Z1.YVWRINK -5.N M-1'2'2DY F7OL2USN00Q16/U/0P%Q'<2CE=>CYNJ1S&G=< M&F'E/D;#&C%<1'E C 1J'P6A'>=2'W>=<O'N'>\$R8HKP<-(U?<
GWIWO>3? M56PGG+C6%\$<1=3Q2@.TBFK<1P H EC.S'D<1KS>Q70:1G.EA.D'530<3Q MBOD0\$VL@<=56J@<N'2<J&J&T:2V'61+<+WW<=<+1+L+J@IZDR1L
Q<HFSIWF3Q17DF<1M6D66L+8JH<KL BPF3UJWGSZ\$1-17GL4'V156DUGA29 M2LRR02T GCKQJ7Y(Y#1'2A'<@>20'4V+8&=<1'U9XJ>0YIF@10+FN177PZL A5
(95<1@1\$VRS)M)<=>WG>=>XHJ73Z'>D>J>GB MF3ETH D4 T1\$<4EP'@<?<CYOT'LB'54X\$=4TQOF1L'WCS2H-IBRK5-EAK<L'K\$<X/YI=<=<\$7+V2#>_8>6<2'
@M<?K01.0+12877#1@1.50RZ/W DDI MDR/1A@MD-BPUBBWH&J?TeUGP<A\$=9<T(Q<3'4Q2<1:FOQTP<#75 M2ZPS' MKTIA'@1GIGUA>1
2F\$2ATP@L.G#R58A87'23PCPSFR@N>=<4G.01LIS>Q3 Q M4-1A=<1'<Q0'4'1L2IQX'FYSP9@A.81+4H>S3U2U>UB4IV<IT>1+<+K M5Q-83B/74A@<L H1IXA.5Y0.51:53ZM>=<
M5XADB5V+V'JGV3P'>TAY7'>4<5X'T J6K5U5PDISUEE+<HJ2T4.AAIZ<@ M'F'2J2'<#<5\$3'V=SUGS+UZU>D4251T<@>P.S1<M5Q-456D'>XISDU?<
M<=>GSVLL=10XU.4H<3&JRU.O 1A8.9'<M51#<N>=>1814S<=<5Y\$>+<1M-MHEP WIT.9H'<FGBHQL@<9Y9QG+7P'9QO'<#1 546\$2/6\$<L4'1M'V'<MGAI>=>?Z%1'<H>@HGV
BH1#</_UM9S.ID:2U?T=DV3AJRWLV5V6)Y.K<M=J8>=>N11TGRDD38K7P.3-5-J5&OUU=U.O.G&I&D<C68R;R1YUAT0 M/M8<=<3FAS0P.3.N(1@)EY3O4A<BRXE'03JH'R'E
10EAH504AH+1XD>=>5& M1TE<+V'OE.9931'<_6%R G<+1'<H#81;9H94>V_1A1R-11'<O>=H3=IE MVGU6AT3K'<N'<NPRO1\$+<15Y4[PJN'G\$SLHC16<FCH1A:;TJH1@<BM1ESP<1
M<=>E1=2R? F8R1UJ>YGNNDX<K1'1Q-G4>JIE20D1F.M1.8KBF3FO5ER;JY-VOFOBUL M5&N.78-R'69N'2CIA\$@<KJHIG -2(A1R;182
M'3<=<SSM.T17F4.45L6J316E'>_SI2'<#<4 K4SS&Z'<C0\$19W67G.JXN<C MQZ1V23NG64D&R&S1KPFJOE85F.2'>=MXN1SH2'WX=V1'VQ'>=>HE>V1'V'<W M:79'7IKBKIP3ZMXM<X
E5/47>+1Q.02<1FBB MMX3/D@<?<10<1D1L'<C'G>FVY'1YTT M'<=<M5.MDY<=O10S?>+M4R'19K>_W6H1Z'WDOE'U2L'N1H'D8<=<P2S.SW.MR'<S2_11%-
ESFEL<=>#V1\$=A1T\$5=<#BZA'<F.V(UJW'<H1@<Y%T'<5.87K'< MEM-10FZ<1L1POW\$54UZI4M95PCHZ0'<K#<ZWI1'<JIS'<D'<?<SWR1Z>T71B7 M4?<=<N1U?>?<#YXIPUV\$0H<X
XWAHV1VITR2OEF4+K'Y.IH1+1ORD&DRP1/6> M&=<1QZ KP1UO&N?<QUA1M_1F@2%M)6@W= B.V9&EA399'DZ1'@19ZY U.MTV7.E5JG5>EVRX1
=<W5>+>P.W50413@<@9H1>1A1BU5'P'<#1>54\$9MFW2 M'31'<56B'X4'V'<TK8Z1+185K5U1'<G'S:5%AX1%6'<H21S1H@<G@T-8D_KJ
MC@<L.D6\$27H&BL&<E-T7<DK\$H1UW=H071=ER/RZ+1'2'Y1>HD24+1FST'<P'<=<1J5&6TBO62'67G 1T_HN'EC<4875.FTB.HZ7'<S'EDF'U1@<G'WV O+DM M%K0-ML\$Z\$'Z1H
F'43:B.G<<1&1<R'S1E'<D'6172>26GVK6+RDP'<1KP2OEMDMUN9E.M.G3-NBEA'W=C1\$;QO'3A'UAT6T1F-TWC-PT082'<06K'Z1L'F255>K=C1'=<N'WV M:56ZO=Z.W3IS?<
MG&3.9B'9<_SRZ-Q\$<'VOV1NR M@ZC.R'80F<A1MMW\$0J'71G:7.3%<H=6&J60JG<S+6=AO3.HJ1-P2.V.MPG1V+1/RP6'DEC\$AE6/GTCZ03
JUD.N'(IG>)>D<B1Q<^+YDR@WZ3+M<C.PE2A(I_109'LV1136TEIT&N-7JIF=1HYE1>7\$A'F912D'Q@<TP L M'0V4TJH13N'K:OX%1%<57O7NT-FDX'Z'5?<
F1VHNG5>16X<^?>FGRKM'4<M'M6GH<1@<4J=I=2H1@<FVY2V MEXIF1Q:TDX1<810U&FDF.CS3U2>LFB3S(M1<C1<51'<J'<1515'<S)A+<8D
M=ZRA010K'F PGJ6ZRS5'4'<M\$MGT1'9+5 XVX_+MA19'0\$<0'<E1J'<@7>=<M.

[illegible]

SW%?%B8PY5URR?Z?5)<458 MI?7=1-1BT6/W8>1WB4RP?{TVUL9}>A7%14(M:9S_20^6&8.V_ "MK1+S8C.M^?>#?>
?TV8B.XT?>I?>E!<=0.#?@Q081XJCINTTF?>4Q^NYYZB?F^<1A MB?<{VS0}14QQ{H^N^N8;E=K//8S91Q?<^&N^DF?61."S9#/?9S3H&I7
MJU?7>?>I.Q.YB&A?>B^>X&F?>7P?>#70.D8?>Q2?>9>4ER>G2CF1?>5 MI&8B?>B.D?>{P89?>9C?>E?>#?>H1G.AHZN96&UC4AIGZ.C^#9=1N^E\$A?>M8@>R1!>PDR<+>SSC6?
<1@>8.WC<=>6SZSF\$?>A8.ZM1@>{INO}GN71\$0\$>68B1D.M0!>DJK=>B&2H=>83_8?>IWK?>3^>HRRHDTM?>WRDWM?>M&Q7N^N^M^>IY246.Q<M^1!>^>W71<
(H^V^>^>DA^W^>6&8T?>H^>Z51&K&M?>Y(K^>Y15:979A\$ M&1^>F?>F?>2Q1X9=>Z^>4&GC@>)<Q?>Q?>G>?>S714X1X1V^>H8V@<C^>MUG06&C^>5B?>J1.G^>5RS1N^>39QX&E^>CZ<
J&K?>T?>BR.G#H^>M^>N^>{G1\$F}>MKG&B4PP^>4W2?>T#>T=64.M^>@2P91X/Z#>T1#>@QFNDDA&RVT2!>F^>T M4?>5Q1H@>U\$>Z?>3D^>GDT^>AB@00^>BVB^>UJZ?>U^>{G\$<^>#Y?>
D6DHA5&S^>M.C&G/GDS!>AYR8F\$>Z&34^>Q1U?>B^>C^>HQO!>^>MHZ.F\$>I^>M5&M0^>M^>?>D1.N^>MBH^>F^>M^>KTR2!>8Z8KD!>+W^>H1H.OU^>TCP!>M^>H^>UOW?>
530Y\$>N&N1^>{UCY!>G6ON?>709Z?>Q^>E?>J^>7QVSMF^>T^>C^>S^>M^>H^>F^>X^>O^>M^>U4^K^>RZQ0!>Q&Z^>M^>D^>3R8Z&@>BON<^>O^>1X4?>T1^>W^>H^>OU^>^>H^>M70>W^>WIAK^>B^>E7@>H^>D7^>2>G@>.
(GM>=>24&A^>22?>=>H6?>J&KW2U^>HORV?>20<MSS.K_244!>AO?>Y>WYQ?>Z^>VNSZ!>H?>1!>=6E^>U^>W^>U>W5K7YS=>G1LH13W^>M^>=>X24^>+1+>9249DK5HK1!>6RY.NDYI
I^>C^>V^>=>C8.1!>L&L&{9U>3Z^>WJB8K^>3C M&G<=>6K>L^>U^>V^>H^>B^>W^>M^>L^>R^>K^>R^>W^>T^>=>BDR^>C^>80T^>Z^>N5D612DUJX2!>E0Z^>WTB30A^>MO19.L0!>32Z7K4H1W?>
?>0&4>H^>83?>@?>K^>W^>O^>M^>81ZY^>T\$4>_8_QG3!>5M0!>=Z0<^>6T&D&X^>R^>C^>N^>N^>P^>Y2>A2K&Z^>F^>S>_4!>62\$>Z^>V^>E@>0A1^>W^>Q^>Z0!>MV@>WYXF^>U1^>U^>S^>@>PQ^>HJ^>P3W@>
X^>U8\$>58Y3CT8^>G@>=>A1F^>0M8\$0_U@>3A ME2!>M^>@>{R3P8L^>OT0LH1^>2.LTE&F^>HIV^>J5^>F^>+K^>I^>Z5^>FED!>F360M<M^>AYRA!>LX&E\$>U1A0!>40Q<^>MR8P3N^>6Q
M0&C<=>C&C^>M^>T^>+>S3&M6V!>G^>2QB^>QZ^>?>Y^>K^>Z^>G^>P^>M^>Q^>7E^>W^>6%>BC4!>6WSOY^>IH212!>Q^>GH^>6!>^>(<+P^>L^>X@>)<Z^>U^>U^>R^>F^>U^>L1^>B+M
M85@>FOIR6C@>Q^>5IS7?>2G.C<2!>Q6!>HCGPAB!>WPD>@>Q0Q135U!>H4X5UB^>M^>DS&T^>F^>=>MCMOR<^>5%\$>5%\$>8F^>A^>9^>G_47<Z^>?>Y12&^>3\$3^>G^>R^>+>HFQ>
M^>H7!>TO^>I243J^>2^KQ@>K^>W^>C^>1!>I^>PZ^>D0!>((GM@>=1^>4Z^>D2^>@>F^>J3&M^>M^>Q^>R^>B^>2!>6)KD^>M0^>=>UUP!>L^>UKA^>+C03S^>XIU>?>OIV^>5U_073 M^>Y67!>N^>W^>Y>=>7E7Y?>
NBI_AZU^>O^>2^>=>5.M82V^>Z^>VQ?>2TW^>+P^K!>I2Q0!>L^>M45!>8^>07N^>K^>E5X!>ZG^>G!>5B^>P666!>0F^>B0E^>C^>T^>UH\$>3^>4^>1RFE^>F^>8^>+Y9S^>
M9AK!>FRG^>C^>HP7^><=>A^>OY89Q!>OJTV>+K^>G^>PEAU^>X^>M^>?>6^>ERT3X\$!>Q?>_MLU@>PBBWJ^>X^>H146?>.&&T+!>VM2P61^>8^>+Y^>M^>9^>C^>B^>F^>VTOBI@>?>I@>XB^>M^>
M&C@>+>P^>K^>S102^>P^>=>L^>S^>U6IOZ^>964!>2CGDF_2CC<C^>=<^>9UVU^>Q^>3^>?>=>Z1M^>Z^>M^>44TIC&81M^>X^>H1^>XN0^>M^>398!>8R^>C^>7^>M^>GBZ0^>=>HCY^>TOR5T6L42F^>W^>
M9K^>G^>PBP1^>B&+>GZ&M^>MX^>2Y\$!>H^>1^>DWB8M^>D00^>Q40^>=>M^>T^>#3^>@>AQSW^>M^>7^>J^>M^>Y1P4^>2^>=>1C^>142!>6221@>T1^>H1^>M6W^>W0M^>XOQ^>TJ16<^>5C^>QV^>O^>VRK<^>8!>N^>+>AHL>=>=>FTACK<
S^>E@>G&^>+>1B^>M^>@>D^>C^>2N^>X3^>MD3^>5PW^>D&7^>6^>L^>C^>M^>H&C@>LY8P8^>Q^>1Z^>FT^>2HN&K^>3^>0TK>=>F^>Y^>T^>0W^>G^>S^>O97169^>F^>C^>N^>1^>MZ6^>6^>4TDH^>.>=>U^>E^>
<=>SE^>F^>?>HDB^>Y^>N^>S^>Q^>M^>C^>Z^>LH^>Z^>DYR6J!>8^>=>B^>M^>K^>M^>T^>Y^>S^>D^>302^>Z^>F^>C^>=<=>V^>Z^>4^>@>IN^>NREGM^>

0@VWVP+1PMPDZHERS*M5 M+*CK*ZFA+>|G<@/RLDEIBAY*9IPL5Z E@(<D1GKI1B5IRB..8N*Q(16..MH1%G)25216 M@NEIHB*560=KPBAPT3:H(C:H+31=K=K)@CSQO|PGR MPPOX\$# N5P187Z:14 Q@FOV+> Q@C(SN1259WBBT:O*G*4+,*\$#HY0HA-MC1:Z6>JK>|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aE1= W=P&K805K7Y10:NHXQ> M^ELN/(GK7E4BDBZ @=>#>TDBV=;|/R#>50A+G:VGV1.FW571PT08 MH1Z3X13<D.MTXPQ@|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

aytu:EclipseBusinessCapitalLcLoanAgreementMemberus-gaap:SecuredDebtMember 2024-10-012024-12-31 0001385818
aytu:EclipseBusinessCapitalLcLoanAgreementMemberus-gaap:SecuredDebtMember 2023-10-012023-12-31 0001385818
aytu:EclipseBusinessCapitalLcLoanAgreementMemberus-gaap:SecuredDebtMember 2024-07-012024-12-31 0001385818
aytu:EclipseBusinessCapitalLcLoanAgreementMemberus-gaap:SecuredDebtMember 2023-07-012023-12-31 0001385818
aytu:EclipseBusinessCapitalLcLoanAgreementMemberus-gaap:SecuredDebtMember 2024-06-30 0001385818 aytu:AvenueCapitalLoanMember 2022-01-26 0001385818
aytu:AvenueCapitalLoanMemberus-gaap:PrimeRateMember 2022-01-262022-01-26 0001385818 aytu:AvenueCapitalWarrantsMember 2022-01-26 0001385818
aytu:AvenueCapitalIssuanceMember 2022-03-07 0001385818 aytu:AvenueCapitalWarrantsMember 2022-03-07 0001385818 aytu:AvenueCapitalWarrantsMember 2022-10-25
0001385818 aytu:AvenueCapitalLoanMember 2022-01-262022-01-26 0001385818 aytu:AvenueCapitalLoanMember 2024-12-31 0001385818 aytu:AvenueCapitalLoanMember
2023-10-012023-12-31 0001385818 aytu:AvenueCapitalLoanMember 2023-07-012023-12-31 0001385818
aytu:AfterJanuary262024ButBeforeJanuary262025Memberaytu:AvenueCapitalLoanMember 2024-06-12 0001385818 aytu:AvenueCapitalLoanMember 2024-06-12 0001385818
aytu:AvenueCapitalLoanMember 2024-04-012024-06-30 0001385818 aytu:EclipseTermLoanMember 2024-06-12 0001385818 aytu:EclipseTermLoanMemberus-
gaap:SecuredOvernightFinancingRateSoftMember 2024-06-122024-06-12 0001385818 aytu:EclipseTermLoanMember 2024-06-122024-06-12 0001385818
aytu:EclipseTermLoanMember 2024-12-31 0001385818 aytu:OnOrBeforeJune122025Memberaytu:EclipseTermLoanMember 2024-06-12 0001385818
aytu:AfterJune122025ButOnOrBeforeJune122026Memberaytu:EclipseTermLoanMember 2024-06-12 0001385818
aytu:AfterJune122026ButOnOrBeforeJune122027Memberaytu:EclipseTermLoanMember 2024-06-12 0001385818
aytu:AfterJune122026ButOnOrBeforeJune122028Memberaytu:EclipseTermLoanMember 2024-06-12 0001385818 aytu:EclipseTermLoanMember 2024-10-012024-12-31
0001385818 aytu:EclipseTermLoanMember 2024-07-012024-12-31 0001385818 us-gaap:FairValueInputsLevel1Member 2024-12-31 0001385818 us-
gaap:FairValueInputsLevel2Member 2024-12-31 0001385818 us-gaap:FairValueInputsLevel3Member 2024-12-31 0001385818 us-gaap:FairValueInputsLevel1Member 2024-
06-30 0001385818 us-gaap:FairValueInputsLevel2Member 2024-06-30 0001385818 us-gaap:FairValueInputsLevel3Member 2024-06-30 0001385818 us-
gaap:FairValueInputsLevel3Member 2024-07-012024-12-31 0001385818 aytu:TrancheBPrefundedWarrantsMember 2024-09-30 0001385818
aytu:June2023WarrantsTrancheAMemberus-gaap:MeasurementInputSharePriceMember 2024-12-31 0001385818 aytu:OtherWarrantsMemberus-
gaap:MeasurementInputSharePriceMember 2024-12-31 0001385818 aytu:June2023WarrantsTrancheAMemberus-gaap:MeasurementInputExpectedTermMember 2024-12-31
0001385818 srt:MinimumMemberaytu:OtherWarrantsMemberus-gaap:MeasurementInputExpectedTermMember 2024-12-31 0001385818
srt:MaximumMemberaytu:OtherWarrantsMemberus-gaap:MeasurementInputExpectedTermMember 2024-12-31 0001385818 aytu:June2023WarrantsTrancheAMemberus-
gaap:MeasurementInputPriceVolatilityMember 2024-12-31 0001385818 srt:MinimumMemberaytu:OtherWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember
2024-12-31 0001385818 srt:MaximumMemberaytu:OtherWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-12-31 0001385818
aytu:June2023WarrantsTrancheAMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0001385818 aytu:OtherWarrantsMemberus-
gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0001385818 aytu:June2023WarrantsTrancheAMemberus-
gaap:MeasurementInputExpectedDividendRateMember 2024-12-31 0001385818 aytu:OtherWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember 2024-
12-31 0001385818 srt:MaximumMemberaytu:TrisKarbinalAgreementMember 2024-12-31 0001385818 us-gaap:RestrictedStockMember 2024-12-31 0001385818
aytu:The2020ShellMember 2020-06-17 0001385818 aytu:TheAugust2022OfferingMember 2022-08-11 2022-08-11 0001385818 aytu:August2022PrefundedWarrantsMember
2022-08-11 0001385818 aytu:August2022CommonWarrantsMember 2022-08-11 0001385818 aytu:August2022CommonAndPrefundedWarrantsMember 2022-08-11
0001385818 aytu:TheAugust2022OfferingMember 2022-08-11 0001385818 aytu:PrefundedWarrantsMember 2022-08-11 0001385818
aytu:SecuritiesPurchaseAgreementMember 2023-06-082023-06-08 0001385818 aytu:PrefundedWarrantsMember 2023-06-08 0001385818
aytu:TrancheACommonWarrantsMember 2023-06-08 0001385818 aytu:TrancheBCommonWarrantsMember 2023-06-08 0001385818 aytu:CommonWarrantsMember 2023-06-
08 0001385818 aytu:CommonWarrantsExchangedForPrefundedWarrantsMember 2023-06-08 0001385818 aytu:SecuritiesPurchaseAgreementWarrantsMember 2023-06-08
0001385818 aytu:SecuritiesPurchaseAgreementWarrantsMember 2023-06-082023-06-08 0001385818 aytu:TrancheBCommonWarrantsMember 2024-06-142024-06-14
0001385818 aytu:TrancheBPrefundedWarrantsMember 2024-06-142024-06-14 0001385818 aytu:TrancheBPrefundedWarrantsMember 2024-06-14 0001385818
aytu:The2024ShellMember 2024-09-26 0001385818 aytu:The2023EquityIncentivePlanMember 2023-05-182023-05-18 0001385818 aytu:The2023EquityIncentivePlanMember
2023-05-18 0001385818 us-gaap:EmployeeStockOptionMemberaytu:The2023EquityIncentivePlanMember 2023-05-182023-05-18 0001385818 srt:MinimumMemberus-
gaap:EmployeeStockOptionMemberaytu:The2023EquityIncentivePlanMember 2023-05-182023-05-18 0001385818 srt:MaximumMemberus-
gaap:EmployeeStockOptionMemberaytu:The2023EquityIncentivePlanMember 2023-05-182023-05-18 0001385818
srt:MinimumMemberaytu:RestrictedStockAndRestrictedStockUnitsRsumMemberaytu:The2023EquityIncentivePlanMember 2023-05-182023-05-18 0001385818
srt:MaximumMemberaytu:RestrictedStockAndRestrictedStockUnitsRsumMemberaytu:The2023EquityIncentivePlanMember 2023-05-182023-05-18 0001385818
aytu:The2023EquityIncentivePlanMember 2024-12-31 0001385818 aytu:The2015PlanMember 2020-02-13 0001385818 us-
gaap:EmployeeStockOptionMemberaytu:The2015PlanMember 2015-06-012015-06-01 0001385818 srt:MinimumMemberus-
gaap:EmployeeStockOptionMemberaytu:The2015PlanMember 2015-06-012015-06-01 0001385818 srt:MaximumMemberus-
gaap:EmployeeStockOptionMemberaytu:The2015PlanMember 2015-06-012015-06-01 0001385818 srt:MinimumMemberus-
gaap:RestrictedStockMemberaytu:The2015PlanMember 2015-06-012015-06-01 0001385818 srt:MaximumMemberus-gaap:RestrictedStockMemberaytu:The2015PlanMember
2015-06-012015-06-01 0001385818 us-gaap:RestrictedStockUnitsRSUMemberaytu:The2015PlanMember 2015-06-012015-06-01 0001385818 aytu:Neos2015PlanMember
2021-04-19 0001385818 us-gaap:RestrictedStockUnitsRSUMemberaytu:Neos2015PlanMember 2021-04-19 0001385818 us-
gaap:EmployeeStockOptionMemberaytu:Neos2015PlanMember 2021-04-192021-04-19 0001385818 srt:MinimumMemberus-
gaap:EmployeeStockOptionMemberaytu:Neos2015PlanMember 2021-04-192021-04-19 0001385818 srt:MaximumMemberus-
gaap:EmployeeStockOptionMemberaytu:Neos2015PlanMember 2021-04-192021-04-19 0001385818 2023-07-012024-06-30 0001385818 us-gaap:EmployeeStockOptionMember
2024-12-31 0001385818 us-gaap:EmployeeStockOptionMember 2024-07-012024-12-31 0001385818 us-gaap:RestrictedStockMember 2024-06-30 0001385818 us-
gaap:RestrictedStockMember 2024-07-012024-12-31 0001385818 us-gaap:RestrictedStockMemberaytu:The2023EquityIncentivePlanMember 2024-07-012024-12-31
0001385818 us-gaap:RestrictedStockMemberaytu:The2023EquityIncentivePlanMember 2024-12-31 0001385818 us-
gaap:RestrictedStockMemberaytu:OutsideEquityIncentivePlanMember 2024-07-012024-12-31 0001385818 us-
gaap:RestrictedStockMemberaytu:OutsideEquityIncentivePlanMember 2024-12-31 0001385818 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001385818 us-
gaap:RestrictedStockUnitsRSUMember 2024-07-012024-12-31 0001385818 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001385818 us-
gaap:ResearchAndDevelopmentExpenseMember 2024-10-012024-12-31 0001385818 us-gaap:ResearchAndDevelopmentExpenseMember 2023-10-012023-12-31 0001385818
us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-12-31 0001385818 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-12-31
0001385818 us-gaap:SellingAndMarketingExpenseMember 2024-10-012024-12-31 0001385818 us-gaap:SellingAndMarketingExpenseMember 2023-10-012023-12-31
0001385818 us-gaap:SellingAndMarketingExpenseMember 2024-07-012024-12-31 0001385818 us-gaap:SellingAndMarketingExpenseMember 2023-07-012023-12-31
0001385818 us-gaap:GeneralAndAdministrativeExpenseMember 2024-10-012024-12-31 0001385818 us-gaap:GeneralAndAdministrativeExpenseMember 2023-10-012023-12-
31 0001385818 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-12-31 0001385818 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-
12-31 0001385818 aytu:NetLossFromDiscontinuedOperationsMember 2024-10-012024-12-31 0001385818 aytu:NetLossFromDiscontinuedOperationsMember 2023-10-012023-
12-31 0001385818 aytu:NetLossFromDiscontinuedOperationsMember 2024-07-012024-12-31 0001385818 aytu:NetLossFromDiscontinuedOperationsMember 2023-07-012023-
12-31 0001385818 aytu:SecuritiesPurchaseAgreementWarrantsMember 2023-06-08 0001385818 aytu:SecuritiesPurchaseAgreementWarrantsMember 2023-06-082023-06-08
0001385818 srt:MinimumMemberaytu:August2022CommonWarrantsMember 2022-08-11 0001385818 srt:MaximumMemberaytu:August2022CommonWarrantsMember 2022-
08-11 0001385818 aytu:August2022CommonWarrantsMember 2022-12-31 0001385818 aytu:ReverseStockSplitMember 2023-01-062023-01-06 0001385818
aytu:August2022CommonWarrantsMember 2023-06-30 0001385818 srt:WeightedAverageMember 2024-06-30 0001385818 srt:WeightedAverageMember 2024-07-012024-12-
31 0001385818 srt:WeightedAverageMember 2024-12-31 0001385818 aytu:LiabilityWarrantsMember 2024-06-30 0001385818 aytu:LiabilityPrefundedWarrantsMember 2024-
06-30 0001385818 aytu:TrancheBCommonWarrantsMember 2024-06-30 0001385818 aytu:EquityWarrantsMember 2024-06-30 0001385818
aytu:TrancheBCommonWarrantsMember 2024-07-012024-09-30 0001385818 aytu:LiabilityWarrantsMember 2024-09-30 0001385818 aytu:LiabilityPrefundedWarrantsMember
2024-12-31 0001385818 aytu:TrancheBCommonWarrantsMember 2024-12-31 0001385818 aytu:EquityWarrantsMember 2024-12-31 0001385818 us-
gaap:SegmentContinuingOperationsMember 2024-10-012024-12-31 0001385818 us-gaap:SegmentContinuingOperationsMember 2023-10-012023-12-31 0001385818 us-
gaap:SegmentContinuingOperationsMember 2024-07-012024-12-31 0001385818 us-gaap:SegmentContinuingOperationsMember 2023-07-012023-12-31 0001385818 us-
gaap:SegmentDiscontinuedOperationsMember 2024-10-012024-12-31 0001385818 us-gaap:SegmentDiscontinuedOperationsMember 2023-10-012023-12-31 0001385818 us-
gaap:SegmentDiscontinuedOperationsMember 2024-07-012024-12-31 0001385818 us-gaap:SegmentDiscontinuedOperationsMember 2023-07-012023-12-31 0001385818
aytu:LiabilityWarrantsMember 2024-10-012024-12-31 0001385818 aytu:LiabilityWarrantsMember 2023-10-012023-12-31 0001385818 aytu:LiabilityWarrantsMember 2024-
07-012024-12-31 0001385818 aytu:LiabilityWarrantsMember 2023-07-012023-12-31 0001385818 aytu:EquityBasedWarrantsMember 2024-10-012024-12-31 0001385818
aytu:EquityBasedWarrantsMember 2023-10-012023-12-31 0001385818 aytu:EquityBasedWarrantsMember 2024-07-012024-12-31 0001385818
aytu:EquityBasedWarrantsMember 2023-07-012023-12-31 0001385818 us-gaap:RestrictedStockMember 2024-10-012024-12-31 0001385818 us-gaap:RestrictedStockMember
2023-10-012023-12-31 0001385818 us-gaap:RestrictedStockMember 2024-07-012024-12-31 0001385818 us-gaap:RestrictedStockMember 2023-07-012023-12-31 0001385818 us-
gaap:RestrictedStockUnitsRSUMember 2024-07-012024-12-31 0001385818 us-gaap:RestrictedStockUnitsRSUMember 2023-07-012023-12-31 0001385818 us-
gaap:EmployeeStockOptionMember 2024-10-012024-12-31 0001385818 us-gaap:EmployeeStockOptionMember 2023-10-012023-12-31 0001385818 us-
gaap:EmployeeStockOptionMember 2024-07-012024-12-31 0001385818 us-gaap:EmployeeStockOptionMember 2023-07-012023-12-31 0001385818
aytu:GrandPrairieTexasManufacturingSiteMember 2024-10-012024-12-31 0001385818 aytu:GrandPrairieTexasManufacturingSiteMember 2024-07-012024-12-31 0001385818
aytu:ConsumerHealthDivestitureMember 2024-10-012024-12-31 0001385818 aytu:ConsumerHealthDivestitureMember 2023-10-012023-12-31 0001385818
aytu:ConsumerHealthDivestitureMember 2024-07-012024-12-31 0001385818 aytu:ConsumerHealthDivestitureMember 2023-07-012023-12-31 0001385818
aytu:ConsumerHealthDivestitureMember 2024-06-30 shares thunderdome:item iso4217:USD iso4217:USD shares pure utr:Y0001385818false--0630Q22000-
0.00010.000150000000500000000000.00010.00012000000002000000006156981616968159726385972638100000http://fasb.org/us-
gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-
gaap/2024#OtherLiabilitiesNoncurrent0100000100000P4YP7YP4Yhttp://fasb.org/us-
gaap/2024#DerivativeGainLossOnDerivativeNet1.7171P5Y1P5Y01P5Y1P5Yfalsefalsefalse10-0true2024-12-31false001-38247AYTU-BIOPHARMA,INC.DE47-08831447900
East Union Avenue, Suite 920DenverCO80823720437-6580Company stock, par value \$0.0001 per shareAYTU:USASDAQYesYesNon-accelerated
Filertruefalsefalse61698482039800020006000254030002352600011085000121410006167000509770000121000630530006189100051600069300011780008290004995800052
317711000-
31997300030765000277160001162270001180950001622100018748000327950003656500054350004145000100240008924000107860001460300022771000276410005272000
16950003146000-262500022790001400009600068200068000010790001266000207300025490003016000-5770005896000-648400038200013990001880000-6074000-
2830007800001220007800006650006190001758000-6854000123000-839000504000-14860000788000-2200002262000-
8340006613206055176706100204549959184851125517670878279454995918.110.110.29-1.25-0.280.11-0.47-1.250.02-0.270.01-0.150.06-0.270.13-0.040.37-1.52-
0.26-0.04-0.41-1.5259726381000347688000-319973000277160005641730001730001760004630004630000147400061492001000348324000-
318499000298260002047915100051000078800078800061696811000348475000-3177110003076500055171741000343485000-30412900039357000130619300009300000-
8120000-812000055302351000344415000-312249000321670001088200008200003700486000860000-22000-22000053673471000345321000-31246900032853000262000-
83400062766000363400032400014320005896000-648400055000302000500051000529000500025400017600017940001566000-96100018050006790008300001329000-
306000202341900-3554000-306000-380500080000-19770001715000-34600066800001429000-0.0250000526000-2500000860001617000-53700025370002204000-
016000092900045000-1849000-2860000392000-345600020006000229850002039800019529000752000217000014190004320004830000 <p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">1- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">2- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">3- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">4- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">5- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">6- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">7- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">8- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">9- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">10- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">11- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">12- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">13- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">14- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">15- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">16- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">17- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">18- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">19- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">20- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">21- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">22- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">23- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">24- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">25- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">26- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">27- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">28- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">29- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">30- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">31- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">32- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">33- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">34- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">35- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">36- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">37- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">38- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">39- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">40- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">41- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">42- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">43- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">44- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">45- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">46- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">47- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">48- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">49- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">50- Nature of Business</p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;margin:

incorporated as Aytu BioScience, Inc. in the state of Delaware on <em style="font: inherit;"> June 8, 2015. Following the acquisition of Neos Therapeutics, Inc. ("Neos") in <em style="font: inherit;"> March 2021 the "Neos Acquisition", the Company changed its name to Aytu BioPharma, Inc. <p><em style="font: inherit;"> Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"> The Company's strategy is to become a leading pharmaceutical company that improves the lives of patients. The Company uses a focused approach of in-licensing, acquiring, developing, and commercializing novel prescription therapeutics in order to continue building its portfolio of revenue-generating products and leveraging its commercial team's expertise to build leading brands within large therapeutic markets. The Company's primary focus is on commercializing innovative prescription products that address conditions frequently developed or diagnosed in childhood. <p><em style="font: inherit;"> Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"> The Company's business from continuing operations is focused on its prescription pharmaceutical products sold primarily through <em style="font: inherit;"> third party wholesalers and pharmacies and which primarily consists of <em style="font: inherit;"> two product portfolios. The <em style="font: inherit;"> first consists of <em style="font: inherit;"> two products for the treatment of attention deficit hyperactivity disorder ("ADHD"): Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets ("Adzenys") and Cotelma XR-ODT (methylphenidate) extended-release orally disintegrating tablets ("Cotelma") and Adzenys together with Cotelma the "ADHD Portfolio". The <em style="font: inherit;"> second consists primarily of Karbinal® ER (carbinoxamine maleate extended-release oral suspension) ("Karbinal"), an extended-release <em style="font: inherit;"> first generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, <em style="font: inherit;"> two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency (the "Pediatric Portfolio"). <p><em style="font: inherit;"> Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"> Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker ("CODM"). After the previously announced successful wind down and divestiture of the Consumer Health business that occurred during the <em style="font: inherit;"> first quarter of fiscal <em style="font: inherit;"> 2025 the Company determined that its continuing operations now operate in a single operating and reportable segment. The Company's CODM is its Chief Executive Officer who manages operations and regularly reviews the financial information of the Company's continuing operations as a single operating segment for the purposes of allocating resources and evaluating its financial performance, and for which discrete financial information is available. The results of the Consumer Health business have been reported as discontinued operations (see <i>Note <em style="font: inherit;"> 20 Discontinued Operations </i>). <p><em style="font: inherit;"> Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"> In <em style="font: inherit;"> July 2023 the Company entered into an exclusive collaboration, distribution and supply agreement with Medomie Pharma Ltd ("Medomie"), a privately owned pharmaceutical company, for Medomie to sell Adzenys and Cotelma in Israel and the Palestinian Authority. In <em style="font: inherit;"> September 2024 the Company entered into an exclusive collaboration, distribution and supply agreement with Lupin Pharma Canada Ltd ("Lupin"), a subsidiary of global pharmaceutical company Lupin Limited, for Lupin to sell Adzenys and Cotelma in Canada. The Company will supply Adzenys and Cotelma to Medomie and Lupin based on forecasts and provide various product commercialization resources. Medomie and Lupin are responsible for seeking local regulatory approvals and marketing authorizations for both Adzenys and Cotelma, which is expected to occur over the next <em style="font: inherit;"> 18 to <em style="font: inherit;"> 24 months. The agreement with Medomie and the agreement with Lupin represent the Company's <em style="font: inherit;"> first and <em style="font: inherit;"> second international commercial agreements for Adzenys and Cotelma, respectively. <p><em style="font: inherit;"> Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"> Notes <em style="font: inherit;"> 2 Summary of Significant Accounting Policies </p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"> Principals of Consolidation </p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"> The Company's unaudited consolidated financial statements and notes thereto include the accounts of its wholly owned subsidiaries Aytu Therapeutics, LLC and Neos Therapeutics, Inc. and their respective wholly owned subsidiaries, as well as Innovus Pharmaceuticals, Inc. ("Innovus") and its wholly owned subsidiaries prior to the divestiture of Innovus on <em style="font: inherit;"> July 31, 2024 All significant inter-company balances and transactions have been eliminated in consolidation. <p><em style="font: inherit;"> Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;text-align:left;"> </p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"> Basis of Presentation </p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> The unaudited consolidated financial statements and notes thereto contained in this Form <em style="font: inherit;"> Q represent the financial statements of the Company and its wholly owned subsidiaries and have been prepared pursuant to the rules and regulations of the SEC regarding interim financial reporting. Accordingly, certain information and disclosures normally included in the complete financial statements prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") have been omitted pursuant to such rules and regulations. The unaudited consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Form <em style="font: inherit;"> K , which included all disclosures required by U.S. GAAP. In the opinion of management, these unaudited consolidated financial statements and notes thereto contain all adjustments necessary for the fair statement of the financial position of the Company and the results of operations and cash flows for the interim periods presented. The consolidated balance sheet as of <em style="font: inherit;"> June 30, 2024 , was derived from the audited annual financial statements but does <em style="font: inherit;"> not contain all of the footnote disclosures from the annual financial statements. The results of operations for the period ended <em style="font: inherit;"> December 31, 2024 , are <em style="font: inherit;"> not necessarily indicative of expected operating results for the full year or any future period. <p><em style="font: inherit;"> Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"> Use of Estimates </p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"> The preparation of financial statements and footnotes requires the use of management estimates, judgments and assumptions. Actual results <em style="font: inherit;"> may differ from estimates. In the accompanying unaudited consolidated financial statements and notes thereto, estimates are used for, but <em style="font: inherit;"> not limited to, stock-based compensation; revenue recognition; determination of variable consideration for accruals of chargebacks, administrative fees and rebates; government rebates, returns and other allowances; allowance for credit losses; inventory impairment; determination of right-of-use ("ROU") assets and lease liabilities; valuation of financial instruments, warrants and derivative warrant liabilities, intangible assets, and long-lived assets; purchase price allocations and the depreciable lives of long-lived assets; accruals for contingent liabilities; and determination of the income tax provision, deferred taxes and valuation allowance. Because of the uncertainties inherent in such estimates, actual results <em style="font: inherit;"> may differ from those estimates. The Company periodically evaluates estimates used in the preparation of the financial statements for reasonableness. <p><em style="font: inherit;"> Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"> Prior Period Reclassification </p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"> Certain prior year amounts in the Company's unaudited consolidated financial statements and the notes thereto have been reclassified to conform to the current year presentation. These reclassifications did <em style="font: inherit;"> not impact operating results for the <em style="font: inherit;"> three and <em style="font: inherit;"> six months ended <em style="font: inherit;"> December 31, 2024 and <em style="font: inherit;"> December 31, 2023 , or cash flows for the <em style="font: inherit;"> six months ended <em style="font: inherit;"> December 31, 2024 and <em style="font: inherit;"> December 31, 2023 , or the Company's financial position as of <em style="font: inherit;"> December 31, 2024 , or <em style="font: inherit;"> June 30, 2024 . <p><em style="font: inherit;"> Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"> Warrants </p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"> The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance in Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic <em style="font: inherit;"> 480 Distinguishing Liabilities from Equity ("ASC <em style="font: inherit;"> 480) and ASC Topic <em style="font: inherit;"> 815 Derivatives and Hedging ("ASC <em style="font: inherit;"> 815). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;"> 480 meet the definition of a liability pursuant to ASC <em style="font: inherit;"> 480 and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;"> 815 including whether the warrants are indexed to the Company's own common shares and whether the warrant holders could potentially require "net cash settlement" in a circumstance outside of the Company's control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option pricing model or Monte Carlo simulation model at issuance and for each reporting period when applicable. <p><em style="font: inherit;"> Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"> Income Taxes </p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"> The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been <em style="font: inherit;"> no changes in tax law affecting the tax provision during the <em style="font: inherit;"> three and <em style="font: inherit;"> six months ended <em style="font: inherit;"> December 31, 2024 and <em style="font: inherit;"> December 31, 2023 . <p><em style="font: inherit;"> Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;text-align:justify;"> </p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> The Company recorded for income (loss) from continuing operations an income tax benefit of \$0.3 million, which represented an effective tax rate of negative 74.1% and income tax expense of \$0.8 million, which represented an effective tax rate of 55.8%, for the <em style="font: inherit;"> three months ended <em style="font: inherit;"> December 31, 2024 and <em style="font: inherit;"> December 31, 2023 , respectively. The Company recorded for income (loss) from continuing operations an income tax expense of \$0.1 million, which represented an effective tax rate of 6.5% and income tax expense of \$0.8 million, which represented an effective tax rate of negative 12.8% for the <em style="font: inherit;"> six months ended <em style="font: inherit;"> December 31, 2024 and <em style="font: inherit;"> December 31, 2023 , respectively. These effective tax rates were primarily driven by the limitations on losses as a result of Section <em style="font: inherit;"> 382 of the Internal Revenue Code changes in ownership coupled with existing valuation allowances, the divestiture of the Company's Consumer Health business that occurred during the <em style="font: inherit;"> first quarter of fiscal <em style="font: inherit;"> 2025 and changes to the Company's <em style="font: inherit;"> first quarter of fiscal <em style="font: inherit;"> 2025 projections, which resulted in an income tax benefit for the current quarter. <p><em style="font: inherit;"> Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> An ownership change has limited the Company's ability to offset, post-change, United States federal taxable income. Section <em style="font: inherit;"> 382 of the Internal Revenue Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation <em style="font: inherit;"> may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. Previous acquisitions, financing transactions, and equity ownership changes in the past <em style="font: inherit;"> five years have caused a significant limitation on the Company's ability to use the change in control net operating loss carryovers. The ownership changes result in increased future tax liability and are a driver of the change from a <em style="font: inherit;"> font:

[illegible]

[illegible]

"-sec-extract:exhibit;"<em style="font: inherit;">2024 Form <em style="font: inherit;">10 K-1a>. There have been <em style="font: inherit;">no significant changes to the Company's significant accounting policies and there is <em style="font: inherit;">no other accounting guidance that has been issued and <em style="font: inherit;">not yet adopted that is applicable to the Company and that would have a material effect on the Company's unaudited consolidated financial statements and related disclosures as of <em style="font: inherit;">December 31, 2024, and through the filing of this Form <em style="font: inherit;">10 Q:

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">3 - Revenue</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Net revenue from continuing operations consists of sales of prescription pharmaceutical products from the Company's ADHD Portfolio and Pediatric Portfolio, principally to a limited number of wholesale distributors and pharmacies in the United States. Net revenue is recognized at the point in time that control of the product transfers to the customer, which typically aligns with shipping terms (i.e., upon delivery), generally "free on-board" destination when shipped domestically within the United States, consistent with contractual terms.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Savings offers, rebates, and wholesaler chargebacks reflect the terms of underlying agreements, which <em style="font: inherit;">may vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns <em style="font: inherit;">may <em style="font: inherit;">not follow historical trends. The Company's periodic adjustments of its estimates are subject to time delays between the initial product sale, and the ultimate reporting and settlement of deductions. The Company entered into negotiations with a vendor related to certain variable interest accruals that reduce revenue for the Company's ADHD Portfolio. As a result of these negotiations, the Company and the vendor agreed to a reduction to the liability purportedly owed by the Company of \$3.3 million, which resulted in a decrease in the estimated variable consideration accrual, and a related increase in net revenue of \$3.3 million in the <em style="font: inherit;">first quarter of fiscal <em style="font: inherit;">2025.

<em style="font: inherit;">December 31, 2024, <em style="font: inherit;">2023, were as follows:</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><tr><th style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</th><th style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</th></tr><tr><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</td><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</td></tr><tr><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</td><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</td></tr><tr><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</td><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</td></tr><tr><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</td><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</td></tr><tr><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</td><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</td></tr><tr><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</td><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</td></tr><tr><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</td><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</td></tr><tr><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</td><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</td></tr><tr><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</td><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</td></tr><tr><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</td><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</td></tr><tr><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</td><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</td></tr><tr><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</td><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</td></tr><tr><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</td><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</td></tr><tr><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</td><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</td></tr><tr><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</td><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</td></tr><tr><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</td><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</td></tr><tr><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</td><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</td></tr><tr><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</td><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</td></tr><tr><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</td><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</td></tr><tr><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</td><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</td></tr><tr><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Revenue</td><td style="width:100%; font-size:10pt; font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By Product Portfolio</td></tr><tr><td style="width:100%; font-size:10pt;

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Acquired technology rights

On June 30, 2024, the Company acquired technology rights from a third party. The rights are intangible assets that will be amortized over their estimated useful lives. The estimated useful lives of the rights are as follows:

Asset	Estimated Useful Life
Acquired technology rights	10 years

The following table summarizes the estimated future amortization expense to be recognized over the next five fiscal years and periods thereafter:

Period	Estimated Future Amortization Expense
2023	\$1.2 million
2024	\$1.2 million
2025	\$1.2 million
2026	\$1.2 million
2027	\$1.2 million
2028	\$1.2 million
2029	\$1.2 million
2030	\$1.2 million
2031	\$1.2 million
2032	\$1.2 million
2033	\$1.2 million
2034	\$1.2 million
2035	\$1.2 million
2036	\$1.2 million
2037	\$1.2 million
2038	\$1.2 million
2039	\$1.2 million
2040	\$1.2 million
2041	\$1.2 million
2042	\$1.2 million
2043	\$1.2 million
2044	\$1.2 million
2045	\$1.2 million
2046	\$1.2 million
2047	\$1.2 million
2048	\$1.2 million
2049	\$1.2 million
2050	\$1.2 million
2051	\$1.2 million
2052	\$1.2 million
2053	\$1.2 million
2054	\$1.2 million
2055	\$1.2 million
2056	\$1.2 million
2057	\$1.2 million
2058	\$1.2 million
2059	\$1.2 million
2060	\$1.2 million
2061	\$1.2 million
2062	\$1.2 million
2063	\$1.2 million
2064	\$1.2 million
2065	\$1.2 million
2066	\$1.2 million
2067	\$1.2 million
2068	\$1.2 million
2069	\$1.2 million
2070	\$1.2 million
2071	\$1.2 million
2072	\$1.2 million
2073	\$1.2 million
2074	\$1.2 million
2075	\$1.2 million
2076	\$1.2 million
2077	\$1.2 million
2078	\$1.2 million
2079	\$1.2 million
2080	\$1.2 million
2081	\$1.2 million
2082	\$1.2 million
2083	\$1.2 million
2084	\$1.2 million
2085	\$1.2 million
2086	\$1.2 million
2087	\$1.2 million
2088	\$1.2 million
2089	\$1.2 million
2090	\$1.2 million
2091	\$1.2 million
2092	\$1.2 million
2093	\$1.2 million
2094	\$1.2 million
2095	\$1.2 million
2096	\$1.2 million
2097	\$1.2 million
2098	\$1.2 million
2099	\$1.2 million
2100	\$1.2 million

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Eclipse Amendment

loan agreements, a term loan (the “Eclipse Term Loan”) and a revolving credit facility (the “Eclipse Revolving Loan”). The Eclipse Term Loan is described further in Note

under the Eclipse Agreement of \$14.5 million at an interest rate of the secured overnight financing rate as administered by the SOFR Administrator (“SOFR”) plus 4.5%. In addition, the Company is required to pay an unused line fee of 0.5% of the average unused portion of the maximum Eclipse Revolving Loan amount during the immediately preceding month. The ability to make borrowings and obtain advances of revolving loans under the Eclipse Agreement remains subject to a borrowing base and reserve, and availability blockade requirements. The Eclipse Revolving Loan maturity date, as amended, is June 12, 2028, and the effective interest rate was 9.2% as of December 31, 2024.

The amounts drawn on the Eclipse Revolving Loan were \$4.0 million and \$2.4 million as of January 26, 2022 (the “Closing Date”), the Company entered into a loan and security agreement (the “Avenue Capital Agreement”) with Avenue Venture Opportunities Fund H, L.P. and Avenue Venture Opportunities Fund H, L.P. as lenders (the “Avenue Capital Lenders”), and Avenue Capital Management H, L.P. as administrative agent (the “Avenue Capital Agent”), collectively (“Avenue Capital”), pursuant to which the Avenue Capital Lenders provided the Company and certain of its subsidiaries with a secured \$15.0 million loan. The interest rate on the loan was the greater of the prime rate or 3.25%, plus 7.4%, payable monthly in arrears. The maturity date of the loan was January 26, 2022. The proceeds from the Avenue Capital Agreement were used towards the repayment of the term loans.

Pursuant to the Avenue Capital Agreement, the Company was required to make interest-only payments for the first 18 months following the Closing Date (the “Interest-only Period”). The Interest-only Period could be extended automatically without any action by any party for six months provided as of the last day of the Interest-only Period then in effect, the Company received, prior to June 15, 2023, a specified amount of net proceeds from the sale and issuance of its equity securities (“Interest-only Milestone”). The Interest-only Period was able to be further extended automatically without any action by any party for an additional six months provided, the Company had achieved, prior to December 31, 2023, (i) Interest-only Milestone and (ii) a specified amount of trailing twelve months revenue as of the date of determination.

The Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to \$24.20 per share (the “Avenue Capital Warrants”). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than \$24.20 prior to June 30, 2022, the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on January 31, 2027. At inception, the Company accounted for the Avenue Capital Warrants as a derivative warrant liability as the number of warrants was not fixed at the Issuance Date. The fair value of the Avenue Capital Warrants at issuance was approximately \$0.6 million.

The Company closed on an equity offering of shares of common stock and warrants at an offering price of \$25.00 per share. As this offering precluded the Company from pursuing any equity financing prior to July 7, 2022, and the effective price of the offering was more than the exercise price of the Avenue Capital Warrants, the shares of common stock issuable upon exercise of the Avenue Capital Warrants were set at an exercise price of \$24.20.

The Company entered into an agreement with Avenue Venture Opportunities Fund, L.P. (“Avenue”) to extend the interest-only period of its existing senior secure loan facility held with Avenue. The amendment to the original loan agreement, which was executed in January 2022, extended the interest-only period to January 2024. In exchange for this extension of the interest-only period, the Company and Avenue agreed to reset the exercise price of the warrants issued in conjunction with the original loan agreement to \$8.60, corresponding to the warrant exercise price associated with the Company’s August 2022 equity financing.

The debt discount and issuance costs were being amortized over the term of the loan, using the effective interest method resulting in an effective rate of 16.6%. Total interest expense on the Avenue Capital loan, including debt discount amortization, was \$0.7 million and \$1.5 million for the three and six months ended December 31, 2023, respectively.

The Company used the proceeds from the exercise of warrants to repay the Avenue Capital loan in full. Upon early repayment of the Avenue Capital loan, the Company was required to pay Avenue Capital a fee in the amount of \$0.6 million (“Final Payment”). At inception, the Company accounted for the Final Payment as additional obligations on the debt, with the corresponding charge being recorded as debt discount. At retirement, the early termination fee, the Final Payment fee, and the write-off of all remaining related debt discount and deferred financing costs were included in the calculation of loss on extinguishment of debt. The Company recorded a loss on extinguishment of debt of \$0.6 million related to the retirement of the Avenue Capital loan in the fourth quarter of fiscal 2024.

The Company entered into the Eclipse Term Loan and a portion of the proceeds from the exercise of warrants to repay the Avenue Capital loan in full. Upon early repayment of the Avenue Capital loan, the Company was required to pay Avenue Capital a fee in the amount of \$0.6 million (“Final Payment”). At inception, the Company accounted for the Final Payment as additional obligations on the debt, with the corresponding charge being recorded as debt discount. At retirement, the early termination fee, the Final Payment fee, and the write-off of all remaining related debt discount and deferred financing costs were included in the calculation of loss on extinguishment of debt. The Company recorded a loss on extinguishment of debt of \$0.6 million related to the retirement of the Avenue Capital loan in the fourth quarter of fiscal 2024.

The Company entered into the Eclipse Term Loan and a portion of the proceeds from the exercise of warrants to repay the Avenue Capital loan in full. Upon early repayment of the Avenue Capital loan, the Company was required to pay Avenue Capital a fee in the amount of \$0.6 million (“Final Payment”). At inception, the Company accounted for the Final Payment as additional obligations on the debt, with the corresponding charge being recorded as debt discount. At retirement, the early termination fee, the Final Payment fee, and the write-off of all remaining related debt discount and deferred financing costs were included in the calculation of loss on extinguishment of debt. The Company recorded a loss on extinguishment of debt of \$0.6 million related to the retirement of the Avenue Capital loan in the fourth quarter of fiscal 2024.

[illegible]

Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">**>2024**

Total debt, net of current portion	\$12,071
Less: current portion of debt	(9,983)
Future Principal Payments	\$2,087

The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to determine fair value as follows:

Level	Description
1	Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities.
2	Inputs that include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly.
3	Unobservable inputs that are supported by little or no market activity.

The Company's financial instruments include cash and cash equivalents, accounts receivable, accrued liabilities, derivative warrant liabilities, contingent consideration liabilities, fixed payment arrangements, and current and non-current debt. The carrying amounts of certain short-term financial instruments, including cash and cash equivalents, accounts payable, and accrued liabilities approximate their fair value due to their short maturities. Current and non-current debt are reported at their amortized costs on the Company's consolidated balance sheets. The remaining financial instruments are reported on the Company's consolidated balance sheets at amounts that approximate current fair values. The Company's carrying value of its consolidated

[illegible]

[illegible]

[illegible]

[illegible]

“<em style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;”>”</td></tr></tbody></table> 3.42.12.70.8080.7470.8050.0430.04300 <em style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;”>”Note <em style=“font: inherit;”>13 – Commitments and Contingencies</p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;”></p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-align: justify;”><i>Pediatric Portfolio Fixed Payments and Product Milestone</i></p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;”></p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-indent: 36pt;text-align: justify;”>The Tris Karbinal Agreement grants the Company the exclusive right to distribute and sell Karbinal in the United States. The initial term of the agreement was 20 years. The Company pays Tris a royalty equal to 23.5% of net revenue from the product.</p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;”></p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-indent: 36pt;text-align: justify;”>The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from <em style=“font: inherit;”>August <em style=“font: inherit;”>1 through <em style=“font: inherit;”>July <em style=“font: inherit;”>31, of 70,000 units annually through <em style=“font: inherit;”>2025. The Company is required to pay Tris a royalty make-whole payment of \$30 for each unit under the <em style=“font: inherit;”>70,000-unit annual minimum sales commitment through <em style=“font: inherit;”>2025. The Tris Karbinal Agreement make-whole payment is capped at \$2.1 million each year. The final annual make-whole payment is due in <em style=“font: inherit;”>August 2025. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to \$3.0 million based on cumulative net revenue from the product, the <em style=“font: inherit;”>first of which is triggered at \$40.0 million.</p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;”></p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;”><i>Legal Matters</i></p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;”></p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-align: justify;”><i>Witmer Class Action Securities Litigation</i></p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-indent: 36pt;”></p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-indent: 36pt;text-align: justify;”>A stockholder derivative suit was filed on <em style=“font: inherit;”>September 12, 2022, in the Delaware Chancery Court by Paul Witmer, derivatively and on behalf of all Aytu stockholders, against Armistice Capital, LLC, Armistice Capital Master Fund, Ltd., Steve Boyd (Armistice’s Chief Investment Officer and Managing Partner, and a former director of Aytu), and certain other current and former directors of Aytu, Joshua R. Dishrow, Gary Cantrell, John Donofrio, Jr., Michael Macaluso, Carl Dockery and Ketan B. Mehta. Plaintiff amended the complaint on <em style=“font: inherit;”>April 5, 2023. The Amended Complaint dropped Mr. Macaluso as a defendant and alleges that (i) Armistice facilitated the sale of assets of Cerecor in <em style=“font: inherit;”>2019 and <em style=“font: inherit;”>2020 to Aytu in exchange for convertible securities which it subsequently converted and sold at a profit on the open market; (ii) the Armistice defendants breached their fiduciary duties, were unjustly enriched and wasted corporate assets in connection with these acquisitions; (iii) the Armistice defendants breached their fiduciary duties by engaging in insider trading; and (iv) the other directors breached their fiduciary duties, and aided and abetted the Armistice defendants’ breaches of fiduciary duties, in connection with these acquisitions. The Amended Complaint sought unspecified damages, equitable relief, restitution, disgorgement of profits, enhanced governance and internal procedures, and attorneys’ fees. While the Company believes that this lawsuit is without merit and have vigorously defended against it, the Company agreed to settle the matter for various corporate governance modifications and the payment of plaintiff’s attorneys’ fees. On <em style=“font: inherit;”>January 13, 2025, the court approved the settlement.</p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-align: justify;”></p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-align: justify;”><i>Granules PIV</i></p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-indent: 36pt;text-align: justify;”></p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-indent: 36pt;text-align: justify;”>On <em style=“font: inherit;”>October 31, 2024, the Company received a Paragraph IV Certification Notice Letter (“Notice Letter”) from Granules Pharmaceuticals, Inc. (“Granules”), stating that it intends to market a generic version of Adzenys before the expiration of all patents currently listed in the Orange Book. The Notice Letter states that Granules’ New Drug Application (“NDA”) for the generic version of Adzenys contains a Paragraph IV certification alleging that these patents are <em style=“font: inherit;”>not valid, <em style=“font: inherit;”>not enforceable, and/or will <em style=“font: inherit;”>not be infringed by the commercial manufacture, use or sale of the generic version of Adzenys. On <em style=“font: inherit;”>December 11, 2024, the Company filed a patent infringement lawsuit against Granules which triggered a stay precluding the United States Food and Drug Administration (“FDA”) from approving Granules’ NDA for a generic version of Adzenys for up to <em style=“font: inherit;”>30 months or entry of judgment holding the patents invalid, unenforceable, or <em style=“font: inherit;”>not infringed, whichever occurs first. On <em style=“font: inherit;”>January 7, 2025, Granules submitted an answer to the complaint. This litigation is ongoing, and a trial has been scheduled for to be on <em style=“font: inherit;”>December 7, 2026. The Company plans to vigorously enforce its intellectual property rights related to Adzenys.</p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-indent: 36pt;text-align: justify;”></p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-align: justify;”><i>Revive Investing</i></p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-indent: 36pt;text-align: justify;”></p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-indent: 36pt;text-align: justify;”>The Company had been named as a nominal plaintiff in a lawsuit by <em style=“font: inherit;”>two shareholders against Armistice Capital Master Fund, Ltd. et al, entitled Revive Investing, LLC, et al v. Armistice Master Fund, Ltd. et al. Case <em style=“font: inherit;”>1:20 cv- <em style=“font: inherit;”>02849 – CMA-TPO, in the United States District Court for the District of Colorado, contending that Armistice was liable for short swing trading profits in violation of Section <em style=“font: inherit;”>16 (b) of the Exchange Act for certain trades it made in Company stock in <em style=“font: inherit;”>2019 and <em style=“font: inherit;”>2020 and must disgorge those profits to the Company. That matter proceeded to trial before a jury, which on <em style=“font: inherit;”>January 29, 2025, returned a verdict finding <em style=“font: inherit;”>no liability.</p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-indent: 36pt;text-align: justify;”></p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-indent: 36pt;text-align: justify;”>Note <em style=“font: inherit;”>14</p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-indent: 36pt;text-align: justify;”>Stockholders <i>Equity</i></p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-indent: 36pt;text-align: justify;”></p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-indent: 36pt;text-align: justify;”>The Company has 200 million shares of common stock authorized with a par value of \$0.0001 per share and 50 million shares of preferred stock authorized with a par value of \$0.0001 per share. As of <em style=“font: inherit;”>December 31, 2024, included in common stock outstanding are 36,256 shares of unvested restricted stock issued to executives, directors and employees.</p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-indent: 36pt;”></p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-indent: 36pt;text-align: justify;”>On <em style=“font: inherit;”>September 28, 2021, the Company filed a shelf registration statement on Form S- <em style=“font: inherit;”>3, which was declared effective by the SEC on <em style=“font: inherit;”>October 7, 2021. This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of \$100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the <em style=“font: inherit;”>“2021 Shelf”). The <em style=“font: inherit;”>2021 Shelf expired in <em style=“font: inherit;”>October 2024.</p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-indent: 36pt;text-align: justify;”></p><p style=“font-family: Times New Roman;font-size: 10pt;font-variant: normal;margin: 0pt;text-indent: 36pt;text-align: justify;”>On <em style=“font: inherit;”>August 11, 2022, the Company closed on an underwritten public offering (the <em style=“font: inherit;”>“August 2022 Offering”) utilizing the <em style=“font: inherit;”>2021 Shelf, pursuant to which it sold an aggregate of (i) 1,075,290 shares of its common stock; (ii) in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 87,500 shares of its common stock; and (iii) accompanying warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase <em style=“font: inherit;”>one share of common stock for each share of common stock or each pre-funded warrant sold. The combined public offering price for each share of common stock and accompanying common warrant was \$8.60, and the combined offering price for each pre-funded warrant and accompanying common warrant was \$8.58, which equated to the public offering price per share of the common stock and accompanying common warrant, less the \$0.02 per share exercise price of each pre-funded warrant. The pre-funded warrants were exercised in full in <em style=“font: inherit;”>August 2022. The common warrants have an exercise price of \$8.60 per share of common stock and are exercisable for a period of &

text-align: justify;">On June 1, 2023, the Company's stockholders approved the Aytu BioPharma, Inc. Equity Incentive Plan (the "Equity Incentive Plan"). Prior to the Company's adoption of the Equity Incentive Plan, the Company awarded equity incentive grants to its directors and employees under the Aytu BioScience, Inc. Stock Option and Incentive Plan (the "Aytu Plan") and the Neos Therapeutics, Inc. Stock Options and Incentive Plan (the "Neos Plan"), and collectively with the Aytu Plan, the "2015 Plans". For the 2023 Equity Incentive Plan, the stockholders approved (i) 200,000 new shares; (ii) 87,129 shares available for grant under the 2015 Plans be "rolled over" to the 2023 Equity Incentive Plan; and (iii) any shares that are returned to the Company under the 2015 Plans be added to the 2023 Equity Incentive Plan. With the approval of the 2023 Equity Incentive Plan, no additional awards will be granted under the 2015 Plans. All outstanding awards previously granted under previous stock incentive plans will remain outstanding and subject to the terms of the plans. Stock options granted under the 2023 Equity Incentive Plan have contractual terms of 10 years or less from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards and restricted stock units have a vesting period of 3 to 4 years. As of December 31, 2024, the Company had 87,636 shares that are available for grant under the 2023 Equity Incentive Plan. Pursuant to the Neos Acquisition, the Company assumed 3,486 stock options and 1,786 restricted stock units previously granted under the Neos 2015 Equity Incentive Plan. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards have a vesting period ranging from 4 to 10 years, and the restricted stock units have a vesting period of 4 years. Stock option activity is as follows:

	Average	Contractual	Remaining
Weighted-Average	255.255	255.255	255.255
Life in Years	6.18	6.18	6.18
Outstanding at June 30, 2024	146,539	146,539	146,539
Granted	184	184	184
Forfeited/cancelled	5.73	5.73	5.73
Background-color: #f2f2f2	221,392	221,392	221,392
Background-color: #f2f2f2	8,147	8,147	8,147
Background-color: #f2f2f2	5,730	5,730	5,730
Background-color: #f2f2f2	221,392	221,392	221,392

[illegible]

font-family: Times New Roman;**font-size:** 10pt;"></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24.14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"></td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family:"Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 0pt;">Vested</p></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"></td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">(1,043</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"></td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24.13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"></td></tr><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; padding-bottom: 0px;"><p style="margin: 0pt 0pt 0pt 0pt;">Forfeited</p></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; padding-bottom: 1px solid rgb(0, 0, 0);"></td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; padding-bottom: 1px solid rgb(0, 0, 0);">(167</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; padding-bottom: 0px;"></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; padding-bottom: 0px;"></td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; padding-bottom: 0px;">26.20</td><td style="width: 1%; font-family: "Times New Roman"; font size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; padding-bottom: 0px;"></td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested at December 31, 2024</p></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"></td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">565</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-left: 0pt;"></td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-left: 0pt;">23.55</td><td style="width: 1%; font-family: Times New Roman; font size: 10pt; padding-bottom: 3px; margin-left: 0pt;"></td></tr></tbody></table><p style="font-family: Times New Roman; font-size: 10pt;font-variant:normal;margin:0pt;"></p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;text-align: justify;">During the <em style="font: inherit;">six months ended <em style="font: inherit;">December 31, 2024, no RSUs were granted. As of <em style="font: inherit;">December 31, 2024, there was less than \$0.1 million of unrecognized compensation costs related to non-vested RSUs granted under the Company's equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 0.2 years.</p><p style="font-family: Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Stock-based compensation expense related to the fair value of stock options, restricted stock, and RSUs was included in the consolidated statements of operations as set forth in the below table.</p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"></p><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"></td><td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"></td><td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Three Months Ended</p></td><td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"></td><td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"></td><td colspan="6" style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"></td><td colspan="6" style="text-align: center; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Six Months Ended</p></td><td colspan="6" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"></td><td colspan="6" style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"></td><td colspan="6" style="text-align: center; font-family: "Times New Roman"; Times, serif; font-size: 10pt;"></td><td colspan="6" style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31,</p></td><td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt;"></td><td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; padding-bottom: 1px;"></td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; Times, serif; font-size: 10pt;"></td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31,</p></td><td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt;"></td><td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; padding-bottom: 1px;"></td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; Times, serif; font-size: 10pt;"></td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p></td><td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; padding-bottom: 1px;"></td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; Times, serif; font-size: 10pt;"></td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p></td><td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; padding-bottom: 1px;"></td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; Times, serif; font-size: 10pt;"></td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

commerce platform, certain inventory and associated consumer brands, intellectual property, external workflow and contracts, and provides for the Company to receive contingent consideration payments on certain future sales of former Consumer Health business products.

The accounting requirements for reporting the Consumer Health business as discontinued operation were met when the wind down and divestiture was completed on July 31, 2024. Accordingly, the accompanying unaudited consolidated financial statements for all periods presented reflect this business as a discontinued operation and certain assets and liabilities of discontinued operations have been reclassified to the current assets of discontinued operations, non-current assets of discontinued operations, and current liabilities of discontinued operations financial statement line items on the accompanying unaudited consolidated balance sheet as of June 30, 2024. The Company elected to record the contingent consideration portion of the arrangement when the consideration is determined to be realizable and therefore, the Company did not record a contingent consideration asset at the transaction date and any subsequent proceeds will not be recognized until the contingent consideration asset is realizable, at which point the Company recognizes it to income (loss) from discontinued operations.

Three Months Ended December 31, 2024

	2024	2023
Net revenue	\$4,186	\$4,468
Cost of sales	(2,586)	(1,358)
Gross profit	\$1,600	\$3,110
Operating expenses	(1,155)	(1,552)
Operating income	\$445	\$1,558
Other income (expense)	(1)	(1)
Income before income taxes	\$444	\$1,557
Income tax expense	(131)	(131)
Net income	\$313	\$1,426

Amortization of intangible assets

Selling and marketing

[illegible]

Accounts receivable, net

Inventories

Prepaid expenses and other current assets

Non-current assets of discontinued operations

LIABILITIES

Current liabilities of discontinued operations

Accrued liabilities

Accrued liabilities

December 31, 2024

December 31, 2023

Net revenue

[illegible]

[illegible]

Roman"Times, serif, font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">431</td> <td style="width: 1%; font-family: "Times New Roman"Times, serif, font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"Times, serif, font-size: 10pt; width: 83%;"> <p style="font-family: "Times New Roman"Times, serif, font-size: 10pt; font-variant: normal; margin: 0pt;">Total current liabilities of discontinued operations</p> </td> <td style="width: 1%; font-family: "Times New Roman"Times, serif, font-size: 10pt;"></td> <td style="width: 1%; font-family: "Times New Roman"Times, serif, font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">\$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman"Times, serif, font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">557</td> <td style="width: 1%; font-family: "Times New Roman"Times, serif, font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"></td> </tr> </tbody> </table> 041860007170008468000-025860003590005122000-013580001550002689000-064200020001312000-0382000-0764000-0900040001900017500005870000-0-0254000-0175000-791000530000-1438000-52000-48000-26000-48000123000-839000504000-1486000910004920005380001121000440001165000126000431000557000 Relates to the exercise of 176,000 of the Tranche B Pre-Funded Warrants during the first quarter of fiscal 2025, which were liability classified and exercised at a price of \$0.0001 per share. Includes August 2022 Warrants, March 2022 Warrants, Avenue Capital Warrants and Tranche B Pre-Funded Warrants. See Note 16 - Warrants for definitions of these terms and further information. Warrants exercised during the first quarter of fiscal 2025 were 176,000 of the Tranche B Warrants, which were exercised at a price of \$0.0001 per share. The number of warrants outstanding as of December 31, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,630,424 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants. The number of warrants outstanding as of June 30, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,806,434 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants. As pre-funded warrants do not have an expiration date, they have been excluded from the calculation of the weighted average remaining contractual life in years.